
==== Front
Signal Transduct Target Ther
Signal Transduct Target Ther
Signal Transduction and Targeted Therapy
2095-9907
2059-3635
Nature Publishing Group UK London

39256346
1917
10.1038/s41392-024-01917-x
Review Article
Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control
Wang Shen 1
Li Wujian 12
Wang Zhenshan 13
Yang Wanying 1
Li Entao 45
Xia Xianzhu 1
Yan Feihu yanfh1990@163.com

1
http://orcid.org/0000-0001-9034-5755
Chiu Sandra qiux@ustc.edu.cn

456
1 https://ror.org/0313jb750 grid.410727.7 0000 0001 0526 1937 Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun, 130000 China
2 https://ror.org/00js3aw79 grid.64924.3d 0000 0004 1760 5735 College of Veterinary Medicine, Jilin University, Changchun, Jilin China
3 https://ror.org/05dmhhd41 grid.464353.3 0000 0000 9888 756X College of Veterinary Medicine, Jilin Agricultural University, Changchun, Jilin China
4 https://ror.org/04c4dkn09 grid.59053.3a 0000 0001 2167 9639 Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230027 Anhui China
5 Key Laboratory of Anhui Province for Emerging and Reemerging Infectious Diseases, Hefei, 230027 Anhui China
6 https://ror.org/04c4dkn09 grid.59053.3a 0000 0001 2167 9639 Department of Laboratory Medicine, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui China
11 9 2024
11 9 2024
2024
9 22322 2 2024
13 6 2024
5 7 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
To adequately prepare for potential hazards caused by emerging and reemerging infectious diseases, the WHO has issued a list of high-priority pathogens that are likely to cause future outbreaks and for which research and development (R&D) efforts are dedicated, known as paramount R&D blueprints. Within R&D efforts, the goal is to obtain effective prophylactic and therapeutic approaches, which depends on a comprehensive knowledge of the etiology, epidemiology, and pathogenesis of these diseases. In this process, the accessibility of animal models is a priority bottleneck because it plays a key role in bridging the gap between in-depth understanding and control efforts for infectious diseases. Here, we reviewed preclinical animal models for high priority disease in terms of their ability to simulate human infections, including both natural susceptibility models, artificially engineered models, and surrogate models. In addition, we have thoroughly reviewed the current landscape of vaccines, antibodies, and small molecule drugs, particularly hopeful candidates in the advanced stages of these infectious diseases. More importantly, focusing on global trends and novel technologies, several aspects of the prevention and control of infectious disease were discussed in detail, including but not limited to gaps in currently available animal models and medical responses, better immune correlates of protection established in animal models and humans, further understanding of disease mechanisms, and the role of artificial intelligence in guiding or supplementing the development of animal models, vaccines, and drugs. Overall, this review described pioneering approaches and sophisticated techniques involved in the study of the epidemiology, pathogenesis, prevention, and clinical theatment of WHO high-priority pathogens and proposed potential directions. Technological advances in these aspects would consolidate the line of defense, thus ensuring a timely response to WHO high priority pathogens.

Subject terms

Infectious diseases
Biological models
issue-copyright-statement© West China Hospital, Sichuan University 2024
==== Body
pmcIntroduction

Over the past few decades, humanity has experienced novel and increasingly frequent waves of emerging and re-emerging infectious diseases, for which timely and effective countermeasures are lacking. Notably, the Ebola virus disease (EVD) outbreak in West Africa occurred between 2013 and 2016 and caused more than 11,000 deaths.1 In fact, many viral hemorrhagic fevers with high morbidity and mortality rates, including pathogens from Filoviridae, Arenaviridae and Bunyaviridae, which are associated with Marburg virus disease (MVD), Lassa fever (LF), Crimean-Congo hemorrhagic fever (CCHF) and Rift Valley fever (RVF), should be noted.2–6 Moreover, emerging beta-coronaviruses (Beta-CoVs) constitute a large group of highly transmissible respiratory pathogens associated with waves of outbreak. Severe acute respiratory coronavirus (SARS-CoV) emerged in 2003, Middle East respiratory syndrome coronavirus (MERS-CoV) emerged in 2012, and severe acute respiratory coronavirus 2 (SARS-CoV-2) emerged in 2019.7–9 More recently, SARS-CoV-2 infection has led to billions of cases and millions of deaths by 2024. In addition, Nipah virus (NiV), together with Zika virus (ZIKV), are causative agents of lethal encephalitis, which results in a cluster of associated neurological disorders, of which Zika virus disease is characterized by neonatal malformation (Table 1).10,11 In response, the WHO has launched a blueprint list of priority diseases to accelerate research and development (R&D) efforts for pathogens with the potential to cause future public health emergencies, depending on whether and how the pathogen is transmitted to humans, the extent of medical countermeasures available, and the severity and fatality rate of the corresponding disease.12,13 The most recent blueprint issue by WHO in February 2018, presented the most priority diseases, including EVD, LF, MVD, CCHF, Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS), Nipah and henipaviral diseases, RVF, Zika, and “Disease X”, a yet unknown disease (Fig. 1) (Table 1).14Table 1 WHO high-priority pathogens and corresponding diseases

Virus family	Virus	Receptor	Fatality rate	Clinical symptoms	Reference	
Filoviruses	Ebola virus	NPC1	25–90%	Fever, fatigue, vomiting, sore throat, diarrhea, internal/external bleeding, conjunctivitis, uveitis, hypovolemic shock, multiorgan failure	188	
Marburg virus	NPC1	24–88%	Fever, headache, malaise, diarrhea, vomiting, lethargy, orchitis, conjunctivitis, iritis, retinitis, uveitis, increased intraocular pressure, multiorgan failure	2	
Arenavirus	Lassa virus	Matriglycan	1–3%	Fever, sore throat, vomiting, malaise, hemorrhagic, neurological complications like hearing loss, conjunctivitis, cataract, retinal fibrosis, uveitis, iritis	3,4	
Coronaviruses	SARS-CoV	hACE2	~10%	Fever, malaise, respiratory symptoms, pneumonia, headache	7–9	
MERS-CoV	hDPP4	30–40%	Asymptomatic to severe pneumonia, fever, cough, hemoptysis, diarrhea, vomiting, renal failure	7,9	
SARS-CoV-2	hACE2	0.35–3.85%	Pneumonia, fever, cough, fatigue, headache, shortness of breath, sore throat, multiple complications like loss of taste or smell	7,891	
Bunyaviruses	CCHFV	LDLR	~30%	Headache, chills, photophobia, myalgia, hemorrhage, fever, multiple complications, backpain, joint pain, vomiting, severe bruising, uncontrolled bleeding	5,560	
RVFV	–	~1%	Hemorrhagic fever, malaise, meningitis, retinopathy, backpain, and dizziness, neurological complications like seizures, uveitis, retinitis, vasculitis	6	
Paramyxovirus	Nipah virus	EphrinB2	40–75%	Encephalitis, fever, headache, vomiting, respiratory and neurologic, complications like seizures, pupillary abnormalities, oculomotor palsies, nystagmus	10	
Flavivirus	Zika virus	–	~0.1%	Asymptomatic in most cases, mild symptoms including fever, rash headache, joint pain seen in some cases, microcephaly in fetus	11	
SARS-CoV severe acute respiratory syndrome coronavirus, MERS-CoV Middle East respiratory syndrome coronavirus, SARS-CoV-2 severe acute respiratory syndrome coronavirus 2, CCHFV Crimean Congo hemorrhagic fever virus, RVFV Rift valley fever virus, NPC1 Niemann-PickC1, LAMP1 lysosome-associated membrane protein 1, hACE2 human angiotensin converting enzyme 2, hDPP4v human dipeptidylpeptidase-4, LDLR low density lipoprotein receptor, – not applicable

Fig. 1 Transmission routes of high-priority pathogens to humans. a The source of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has not been identified. Bats and pangolins are presumed to be natural hosts, while transmission to humans may be mediated by intermediate hosts and cold chains.935 Severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) originate from bats and are transmitted to humans by Paguma larvata and Camelus dromedarius, respectively.325 b Filoviruses originate from bats and are transmitted to humans, such as nonhuman primates, by wildlife.45 c Rift Valley fever virus (RVFV) originates from Aedes mosquitoes and is transmitted to humans by ruminants.936 Crimean Congo hemorrhagic fever virus (CCHFV) originates from Hyaloma asiaticum and is transmitted to humans by ruminants and domestic animals.551 d Lassa fever virus (LASV) originates from Mastomys natalensis and is transmitted to humans by corresponding contaminants.937 Zika virus (ZIKV) is transmitted to humans via the bite of Ades mosquitoes.938 Nipah virus (NiV) originates from bats and is transmitted to humans via pigs.939 (Created in BioRender)

In R&D efforts, appropriate animal models are stepping stones that help provide preliminary insights into the epidemiology and pathogenesis of these high-priority diseases and support preclinical evaluation of preventive and therapeutic approaches. Common small laboratory animals, such as mice, hamsters and guinea pigs, are generally less susceptible to these WHO high-priority pathogens.15–18 Novel techniques, such as immunodeficiency, receptor-transgenic/transduction, virus adaptation and humanization, have been actively used to establish competent infection models. Both traditional and emerging vaccine platforms, including inactivated vaccines, live attenuated vaccines, protein subunit vaccines, viral vector vaccines and nucleic acid vaccines, are actively being developed. Owing to the interdisciplinary collaboration between immunology, structural biology, multiomics, and artificial intelligence (AI), antibodies and small molecule drugs, which exhibit improved targeting, tolerance, and stability, are being developed as popular therapies for infectious diseases.

In this review, we summarize the overall profile of the epidemiology, pathogenesis, and rational application of animal models, vaccines, antibodies, and small molecular drugs for the aforementioned priority diseases. Moreover, we prospect directions and novel techniques that may supplement, replace, or guide prevention and control strategies, such as the use of organoids and AI. Overall, comprehensive knowledge of global trends and cutting-edge technologies could accelerate breakthroughs in the prevention and control of WHO blueprint priority pathogens.

Filovirus diseases

Etiology, epidemiology, and pathogenesis of filovirus diseases

The Filoviridae family includes a large group of filoviruses that cause lethal viral hemorrhagic fever (VHF). With a genome size of approximately 19 kb, filoviruses are nonsegmented single-stranded negative-sense RNA viruses. The eight subgenomic mRNAs encode seven structural proteins, including nucleoprotein (NP), glycoprotein (GP), matrix protein VP40, viral proteins VP24, VP30, and VP35, and polymerase L.19 The Ebola virus genus comprises 6 different species: Zaire virus (EBOV), Reston virus (RESTV), Sudan virus (SUDV), Bundibugyo virus (BDBV), Tai Forest virus (TAFV), and Bombali virus (BOMV).20 The amino acid sequences of SUDV and BDBV GP vary from that of EBOV by 50 and 30%, respectively.21 GP is the only structural protein assembled on the surface of the virion and is responsible for viral attachment, entry, membrane fusion and release. Additionally, GPs are main targets for triggering the immune response.22 GP harbor two disulfide-linked furin cleavage sites and can be cleaved into GP1 and GP2.23 The GP1 subunit of GP is composed of the receptor binding domain (RBD), two highly glycosylated domains, a glycan cap that shields the receptor binding site (RBS), and a mucin-like domain (MLD) with many N- and O-linked glycosylation sites. Axl, TIM-1, DC-SIGN, integrins, and C-type lectins are attachment factors.24–26 Filovirus infection of initial innate immune cells, such as monocytes, macrophages, dendritic cells, hepatocytes, and endothelial cells, is dependent on the expression of C-type lectins, while infection of other cell types later in infection appears to depend on other attachment factors.27,28 It is known that membrane-anchored C-type lectins and EBOV GPs interact mostly through the MLD.25,29,30 After GPs bind to attachment factors, the virus particles are absorbed into endosomes via micropinocytosis.31–33 GP removes the glycan cap and MLD, exposing the RBD, following protease processing in late endosomes and/or lysosomes at low pH. This results in the formation of GPCL, which can bind the intracellular receptor Niemann-Pick C1 (NPC1).34,35 The GP2 subunit consists of a stalk domain, a transmembrane (TM) domain that anchors GPs to the viral membrane, and an internal fusion loop (IFL) that contributes to the viral fusion with target cell membranes. Notably, the antagonism of GP2 with tetherin proteins during membrane fusion and the spatial shielding effect of GP exist in filoviruses.36,37 GP shields the transmembrane protein Fas and interferes with its spatial shielding effect, which helps to protect MARV-infected cells from premature death.37 The shielding effect of GPs varies among strains, and the spatial shielding of host proteins by GPs of MARV Angola is more pronounced than that of Musoke GPs, suggesting that GPs may play a role in the specific pathogenicity of the virus.38 VP35 was reported to block the phosphorylation of endogenous STAT1 and suppress the nuclear translocation of STAT1 to facilitate viral replication.39 Further evidence has demonstrated that the structural protein VP40 effectively assists in thwarting the host immune response to IFN.40 The main product of the GP gene, known as the secreted glycoprotein, sGP, is a 364-amino acid protein that contains 295 amino acids from the N-terminus of GP but lacks the MLD and GP2.41 Significant linear and conformational amino acid epitopes that are accessible for antibody binding are shared by sGP and GP. sGP can antagonize the host immune response by producing nonneutralizing antibodies.42 Furthermore, interactions between sGP and neutrophils may disrupt the physical interactions that FcgR IIIB and complement receptor 3 share, preventing neutrophil function.43 By promoting the restoration of endothelial barrier function, sGP is also believed to intensify anti-inflammatory effects.44

Filoviruses originate from bats and are transmitted to humans by wildlife, such as nonhuman primates.45 Filoviruses spread through broken skin or mucous membranes in the eyes, nose, or mouth in contact with contaminated blood or body fluids, objects, and infected fruit bats or NHPs. Domestic pigs in China and the Philippines are hosts of RESTV.46,47 Identification of the natural host becomes considerably more challenging due to the striking similarity between human-to-human transmission of MARV and that of EBOV and episodic outbreaks. Apart from the primary natural host of MARV, the North African fruit bat (Rousettus aegyptiacus) and other pteropod bats such as the South African hoofed bat (Hipposideros caffer) have also been demonstrated to be natural reservoir hosts.48,49 Different species of the Ebola virus genus exhibit distinct epidemiological characteristics. Over 34,000 human cases and 15,000 deaths have been reported for Ebolavirus infections. SUDV resulted in 779 cases and 412 fatalities.50 Only one documented human case of TAFV occurred in Côte d’Ivoire in 1994. In contrast, RESTV did not cause illness in human infections. The largest Ebola outbreak to date, which was associated with EBOV-Makona, resulted in more than 28,600 cases and 11300 fatalities between 2014 to 2016 in Beria, Guinea, and Sierra Leone. More recently, SUDV caused 164 cases and 77 fatalities in Uganda from 2022 to 2023. In 1967, MARV was first identified in Germany. Since then, MVD outbreaks have occurred more than 15 times and causing 474 cases and 379 deaths.51 In recent years, imported cases of EVD have been reported in Europe, Asia, and the Americas, which emphasizes the urgent need to develop medicinal countermeasures.

EVD can lead to a wide range of diseases, ranging from asymptomatic infection to severe disease in humans and other primates, depending on the virus species, which might be due partly to genetically determined differences in innate immune responses to the viruses.52 It is characterized by the rapid onset of symptoms such as fever, fatigue, muscle pain, headache, sore throat, vomiting, diarrhea, rash, and multiorgan failure, as well as hemorrhagic manifestations in patients in the terminal stages.1 The incubation period of EVD, the time from viral infection to symptom onset, is 2–21 days. Additionally, decreased white blood cell (WBC) counts, platelet counts, and elevated liver enzymes are found in laboratory tests. Similarly, MVD progresses rapidly with fever, headache, malaise, muscle aches and pain. Watery diarrhea, abdominal pain, cramping, nausea, and vomiting occur during the symptomatic period. In some cases, diarrhea can persist for one week. Many patients experience severe hemorrhage within 7 days post infection (dpi), which is closely associated with fatal outcomes. Death usually occurs 8–9 days after the patient becomes symptomatic. MVD is a virulent zoonotic illness with an overall case fatality rate of approximately 50%.53

Severe filovirus disease can be attributed to a complex of pathogenetic mechanisms that allow the virus to invade and suppress innate and adaptive immune responses, infect and kill a wide variety of cell types, and elicit strong inflammatory responses and diffuse intravascular coagulation, producing a syndrome resembling septic shock. Specifically, after filovirus entry, the primary target of filovirus is antigen presenting cells (APCs), including dendritic cells, macrophages, and monocytes, which cause cell degeneration and necrosis,52,54 followed by rapid viral replication, resulting in clotting, blockage of blood vessels, and retention of tissue fluid, blood macromolecules, and cells. When the virus invades endothelial cells located in internal organs such as the heart, blood vessels, liver and kidney, it causes small pores in blood vessels and organs, and blood components flow through these pores. Therefore, the onset of filovirus hemorrhagic fever is mainly characterized by massive bleeding. An important organ for filovirus replication is the liver, where the virus preferentially targets lymphoid tissues.55 Simultaneously, a large amount of synthesized envelope glycoproteins leads to cell necrosis and induces immune suppression and damage, which are also the main reasons for the high mortality of filoviruses. In contrast, studies in nonhuman primates have shown that blocking certain host responses, such as the coagulation cascade, can result in reduced viral replication and improved host survival.56

Animal models for filovirus diseases

Given that limited medical countermeasures are available for filovirus diseases, preclinical animal models, including mouse, hamster, guinea pig, ferret, and nonhuman primate models, have been actively developed and applied to accelerate breakthroughs in medical countermeasures. In this section, animal models for filovirus diseases are reviewed in detail (Table 2).Table 2 Animal models of filoviruses

Species	Approaches/animals	Pathogens	Dose	Route	Lethality	Signs of Disease	Strengths/Weaknesses	References	
Mouse	Neonatal mice	EBOV	1 PFU	IP	100%	No	No need for additional sensitive approaches/Not applicable for evaluation of immune correlates	59	
Mice adapted virus	EBOV Mayinga	102 PFU	IP or IC	100%	Ruffled fur, malaise, weight loss, and hemorrhage	Target cells and tissue tropism comparable to humans/Only sensitive to IP injection, additional mutants introduced by adaptation	799	
SC	0–100%	
IFN-α/βR−/− mice	maEBOV	103 PFU	IP or SC	100%	Lethargy, weight loss, anorexic and piloerection	Lethality to wild type viruses, valuable for the pathogenesis study/Mimicking limited clinical features of infection, barrier conditions needed, not applicable to vaccine evaluation	58,70	
EBOV Mayinga	103 PFU	IP	
EBOV E718	10 TCID50	IP or Aerosol	
SUDV Boneface	103 PFU	IP	
MARV Popp	10 TCID50	IP or Aerosol	
STAT1−/−mice	maEBOV	103 PFU	IP or SC	100%	Ruffled fur, malaise, weight loss	Lethality to wild type viruses, valuable for the pathogenesis study/Inconsistent clinical performance for different subtype of virus infections, barrier conditions needed, not applicable for vaccine evaluation	58,69,71	
EBOV Mayinga	103 PFU	IP	0	
EBOV Kikwit	102 PFU	IP	40%	
SUDV Gulu	100%	
BDBV	20%	
MARV Angola	80%	
SCID mice	maEBOV/EBOV/SUDV	103 PFU	IP or SC	100%	Weight loss	Natural susceptibility to specific isolates/Inconsistent susceptibility to different subtypes or isolates	58	
gpaMARV Ravn	
MARV Musoke	103 PFU	IP	100%	Ruffled fur, weight loss, anorexia, hunched posture	Shorter time to death than other SCID mice model/Lack typical biochemical parameters	72,73	
MARV Ravn	
MARV Ci67	
maMARV Angola	2.72 TCID50	IP	100%	Weight loss	
SCID mice	maMARV-Ravn	103 PFU	IP	100%	Weight loss, ruffled fur, hunched posture, lethargy	Exhibited most clinical hallmarks in humans/Time consuming, additional mutants introduced by virus adaptation	57,73	
maMARV Angola	102 TCID50	
Humanized mice	EBOV Mayinga	105 TCID50	IP	100%	Ruffled fur, weight loss, fever, and hunched posture, hypothermia, and moribundity	Recapitulating disease severity of different EBOV subtypes in humans/Lack of disease hallmarks	76	
EBOV Makona	103 FFU	IN	92.86%	77	
SUDV Gulu	71.43%	
BDBV Bundibugyo	28.58%	
TAFV Pauleoula	20%	
RESTV	19.2%	
EBOV Makona	IM	56%	79	
MARV-Angola	25%	Weight loss, anemia	Reveal how MARV modulate specific components of the immune system/Poor disease severity	
Syrian hamster	Hamster	maEBOV	103 FFU	IP	100%	Ruffled fur, malaise, severe coagulation disorders	Displaying most clinical hallmarks of EVD/Virus adaptation needed	82	
STAT2−/−hamster	MARV RAVV	105 PFU	IP	0	Ruffled fur, lethargy, hunched posture, and weight loss	Susceptibility to wild-type viruses/barrier conditions needed, not applicable for vaccine evaluation	84	
MARV Musoke	100%	
MARV Voege	100%	
MARV Angola	80%	
Hamster	haMARV	103 PFU	IP	100%	Weight loss, fever, rash, coagulation abnormalities, and hemorrhagic	Recapitulating most clinical hallmarks in humans/Virus adaptation needed	85	
Guinea pig	Guinea pig	gpaEBOV Mayinga	104 PFU	SC/IP	100%	Fever, weight loss, diarrhea, anorexia, ataxia, hemorrhage, ceased eating, dehydration	Similar disease features to humans/Additional mutants induced by virus adaptation	87,89	
gpaSUDV	103 TCID50	IP	100%	Weight loss, coagulation disorders	91	
gpaMARV Angola/Ravn	5000 PFU	IP	100%	Weight loss, fever, and hypothermia	Differentiated pathogenicity among MARV strains/Additional mutants induced by virus adaptation	93	
Ferret	–	EBOV Kikwit	103 PFU	IN	100%	Hypothermia, rash, hemorrhage, weight loss, depression, diarrhea, dehydration, nasal and ocular discharge, dyspnea, hunched posture, and altered gait	Uniform lethality with wild type viruses, low dose needed, susceptible to multiple challenge routes/Inconsistent clinical performance for different subtype of virus infections compared with humans, lack of apparent disease following ocular challenge, lack of disease hallmarks	96	
SUDV Gulu	
BDBV	
rgEBOV-C07	1 PFU	IM	97	
EBOV Makona-C07	200 TCID50	IM or IN	100%	Rash, fever, weight loss, and coagulation disorders	98	
BDBV	159 TCID50	IM	
EBOV	13.3 PFU	Oronasal	100%	Rash, fever, weight loss, lethargy, unkempt appearance, dyspnea, diarrhea, and coagulation disorders	99	
76.6 PFU	Oral	
76.6 PFU	Ocular	0	No	
SUDV Boneface	1260 TCID50	IM or IN	100%	Fever, weight loss, malaise, anorexia, dyspnea, absence of urine, diarrhea, and coagulation disorders	100	
RESTV	IM	103	
IN	
gpaEBOV	104 PFU	IP	100%	Weight loss, anorexia, fever, hemorrhages and rash	892	
NHPs	Rhesus monkey	EBOV	103 FFU	IM	67–100%	Fever, multiple organomegaly, pancytopenia, and coagulation disorders	Naturally, susceptible model/Mimicked limited physiological features of infection, expensive and ethical issues	83,107–109,112	
SUDV Gulu	103 FFU	IM	91%	Fever, depression, rash, anorexia, dyspnea, dehydration, shock and multiorgan failure	Recapitulate the disease course seen in human, aerosolized exposure model/Expensive and ethical issues	116	
SUDV Boniface	500 PFU	Aerosol	100%	117	
BDBV 200706291	103 PFU	IM	40%	Fever, anorexia, macular rash, depression	Models for immune signatures/Expensive and ethical issues	119	
MARV Angola/Musoke	103 FFU	IM	100%	Hemorrhagic	Varied susceptibility to differently virulent strains/Expensive and ethical issues	120,893,894	
Rhesus monkey	MARV-Ozolin/Ravn/Angola	103 FFU/PFU	IM/Aerosol	0–100%	Fever, lymphadenopathy, anorexia, malaise, edema, dehydration and rash	Varied susceptibility to differently strains, aerosolized MARV exposure model/Expensive and ethical issues	120,121,893,894	
Cynomolgus macaque	EBOV Kikwit EBOV Mayinga	104 PFU	Conjunctival	40%~100%	Weight loss, fever, anorexia, and hypothermia	Mucosal (Conjunctival) exposure model/Expensive and ethical issues	128,133	
Oral	40%~60%	Ruffled fur, Weight loss, fever, anorexia, malaise hypothermia, petechia, dehydration, rash	Mucosal exposure model, obvious gastrointestinal symptoms in IN exposed group, recapitulating the hallmark features of human disease/Do not reflect the difference in virulence between strains, expensive and ethical issues	128,133,134	
64 PFU	IN	100%	
74 PFU	IM	
104 PFU	IM	
EBOV Makona	104/100 PFU	IM/Oral/IN	100%	Malaise, fever, weight loss, rash, lymphadenopathy, anorexia, motor dysfunction, coagulopathy, and hypothermia	Recapitulating the hallmark features of human disease, Mucosal exposure model/Do not reflect the difference in virulence between strains, expensive and ethical issues	129,132,134	
SUDV Gulu	103 PFU	IM	100%	Fever, weight loss, malaise, diarrhea, dehydration, bleeding, petechia, anorexia, reduced stool output, rash	Rapid systemic disease/Significant difference in clinical signs among infected macaques	136,895	
RESTV	5 × 103 PFU	SC	83%	Anorexia, fever, weight loss, nasal discharge, hemorrhages.	Predict interspecies transmission potential of RESTV/Not recapitulating the hallmark features of human RESTV disease	145	
MARV Angola	103 FFU	IM	100%	Severe MHF	Varied susceptibility to differently virulent strains/Expensive and ethical issues	120,131,150	
MARV Musoke	50%	Severe MHF	
MARV Ozolin	0	Fever, hunched posture, and anorexia	
African green monkey	EBOV	103 PFU	Aerosol	100%	Fever, anorexia, dehydration, lymphadenopathy	Aerosolized model/Lack of rash and behavioral changes	
SUDV Boniface	500 PFU	Aerosol	100%	Fever, anorexia, malaise, depression, rash, dyspnea, reduced urine and fecal output, dehydration	Aerosolized model/No pronounced changes in hematology	117	
EBOV Kikwit	106 TCID50	Aerosol	92%	Fever, ruffled fur, malaise, dyspnea, anorexia, hemorrhage	Aerosolized model/Rapid onset of symptoms and death	152,153	
Marmoset monkey	EBOV Kikwit	103 PFU	IM	100%	Fever, weight loss, anorexia, depression, and reduced stool output	Small NHP model/Lack of widespread intravascular coagulation	152,153	
MARV Musoke	152	
Baboon	gpaEBOV	100 PFU	SC	100%	Weight loss, hyperthermia, anorexia, adynamia, ataxia, abasia, rash, diarrhea, dyspnea, and hemorrhages	Recapitulating the hallmark features of human disease/virus adaptation needed	155	
Surrogate model	Neonatal Mice	rVSVΔG-ZEBOV-GP	103 TCID50	SC	100%	Tremors, widened stance, ataxia, seizures and paresis and/or paralysis	Model for neurologic and ocular symptoms, models in BSL-2 conditions/Data cannot be directly extrapolated to humans	156,158	
Hamsters	rVSVΔG-ZEBOV-GP	103–106 PFU	IP	33–100%	Weight loss	Models in BSL-2 conditions, model for entry of EBOV or MARV depends on glycoproteins/Detailed pathogenesis of the disease different from EBOV and MARV infection	159	
rVSVΔG-MARV-GP	105.5–107.5 PFU	25–100%	
EBOV ebola virus, PFU plaque forming unit, IP intraperitoneal, IC intracutaneous, SC subcutaneous, IFN interferon, SUDV Sudan virus, MARV Marburg virus, STAT signal transducer and activator of transcription, BDBV Bundibugyo virus, TAFV Taï Forest virus, RESTV Reston virus, FFU focus-forming unit, IN intranasal, IM intramuscular, TCID50 50% tissue culture infective dose, ma mouse-adapted, scida SCID mouse-adapted, ha hamster-adapted, gpa guinea pig-adapted, rg reverse-genetics, BSL-2 biosafety level 2, – not applicable

Mice

Mice are the most frequently used animal models in preclinical studies. Mice are economical, abundant, well characterized, and easy to manipulate. The wide availability of biochemical reagents and immunological tools further supports the application of mouse models. However, wild-type immunocompetent mice are resistant to filoviruses. Filoviruses replicate poorly and are eliminated in a short period of time in mice. Consequently, filovirus infection in mice did not result in symptomatic or lethal outcomes.57,58 In response, newborn mice and immunodeficient mice were established to obtain an effective infection model. In combination with an immunodeficient strategy, mouse-adapted approaches have also been adopted to establish lethal models.

Neonatal suckling mice

Neonatal suckling mice are susceptible to multiple viruses due to their immature immune system. EBOV can cause fatal infection in newborn mice after intracranial (IC) or intraperitoneal (IP) injection.59 A viral load as low as 1 plaque-forming unit (PFU) could be detected in newborn mice.60 However, due to the incomplete immune system of newborn mice, this model is not applicable for pathogenesis studies or vaccine evaluation.

Mouse adapted model

Successive passages of wild type (WT) EBOV in mice yielded mouse-adapted Ebola viruses (maEBOVs), which can cause symptomatic infection in wild-type mice. Uniform disease and lethality were achieved only by IP injection rather than intramuscular (IM) or subcutaneous (SC) injection.61 When maEBOV was intraperitoneally injected into adult BALB/c, CD-1, or C57BL/6 mice, the animals died at approximately 5–6 dpi, which resembled EVD in NHPs. Further studies revealed that the median lethal dose (LD50) of maEBOV was 0.03 PFU.62,63 To investigate the genetic determinants of virulence, recombinant maEBOV and wtEBOV viruses were constructed using reverse genetic approaches. Recombinant viruses harboring NP and VP24 mutations were found to be lethal in mice and resistant to type I IFN in vitro.63 Although the VP35 protein of EBOV was found to block type I IFN responses in vitro through multiple mechanisms, it did not affect the virulence of maEBOV in mice.64 MaEBOV replicated rapidly in mice, with serum viral titers as high as 109 PFU/ml. Systemic dissemination of the virus can lead to widespread infection and necrosis of the liver, spleen, and other organs in mice. Histopathological and biochemical data showed liver and kidney damage in mice, similar to what has been observed in NHPs.65 Massive lymphocyte apoptosis, which is a marker of poor prognosis in patients with EBOV infection and NHPs, was observed in maEBOV-infected mice.62,65,66 TNF-α, IFN-γ, IL-8, MIP-1 α, MIP-1 β and proinflammatory cytokines such as MCP-1 were also produced in a pattern similar to that of wtEBOV-infected NHPs.67,68 Moreover, lymphocyte activation during lymphoblastoid formation, increased CD44 expression on the surface of T cells, and increased lymphocyte numbers in the blood at later stages of infection were observed in mice. The above results showed that, compared with infection in NHPs, infection in mice caused a similar pathogenesis in maEBOV cells. Like NHPs, mice are suitable models for the study of filovirus-induced coagulopathy. Consequently, anticoagulant treatment of mice infected with maEBOV could demonstrate the role of coagulopathy in EVD pathogenesis. Although the maEBOV-infected mouse model resembled the disease of wtEBOV-infected NHPs in many respects, there are also some differences. Mice were sensitive to maEBOV injected via the IP route.62 In addition, fibrin deposition was not observed in tissue sections after maEBOV infection in mice, whereas in NHPs, D-dimers appeared in plasma as a result of fibrin deposition and breakdown, and fibrin deposition could be observed in the spleen of infected animals and other tissues where viral replication occurred.

Immunodeficient mouse models

Interferon receptor (IFN-α/βR−/−) or cytoplasmic signal transducer and activator of transcription-1 (STAT-1) protein knockout mice are susceptible to filovirus infection. Both types of mice progressed to fatal infection with wtEBOV.58,69 Further studies revealed that infection with EBOV Mayinga was lethal in IFN-α/βR−/− mice, whereas infection with EBOV Kikwit did not cause mortality, suggesting that different responses to type I IFNs occur among different isolates of EBOV. Similarly, Sudan virus (SUDV) has been shown to cause differences in lethality in type I IFN-deficient mice.58,70 These results suggest that the type I IFN response is critical for the pathogenesis of filovirus infection. When STAT-1−/− mice were infected with five different wild-type filoviruses, SUDV and MARV caused 100% and 80% lethality, respectively. EBOV, BDBV, and TAFV caused 40%, 20%, and no mortality, respectively.71 Similarly, MARV-Musoke-infected STAT1−/− mice developed lymphopenia and died within 7 days.69 Serial passages of MARVs in SCID mice resulted in mouse-adapted Angola (ma-Ang) and RAVV (ma-RAVV) strains, which were able to infect and cause lethal disease in adult immunocompetent BALB/c mice.57,72,73 The single IP challenge route resulted in lethal disease. BALB/c mice infected with ma-RAVV became lethargic and hunched, while no evidence of hemorrhagic symptoms or maculopapular rash was noted, all animals succumbed to infection within 8 days. Moreover, ma-MARV-Ang and ma-RAVV infection in BALB/c mice led to multiorgan failure.57,73 This systemic infection was similar to that observed in MVD patients. A total of 11 amino acid mutations were introduced into ma-MARV-Ang compared to wtMARV-Angola; these mutations were distributed in VP40, VP35, GP, VP30, and VP24 of MARV.74 Key amino acid changes attributed to lethal disease in BALB/c mice have not yet been clearly defined. The VP40 matrix protein of the MARV Musoke strain and Ravn strain has been proven to antagonize IFN-α/β and IFN-γ signaling by inhibiting the activation of the cellular tyrosine kinase Jak1 in primate cells. However, neither MARV nor RAVV VP40 effectively inhibited IFN signaling in mouse cells. VP40 from maRAVV inhibited IFN signaling in a species-dependent manner.75 Two (V57A and T165A) amino acid changes that accumulate in VP40 are responsible for efficient IFN signaling antagonism by RAVV VP40 in mouse cells. wtEBOV can cause fatal infection in SCID mice lacking B and T cells, but the course of disease is prolonged compared to that in other lethal mouse models.58,72 After challenge with filoviruses, SCID mice gradually develop progressive weight loss and hypokinesia and subsequently die at 20–25 dpi.57 Compared to common mice, immunocompromised mice enabled rapid evaluation of candidate medical therapies using WT filovirus strains without the need for adaptation. However, this model has a high unit cost, requires sterile conditions, and lacks normal immune functions, which hamper the investigation of immune correlates of protection or pathogenesis. Consequently, this model is not applicable for widespread usage.

Humanized mice

Humanized mice were obtained using genetic engineering approaches in which a human-like environment was established. Bird et al. generated a humanized mouse model of EBOV infection by implantation of human immune cells (Hu BLT). Hu BLT mice developed EVD upon wtEBOV infection. Infection with high-dose EBOV results in rapid, fatal EVD characterized by high viral loads, alterations in key antiviral immune cytokines and chemokines, and severe histopathological changes. Dose- and donor-dependent clinical features were observed in Hu BLT mice infected with low-dose EBOV Mayinga and Makona isolates.76 Similarly, HLA-A2–transgenic, NOD–scid–IL-2γ receptor–knockout (NSG-A2) mice were used to compare the pathogenesis of EBOV and RESTV. Compared to EBOV, RESTV was markedly less pathogenic and killed 20% of infected mice due to exacerbated inflammation and viral replication in the liver. Interestingly, different case fatality rates of Ebolavirus species in humans were recapitulated in humanized mice. Specifically, among the strains of Zaire Ebola virus tested, huNSG-A2 mice were significantly less susceptible to the Makona virus strain than to the Mayinga virus. These results suggested that humanized mice could be a model for the pathogenicity of emerging filoviruses.77 The use of collaborative cross (CC) mice further recapitulated EBOV-related disease phenotypes. Exposure of CC mice to maEBOV has yielded a wide variety of outcomes, ranging from complete resistance to lethal disease.78 MaEBOV-infected CC mice exhibited typical lesions. As the disease progressed, the CC mice exhibited prolonged blood coagulation, internal hemorrhage, coffee-colored blood, splenomegaly, hepatic discoloration, and a soft texture. Compared to C57BL/6J mice, CC mice exhibit significantly greater thrombin and prothrombin times, which emphasizes that the host genetic background plays a role in disease development. To address the shortcomings of immunodeficient mice and obtain a unique opportunity to study the interactions of filoviruses with human immune cells in vivo, an immunodeficient mouse strain in which the Rag2, γc, and CD47 genes were knocked out was generated using the bone marrow, liver, and thymus (BLT) methods. This model produced human dendritic cells, monocytes, monocyte-derived macrophages, natural killer cells, B cells, and T cells. When these triple knockout BLT (TKO-BLT) mice were IM inoculated with MARV-Angola, symptoms started at 16 dpi and ultimately resulted in partial morbidity.79

Overall, mouse models of filoviruses exhibit viremia and a high viral burden in the spleen, liver, blood, and multiple organ tissues. Lymphopenia, thrombocytopenia, renal dysfunction, and liver damage were recaptulated.73,80,81 Fluctuations in blood glucose, albumin, globulin, and alanine aminotransferase (ALT) levels were also noted and are consistent with the findings of other models of filovirus infection. As in NHP models, both proinflammatory and anti-inflammatory cytokines are frequently produced in mice, together with lymphocyte activation, increased T-cell CD44, and increased circulating lymphocytes, indicating dysregulation of the immune system.62,73,80

Syrian golden hamsters

Hamsters are insusceptible to wild-type filoviruses, and virus adaptation is required to establish a sensitive infection.62 Hamsters infected with maEBOV developed clinical signs, such as ruffled fur and hypokinesia, and died of the disease at 4–5 dpi. Severe coagulation disorders and thrombocytopenia were also observed in infected animals in the late stages of disease.82 High virus titers were detected in the heart, liver, spleen, lungs, kidneys, brain, and blood. Moreover, maEBOV infection caused histopathological changes, including inflammatory cell infiltration, cell necrosis, and apoptosis, which were mainly restricted to the lymphoid organs and liver. Liver lesions, including disseminated hepatocyte degeneration and necrosis, moderate neutrophil counts, slight infiltration of macrophages, and spleen damage, characterized by lymphocyte necrosis and a marked reduction in white marrow, were noted.28 However, fibrin deposition was not observed in liver sinusoids.83

When STAT2−/− hamsters were inoculated with 105 PFU of MARV-associated musoke via the IP route, they developed clinical signs at 5 dpi, including a scruffy coat, lethargy, a hunched posture, irregular breathing, orbital tightening, nasal discharge, abnormal gait, weight loss, hyperreflexia, and head tilt, and succumbed to the disease at 12 dpi.84 High titers of MARV were detected in the blood, kidneys, spleen, liver, lymph nodes, and heart, while moderate titers were detected in the brain.84 Splenitis, hepatitis and massive release of cytokines were observed at 6 dpi, indicating a dysregulated immune response. Neither maculopapular nor punctate rashes were found in the infected animals.84 Notably, hamsters infected with haMARV, which was obtained by serial passaging of MARV Angola three times in Hartley guinea pigs and then serial passaging five times in hamsters, developed a maculopapular rash with visible petechiae on the face, chin, chest, abdomen, extremities, and severe coagulation disorders, consistent with what has been observed in humans. On autopsy, the liver was covered with necrotic lesions and neutrophilic infiltrates, while the spleen was infiltrated with neutrophils and macrophages, with fibrin deposits in the red marrow.85 Unfortunately, the lack of commercial reagents for accurately monitor host immune responses limits the use of hamster models in the study of the pathogenesis and medical countermeasures of EVD.

Guinea pigs

Both outbred and inbred guinea pigs are insusceptible or less susceptible to filoviruses and are characterized by transient illness.86 To overcome this issue, a lethal model of Strain 13 guinea pigs was established by serial passages of EBOV-Mayinga 4 times.87 After viral adaptation and inoculation, guinea pigs presented obvious clinical signs, such as weight loss, anorexia, fever, and dehydration, and died at 8–11 dpi without apparent hemorrhage. Viremia was detected in multiple organs. Abnormal blood biochemical parameters, which reflect liver and kidney damage, were observed. By necropsy, swollen lymph nodes, pale, friable livers, and slightly enlarged spleens, as well as pathological changes, including fluid accumulation in the small intestine and cecum, bruised spots on the surface of the kidneys, distal gastric erosions, and enlarged adrenal glands, were observed. Fibrin deposition occurs in interstitial fibroblasts and endothelial cells in various tissues in the late stage of EBOV infection.87 Serial passage of the EBOV strains 7–9 times was uniformly lethal to Hartley guinea pigs.88,89 Diarrhea and intestinal hemorrhage presented in the late stage of the disease.89 The typical disease features of guinea pigs, such as early infection of macrophages and dendritic cells, apoptosis of bystander lymphocytes, increased levels of proinflammatory cytokines, and abnormal coagulation, are highly consistent with those observed in humans.90 Similarly, Hartley guinea pigs showed signs of disease and uniformly succumbed at 9–14 dpi after infection with Gpa-SUDV.91

When inoculated with whole blood from MVD patients, Hartley guinea pigs showed reduced appetite, weight loss, fever, and lethargy during the incubation period of 4–10 days. Subsequently, the animals gradually recovered.92 After adaptation to Hartley guinea pigs, whole-blood guinea pigs were adapted (GPA) to MARV, causing uniform lethality, febrile illness, and clotting abnormalities. GPA MARV-infected Hartley guinea pigs succumbed to the disease at 6–9 dpi, and infectious viruses were detected in the liver, kidneys, lungs, and spleen. Compared to GPA MARV Ang pigs, GPA MARV-Ravn-infected guinea pigs presented more obvious weight loss, greater body temperature, and fewer tissue lesions.93 Strain 13 guinea pig-adapted MARV variants, namely GPA-MARV Musoke and GPA-MARV Ravn, were also developed.94 Both adapted variants caused viremia and clinical signs in Strain 13 guinea pigs. However, only GPA-MARV Ravn was uniformly lethal in Strain 13 guinea pigs.94 Compared to mice and hamsters, guinea pigs are timid and stressed, which poses obstacles in housing and handling; additionally, they have a high unit cost and lack reagents to characterize aspects of immune responses, indicating that they are more suitable as a secondary animal model for confirming experimental results and trends from mouse/hamster studies.

Ferrets

The domestic ferret (Mustela putorius furo) is a member of the genus Mustela in the Mustelidae family.95 Ferrets are naturally susceptible to EBOV. EBOV-infected ferrets exhibited obvious fever and weight loss at 3–4 dpi and died at 7 dpi. Other clinical signs, such as progressively worsening depression, diarrhea, dehydration, nasal and ocular discharge, labored breathing, hunched posture, and altered gait, were also observed. The most common lesions in ferrets were lymphohistiocytic, neutrophilic necrotizing hepatitis, and necrotizing splenitis.96 To investigate the pathogenicity of EBOV, EBOV-Makona was rescued by reverse genetic approaches, and the resulting strain was known as rgEBOV-C07. rgEBOV-C07 was highly pathogenic in ferrets. All animals succumbed to the disease at 6–7 dpi after infection with 0.1 PFU of rgEBOV-C07 via the IM route. In the nonlethal challenge groups, symptomatic infections persisted until 15 dpi. The LD50 of rgEBOV-C07 in ferrets was 0.015 PFU.97 Biochemical results in infected animals revealed increases in liver markers, ALT, alkaline phosphatase (ALP), and BIL; renal markers, BUN, and CRE; and decreased levels of ALB, indicating liver damage, kidney dysfunction, and edema. Additionally, ferrets recapitulated disseminated intravascular coagulation, with prolonged activated partial thromboplastin time (APTT) and thrombin time (TT), increased fibrinogen levels, and decreased prothrombin activity percentage (PT). Multiple organ injuries with uncontrolled virus replication were observed in infected animals, including the kidneys, liver, spleen, and lungs.98 There are also investigations of mucosal challenge routes, including oronasal, oral, and ocular inoculation. Animals administered at target doses of 1, 10, or 100 PFU via the oral-nasal or oral route died at median times of 152, 136, and 126 h, respectively. All animals infected via the ocular route survived for 28 days; however, when the study was terminated, the ferrets presented with mild or no symptoms.99

When ferrets were challenged with SUDV at a dose of 1000 TCID50 via the IM or IN route, signs of illness were observed at 4 dpi and included fever, weight loss, viremia, multiple-organ dysfunction, viral shedding, and death. SUDV infection induced a decrease in the serum ALB and calcium concentrations and an increase in the globulin, ALP, ALT, and amylase (AMY) levels. In plasma, increased fibrinogen, APTT, and TT and decreased PLT and PT% were observed, indicating disseminated intravascular coagulopathy.100 In another study, typical symptoms, including hemorrhage and rash, which are also observed in humans, were observed in ferrets.96 When the ferrets were challenged with BDBV, common signs such as fever, weight loss, hypothermia, euthanasia, viremia and virus shedding, rash and liver, and renal and pancreatic damage were observed. Compared with EBOV- and SUDV-infected animals, ferrets infected with BDBV died of disease within a mean period of 8–9 days, indicating a prolonged disease course.96 The disease course observed in BDBV-infected ferrets was similar to that found in NHPs.98 Despite asymptomatic infections in humans, RESTV is highly lethal to both humanized mice and NHPs, which are at potential risk of introducing mutations and causing the emergence of the human-pathogenic RESTV.77,101,102 As in cases of EBOV and SUDV infection, RESTV infection in ferrets was associated with similar signs of disease, including common signs of disease and abnormal hematological parameters. alterations in plasma biochemistry markers, viremia, viral shedding, and histopathological changes in multiple organs.103 In comparison, TAFV does not cause lethal infection in ferrets.104 Additionally, infection with MARV or ravn virus (RAVV) did not cause obvious signs in adult or naive ferrets.105,106 The above results demonstrated that ferrets are a naturally susceptible animal model for filovirus infection and recapitulated some disease parameters in humans.

Nonhuman primates

NHPs are considered the gold standard models for multiple pathogens due to their similar physiological characteristics and immune regulation. Preclinical rhesus monkeys and cynomolgus macaques are the most frequently used models of EBOV infection. In addition, African green monkeys, marmoset monkeys and baboons were included.

Rhesus monkeys

Rhesus monkeys (RMs) can precisely imitate the clinical features of human EVD, and are characterized by hemophagocytic and lymphohistiocytosis/macrophage activation syndrome.64,107 After intramuscularly injecting 103 PFU of EBOV, the RMs were febrile, which typically started at 2–4 dpi, peaked at 41 °C, and then drcreased sharply before death. Additionally, infected RMs exhibited anorexia, dehydration and decreased activity and subsequently lost more than 10% of their initial weight. Skin rashes were noted in all RMs at 4–7 dpi. Most animals succumbed to EBOV infection at 5–9 dpi.83,108 In some cases, diarrhea, bleeding from nose puncture points, gums, the rectum, and the vagina were observed in infected animals.83,108 Persistent intraocular Ebola virus RNA was associated with severe uveitis in a convalescent rhesus monkey.109 Blood analysis of infected animals revealed significant reductions in hemoglobin and hematocrit, together with a decrease in C-reactive protein (CRP) and increases in fibrinolytic degradation products, plasminogen activator inhibitor-1, and tissue type plasminogen source activators. Additionally, increased leukocyte counts, decreased platelet counts, lymphocyte counts, CD8+ T-cell counts and natural killer (NK) cell counts and extensive bystander cell apoptosis in peripheral blood monocytes and lymphoid tissues were observed.66,110–112 In the late stage of EVD, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), gamma-glutamyltransferase (GGT), serum creatinine (SCre) and blood urea nitrogen (BUN) concentrations increased, while the total serum protein concentration decreased.111,113 In addition, increased serum concentrations of proinflammatory cytokines and chemokines were detected.83,114 During necropsy, lymph node enlargement accompanied by congestion, bleeding and edema was noted. The mesenteric lymphatic tissue was congested with erythema, and duodenal bleeding was observed. The liver was enlarged and fragile, with a grid shape and rounded edges. Multifocal or concomitant bleeding was observed in the bladder. Bleeding, congestion, and fibrin deposition were found in the liver, kidneys, and spleen.115 SUDV- or BDBV-infected RMs exhibit histopathological manifestations similar to those observed in EBOV infection.116 The disease course in patients with SUDV infection was slightly later than that in patients with EBOV infection. When infected with SUDV at a dose of 103 PFU, the RMs succumbed to the disease at 7–10 dpi, with an average of 8.3 ± 1.3 days;116 in some cases, the disease duration was 11–15 days or even 17 days.117 An equal dose of BDBV caused 40% of the RMs to die at 13–19 dpi. A large number of virions were detected in the liver, lung, and spleen of EBOV-infected RMs, whereas in SUDV-infected RMs, few virions were detected in only the liver.118,119 After inoculation with MARV-Angola via IM injection at a dose of 103 PFU, RMs developed fever, lymphocytopenia, leukocytosis, anorexia and rash at approximately one week, and a few groups of individuals developed thrombocytopenia at 7 dpi.120,121 All animals succumbed to the disease at 7–8 dpi. Liver damage and elevated alanine transaminase (ALT), aspartate transaminase (AST), total bilirubin, and gamma-glutamyl transpeptidase (GGT) levels were observed. Increased D-dimer concentrations and decreased C-protein activity indicate coagulation dysfunction. Viremia was detected at 3 dpi and peaked at 6 dpi. MARV was highly expressed in the spleen and liver, as well as monocytes, macrophages, and fibroblasts from other organs. Pathology revealed reticular liver and liver discoloration, hepatocyte degeneration, and necrosis.

Cynomolgus macaque

Cynomolgus macaque (CM) is another NHP model that accurately recapitulates the hallmarks of filovirus infection in humans.122,123 Compared with RMs and African green monkeys (AGMs), CMs were more susceptible to EBOV and SUDV and presented shorter survival times, earlier onset of viremia and greater viral loads.116,117 Host transcriptional characteristics are correlated with clinical signs and corresponding organ damage, particularly in severe EVD patients.124,125 The distinct transcriptional responses to virus infection in NHPs may explain the differences in disease manifestations and viral replication among primates. The significant upregulation of IRF1, BST-1/2, TLR4, and BCL6, which play roles in limiting virus spread, resulted in a delayed disease course in RMs. In challenged CMs, the significant downregulation of genes, including CD3G, CD3E, ZAP70, CD8B, and IL7R, which are indicators of T-cell loss, and CCNY, CHD9, SHPRH, and TPI1, which play roles in cell division and nucleic acid metabolism, indicated more severe cell injury and stress, which predict low-level neutralizing antibody responses and T-cell-mediated antiviral responses.126,127 In a study investigating mucosal exposure to EBOV in CMs, IN-exposed CM models were found to be uniformly lethal and correlated with significantly delayed times to death compared to exposure via the IM route.128,129 The prolonged time from challenge to death in IN-exposed animals accurately reflects the time frame in humans.128 The clinical manifestations and gross pathological features of the infected animals were similar between these two exposure routes and included weight loss; increased rectal temperature, GGT, and BUN; and decreased serum ALB and RBC counts, except for less dramatic and delayed increases in ALP and ALT and more variable viremia in the IN group. Gastrointestinal (GI) tract pathology, which recapitulates gastrointestinal symptoms observed in humans, was more frequently observed in the IN-exposed group than in the control group.128 The differences in disease course between the two groups may be due to the lower percentage of permissible initial target cells in the upper respiratory tract than in muscle tissue.129 Low doses of EBOV-Kikwit or Mayinga via the IM or aerosol route cause severe clinical signs and uniform lethality in CMs.130,131 However, except for low-level virus replication, no clinical manifestations of EVD were observed in macaques infected with EBOV-Makona at a dose of 10 PFU via the oral or conjunctival route. A high dose of EBOV-Makona was required for the oral or conjunctival route to produce a lethal disease in CMs.132 Oral challenge of CMs with EBOV Kikwit resulted in an overall mortality rate of 50%. Animals challenged with a target dose of 102 PFU or 104 PFU of the virus via the conjunctival route showed 40% and 100% mortality, respectively.133 Infected animals developed clinical signs, including weight loss, fever, and hypothermia. In addition, persistent viral loads in the eye were observed in NHPs challenged via the conjunctival route. The above results paved the way for research into the transmission of EBOV disease, including early mucosal infections and the establishment of persistent viral infections from NHPs. In addition to the exposure route, strain-dependent clinical courses were also investigated in CMs.134,135 The time from exposure to death was 2 days later in the EBOV-Makona-infected cynomolgus macaques than in the EBOV-Mayinga-infected animals. Compared to the systemic rash observed in EBOV-Mayinga-infected animals, the rash observed in EBOV-Makona-infected animals was restricted to the arms, legs, chest and face. A decrease in liver enzyme levels and a greater increase in IFN-γ levels were detected in the EBOV-infected group.134 After exposure to the SUDV strain Gulu, CMs succumbed to the disease at 7–8 dpi, with detectable viral RNA and infectious particles.136 Common manifestations as well as hallmark symptoms, such as rash, vomiting, diarrhea, hemorrhage, gastrointestinal ulceration and multiple-organ failure, were observed.137 In humans, high levels of proinflammatory cytokines and chemokines are observed during acute SUDV infection and are correlated with disease severity.138,139 Accordingly, upregulated expression of IP-10, IL-6, MCP-1, MIP-α, and MIP-β was detected in SUDV-infected CMs from patients with middle- and late-stage disease.116,136 Furthermore, increased ALT, AST, ALP, GGT, BUN, and CRE levels were indicative of liver and kidney injury. The level of activated platelet-produced sCD40L could reflect the repair of damaged endothelial cells by platelets.140 The insertion of an extra uridine residue at the glycoprotein (GP) editing site during the passage process results in a mutant virus with an 8U residue. Different clinical signs were observed in cynomolgus macaques challenged with 7 U or 8 U of EBOV/SUDV.141,142 The “7U” virus produced secreted nonstructural GP (sGP), which appears to play a role in immune escape, whereas the “8U” virus produced GP. Decreased sCD40L levels were observed in severe patients, while high levels of sCD40L were observed in survivors. An increase in GP was detected, which was consistent with the increase in viral RNA and infectious particles in exposed animals that succumbed to disease.143 Therefore, sCD40L and sGP could be novel biomarkers for characterizing EBOV-challenged models. The mortality rate of BDBV was 66–75% in cynomolgus macaques.144 Macaques challenged with BDBV via the IM route succumbed to the disease at 10–11 dpi, which was longer than that observed in EBOV-infected macaques. Clinical signs included maculopapular rash; increased PT, aPTT, ALT, ALP, and BUN; and decreased ALB. RESTV naturally infects cynomolgus macaques and caused an outbreak in the Philippines in 1996. Infected macaques developed clinical signs, including fever, weight loss, and abrupt anorexia at 4–5 dpi, followed by viremias at 5–6 dpi. The period from exposure to death was 8–14 days.145 Moreover, the biochemical parameters of RESTV-infected macaques were similar to those of macaques infected with EBOV or SUDV.146,147 In addition, histopathological analysis revealed injuries in the spleen, liver, and kidney.148 Taï Forest virus caused 60% lethality in NHPs.149 After TAFV infection, cynomolgus macaques develop fever, reduced responsiveness, weight loss, anorexia, and viremia and reach the euthanasia criteria at 10–12 dpi. After exposure to MARV-Angola, cynomolgus macaques exhibited typical clinical signs of MVD and succumbed to the disease at 8–9 dpi. Infectious viruses and viral RNA were first detected at 3 dpi and increased rapidly until euthanasia. There were significant increases in ALT, AST, BUN, and creatine (CRE) levels.150 Additionally, decreased lymphocyte and platelet counts and prolonged PTT were also observed in exposed macaques.143

African green monkeys

In African green monkeys, EBOV initially infects monocytes and macrophages and subsequently spreads to hepatocytes, adrenal cortical cells, fibroblasts, and endothelial cells.151 Infected monkeys had depleted B-cell follicles and spleen lymphoid cells and died of the disease at 6–8 dpi. Autopsy revealed impaired microcirculation due to fibrin clumps and thrombi deposits in the organs and necrosis of the liver, spleen, and kidneys. After peritoneal infection with 104 LD50 of EBOV, all African green monkeys died at 6 dpi with diarrhea and intermittent black stool, similar to what was observed in RMs. Infectious viruses were detected in the blood, heart, lungs, liver, spleen, adrenal glands, kidneys, mesenteric lymph nodes, and urine.117 Compared to cynomolgus macaques, African green monkeys are less sensitive to EBOV and do not produce the typical skin rash, which limits their application as an animal model for viral infection.

Other NHPs

When inoculated with 10 or 103 PFU of EBOV via the IM route, marmoset monkeys developed severe systemic diseases similar to those observed in patients.152 Marmosets showed symptoms of anorexia and weight loss at 3 dpi, followed by depression, decreased stool, weight loss, and death at 4–5 dpi. Blood analysis revealed increased ALT, ALP, and GGT levels; decreased platelet counts; and increased neutrophil counts. Histopathological results revealed disseminated intravascular coagulation (DIC) and multifocal to concurrent hepatic necrosis. Like African green monkeys, marmosets lack the typical signs of EBOV infection.153

Baboons infected with EBOV presented abnormal blood parameters, increased hepatic vascular permeability, and impaired hepatic cell function.151 Most baboons suffer bleeding and vomiting, accompanied by bleeding from the rectum, vagina, skin, and mucous membranes.154 DIC appeared in infected baboons, with rapid hypercoagulation in the early stage of infection, peaking at 4 dpi and then decreasing to hypocoagulation. Before death, the lymphocyte and platelet counts decreased to 15.2% and 67%, respectively. Pathological examination of organs in the advanced stages of infection revealed numerous hemorrhagic sites of varying sizes in the liver and spleen, but no fibrin or thrombin in the vascular lumen and no extravascular deposition of fibrin. Ignatiev et al. infected three baboons with the guinea pig-adapted strain EBOV at a dose of 102 PFU via the SC route.155 Viremia was detected at 3 dpi, but clinical symptoms were not observed until 6 dpi. The animals succumbed to the disease at 10–11 dpi. These animals experienced a period of initial hypercoagulability, followed by hypocoagulability at 7 dpi and recovery at 9 dpi.

Compared to other NHP species, cynomolgus and rhesus macaques are the best animal models available due to their susceptibility to EBOV infections. In contrast, African green monkeys and baboons infected with EBOV exhibit several typical disease features, such as abnormal coagulation.151,155 In contrast to those in small animal models in which infection was established solely by IP injection, the routes of infection in NHPs were more consistent with those in humans.

Surrogate models

Surrogate models are generally developed using viruses from the same family or genus with lower biosafety levels or model viruses. A surrogate model of EVD was established based on replication-competent recombinant vesicular stomatitis virus (rVSV) pseudotyped with the envelope glycoproteins (GPs) EBOV and MARV.156,157 In 3-day-old C57BL/6 mice, infection with 103 TCID50 of rVSVΔG-EBOV-GP via the SC route caused transient viremia and neurological symptoms, such as tremors, widened stance, ataxia, seizures and paresis, as well as high viral titers in the eyes and brain. These neonatal mice died at 15 dpi.156 Severe retinitis was caused by infection of the inner layers of the retina by recombinant virus. When rVSVΔG-EBOV-GP was used to infect neurons in the granular and Purkinje layers of the cerebellum, it caused increasing foci of neurodegeneration and death. In addition, after treatment with the human polyclonal anti-EBOV-GP antibody SAB-139, decreased viral titers, microglial loss, cellular infiltration, and inflammatory responses in the central nervous system and increased survival rates were observed in infected mice.158 Hamsters intraperitoneally inoculated with rVSV/EBOV or rVSV/MARV showed disease signs and died within 4 dpi. Recombinant viruses were detected in multiple organs, including the liver, spleen, kidney, and lungs, of infected hamsters, indicating acute and systemic infection and resulting in fatal outcomes. The therapeutic effects of EBOV NAbs were validated in this model.158,159

Medical countermeasures for filovirus diseases

Due to the high case fatality rate of filovirus diseases, preventive and therapeutic approaches have been widely investigated in preclinical trials. Among them, multiple vaccines and therapies for EVD have entered clinical trials, several of which have been approved while no medical responses have been approved for MVD. Here, we focus on approved or cutting-edge approaches for the prevention and control of filovirus diseases (Table 3).Table 3 Representative medical countermeasures for filoviruses

Classification	Manufacturer	Name	Platform/Strategy	Stage	Efficacy/Benefic	References	
Vaccines	Merck	Ervebo	Encoding the GP of EBOV based on VSV	Licensed	100% overall protective efficacy	166	
CanSinoBIO	Ad5-MakGP	Encoding the GP of EBOV based on Ad5	Licensed	Tolerate and immunogenic	169–171	
NIAID and Okairos	cAd3-EBO	Encoding the GPs of EBOV and SUDV based on ChAd3	Licensed	Tolerate and immunogenic	174	
Bavarian Nordic	MVA-BN Filo	Expressing GPs of filovirus based on MVA vector	Licensed	Long-lasting immune response	176	
Russia	rVSV +Ad5-EBOV	Prime-boost strategy of two viral vector vaccines	Licensed	Quickly awaken of immune memory and a robust immune response	177	
Antibodies	Mapp Biopharmaceutical	ZMapp	Antibody cocktail contains of three different monoclonal antibodies	Licensed	Tolerated and showed promise efficacy	191,193	
Regeneron Pharmaceuticals	REGN-EB3 (Inmazeb)	Cocktail of three fully human monoclonal antibodies	Licensed	Reduce fatality rate in clinical cases	192,195	
Ridgeback Biotherapeutics	mAb114	Monoclonal antibody isolated from a survivor	Licensed	Binds to conserved region and was safe in clinical	197	
University of T exas Medical Branch	MR191-N	Isolated from MARV convalescent patient	Preclinical	80%-100% protective efficacy in NHPs	201,202	
Small molecular drugs	Biocryst	Galidesivir (BCX4430)	Adenosine analog	Clinical	83%-100% protective efficacy in NHPs	203	
Toyama chemical	Favipiravir (T-705)	RNA polymerase inhibitor	Clinical	Protect against EBOV and MARV in animal models	204,205	
Gilead technology	Remdesivir (GS-5734)	Adenosine analog	Clinical	Showed protective efficacy in nurses and infants with EVD	206–208	
Oligonucleotides	University of Washington	AVI-6003	Oligonucleotide analogs that inhibit mRNA	Clinical	Protective in NHPs and tolerate in humans	209–211,896	
siRNAs	Tekmira Pharmaceuticals	NP-718 m	Interferes with mRNA translation	Preclinical	Protective in guinea pigs and NHPs	212,213	
siRNAs small interfering RNA, GP Glycoprotein, EBOV Ebola virus, VSV Vesicular stomatitis virus, Ad5 Adenovirus type 5, SUDV Sudan virus, ChAd3 Chimpanzee adenovirus type 3, MVA Modified vaccinia virus Ankara, MARV Marburg virus, NHPs Nonhuman primates, EVD Ebola viral disease

Preventive vaccines for filovirus diseases

Three viral vector-based vaccines have been approved for prevention of EVD. Ervebo (V920) was developed by Merck and is also known as rVSV-ZEBOV. It is a recombinant VSV-based EBOV vaccine candidate in which the VSV G gene was replaced with that of Zaire Ebola virus (ZEBOV) to obtain a recombinant virus. According to preclinical studies, a single dose vaccination with rVSV-ZEBOV was safe, high immunogenic and fully protected both mice and NHPs against lethal challenge with EBOV.160,161 Innate antiviral responses induced by vaccination are responsible for rapid protection.162 Subsequently, the safety, immunogenicity and protective efficacy of rVSVΔG-ZEBOV have been investigated in several clinical trials. In human recipients, EBOV-specific antibodies appeared at 14 dpv, peaked at 28 dpv, and were maintained for more than 2 years.163–165 In a large-scale Phase III Guinea ring vaccination trial, substantial protection from EVD was achieved in rVSV-ZEBOV recipients. A single dose of 2 × 107 PFU of rVSV-ZEBOV was tolerated and immunogenic in volunteers, corresponding to an overall protective efficacy of 100%.166 In 2019, rVSV-ZEBOV was approved by the European Medicines Agency (EMA) and has been licensed for emergency use by the FDA.167 In 2023, the expanded indications of Ervebo have been approved by the FDA. Now, Ervebo is applicable for individuals older than 12 months.

Directed against the epidemic strain in 2013–2016, Ad5-MakGP, which contains a recombinant Adenovirus type 5 (Ad5) expressing the GP of EBOV Makona strain, was developed by CanSinoBIO. In NHPs, a single dose of Ad5-MakGP provided sterile immunity and protected all animals from lethal challenge.168 In Phase I clinical trial, Ad5-MakGP was tolerated and immunogenic. To some extent, humoral and cellular immune responses are blunted by the presence of anti-vector immunity.169,170 Boosting immunization with Ad5-MakGP at 6 months after the primary immunization resulted in robust immune memory and humoral immune responses.171 Notably, tolerability, immunogenicity and immune response persistence varied among different races.172 For example, the duration of the immune response in African participants was shorter than that in Chinese participants. This phenomenon has also been observed in clinical trials of rVSV-ZEBOV.164 These results highlight the need to include ethnicity-related factors in clinical trials.

Based on chimpanzee adenovirus type 3 (ChAd3), a bivalent vaccine was constructed that encodes the GPs of EBOV and SUDV, termed cAd3-EBO. In parallel, compared with chimeric adenovirus type 63 (ChAd63) and (MVA) vaccine, cAd3-EBO induced superior immune responses and conferred uniform protection against EBOV challenge in macaques.173 cAd3-EBO entered Phase I clinical trial and was proven to be safe and immunogenic.174 A ChAd3-based monovalent vaccine encoding the GP of ZEBOV was also constructed, namely ChAd3-EBO-Z. In a Phase I clinical trial, after a single-dose vaccination, antibody titer induced by ChAd3-EBO-Z was slightly lower than those induced by rVSV-ZEBOV.175 MVA-vectored vaccine candidates expressing ZEBOV GP, SUDV GP and MARV-Musoke GP, termed MVA-BN-Filo, which confer long-lasting protection, were also investigated.176

Several heterologous prime-boost strategies that induce potent immune responses have also been developed. Based on the positive results obtained from rVSV-ZEBOV and Ad5-EBOV, a heterologous prime-boost strategy was developed based on these two vaccine platforms. In Phase I/II clinical trials, the heterologous prime-boosting vaccination rVSV-ZEBOV+Ad5-EBOV quickly induced the awaking of immune memory and a robust immune response.177 Moreover, this strategy alleviated the impact of anti-vector immunity. In December 2015, Russia approved the registration of these approaches. There have also been attempts to boost DNA vaccines with Ad5-EBOV. In cynomolgus macaques, vigorous cellular/humoral immunity and full cross-protection were achieved in vaccinated animals.144,178 Additionally, boosting cAd3-EBO with an MVA-vectored vaccine conferred long-lasting protection.173 When ChAd3-EBO-Z was boosted with MVA-EBO-Z, the levels of virus-specific antibodies and CD8+ T cells increased by 12 and 5 times, respectively. Virus-specific antibody responses in participants primed with ChAd3-EBO-Z remained positive at 6 months post immunization but were significantly lower than those in participants who received the MVA-EBO-Z booster.175 In addition, a prime-boost strategy involving ChAd3-EBO-Z and MVA-BN-Filo was shown to trigger immune responses that were maintained for over 12 months.179,180

Some studies have attempted to elucidate the correlations of immune protection of EBOV vaccines. Depletion of CD8+ cells in vivo abrogated the protection against the lethal challenge of EBOV, while passive antibody transfer from vaccinated animals to naive macaques failed to confer protection.181 These results indicated that CD8+ T cells play a major role in vaccine-induced immune protection against EBOV infection, but antibodies are not sufficient to confer protection. Overall, acute protection was strongly associated with antibody responses, while long-term protection required the generation of both effector and memory CD8+ T-cell responses and cytokines.

In a similar manner, vaccines for MVD were developed mainly based on VSV, cAd3, MVA and DNA platforms, which have been proven to be immunogenic in NHPs and are under investigation in clinical trials.182 DNA vaccines for filoviruses have shown good safety in NHPs and potent immune responses. However, in clinical trials, the immunogenicity and benefits of these vaccines are limited.183,184 DNA vaccines expressing MARV-Musoke GP and MARV-Angola GP were tested in cynomolgus monkeys. Although IgG responses were generated and protection was conferred, clinical symptoms were observed in all challenged animals.185 In response, the DNA-Adv prime boost strategy optimized the protective efficacy.

Multivalent vaccines for panfiloviruses are highly important for multiple pathogens overlap areas. rVSV vectored vaccines expressing different foreign proteins could be inoculated simultaneously without interference from each other.186 Consequently, VSV vectored vaccines were applied as multivalent vaccines for filoviruses. Tetravalent vaccines against SUDV, ZEBOV, Cote d’Ivoire Ebola virus (CIEBOV) and MARV have been developed.149 In cynomolgus monkeys, protection against the above four filoviruses was conferred. Similarly, tetravalent VSV-vectored vaccines expressing glycoproteins from LASV, EBOV, MARV and SUDV achieved 100% protection against hemorrhagic fever after two-dose vaccination.187

Therapies for filovirus diseases

During the outbreak of EBOV in West Africa, several potential therapies, including antibodies, small-interfering RNAs, convalescent plasma or whole blood, and small-molecule inhibitors such as favipiravir, were tested in clinical trials.188 Four investigational drugs, the monoclonal-antibody cocktails ZMapp and REGN-EB3, a single monoclonal antibody (mAb), MAb114, and remdesivir, a small-molecule antiviral drug, were given to hundreds of patients during the Ebola outbreak in the Democratic Republic of the Congo under the Monitored Emergency Use of Unregistered and Investigational Interventions (MEURI) framework and in a randomized clinical trial.189,190

There are two FDA-approved antibody therapies for EVD. ZMapp was optimized based on two previous antibody mixtures, one from MB-003 (human or human-mouse chimeric monoclonal antibodies c13C6, h13F6 and c6D8) and two from ZMab (mouse monoclonal antibodies m1H3, m2G4 and m4G7), which have been shown to reverse Ebola virus disease in rhesus macaques after challenge.191 Likewise, the ZMapp antibody cocktail contains three GP-targeting antibodies, two of which are GP-specific (c2G4 and c4G7) and one of which is a GP/sGP cross-reactive antibody (c13C6).192 During the 2013–2016 West African EVD pandemic, the WHO considered the use of investigational products in an effort to increase access to effective therapies for EBOV infections.189 Accordingly, after receiving consent from the appropriate authorities, ZMapp was first given to two American missionaries in Liberia in 2014. The missionaries had contracted EBOV infection and had fallen quite unwell while providing patient care. Both patients survived EVD, and decreased viremia was observed.193 In a randomized, controlled trial during the later stages (2015) of the outbreak, a high survival rate (78%) was observed in people treated with ZMapp.194

REGN-EB3 (Inmazeb) is a cocktail of three fully human monoclonal antibodies, REGN3470 (atoltivimab), REGN3471 (odesivimab), and REGN3479 (maftivimab), which bind to different glycoprotein regions.192,195 These three antibodies bind to nonoverlapping epitopes, including a potentially new protective epitope. REGN3471 binds nearly perpendicular to the viral surface, close to the GP structure’s head, and may even be exposed to the glycan cap. REGN3479 binds to a region between the promoters of GP1/GP2 at the trimer base, and REGN3470 binds to a region outside the glycan cap. REGN3479 is a neutralizing antibody that prevents viral entry. REGN3471 is a nonneutralizing antibody that activates antibody-dependent effector actions, which attract immune cells to the virus. REGN3470 combines both neutralization and effector functions. mAb114 (Ebanga, Ansuvimab) is an FDA-approved single mAb isolated from memory B cells of two patients who survived the EBOV outbreak in Kikwit in 1995.196,197 Recently, mAb114 has been the only protective antibody used as monotherapy in macaques. mAb114 combines both neutralization and effector functions. For optimal results, 50 mg/kg of each component of REGN-EB3 was delivered a single IV infusion198. During the 2018 Ebola epidemic, an umbrella trial was conducted in the Democratic Republic of Congo, and a polymerase inhibitor (remdesivir), two mAb combinations (REGN-EB3 and ZMapp), and a single human mAb (mAb114), were rolled out under the Monitoring Emergency Use of Unregistered Interventions (MEURI) protocol.199 The results showed that 66% of the 154 patients who received REGN-EB3 were still alive at 28 days.199,200 In addition, 65% of patients who received mAb114 survived. ZMapp and remdesivir had case fatality rates of 85% in the patient group with a high viral load, while REGN-EB3 and mAb114 had CFRs of 64% and 70%, respectively. Overall survival increased in all treatment groups when the viral load was low, with CFRs of 25%, 29%, 10%, and 11%, for ZMapp, rRemdesivir, REGN-EB3, and mAb114, respectively.

For MARV, a panel of neutralizing mAbs have been isolated from B cells of a MARV convalescent patient. These mAbs are thought inhibit the binding of the GP1 RBD to NPC1 receptors.201 Several mAbs have been demonstrated to be effective in mice and rhesus monkeys; these mAbs bind to the same major antigenic site on the MARV GP and some have been shown to cross-react with the RAVV GP. Of which therapeutic given of MR191-N conferred a 100% protective rate. In another study, MR191-N showed protective efficacy of 80 and 100%, against MARV and RAVV, respectively.202 Overall, mAb MR191-N is a promising candidate treatment for MARV.

Several small molecule drugs for treating EBOV and MARV have been tested. Galidesivir (BCX4430) is a potential broad-spectrum antiviral drug developed by Biocryst. It is a synthetic adenosine analog that inhibits viral RNA polymerase through a nonspecific RNA strand terminator, which blocks the replication of the RNA genome and inhibits virus propagation.203 BCX 4430 inhibited the replication of MARV in cells. In addition, in MARV-challenged cynomolgus monkeys, treatment with BCX 4430 resulted in a survival rate of 83–100%. No obvious symptoms of viral infection were found in the treated animals, and laboratory indices improved, while all animals in the control group died.203 The Phase 1 clinical study of this drug was finished in 2016, and the results have not yet been published. Favipiravir (T-705) was developed by Toyama Chemical in Japan and is another RNA polymerase inhibitor. This drug has broad-spectrum antiviral activity against a variety of RNA viruses, and has been approved for the treatment of influenza in Japan. In previous studies, T-705 was shown to be effective in protecting against EBOV in a mouse model.204 It was demonstrated that when T-705 was intravenously administered after MARV challenge, a survival rate of 83% was achieved in cynomolgus monkeys. Oral administration showed no protective efficacy.205 Remdesivir (GS-5734), developed by Gilead Technology, is a prodrug for adenosine analogs. This drug has been successfully used to treat EVD in NHPs and has been used in nurses and infants with EVD. It has been proven to provide protective effects.206,207 In rhesus macaques, GS-5734 protected animals in a dose-dependent manner, with a protective effect of 50–83%.208 Positively charged phosphodiester morpholino oligomers (PMOs) are a class of oligonucleotide analogs that inhibit mRNA through steric hindrance of translation, thereby inhibiting viral replication. Functionally, the ribobase is replaced by a structurally similar morpholino, and methylene phosphate diester bonds bind to mRNA, which in turn prevents mRNA translation, while the addition of piperazine residues to PMOs provides a positive charge that can enhance the interaction with negatively charged mRNA. Combinatorial PMO drugs, namely AVI-6003, which consists AVI-7287 and AVI-7288, which target the VP24 and NP mRNAs of MARV, respectively, were prepared. In NHPs, AVI-6003 provided complete protection. However, a subsequent study showed that ACI-7287 treatment did not improve survival or reduce the viral titer, although it inhibited the synthesis of NPs.209,210 In clinical trials, AVI-6003 was well tolerated.211 Based on the area under the curve of the NHPs and 24 h drug duration, the human protective dose was 9.6 mg/kg, while the protective dose supported by Monte Carlo simulation was 11 mg/kg.210

Small interfering RNAs (siRNAs) are emerging antiviral agents. siRNA interferes with mRNA translation by spatially blocking or triggering DNA/RNA double strand breaks. MARV NP targeting siRNA (NP-718 m) was identified. When encapsulated with lipid nanoparticles, NP-718 m inhibits MARV replication in vitro, enters cells through fusion with the endomembrane, and shows extensive protective effects on three Marburg virus strains (Angola/Musoke/RAVV) in guinea pigs.212 In rhesus monkeys, NP718-LNP protected all treated animals against the lethal challenge of MARV-Angola.213

Lassa fever

Etiology, epidemiology, and pathogenesis of Lassa virus

Lassa virus (LASV) is the causative agent of Lassa fever (LF) and it is a human pathogen of the Arenaviridae family that is transmitted to humans by the rodent reservoir Mastomys natalensis.214 LASV is an enveloped virion that contains two single-stranded RNA segments and each segment encodes two proteins.215 The NP encapsulates the viral genome segments, which are associated with the transcription of viral mRNAs and replication of genome segments for incorporation into progeny virions.216,217 As a surface protein, the glycoprotein complex (GPC) mediates the attachment and entry of virions.218 Specifically, after receptor-ligand recognition, LASV virions are internalized via endocytosis. GPC undergoes a conformational shift responds under the regulation of the acidic endosomal environment, causing its binding to the endosomal receptor lysosomal-associated membrane protein 1 (LAMP1).219,220 Subsequently, GPC undergoes additional conformational changes that mediate virus-endosomal membrane fusion and enable the release of LASV genome segments into the cytosol. The large (L) protein is an RNA polymerase that is involved in transcription, viral replication, and cap-snatching.221. The Zinc-binding (Z) protein serves as the matrix protein and is involved in viral assembly and budding. It is responsible for suppressing both viral and host cell translation and thus negatively regulates viral replication and transcription.222

LASV originated in Nigeria, first described in 1969, and subsequently spread to other West African countries.223,224 After selection for immune escape and region-associated genetic divergence, mutations accumulate, resulting in the formation of 7 lineages. Three distinct lineages (Lineages I-III) are found in Nigeria and Lineage IV is present in Sierra Leone, Guinea and Liberia.225,226 More recently, Lineages V, VI and VII have emerged in Mali, Côte d’Ivoire, Nigeria, Benin and Togo.227 According to serological studies, over 500,000 LASV infections and 5,000 deaths occur annually in West Africa.228 Imported cases were also documented in nonendemic countries, such as Germany and the Netherlands.229,230

Using the functional cellular receptor, alpha-dystroglycan, LASV effectively targeted macrophages, dendritic cells, and endothelial cells as focal points.231 LASV antagonizes interferons and subdues the immune system thus preventing their secretion of proinflammatory cytokines. Double-stranded RNAs targeting the exonuclease LASV inhibit IFN responses. This is achieved by assimilation of PAMPs, which helps LASV circumvent the host immune response. Immunosuppression of the host’s innate IFN response is accomplished by halting of interferon regulatory factor-3 (IRF-3) translocation.232 Subsequently, LASV can infect most human tissues, resulting in multisystemic malfunctions. The blood vessels are the most afflicted tissues and the LASV replicates in the cells of the reticuloendothelial system, culminating in capillary injury. Bleeding might be observed in the following organs: hepatocytes, intestines, myocardium, lungs and the brain.233 Unregulated cytokine expression could be another possible mechanism of LF pathogenesis. In the clinic, failure of multiple organs and shock are accompanied by elevated concentrations of proinflammatory cytokines, IFN- γ, and TNF- α. However, no increase in the levels of either cytokine was detected was observed in another study of lethal LF patients, indicating that IFN- γ and TNF- α concentrations are either increased only in a subset of infected individuals or within a brief duration that could entail continuous testing for detection.234 The malfunction of infected DCs culminates in the failure in the secretion of proinflammatory cytokine secretion, the upregulation of costimulatory molecules including CD40, CD80, and CD86, and the abysmal induction of T-cells growth.235,236 In another study, human DCs infected with Mopeia virus exhibited stronger induction of CD4+ and CD8+ T-cell responses than did patients infected with LASV.237 The repression of immunological reactions orchestrated by LASV contamination revealed ex vivo is similar in tandem with the outcomes of medical examination, indicating that the lethality result of LF is associated with reduced concentrations or a paucity of interleukin (IL) 8 and IFN inducible protein 10 (IP-10) in circulation.234

Lassa fever exhibits a variable clinical course. The incubation period for LF was 6–21 days. LF can progress slowly, and symptoms include general discomfort, fever, sore throat, cough, nausea, vomiting, diarrhea, myalgia, and chest pain.3,4 Missed continued/remittent fever, inflammation, and exudation of the eyes and conjunctiva are common symptoms. The vast majority of human infections are mild or asymptomatic, while in some cases multisystem diseases occur. The disease is particularly severe during pregnancy and usually leads to abortion. In severe cases, hypotension, shock, pleural effusion, hemorrhage, epileptic seizures, encephalopathy, facial disease, and neck edema were observed, accompanied by proteinuria and blood concentration. Temporary alopecia and dyskinesia may occur during the recovery period. A small number of patients can develop eighth cranial nerve deafness, and only half of patients can recover some function after 1–3 months. The overall case fatality rate of LF is 1–3%, and the hospitalization case fatality rate is close to 15%. Critical patients usually die within 14 days after disease onset.

Animal models for Lassa fever

With respect to preclinical animal models of LF, wild-type mice and hamsters were insusceptible to LASV; thus, further approaches such as virus adaptation and immunodeficiency are needed. In contrast, inbred guinea pigs and NHPs are natural susceptibility models for LASV and have been extensively investigated. Additionally, surrogate models based on associated viruses have been developed. In this section, the aforementioned animal models for LF are discussed (Table 4).Table 4 Animal models of Lassa fever

Species	Animal model	Strains	Dose	Route	Lethality	Signs of Disease	Strengths/Weaknesses	References	
Rodents	Neonatal mice	–	100 TCID50	IP	No	No	Natural host/No clinical signs or lesions	238	
CBA mouse	Josiah	103 PFU	IC	70–100%	Weight loss, immobility, scruffy fur, seizures, severe decubitus paralysis	Applied in drug evaluation/Immunodeficient and inapplicable to immune correlates	239	
HHD mouse	Ba366	106 PFU	IV	22%	Ruffled fur, lethargy, high level viremia, elevated AST level, severe pneumonitis	Model for pathogenesis study/Immunodeficient and inapplicable to immune correlates	246	
STAT1−/− mouse	Josiah	103 PFU	IP	100%	Fever, weight loss, SNHL, viremia	Model for pathogenesis study/Barrier environment needed, MHC-related, age-associated, injection route-dependent pathogenicity, distinguishing characteristics of the human immune system, not applicable to live vaccine evaluation	241,242,245	
LF2384	105 PFU	80%	
LF2450	105 PFU	50%	
IFNAR−/− mouse	Josiah/AV

Ba366/Nig04-10

	103 PFU	IV	No	Weight loss, persistent viremia, ruffled fur, hypoactivity	240–243	
Chimeric IFNAR−/− B6 mouse	Ba366/Ba298

NNig04-10/Nig-CSF

	103 PFU	IP	100%	Weight loss, vascular leakage	242,244	
Inbreed Strain13 guinea pig	Josiah	104 TCID50	SC IP	>90%	Fever, weight loss, ruffled fur, hunched posture, pneumonia, pneumorrhagia	Obvious clinical symptoms, natural susceptibility/Distinguishing characteristics of the human immune system	238,251,–253,256,258	
Z-132	IP	100%	
Soromba-R	IP	0~57%	
Pinneo	IP	No	Mild to moderate disease	
NJ2015	104 PFU	SC	No	Fever, weight loss, conjunctivitis	
Outbreed Hartly guinea pig	Josiah	SC IP	30~67%	Fever, weight loss, hypothermia neutropenia, lymphopenia, thrombocytopenia	Accessibility, obvious clinical symptom/viral adaptation required and addition mutants acquired	
GPA-Josiah	103 TCID50	IP	100%	
LF2384	104 PFU	IP	100%	
Nonhuman primates	Squirrel monkey	Bah	106.8 TCID50	IM	25%	Anorexia, lassitude, depression, polydipsia	Small size and available NHP/Individuals heterogeneity	273	
Marmoset	Josiah	106 PFU	SC	100%	Fever, weight loss, viremia, depression, anorexia	Small size, lower caging and feeding costs/variable clinical course	271	
Rhesus monkey	Josiah	106.1 PFU	SC	50–60%	Cough, fever, weight loss, rash, hiccups, lethargy, aphagia, huddled posture, constipation, conjunctivitis, anorexia, decreased water intake, bleeding from the gums and nares	Accurately simulate clinical signs of human/ethical concerns, high cost, inaccessible	262,263,314	
Cynomolgus macaque	Josiah	104 PFU	IM	100%	Fever, weight loss, lethargy, anorexia, rashes, facial edema, hunched posture, ruffled fur, piloerection, bleeding from puncture sites, dehydration, epistaxis, acute respiratory syndrome, neurological signs, deafness	Simulate sever cases of human infection/Ethical concerns	253,264–270,289–292	
Z-132	104 PFU	IM	100%	
Soromba-R	104 TCID50	IM	66%	
Surrogate models	Inbreed Strain13 guinea pig	Pichinde virus	>3 PFU	SC	100%	Weight loss, ruffled fur, rapid breathing, hypoactivity, decreased appetite	Obvious clinical symptoms, natural susceptibility/difficult to obtain, potential difference between original strains	277,278	
Outbreed Hartly guinea pig	Pichinde virus/P18	100 PFU	IP	100%	274	
Outbred hamsters	Pirital virus	105 TCID50	IP	>50%	Moribund, hemorrhage, pneumonia	Models for studying the mechanism of hepatic injury/Potential differences between Pichinde virus and LASV	248	
LVG/Lak hamsters	Pichinde virus	500 PFU	SC	0–100%	Not mentioned	Accessibility/Neonatal or Immunosuppression needed to render lethal infections in adult animals, less susceptible to Pichinde virus compared with MHA/Lak hamsters	247	
MHA/Lak inbred hamsters,	35/3.5 × 104/3.5 × 106 PFU	IP	100%	Susceptible to lethal virus infection in both newborns and adult animals/Potential differences between Pichinde virus and LASV	
TCID50 median tissue culture infective dose, PFU plaque formation unit, IP intraperitoneal, IC intracranial, IV intravenous, SC subcutaneous, IM intramuscular, SNHL sensorineural hearing loss, NHP nonhuman primate, – not applicable

Mice

Mastomotic Nasts are the natural hosts of LASV. LASV causes chronic asymptomatic infection in Natal mastomies despite the high virus titers detected in multiple organs.238 Due to asymptomatic infection, its use in viral pathogenesis or as a vaccine and therapeutic agent is limited. This model may be useful for basic transmission studies. Similarly, infection with LASV was not lethal for immunocompetent adult mice. Alternatively, LASV can cause lethal disease in suckling mice, SCID mice, IFNAR−/− mice and STAT1−/− mice.58

CBA mice

Intracranial infection of inbred CBA mice with LASV-Josiah resulted in disease manifestation.239 Infected CBA mice presented with scruffy fur, seizures, weight loss, immobility, severe decubitus paralysis, and death. This route of inoculation allowed the onset of signs of disease between 5 and 7 dpi, with 70–100% lethality within 7–12 days.

Immunodeficient mice

LASV caused a nonlethal acute infection in 129 Sv IFNAR−/− mice, accompanied by persistent viremia.240–243 The infected mice lost weight and exhibited ruffled fur and hypoactivity by 11 dpi.241–243 The viral load was detected in multiple organs.240 Similar pathological changes and disease signs were found in these animals upon infection with a variety of LASV strains, including Josiah, AV, BA366, and Nig04–10.240,241 To establish a lethal model of LASV, chimeric IFNAR−/−B6 mice were established by irradiating and transplanting bone marrow progenitor cells from wild-type C57BL/6 mice into IFNAR−/− mice. These IFNAR−/−B6 chimeric mice succumbed to LASV infection within 10 days164,166 This model recapitulates the abnormal hematological indices observed in LF patients, including an elevated AST/ALT ratio, FAS and FAS-L.242,244 Depletion of CD8+ T cells in IFNAR−/−B6 mice significantly increased the postinfection survival rate to 87.5% and reduced the FAS and FAS-L concentrations, as well as vascular leakage in the liver and lung despite persistent viremia, which indicated that T cells play a role in the pathogenesis of LF.242 In contrast, IFNαβ/γR−/− 129 Sv mice did not develop clinical signs of disease upon LASV infection apart from minor and transient weight loss.243

STAT1−/−129Sv mice are highly susceptible to LASV, which progresses to lethal disease accompanied by typical clinical manifestations, such as sensorineural hearing loss (SNHL).241,245 Mice intraperitoneally infected with 104 PFUs of LASV-Josiah lost weight and died at 7 dpi.241 This model recapitulates the clinical outcome of patients infected with LASV-LF2384 and LASV-LF2350.245 Clinical signs of disease, disseminated viruses to multiple organs, prolonged viremia, and abnormal hematological indices and histologic results were observed after lethal infection with LASV-LF2384 in STAT1−/−129Sv mice. Notably, compared to that in IFNαβ/γR−/− mice, IFN signaling was not completely disrupted in STAT1−/− mice. Partial knockout of the STAT1 gene results in the expression of a truncated form of STAT1 that can still mediate minimal T-cell responses. Since T cells contribute to the pathogenesis of LF, differences in IFN signaling may explain why STAT1−/− mice are more susceptible to LASV than are IFN αβ/γR−/− mice.242 Notably, the STAT1−/− model is the only available small animal model of SNHL. The clinical isolates LASV/LF2384 and LASV/LF2350 from the 2012 Sierra Leone outbreak caused deafness in survivors.245 A total of 105 PFU of viral infection resulted in permanent hearing loss in all survivors. With the lower dose of LASV infection (104 PFU), hearing loss was observed in 20% of the survivors.

Humanized HHD mice

C57BL/6 mice expressing human/mouse chimeric HLA-A2.1 instead of the normal MHC class I gene product (humanized HHD mice) were established as a model for LASV infection.246 HHD mice were susceptible to LASV-BA366 infection, for which the fatality rate was approximately 22%. LASV infection leads to the rapid onset of disease, which can include ruffled fur, lethargy, and elevated serum AST concentrations. High viral titers were detected in the liver, lung, and spleen, whereas lower titers were detected in the kidney. Histological examination revealed severe pneumonia with signs of pleural effusion, interlobular septal thickening, collapse of the alveolar space, and infiltration of monocytes and macrophages. The liver contains monocytes and macrophages with altered cellular distribution, orientation, and shape. The spleen also exhibited destruction of both the white and red pulp areas. Depletion of CD4+ T cells, CD8+ T cells, or both, resulted in significant differences in disease severity in this model. After infection, the serum AST concentrations in HHD mice lacking CD4+ and CD8+ T cells remained normal, whereas the AST concentrations increased in HHD mice. In addition, depletion of CD4+ T cells or CD8+ T cells resulted in a partial increase in the AST concentration. In all the groups, similar cases of high-titer viraemia developed, indicating that T cells did not have a substantial effect on viraemia. C57BL/6 mice lacking only CD4+ T cells were able to clear the viral infection, whereas C57BL/6 mice lacking only CD8+ cells exhibited persistent viremia. These findings were confirmed in MHC-I−/− mice, which lack CD8+ T cells; despite high viremia, no clinical manifestations were observed post infection. Neither CD4+ nor CD8+ T-cell-depleted mice exhibited any significant histological changes in the lungs or spleen after infection or signs of disease, which underscores the role of T cells in LASV pathogenesis.

Overall, immunodeficient mice are susceptible to LASV infection but generally develop mild disease and survive infection. Chimeric IFNAR−/−B6 mice are susceptible to lethal LASV infection but require irradiation and transplantation of bone marrow progenitor cells from wild-type C57BL/6 mice. The findings from STAT1−/− mice recapitulated the pathogenic potency of different LASV isolates and some LF disease signs, including hearing loss.

Syrian hamsters

Syrian hamsters were insusceptible to LASV. Pichinde virus, another member of the Arenaviridae genus, was used to establish an infection model in hamsters. Pichinde virus infection caused LF-like disease in Syrian hamsters, and the lethality of the virus varied depending on the strain. Newborn LVG/Lak outbred hamsters, together with newborn and adult MHA/Lak inbred hamsters, were up to 100% lethal to Pichinde virus. Both models produced antibodies against Pichinde virus. The main target organs were the spleen, liver, and kidney.247 Pirital virus, a nonhuman pathogenic New World mammarenavirus isolated from western Venezuela, also causes LF-like disease in Syrian hamsters.248 Infected hamsters developed severe disease and died at approximately 7 dpi.248 Histopathology revealed interstitial pneumonia, multifocal hepatic necrosis, and reduced and necrotic splenic lymphoid tissue. A proportion of the hamsters exhibited oral hemorrhage and coagulopathy.248 Although these surrogate viruses effectively infect hamsters, the genetic differences between LASVs should be fully addressed.

Guinea pigs

The guinea pig model has been extensively used to study the pathogenesis of LF and to evaluate potential treatments and vaccine candidates for this disease.249 The inbred Strain 13 guinea pigs are naturally susceptible model of LASV, while outbred Hartley guinea pigs require viral adaptation in vivo to achieve uniform lethality. The lethality of different strains in guinea pigs infected with LASV varied. Clinical signs in Strain 13 guinea pigs infected with LASV-Josiah include fever, anorexia, weight loss, humping, fur crumpling, and altered mental status.250,251 SC inoculation of two or more PFU of LASV-Josiah in Strain 13 guinea pigs resulted in death, while Hartley guinea pigs were relatively resistant and had a mortality rate of 30–67% following infection. More rapid viraemia and higher viral titers were observed in strain 13 guinea pigs than in Hartley guinea pigs. Virus titration in guinea pigs revealed that the highest titers were extracted from the lung and spleen, followed by the pancreas, lymph nodes, adrenal glands, kidneys, salivary gland, liver, and heart. Histopathological findings indicated mild to moderate interstitial pneumonia, acute necrotizing nephritis, mild myocarditis, and mild hepatitis. Conjunctivitis and conjunctival edema with ocular discharge were also observed.172,174,175 Infected animals did not generate neutralizing antibodies.250 The concentrations of LASV-Soromba-Rand and Z-132 were also assessed in Strain 13 guinea pigs. Following IP challenge with 104 TCID50 of the virus, all the guinea pigs died, and the mortality rate in guinea pigs infected with Soromba-R was 57%. No obvious disease features were apparent in the surviving guinea pigs after Soromba-R infection. Histopathological changes were observed in the lungs, liver, and spleen, and these changes were identical to those observed in LASV-Josiah infection.172,176 LASV-NJ2015 and Pinneo were nonlethal in Strain 13 guinea pigs. Infected animals exhibited mild to moderate disease.252 Animals infected with LASV-NML-57 exhibited rapid increases in temperature and weight loss, while those infected with the isolate NML-33 had a high mortality rate of up to 90%.253 LF survivors exhibited sequelae, including polyserositis, visual distortion, vertigo, epididymitis, back pain, and partial or permanent hearing loss. The persistence of the virus in the smooth muscle cells of the tunica media of arteries in surviving guinea pigs suggested that guinea pigs may be used as a model for studying chronic LF infection in humans.254 Although no viral antigens were detected in the ears of the surviving guinea pigs, perivascular mononuclear cell inflammation was present in the ears and pars compacta, which led us to hypothesize that the inflammatory response was the primary cause of hearing loss.255 The similarity of the symptoms of LASV infection in Strain 13 guinea pigs to those in humans and the persistence of the virus in surviving guinea pigs further support the rational application of the guinea pig model.

To obtain a uniform lethal model, a guinea pig-adapted LASV was established by successive passages of LASV-Josiah.238,256,257 Guinea pigs intraperitoneally injected with 103 PFU of guinea pig-adapted LASV (GPA-LASV) exhibited significant weight loss of 8–20%, up to the criteria for euthanasia. On average, death occurred at 15 dpi.258 Viral titers were detected in serum, spleen, liver, and lung.252 The histopathological manifestations of infection with guinea pig adapted LASV (GPA-LASV) were hepatocellular degeneration, lymphohistiocytic hepatitis, sinus histiocytosis, and interstitial pneumonia. Clinical isolates of LASV that cause lethal infection in Hartley guinea pigs have also been reported.259 A dose of 102 PFU of LASV LF2384 was 100% lethal in guinea pigs. As in IF patients, guinea pigs presented thrombocytopenia, neutropenia, and lymphopenia. Unfortunately, nonspecific symptoms, such as respiratory and cardiac involvement, which differentiate these patients from human patients were noted.252,260,261

Nonhuman primates

Rhesus macaques

Rhesus macaques developed severe disease and prolonged viremia after LASV-Josiah infection.262 Symptoms of disease, including severe petechial rash, hiccups, lethargy, aphagia, huddled posture, constipation, conjunctivitis, anorexia, weight loss, decreased water intake/dehydration, facial and periorbital edema, bleeding from the gums and nares, cough, and a slight fever, appeared at 7 dpi.262,263 Fever persisted until death, or sudden hypothermia occurred before death. SC inoculation with 106.1 PFU of LASV Josiah was lethal in 60% of the animals. Serologic analysis indicated that the serum concentration was altered at 10–12 dpi but was not correlated with viral clearance or animal recovery. Elevated AST, ALT, and blood urea nitrogen (BUN) levels with transient and moderate leukopenia were also noted. Hematocrit, hemoglobin, fibronectin, and red blood cell counts decreased. Viremia typically appeared at 4–5 dpi, with titers greater than 104 PFU/mL in lethally infected monkeys, which was significantly greater than that in survivors. Viral loads were detected in the adrenal glands, liver, lung, pancreas, brain, bone marrow, kidney, lymph nodes, spleen, muscle, heart, thymus, testis, salivary gland, urine, CSF, and intestines. The highest titers were in the liver, spleen, and adrenal glands.

Gross pathological analysis indicated scattered petechial and visceral hemorrhage with the presence of mild to moderate pleural effusions. Liver and adrenal gland tissues presented necrosis, with regeneration of hepatocytes and slight infiltration of inflammatory cells. Interstitial pneumonia with edema, thickened alveolar septae, and pulmonary arteritis were present in the lung. Spleen samples indicated lymphocytopenia and the presence of viral antigens in the red pulp. Infected primates also develop mild to moderate interstitial and perivascular myocarditis and pericardial edema. Severe meningoencephalitis with significant perivascular cuffing was noted. Infiltration of erythrocytes and macrophages was noted in the small intestine. Lesions and a multifocal cortical interstitial mononuclear infiltrate were noted in the kidney. Seventy-eight percent of infected primates develop lesions in the central nervous system (CNS) with mild lymphocytic cuffing of the vessels of the brain, spinal cord, and meninges. Twenty percent of the primates suffered lymphocytic infiltration of the spiral ganglia, and mild chorioretinitis was also noted. The arterial lesions, vasculitis, meningoencephalomyelitis and skeletal myositis observed in this monkey model were rarely, if at all, noted in human LF patients. Overall, rhesus macaques are thought to be the most accurate model of human LF.

Cynomolgus macaques

Cynomolgus macaques closely simulate severe cases of LF in humans.264 Disease severity was largely dependent on the viral strain. The LASV lineage IV (Josiah/Z-132) and the lineage VII strains cause uniform lethality in cynomolgus macaques, whereas infection with lineage V strains (Soromba-R/AV) induces mild to moderate manifestations without lethal outcomes.265–268 Compared to those infected with lineage VII in macaques, lineage II-infected animals presented longer survival times and lower mortality rates.267 However, lineage III strains isolated from patients during the 2018 Nigerian outbreak showed differences in pathogenicity in cynomolgus macaques.253 Common symptoms in LASV-infected cynomolgus macaques include fever, epistaxis, weight loss, tachycardia, hypotension, and tachypnea, which are similar to those observed in severe human diseases.269 Notably, in infected macaques, LASV causes neurological diseases such as meningoencephalitis and neuronal necrosis. During necropsy, axillary and inguinal lymphadenopathy and congestion are observed in infected animals.266 Biochemical analysis revealed that infection with LASV increased AST, ALT, ALP and CRP in macaques.265–268,270 The inflammatory response and extent of viral replication are associated with the severity of the disease. Post infection, increased levels of cytokines and chemokines, such as IL-1β, IL-6, TNFα, MCP1, and MIP1β, were observed in a macaque model.265–268,270

Marmosets

The common marmoset (Callithrix jacchus) is a small anthropoid primate that generally weighs between 320 and 450 g and has been developed as another small NHP model of LF.271 Experimental infection of common marmosets with a low dose (1 × 103 PFU) or high dose (1 × 106 PFU) of LASV-Josiah resulted in systemic viral distribution, accompanied by a high viral RNA load in multiple tissues. Elevated liver enzymes, decreased plasma ALB levels, weight loss, and morbidity between 15 and 20 dpi were observed. Additionally, increases in AST, ALT, and AKP as well as a gradual decrease in platelet counts were found in both the low-dose and high-dose infection groups. An enlarged liver accompanied by mild inflammation and multifocal hepatic necrosis, an enlarged spleen with mild to moderate lymphoid depletion, and lung abnormalities characterized by hemorrhage in most lobes were confirmed in infected animals.

Squirrel monkeys

Virological and pathological studies of LFV have been performed on squirrel monkeys (Saimiri scirreus).239,272 The small size and availability of marmosets make them attractive alternatives to other NHPs. After intramuscular inoculation with 106.8 TCID50 LASV-Bah, the monkeys developed common clinical symptoms, including anorexia, lassitude, depression, and polydipsia. Early viral lymphoreticulotropism, nephrotropism, hepatotropism, and viraemia were noted. At the endpoint, viral titers in target organs were associated with necrotic changes, such as splenic lymphoid necrosis, renal tubular necrosis, myocarditis, arteritis, and hepatocytic regeneration. In particular, the pathological findings in the liver and spleen were similar to those in humans.272 In convalescent monkeys, viral titers in multiple organs diminished slowly, and viraemia persisted for 28 days without antibody conversion. Renal and splenic regeneration occurred, and a new lesion, choriomeningitis, was present. However, compared to that in other nonhuman primates, the pathogenicity of LASV in squirrel monkeys was relatively low, with a mortality rate of 25%.273 Clinical symptoms showed heterogeneity among individuals, which hindered further application of the model.

Surrogate models

Due to the limitations of biosafety level 4 laboratories (BSL-4), surrogate models of LASV were established, which would be helpful for basic studies and the evaluation of safety at early stages of preclinical development on a case-by-case basis. Infection of guinea pigs and hamsters with alternate viruses can cause LF-like disease; therefore, surrogate models of LF have been established. Pichindé virus (PICV), a new world mammarenavirus isolated from cricetin rodents in Colombia, South America, has been applied in the establishment of models.272 Consecutive passages of PICV more than 4 times in guinea pigs produced a model with 100% lethality.274 Infected strain 13 guinea pigs showed reduced activity, fur ruffling, anorexia, weight loss, lethargy, and rapid breathing; viremia emerged at 2 dpi and increased steadily at 16 dpi until death.275,276 Histopathology revealed lesions in the liver, spleen, pancreas, lungs, and gastrointestinal tract, with scattered areas of necrosis observed in the lymphoid tissue and bone marrow.276 In contrast, Hartley guinea pigs infected with 3 × 102 PFU of PICV CoAn 4763 exhibited a lethality rate of approximately 43%.274 Subsequently, 18 passages of PICV CoAn 4763 were generated in strain 13 guinea pigs, and infection with 102 PFU of PICV P18 resulted in uniform lethality in Hartley guinea pigs. The virus was detected in multiple organs, with the highest titers in the adrenal glands, lungs, stomach, and liver, and lower titers in the brain.277,278 Newborn rats have also been investigated as a model for LF by intracerebral inoculation with lymphocytic choriomeningitis virus (LCMV). Infected animals showed acoustic startle reflexes. Infected animals had higher elicitation and inhibition thresholds and showed recruitment at intense stimulus levels. Histopathology revealed both cochlear and retinal degeneration. These results highlight the potential of this technique for treating severe polysensory neuropathy in rats.279 The LCMV WE strain has also been used to establish a surrogate model in rhesus macaques. Despite the lower biosafety requirement of LCMV, the extent to which this fungus mimics LASV infection is largely uncertain and warrants further investigation.280

Medical countermeasures for Lassa fever

No vaccines or countermeasures have been approved for use in LF. Several vaccine candidates have achieved progress in animal models and moved into clinical trials. Ribavirin is the only off-label treatment.281 More recently, progress has moved towards the development of immunotherapeutic and small-molecule drugs (Table 5).Table 5 Representative medical countermeasures for treating Lassa fever

Classification	Name	Platform/Strategy	Stage	Efficacy/Benefic	References	
Vaccines	LASSARAB	Expressing LASV-G using attenuated RABV vector	Preclinical	Protect guinea pigs and mice; Fc mediated protection	282,283	
Live attenuated	Replacing IGR of LASV S segment or breaking codon bias	Preclinical	Protects guinea pigs	284,285	
ML29	Recombinant virus of LASV and Moopeia virus	Clinical	Sterile immunity and protects guinea pigs and NHPs	286–291	
VSVΔG/LASV GPC	Expressing LASV-GPC based on VSV	Preclinical	Robust and long-lasting immune response and 100% protection in NHPs	252,292,293	
YF17D/LASV-GPC	Expressing LASV GPC based on flavivirus YF17D	Preclinical	Protect guinea pigs but not NHPs	294	
MeV-NPmut/GPC and MeV-Z/GPC	Expressing LASV GPC + NP or GPC + Z based on MeV vector	Clinical	Protect NHPs from lethal challenge and nearly sterile immunity	296–298	
Vaccinia virus-NP /GPC	Expressing LASV GPC(GP1/GP2) or NP based on Vaccinia virus vector	Preclinical	Distinct results in rodents and NHPs	299–301	
RNA replicon	RNA replicon expressing GPC or NP of LASV	Preclinical	Protect guinea pigs	302,303	
INO-4500	DNA vaccine encoding LASV GPC	Clinical	Protect guinea pigs and NHPs	305,306	
Antibodies	Arevirumab-3	Human antibody cocktail contains 8.9F, 12.1F, and 37.2D	Clinical	Protective in guinea pigs and NHPs	53,258,320	
Small molecular drugs	Fapiravir	RdRp inhibitor	Preclinical	Improved situation in mice	317	
Ribavirin	Broad spectrum antiviral drug	Preclinical	Recommended to use in the early stage of the disease	313–315	
LASV Lassa virus, RABV rabies virus, IGR gene interval, GPC glycoprotein precursor, VSV vesicular stomatitis virus, N nucleocapsid protein, Z zinc- binding protein, RdRp RNA dependent RNA polymerase, NHPs nonhuman primates

Preventative vaccines for Lassa fever

Inactivated vaccines for LASV have been developed based on rabies virus vectors. These vaccines were designed by expressing LASV GPC using the live attenuated RABV vector BNSP333. Compared to the LASSARAB live vaccine, inactivated LASSARAB induced robust and persistent humoral immune responses in mice and guinea pigs. Inactivated LASSARAB could protect guinea pigs and mice, and antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP) are the main mechanisms of protection.282,283

Live attenuated rLASV (IGR/S-S) was obtained by replacing the gene interval (IGR) of the LASV S segment. Compared to those of wild-type strains, the growth of strain on the cell decreased, the pathogenicity of the strain on the guinea pig decreased, and the strain could completely protect the guinea pig from lethal attack by LASV.284 After immunization, the serum LASV IgG titer increased, while the neutralizing antibody titer decreased, which could only be detected recently. RLASV (IGR/S-S) has been passed through cells for 15 generations and is genetically stable. Moreover, the team also attempted to modify the attenuated vaccine rLASV-GPC/CD by disrupting codon bias, which has similar protective effects.285

The recombinant MOPV/LASV(ML29) vaccine is a recombinant virus of LASV and Moopeia viruses that retains the nonpathogenic L segment of MOPV and the S segment of the LASV Josiah strain.286,287 Sterile immunity was achieved in guinea pigs and NHPs after immunization, and the protection rate was 100%.288 In addition, the ML29 vaccine still conferred 80% protection when it was administered 2 days after exposure.289,290 Using reverse genetics approaches to knock down the exon function of MOPV, the transmission and replication ability of MOPV were attenuated. The highly attenuated strain MOPEVACLAS included multiple mutations in MOPV NPs and the exchange of the GPC ORF sequences of LASV and MOPV greatly improved its immunogenicity. Single-dose injection of MOPEVACLAS conferred protection in nonhuman primates.291

Several viral vectored LASV vaccines have been investigated and shown to have potential benefits. VSV-based vaccines expressing LASV-GPC was constructed, namely VSVΔG/LASV GPC, a single intramuscular dose vaccination of which induced robust and long lasting cellular and humoral immunity in NHPs and conferred 100% protection.292 Cross-protection between different viral strains in guinea pigs and macaques has also been reported.252,293 A flavivirus vectored LASV vaccine was prepared by inserting LASV GPC between the E and NS1 genes of flavivirus YF17D, termed YF17D/LASV-GPC. YF17D/LASV-GPC was replication-competent and showed significantly reduced toxicity.294 It induced an immune response and protected 80% of guinea pigs against the lethal challenge of LASV. However, the genetic stability of the virus is not ideal, and the expression of GPC decreased after 5 generations. Recombinant viruses expressing GP1 or GP2 were constructed. The combination of the two recombinant viruses protected 83% of the guinea pigs from lethal challenge with LASV, but did not result in sterile immunity. However, these results in guinea pigs could not be replicated in NHPs.295,296 Two measles virus (MV) vector LF vaccines expressing LASV GPC + NP or GPC + Z were constructed. Both MeV-NPmut/GPC and MeV-Z/GPC were immunogenic in NHPs.296 Single dose vaccination with MV-LASV-NP + GPC can protect macaques from lethal challenge and nearly achieve sterile immunity.297,298 The recombinant vaccinia virus encoding LASV NP conferred 100% protection in Hartley guinea pigs from homologous challenge.299 In guinea pigs, the protection rates of recombinant vaccines expressing LASV NP or GPC were 94 and 79%, respectively, while the protection rates of recombinant vaccines expressing both GP and NP were lower. Interestingly, in NHPs, survival rates reached more than 90% when the GP1, GP2 and NP proteins were expressed simultaneously based on vaccinia virus, but none survived when these immunogens were expressed alone.300 These results indicate the different mechanisms involved in triggering the immune response and the mechanism of protection against LASV in rodents and NHPs.

Salvato et al. constructed a novel VLP vaccine by expressing LASV GPC and Z protein based on the MVA vector, termed GEO-LM01.301 A Venezuelan equine encephalitis virus (VEEV) RNA replicon expressing GPC or the NP of LASV was also developed, which completely protected inbred guinea pigs from lethal infection by homologous LASV.302 Two cistron RNA replicons that simultaneously express two GPCs from different lineages of LASV were also developed and can mediate a cross-reactive immune response in mice.303 However, three doses of RNA replicons are needed to achieve protection. Two doses of Ad5-LASV-NPs and Ad5-LASV-GPC could protect guinea pigs from lethal LASV challenge, and the activation of humoral immunity could be detected.304

An optimized DNA vaccine encoding LASV GPC can fully protect guinea pigs and NHPs from LF. Cellular immunity is the main protective mechanism.305,306 Subsequent studies have shown that after secondary immunization, 100% of NHPs produce neutralizing antibodies, and a large proportion of them produce LASV GPC-specific T-cell responses.307 A Phase I clinical trial of INO-4500 (NCT 03805984) is ongoing. Moreover, a broad-spectrum peptide vaccine against seven pathogenic arenaviruses that expressed conserved epitopes from LCM, Lassa, Guanarito, Junin, Machupo, Sabia, and Whitewater Arroyo viruses was reported.308,309

Therapies for Lassa fever

Convalescent plasma therapy (CPT) has been applied in the treatment of LF. In a case report, when plasma was injected in the early stages of the disease, a beneficial effect was observed.310 When CSP was given shortly after exposure to LASV, the cynomolgus monkeys and guinea pigs were protected.311 However, the protective efficacy of the passive transfer of CSP in human clinical trials is controversial.312

Ribavirin has been shown to reduce the mortality of high-risk LF patients with elevated liver enzymes from 55 to 5% on admission, but the drug is relatively expensive, and the premise is to treat LF within a week of disease duration.313,314 Overall, ribavirin is commonly used clinically for LF in the early stage of the disease, but it is not recommended for postexposure prophylaxis.315,316 Currently, data on the clinical efficacy of this drug are limited, and the efficacy of ribavirin is not obvious in patients with mild disease. When favipiravir (T-705) was combined with ribavirin, health of LASV infected mice was improved.317

LHF-535 was discovered after high throughput screening and structural optimization of benzimidazole derivatives. Ikenna G. Madu et al. determined that LHF-535 has subnanomolar potency against viral envelope glycoproteins in all Lassa virus lineages, but the sensitivity of glycoproteins of strains from lineage I is 100 times lower than that of other viruses.318 This decrease is mediated by the unique amino acid substitution V434I in the transmembrane region of the GP2 subunit of the envelope glycoprotein.

Several mouse monoclonal antibodies against LASV and Mopeia viruses were isolated by the hybridoma technique, most of which reacted with NP, GP2 or GP1. Glycoprotein-specific monoclonal antibodies have shown limited neutralization ability.319 Human mAbs against LASV glycoproteins were also isolated from B cells of LF survivors. Of these mAbs, half were able to bind the GP2 fusion subunit, a quarter recognized the GP1 receptor binding subunit, and the remaining quarter specifically recognized the protein complex. Fifteen monoclonal antibodies were able to neutralize the LASV pseudovirus.53 In guinea pigs, humAbs, 25.6A, 2.9D, 8.9F, 12.1F, and 37.7H conferred 100% protection.258 In cynomolgus monkey, 37.2D, 12.1F, 8.9F, 19.7E and 37.7H protected all animals. However, the virus was still detectable at 21 dpi in the 8.9F treatment group, which was attributed to the formulation of an escape strain of LASV, 8.9F(e). LASV, 8.9F(e) escaped the neutralizing effect of 8.9F by affecting the four-level epitope required for 8.9F binding, but was completely neutralized in vitro by a mixture of 8.9F, 12.1F, and 37.2D, as this cocktail binds to GPs from four separate branches of LASV. Treatment with this cocktail at 8 days post LASV treatment protected 100% of the rhesus monkeys. This antibody cocktail, called Arevirumab-3, is under clinical investigation.320

Beta-coronavirus diseases

Etiology, epidemiology, and pathogenesis of beta-coronavirus diseases

Pathogenic coronaviruses are associated with respiratory and intestinal infections in animals and humans. Representatively, SARS-CoV, MERS-CoV and SARS-CoV-2 are highly pathogenic to humans and are responsible for pneumonia and other respiratory symptoms.321–323 SARS-CoV, MERS-CoV and SARS-CoV-2 belong to the beta coronavirus (Beta-CoV) genus, coronavirus subfamily that belongs to the order Nidovirales.324 These viruses are enveloped RNA viruses, with a diameter of approximately 100–160 nm and the largest genome among RNA viruses.325 There are three surface proteins on the lipid membrane that encapsulate virus particles, namely the spike protein (S), envelope protein (E), and membrane protein (M). The S protein is responsible for receptor binding and cell lysis, and mediates viral invasion.326 SARS-CoV and SARS-CoV-2 primarily infect ciliated bronchial epithelial cells and type II lung cells via angiotensin converting enzyme (ACE2) as a functional receptor, while MERS-CoV infects undifferentiated bronchial epithelial cells and type II lung cells via dipeptidyl peptidase 4 (DPP4, also known as CD26) as a receptor.327–329 After receptor-ligand recognition of SARS-CoV/SARS-CoV-2 and host cells, transmembrane serine protease 2 (TMPRSS2) on the cell surface cleaves ACE2 and activates the S protein, thereby promoting virus entry. The viral genome utilizes host ribosomes to directly translate two types of polymeric proteins, pp1a and pp1ab, which are cleaved into 16 nonstructural proteins by two proteases, papain PLpro and the main protease Mpro, which are assembled into transcriptional replication complexes responsible for transcriptional replication of the viral subgenome and genome. These components will continue to assemble mature viruses in the endoplasmic reticulum and Golgi apparatus and be released from the cell membrane to initiate the next round of infection. In this process, the S protein, PLpro, Mpro, and viral RNA-dependent RNA polymerase (RdRP) are all key antiviral drug targets. In addition to the direct pathogenic effect of the virus, an excessive immune response is another pathogenic issue of SARS-CoV-2.330 The affinity between the RBD and ACE2 in the S1 subunit of the S protein of SARS-CoV-2 is 10–20 times greater than that of SARS-CoV, which could explain the stronger transmission ability of SARS-CoV-2.331 In contrast, MERS-CoV mainly infects the lower respiratory tract, promotes the replication and production of viruses in macrophages and dendritic cells, induces the production of proinflammatory cytokines, targets T lymphocytes, and leads to their apoptosis.329

There are multiple gaps in understanding the epidemiology, pathogenesis, and countermeasures of SARS-CoV and MERS-CoV. SARS-CoV and MERS-CoV were transmitted directly to humans from commercial civets and dromedary camels, and both viruses originated from bats.325 There are currently no approved or available prophylactic or therapeutic approaches, and potential vaccines are at an early preclinical stage. Consequently, treatment remains largely supportive in clinical. In contrast, the COVID-19 pandemic has accelerated the advances in animal models, vaccines, antibodies, and small molecule drugs, and a large number of candidate products have been approved or entered Phase III/IV clinical trials. However, the origin of SARS-CoV-2 has not yet been clearly documented. Due to the wide range of techniques and abundant clinical trials involved, we focused on sophisticated or advanced products for the prevention and clinical treatment of COVID-19. These attempts can also provide a reference for the prevention and control of SARS-CoV and MERS CoV.

Animal models for beta-coronavirus diseases

To obtain in-depth insights and better prepare for medical responses, animal models of beta-coronavirus diseases, including naturally susceptible and artificially modified animal models, were generated. In this section, animal models for beta-coronavirus diseases are discussed in detail (Table 6).Table 6 Animal models of beta-coronaviruses

Species	Animal model	Pathogens	Dose	Route	Lethality	Signs of disease	Characteristics (Strengths/Weaknesses)	References	
Mouse	HFH4-hACE2-mice	SARS-CoV-2	3 × 104 TCID50	IN	0	No	Applicable to pathogenesis study/No obvious signs of disease	332	
K18-hACE2/hDPP4 mice	SARS-CoV-2	105 PFU	IN	50 ~ 100%	Encephalitis, pneumonia, anosmia, respiratory distress	Mimic severe disease, a model for anosmia/Nonspecific brain infection	335–337	
SARS-CoV	2.28 × 105 PFU	100%	333	
MERS-CoV	105 PFU	100%	334	
hACE2 knock-in mcie	SARS-CoV-2	4 × 105 PFU	IN	0	Interstitial pneumonia	hACE2 and viral load in line with humans, intragastric infection/Brain infection	338	
hACE2 knock-in mice	SARS-CoV-2	4 × 105 PFU	IT	–	Pneumonia	Model for ARDS, typical pathological changes in lung/-	339	
hCD26/DPP4 mice	MERS-CoV	106 TCID50	IN	100%	Weight loss, pneumonia	Low dose lethal infection/Brain infection	340–342,897	
Humanized mouse	MERS-CoV	2 × 105 PFU	IN	0	No	Humanization of DPP4 using VelociGene technology/No obvious signs of disease	343	
Humanized mouse	MERS-CoV	105 PFU	IN	0	/	Expanded tropism for pathogens, human innate and adaptive immune system	821	
CRISPR–Cas9/mice adapted virus	MERS-CoV	5 × 106 PFU	IN	50%	Weight loss, pneumonia	A model for ARDS, signs indicative of end-stage lung disease/Additional mutants introduced by virus adaptation	344,345	
Ad5-hACE2/hDPP4 transduce	SARS-CoV-2	105 FFU	IN	0	Pneumonia	Rapid acquisition of susceptible animal models/mimic limited physiological features of infection, inaccurate receptor expression	346,347,349	
MERS-CoV	105 PFU	IN	0	348	
Adeno-associated virus transduce	SARS-CoV-2	1–3 × 106 PFU	IN	0	Weight loss, lung fibrosis	Recapitulated human immune response and chronic COVID-19 infection/high unit cost, infection limited to hematopoietic cells	351	
Mice adapted model	SARS-CoV	104.4 TCID50	IN	100%	Viremia, overwhelming infection	High titer viral replication in lungs, dissemination of virus to extrapulmonary sites/Differences from the original strain	353	
MERS-CoV	106 PFU	IN	0 ~ 100%	Weight loss	354	
MASCp6	1.6 × 104 PFU	IN	0	Pneumonia, inflammatory responses Weight loss	Enable sensitive infection/None lethal model, differences from the original strain	355	
HRB26M	104.4 PFU	IN	0	356	
MA10	105 PFU	IN	10 ~ 90%	ALI, ARDS; aged-related disease severity/Differences from the original strain	357	
BMA8/C57MA14	105 TCID50	IN	0 ~ 100%	Genetic and age-dependent severity/Differences from the original strain	358	
Hamster	Wild type	SARS-CoV	103 TCID50	IN	0	No	Rapid acquisition of susceptible animal models/Immunosuppression needed to sensitive infection, not applicable to extensive usage	367,368	
Immunosuppressed	SARS-CoV	103 TCID50	IN	100%	Weight loss	369	
Wild type	SARS-CoV-2	8 × 104 TCID50	IN	0	Rapid breathing, weight loss	Transmission between hamsters, mild to moderate infection, aged-dependent severity/None-lethal model	370–373,898,899	
Chinese hamster	105 PFU	IN	0	Pneumonia and bronchitis	Prolonged period of weight lose/Milder bronchitis and pneumonia and shorter duration	384	
Roborovski hamster	105 PFU	IN	0	Rapid and fatal course, systemic infection	382,383	
STAT2−/− hamsters	2 × 105 TCID50	IN	0	Model for pathogenesis study/Not applicable to study immune correlates	386	
Immunosuppressed	104 PFU	IN	0 ~ 60%	Chronic infection	Low doses of virus and more severe and prolonged disease/Not applicable to extensive usage	387	
hACE2 transgene hamster	SARS-CoV-2	100/1000 PFU	IN	66.7–100%	Extensive respiratory and CNS infection	Severe and lethal infection models/ectopic expression of the hACE2	381	
Ferret	Wild type	SARS-CoV	106 TCID50	IT	0	Fever, lethargic, sneezing, conjunctivitis, pneumonia	Models for contact and aerosol infection/None-lethal model	389–392	
Wild type	SARS-CoV-2	105.5 TCID50	IN	0	Common symptoms, loss of taste or smell, rash, red or irritated eyes, difficulty in breathing, chest pain	Acute bronchiolitis, transmit by direct or indirect contact; dose-dependent infection/Transient virus replication, no obvious clinical symptoms in young animals	398,900	
Mink	Wild type	SARS-CoV-2	5 × 106 PFU	IN	0	Severe pneumonia	Animal model for severe disease, related variants emerged, mild to moderate infection by IN infection route and severe infection by IT route/-	406	
SARS-CoV-2	4 × 105 PFU	IN/IT	Lethargy, diarrhea, nasal and sneezing	407	
NHPs	Rhesus macaques	SARS-CoV-2	4.75 × 106 PFU	IN	0	Respiratory abnormalities	Mild clinical disease, viral replication and pathology/Lack of typical clinical symptoms and no ARDS observed	411,413	
MERS-CoV	7 × 106 TCID50	IT + OR + IN + OC	0	Transient infection, pneumonia	Model for the lower respiratory tract infection and limited transmission/Transient infection, expensive and ethical issues	409	
Cynomolgus macaques	SARS-CoV-2	3.84 × 104 PFU	IN + IT	0	Limited	Model for pulmonary consolidation and diffuse alveolar damage/limited clinical symptoms, expensive and ethical issues	411,422,423,901	
SARS-CoV	107 PFU	IN/IT/IV/IG	0	Mild symptoms	Inflammatory cytokines and chemokines associated with ALI and ARDS, DAD,/Expensive and ethical issues	415,417–421,902	
MERS-CoV	106 TCID50	IN + IT	0	No	Viral replication and pathology/Lack of disease hallmarks, expensive and ethical issues	422	
African green monkeys	SARS-CoV-2	3.84 × 104 PFU	IN + IT	0	Respiratory abnormalities	Thrombocytopenia; type II pneumocyte hyperplasia and alveolar fibrosis; ARDS in aged animals/expensive and ethical issues	
Baboons	SARS-CoV-2	1.05 × 106 PFU	IN + IT	0	Respiratory abnormalities, fever	More severe clinical manifestations than AGMs and RMs, prolonged virus shedding/Expensive and ethical issues	424,431	
Marmosets	SARS-CoV-2	1.05 × 106 PFU	IN + IT	0	No	Insusceptible to SARS-CoV-2	
NHPs nonhuman-primates, SARS-CoV-2 severe acute respiratory syndrome coronavirus 2, SARS-CoV severe acute respiratory syndrome coronavirus, MERS-CoV Middle East respiratory syndrome, PFU plaque formation unit, TCID50 median tissue culture infective dose, FFU focus-forming unit, IN intranasal, IT intratracheal, OR oral, OC ocular, IV intravenous, IG intragastric, hACE2 human angiotensin converting enzyme 2, ARDS acute respiratory distress syndrome, DPP4 dipeptidyl peptidase-4, ALI acute lung injury, AGMs African green monkeys, RMs rhesus macaques, DAD diffuse alveolar damage, – not applicable

Mice

Transgene and humanized mouse model

Receptor knock-in mouse models were generated through transgenic approaches such as microinjection and CRISPR-Cas technology, which yielded precision knock-in or random transgenic plants. Using the lung ciliated epithelial cell-specific HFH4/FOXJ1 promoter, a high SARS-CoV-2 viral load in the lungs was detected in hACE2 transgenic C3B6 mice, and preexposure protection was accomplished.332 However, this endogenous promoter-derived transgenic mouse model was not lethal and showed no obvious signs of disease. The promoter of the cytokeratin 18 gene is expressed predominantly in epithelial cells. Transgenic mice expressing hACE2 driven by the promoter of the cytokeratin 18 gene were generated and termed K18-hACE2 mice.333 SARS-CoV-infected K18-hACE2 mice developed encephalitis and mild pneumonia. Infection with SARS-CoV-2 and MERS-CoV causes severe disease in the lung and, in some cases, in the brain.333,334 Evidence of thrombosis and vasculitis was detected in mice with severe COVID-19 pneumonia. Remarkably, K18-hACE2 mice support SARS-CoV-2 replication in the sinonasal epithelium, which is associated with pathology related to anosmia, a common feature of human disease.335–337 In addition, impaired lung function, including respiratory distress, markedly abnormal lung biomechanics, and labored breathing, was observed in K18-hACE2 mice. Moreover, SARS-CoV-2 caused systemic infection in K18-hACE2 mice, and the virus was detected in the nasal epithelium, trachea, lungs, heart, spleen, liver, kidneys, stomach, large intestine, small intestine and brain.336 With CRISPR/Cas9 knock-in technology, the mACE2 gene of the C57BL/6 mouse model was completely replaced with hACE2 (termed hACE2 mice).338 Viral loads, interstitial pneumonia, and elevated cytokine levels occurred in SARS-CoV-2-infected hACE2 mice. In hACE2 mice, the viral RNA load in the lungs was markedly greater than that in other hACE2 genetically engineered mice generated by pronuclear microinjection, and the distribution of hACE2 in various tissues was more in line with human conditions. Interestingly, intragastric infection with SARS-CoV-2 has been established in hACE2 mice. In addition, SARS-CoV-2-induced acute respiratory illness in transgenic hACE2 model mice exhibited typical pathological changes in the lungs.339 This approach is important for the evaluation of vaccines against severe acute respiratory distress syndrome (ARDS). Transgenic mice expressing hCD26/DPP4-based on the exogenous CAG promoter were also generated. This model was susceptible to MERS-CoV infection, resulting in continuous weight loss and death. Infectious viruses were detected in the lungs and brains of mice, coinciding with the activation of genes encoding antiviral and inflammatory mediators.334,340,341 In addition, viral RNAs were also detected in the heart, spleen, and intestine, indicating disseminated viral infection. Infected mice develop progressive pneumonia characterized by extensive inflammatory infiltration. The transgenic mouse model was highly susceptible to MERS-CoV, and the 50% infectious dose (ID50) and lethal dose (LD50) of the virus were estimated to be <1 and 10 TCID50, respectively.342 In contrast to the overwhelming infection observed in the mice challenged with a high dose of MERS-CoV, 10 TCID50 infections represented asymptomatic or mild MERS patients.

Based on rapid engineering technology involving the mouse genome, termed VelociGene, humanized mice for DPP4 were generated; these mice express human DPP4 in place of mouse DPP4 without cerebral infection.343 This approach preserved the proper expression regulation and protein tissue distribution of DPP4. MERS-CoV could replicate effectively in this model despite the absence of lethality. By combining CRISPR‒Cas9-based genome modification technology and serial passages of MERS-CoV, a mouse-adapted MERS-CoV strain that replicated efficiently in the lungs was established, which caused extreme weight loss, decreased pulmonary function, pulmonary hemorrhage, and pathological signs indicative of end-stage lung disease, particularly ARDS.344 Prophylactic and therapeutic countermeasures protected engineered mice against MERS-CoV-induced ARDS. When hDPP4-transgenic mice were generated by microinjection, they were sufficiently susceptible to MERS-CoV infection and exhibited weight loss, decreased pulmonary function, and increased mortality with minimal perturbation of overexpressed hDPP4 after MERS-CoV infection.345 In addition, progressive pulmonary fibrosis was observed.

Receptor-transduction model

Receptor-transduced models were established by transducing functional receptors in BALB/c and C57BL/6 mice, which facilitated virus entry and infection.346–348 Replication-defective adenoviruses are the most extensively used vectors for transduction. Signs such as pneumonia and virus replication in the lungs were observed in hACE2/DPP4-transduced models after Beta-CoV infection. Immunodeficient animals, such as IFNAR−/− and STAT1−/− mice, presented delayed virus clearance, while immunocompetent mice quickly cleared the virus.349 In IFNAR knockout mice transduced with AAV-hACE2, monocyte and macrophage recruitment were abolished, CD4+, CD8+ or NK cell activation was inhibited, and neutrophil and neutrophil accumulation were noted.350 Similar results were observed in IRF3/7−/− mice. Ad5-hACE2-transduced STAT1−/− mice are the most susceptible to SARS-CoV-2 infection. To recapitulate the sustained immunopathology of patients with severe COVID-19, Sefik et al. described a humanized MISTRG6 mouse model in which hACE2 was delivered by an adeno-associated virus.351 This model maintained an infection period of up to 28 days and exhibited key features of chronic COVID-19 infection, including lung fibrosis, an inflammatory macrophage response, a persistent interferon-stimulated gene signature, and T-cell lymphopenia. Additionally, this model recapitulates the innate and adaptive human immune response. Furthermore, SARS-CoV-2 was shown to replicate in human lung-resident macrophages and drive the disease.352 Undergone receptor recognition, human macrophages activate inflammasomes, release proinflammatory cytokines, and promote pyroptosis, thus contributing to immunopathology in severe disease. Conversely, inhibition of the NOD-like receptor family, pyrin domain containing 3 (NLRP3) inflammasome reversed chronic lung pathology, which confirmed the role of inflammasome activation and the corresponding inflammatory response in lung inflammation. Together with the phenomenon that blockade of inflammasome activation leads to the release of SARS-CoV-2 by infected macrophages, it was concluded that inflammasomes oppose host infection by SARS-CoV-2 by producing inflammatory cytokines and pyroptosis to prevent a productive viral cycle. These studies provided evidence that inflammatory macrophages are involved in early infection while driving immunopathology at later stages.

Overall, these viral vector-transduced approaches enabled rapid acquisition of available animal models for emergency needs, but such disease models can only mimic limited physiological features of infection. Another advantage of the Ad5 receptor transduction strategy is that it can be used in genetically deficient mice, facilitating rapid identification of host genes and pathways that play protective or pathogenic roles in disease. However, receptor expression after intranasal AD5 inoculation is restricted to the lungs and may not be targeted to the correct organ. Moreover, the use of anti-vector immunity limits the full application of this animal model.

Mouse adapted model

Mouse adapted models for beta-CoVs were established by serial passages of viruses of interest in mcie, which resulted in the accumulation of mutations that increased the virulence of mouse-adapted viruses and enabled viral replication in the lungs, viremia, and dissemination of the virus to extrapulmonary sites, accompanied by lymphopenia, neutrophilia, and pathological changes in the lungs.353 The overwhelming extent of viral infection in mice is attributed to lethality. The mDPP4 genomic region encompassing exons 10–12 was replaced with the corresponding genomic region from hDPP4 in hDPP4-KI mice, and a mouse-adapted model was established. After 30 serial passages in KI mice, the titers of mouse-adapted MERS-CoV in the lungs were more than 100 times greater than those of the starting virus, which caused weight loss and fatal infection with little involvement of extrapulmonary tissues.354 Compared with the parent virus, mouse-adapted MERS-CoV contains 13-22 mutations, some of which are in the S gene. These S protein mutations sensitized the virus to enter and rendered it more virulent than the parent virus in hDPP4-KI mice.

For SARS-CoV-2, MASCp6 was generated by six successive passages of SARS-CoV-2 in aged BALB/c mice. MASCp6 efficiently infected both aged and young BALB/c mice. It replicates efficiently in the lung and trachea, resulting in moderate pneumonia and inflammatory responses.355 A key substitution, N501Y, in the RBD was predicted to contribute to the enhanced infectivity of MACSp6 in mice. In addition, the mouse-adapted SARS-CoV-2 HRB26M strain efficiently infected the upper and lower respiratory tracts of young BALB/c mice and C57BL/6J mice.356 Subsequently, a lethal mouse-adapted SARS-CoV-2 MA10 strain, which causes acute lung injury (ALI) in young and aged BALB/c mice, was isolated after ten passages in young BALB/c mice. The epidemiological characteristics of COVID-19, as well as aspects of host genetics, age, cellular tropisms, elevated Th1 cytokines, and loss of surfactant expression and pulmonary function, are linked to the pathological features of ALI.357 Interestingly, SARS-CoV-2 MA10 did not cause any mortality in ten-week-old C57BL/6J mice. The process of adaptation introduces multiple point mutations into the viral genome that are responsible for increasing virulence; however, whether this artificially introduced genetic divergence compromises the relevance of the adapted viruses in the first place has yet to be fully elucidated. Lethal mouse-adapted SARS-CoV-2 strains achieved breakthroughs, with 100% fatality and clear mutation sites.358 All the mouse-adapted SARS-CoV-2 strains cause more severe disease in aged mice. A potential limitation of the mouse-adapted virus model is that lung disease following infection may rely on species-specific mutations of mouse-adapted strains derived from selective pressures. Such selective pressures may not recapitulate all aspects of human infection.

In mice, adenovirus-mediated transduction of huDPP4 resulted in transient expression of functional receptors in many cells and facilitated MERS-CoV replication in the lungs. A concern with this model is that cells that natively express DPP4 will be infected, and this broader infection of cell types may alter pathogenesis. Moreover, no signs of clinical disease were observed. In the transgene model, when the receptor is under the control of the chicken β-actin promoter, all murine cells express huDPP4, and this nonphysiological expression pattern leads to extensive brain infection and ultimately rapid succumb to infection.340,359 However, in hDPP4-Tg mice, the expression of human genes under the control of an endogenous human promoter was not lethal.360 There have also been huDPP4 knock-in attempts to replace the mDPP4 ORF with huDPP4 under the control of the endogenous mDPP4 promoter, which ensures correct physiological expression of the knock-in gene and thus provides a more physiological model of human disease.343 This lethal model was applied to investigate the host response to MERS-CoV infection.361 The depletion of CD8+ T cells protected the animals, while the depletion of macrophages exacerbated MERS-CoV-induced pathology and clinical symptoms. That is, the inflammatory response plays an important role in regulating MERS-CoV pathogenesis in vivo. In contrast, mouse models described by Cockrell et al.344 and Li et al. were susceptible to infection by serially passaged MERS-CoV, which induced severe lung pathology and diffuse alveolar damage (DAD).354 These mice could be good models for studying the pathogenesis of MERS-CoV. The pathogenesis of coronaviruses involves severe acute respiratory infection and immune deregulation; thus, modeling studies should be performed on all cell signals.362 Hence, validation of the animal model is crucial. Errors in animal experimental studies narrow the chances of potential drugs, repurposing or repositioning drugs and vaccines for successful translation to the clinic; moreover, resources are wasted. Thus, it is necessary to validate animal models using different criteria, for instance, face, construct, and predictive validation.

Syrian hamsters

The Syrian hamster (Mesocricetus auratus) is another small mammal model for beta-coronaviruses. Compared with mice, hamsters are naturally susceptible to SARS-CoV and SARS-CoV-2, which is attributed to the differential binding of the spike protein to ACE2 orthologs.363,364 Hamsters infected with SARS-CoV or SARS-CoV-2 exhibit severe pulmonary pathological changes associated with an inflammatory response.365 In contrast, hamsters are not susceptible to MERS-CoV due to the specificity of DPP4.366

SARS-CoV replicates substantially in the respiratory tract and causes pathological changes in the lungs of hamsters. Following IN inoculation, SARS-CoV replication peaked at 3 dpi, and the virus was cleared at 7 dpi. Replication of the virus in the respiratory epithelium at the early stages of infection is accompanied by cellular necrosis, while the inflammatory response corresponds to viral clearance.367 Moreover, SARS-CoV-infected hamsters elicited robust NAb responses and were protected against subsequent infection.367 In hamsters, a correlation between the level of SARS-CoV in the lungs and the extent of pneumonia was demonstrated.368 In addition, Schaecher et al. reported a model of cyclophosphamide-induced immunosuppression caused by SARS-CoV infection in Syrian hamsters. SARS-CoV-infected animals exhibit high morbidity and mortality at approximately 30 dpi.369

SARS-CoV-2 infection leads to mild to moderate symptoms in hamsters, including rapid breathing, weight loss, and alveolar damage. High expression of viral nucleocapsid proteins in the airway and intestine and high viral loads in the lung, spleen and lymph node atrophy were noted. SARS-CoV-2 can be efficiently transmitted from inoculated hamsters to naive hamsters by direct contact and aerosols, and infected naive hamsters exhibit similar pathological changes but no weight loss. All infected hamsters showed no mortality and recovered within 14 days.370,371 In addition, passive transfer of recovery serum to naive hamsters effectively inhibited viral replication in the lungs, even when serum was given two days after infection.372 Hamsters infected with SARS-CoV-2 developed olfactory impairment, similar to the anosmia observed in human patients. Moreover, late-stage SARS-CoV-2 infection in female Syrian hamsters induced cardiovascular disease, including myocardial interstitial fibrosis, ventricular wall, septal thickening, and changes in the serum lipid and metabolite profiles of the hamsters.373,374

The severity and mortality of SARS-CoV-2 infection in elderly hamsters were also compared.375 The extent of viral replication and the lung inflammatory response were age-dependent, and corresponded to proinflammatory cytokine expression, delayed viral clearance, and aggravated lung injury. Aged hamsters exhibited more pronounced and persistent weight loss, significant alveolar and perivascular edema, pulmonary coagulation abnormalities, and acute kidney injury. Proximal urinary tract damage and mesangial matrix expansion were observed in the kidneys of aged hamsters at the early and late disease stages, respectively. Compared to young hamsters, aged hamsters exhibited prolonged infection.376,377 Thus, aged hamsters are suitable models for evaluating the age-associated pathogenesis of SARS-CoV-2 infection. These data suggest that diverse patterns of innate immune response affect disease outcomes in different age groups of hamsters infected with SARS-CoV-2. Gender-dependent SARS-CoV-2 infection was also investigated in hamsters.378,379 Adult male hamsters infected with SARS-CoV-2 had greater morbidity, more pronounced weight loss, more severe lung damage, and a slower recovery than infected female animals, despite the absence of mortality. Male hamsters exhibit testicular damage, as indicated by dramatic decreases in sperm count and serum testosterone, and decreased testicular size, weight, and serum sex hormone levels several months after infection. Moreover, these is evidence that a minimum number of SARS-CoV-2 particles remain in the lungs of hamsters recovering from acute COVID-19. Together with persistent weight loss, viral RNA rebound in nasal washings, an early decline in the humoral immune response at 21 dpi, and persistent lung pathogenesis, these results suggest that hamsters could be a model of long COVID-19.380

There have also been attempts to establish an hACE2 receptor transgene model under the control of the K18 promoter. A low dose of 100 or 1000 PFU of SARS-CoV-2 resulted in a fatality rate of 66.7–100% in K18-hACE2 hamsters. In addition to severe lesions within the respiratory system, SARS-CoV-2 spreads to the CNS and causes neurological injury.381 K18-hACE2 hamsters represent a severe and lethal model of COVID-19 infection.

The Chinese hamster (Cricetulus griseus) is also susceptible to SARS-CoV-2. SARS-CoV-2 infection in Chinese hamsters is associated with lung damage and pneumonia.382,383 However, the progression of bronchitis and pneumonia was milder, and the duration of pneumonia was shorter in these patients than in Syrian hamsters. The advantage of using Chinese hamsters is that they experience significant weight loss over a prolonged period following SARS-CoV-2 infection compared to that of the Syrian hamster model.384 Like transgenic human ACE2 hamsters, Roborovskii hamsters develop severe respiratory disease after infection with SARS-CoV-2, accompanied by severe acute diffuse alveolar damage and hyaline microthrombi in the lungs. In addition to wild-type (WT) hamsters, several immunodeficient hamster models have been adapted.385,386 In addition to the high levels of viral RNA in the blood, spleen, liver, and upper and lower gastrointestinal tract, the lung pathology observed in STAT2−/− hamsters was significantly attenuated.386 Moreover, RAG2 knockout (KO) hamsters infected with SARS-CoV-2 via the respiratory tract exhibited more obvious weight loss, an enormous viral load, and even death.387 It can be used as a model for severe disease. IL2RG knockout (KO) hamsters infected with SARS-CoV-2 exhibit chronic infection that lasts at least 24 days, resulting in disseminated, moderate to severe, chronic active interstitial pneumonia and active recruitment of neutrophils and macrophages.385

Ferrets

Ferrets permit the replication of SARS-CoV and SARS-CoV-2 but not MERS-CoV, which is associated with species restriction of the DPP4 receptor.388 SARS-CoV and SARS-CoV-2 replicate in the respiratory tract of ferrets and are transmitted through direct contact and aerosols. Ferrets infected with 103 TCID50 of SARS-CoV via the IN route presented fever at 2–6 dpi and sneezed at 5–10 dpi. Both viral RNA and infectious virus were detected in the lung and nasal turbinates.389,390 In addition, lymphohistiocytic bronchointerstitial pneumonia is a typical histopathological lesion. Bronchial and bronchiolar hyperplasia and perivascular cuffing were observed in the lung tissue of SARS-CoV-infected ferrets.391 Simultaneously, increased lymphocytes and macrophages were also observed and were associated with the pulmonary vasculature and the connective tissue surrounding conducting airways.392

Compared to SARS-CoV, SARS-CoV-2 replicates mainly in the upper respiratory tract of ferrets. SARS-CoV-2 infection leads to common symptoms, including fever, cough, tiredness, loss of taste or smell, sore throat, headache, aches and pains, diarrhea, a rash on the skin and red or irritated eyes. Serious symptoms, such as difficulty breathing, loss of speech or mobility, and chest pain, were also observed. The virus mainly replicates in the respiratory tract, including the nasal cavity, trachea, bronchi, and lung lobes. Viral RNA and infectious virus were first detected at 3 dpi in nasal turbinate, soft palate, tonsil, and lymphoid tissues. Viral RNA showed transient tissue spread, and infectious antigens were detected only in the nasal epithelium and lymph nodes. Viral shedding was detected in nasal washes, saliva, feces, and urine of infected ferrets until 8 dpi.393 Histopathological findings included rhinitis and tracheitis associated with epithelial damage, as well as interstitial or suppurative pneumonia. However, viral RNA and pathology were not observed in most tissues at 14 dpi.394 Additionally, alterations in biochemical markers, including increased levels of GLU, ALB, and AST and decreased levels of BUN, CRE, and ALP, were observed in infected animals. However, no significant clinical signs were observed in young ferrets after infection via the IN or intratracheal (IT) route.395 Therefore, SARS-CoV-2 infection in young ferrets appears to be a good small animal model for asymptomatic human infection.396 Interestingly, the transmissibility of different SARS-CoV-2 variants varies among ferrets. The SARS-CoV-2 beta strain did not replicate in ferrets, whereas the WA1, alpha, and delta strains replicated in the respiratory tract of ferrets. WA1 viruses can be transmitted via direct contact but not via the air, while delta viruses can be transmitted via both the air and direct contact.397 The susceptibility of ferrets to SARS-CoV-2 infection was also dose dependent.398 After infection, viral RNA was detected in the nasal washes of ferrets in the high-dose (5 × 106 PFU)- and medium-dose (5 × 104 PFU)-infected groups at 1 dpi, and viral RNA shedding peaked at 2–4 dpi and 2–6 dpi, respectively. In contrast, in the low-dose group, 16.7% (1/6) of ferrets (5 × 102 PFU) had detectable viral RNA in their nasal washes. Reduced activity was found in all ferrets at 9 dpi in the high-dose group and one day later in the medium-dose group. Histopathological features of high-dose ferrets included mild necrosis of epithelial cells and inflammatory cell infiltration in the nasal cavity, multifocal bronchopneumonia, interstitial pneumonia, and proliferation of type II pneumocytes. In the medium-sized group, mild multifocal bronchopneumonia and bronchopneumonia were observed in no more than 5% of the lung sections. Inflammatory cell infiltration in the liver portal areas was more severe in animals in the high- and medium-dose groups than in the animals in low-dose group. Consequently, a high dose of SARS-CoV-2 and aged animals may be needed in a COVID-19 ferret model.

Overall, only a small portion of the ferrets exhibited obvious clinical symptoms throughout the infection course. The susceptibility of ferrets to SARS-CoV-2 infection was age-dependent. Aged ferrets presented higher virus loads and longer shedding in respiratory secretions than young animals did due to higher expression levels of ACE2 and TMPRSS2, receptors of virus entry, in the upper respiratory tract.399 Moreover, the expression of type I interferons, activated T cells, and M1 macrophage response genes was strongly upregulated in aged ferret lungs, which is in agreement with what has been observed in patients with severe COVID-19.400 Overall, compared with young ferrets, aged ferrets more accurately mimicked disease features.

Minks

Mink (Neovison vison), a member of the Mustelidae, has previously been used as an animal model for SARS-CoV infection.401 During the COVID-19 pandemic, SARS-CoV-2 was transmitted to minks in the Netherlands, Denmark and other European countries. SARS-CoV-2 is highly transmissible in minks through direct contact and respiratory droplets.402,403 Importantly, SARS-CoV-2 variants have been found in minks, and relevant transmission from minks to humans has also been confirmed.404 Minks are highly susceptible to SARS-CoV-2 due to their functional receptor ACE2.405,406 Clinical manifestations of SARS-CoV-2 infection in minks were dependent on the challenge dose and virus strain. Minks intranasally inoculated with 5 × 106 PFU of the original SARS-CoV-2 strain developed severe pathological injury in the respiratory tract and caused up to 20% weight loss.403 Minks intranasally infected with the SARS-CoV-2 Omicron variant at a dose of 4 × 105 PFU developed mild to moderate clinical signs, including lethargy, diarrhea, nasal signs and sneezing.407 In contrast, mink intratracheally challenged with 106 TCID50 of SARS-CoV-2 Omic mimicked the pathological features of severe COVID-19. Notably, the viral RNA concentration reached 7.15 log10 RNA copies/mL in nasal lavage fluid and 6.73 log10 RNA copies/mL in throat swabs at 1–2 dpi. In addition to the respiratory tract, viral RNA was also detected in the lungs, brains, and eyeballs of infected animals. Pathology revealed diffuse alveolar damage, extensive edema or fibrin exudation in the alveolar lumina, and infiltration of activated macrophages and neutrophils, recapitulating lung signatures observed in COVID-19 patients. Additionally, inflammatory responses were also observed in the gastrointestinal tract, liver, heart, and kidney.408

Nonhuman primates

Rhesus macaques and common marmosets

Rhesus macaques and common marmosets are susceptible to MERS-CoV infection. MERS-CoV caused transient lower respiratory tract infection in rhesus macaques, whereas a more severe disease course was observed in infected common marmosets.409,410 SARS-CoV-2 infection in rhesus macaques leads to mild clinical disease and abundant viral replication in the respiratory tract. Fever, weight loss, decreased appetite, and hypoxia are commonly reported symptoms. In some cases, abnormal blood indices, such as a decrease in platelet count, transient neutropenia, and lymphopenia, has also been reported.411,412 Histopathological lesions included pulmonary discoloration, consolidation, hyperemia, glass opacity, infiltrates, hemorrhage, scarring, necrosis, and interstitial pneumonia.413 Lesions in the liver and spleen were also noted. Although rhesus macaques most closely recapitulate human symptoms of COVID-19, some typical clinical symptoms, including acute respiratory distress syndrome, were not observed, which limits their application in detailed studies of COVID-19.

SARS-CoV mainly infects bronchial epithelial cells and type-1 and type-2 pneumocytes in the respiratory tract of cynomolgus macaques and causes multiple foci of acute DAD.414 Mild symptoms such as cough, mild breathing difficulties, reduced food and water intake and decreased activity were observed.415,416 Viral RNA was detected in both nasal swabs and oral swabs at 3–5 dpi. Respiratory and conjunctival SARS-CoV infections induced unifocal and multifocal pneumonia at 8–10 dpi.417 Although there are dramatic differences in the number of host genes regulated during infection with different SARS-CoV strains, the major genes associated with the inflammatory response are similar.418 Inflammatory cytokines and chemokines, such as IL-6, IL-8, IFN-γ, CXCL1, CXCL2, and CXCL10, which are associated with acute lung injury (ALI) and ARDS, were induced after infection in cynomolgus macaques.419,420 In addition, investigations of the challenge route have been performed in cynomolgus macaques. Challenge with the HKU39849 isolate of SARS-CoV via IN, intravenous (IV), or intragastric (IG) route did not affect the lower respiratory tract, whereas IT inoculation induced lung lesions, which are associated with the replication of SARS-CoV in alveolar cells, macrophages, neutrophils, and cytokine responses. In addition, high levels of IL-8 and TNF-α, which are elicited by activated alveolar macrophages and neutrophils and are responsible for lung lesions, were detected in the lungs and peribronchial lymph nodes of IT-inoculated macaques.421 IN and IT inoculation of cynomolgus macaques with MERS-CoV did not cause clinical signs. Viral RNA was first detected at 1 dpi and peaked at 1 and 2 dpi in nasal and throat swabs. Additionally, a low level of viral RNA was observed in rectal swabs at 2–3 dpi. MERS-CoV RNA was detected mainly in the respiratory tract of infected macaques. Foci pulmonary consolidation was characterized by mildly depressed areas in the lungs. Histopathological features in the lungs manifested as typical DAD, which was consistent with the replication of the virus in the lower respiratory tract.422

Cynomolgus macaques

SARS-CoV-2 replicates mainly in the upper and lower respiratory tracts, and viral infection does not cause lethal outcomes in cynomolgus macaques, which exhibit mild to severe pneumonia, fever, viral shedding, respiratory abnormalities, immune cell infiltration, or inflammatory response. Pathological changes mainly included pulmonary consolidation and diffuse alveolar damage.423 Recent studies have compared susceptibility to SARS-CoV-2 among cynomolgus macaques, rhesus macaques (RMs), common marmosets (CMs), and AGMs.422 After exposure to SARS-CoV-2 at a mean dose of 3.84 × 104 PFU via the aerosol route, AGMs, RMs, and CMs presented respiratory abnormalities and viral shedding. After infection, CMs developed fever, and AGMs and RMs develop thrombocytopenia. Type II pneumocyte hyperplasia and alveolar fibrosis were more frequently observed in challenged AGMs and CMs. CMs developed consistent disease and exhibited the most severe clinical manifestations among these three macaques.424 SARS-CoV-2 was intratracheally and/or intranasally infected into macaques and mainly replicated in the upper and lower respiratory tract, causing pulmonary abnormalities, fever, and weight loss in both cynomolgus macaques and rhesus macaques, whereas fever was observed in only half of the infected common marmosets. Compared with the other two monkeys, rhesus macaques presented the highest levels of inflammatory cytokine expression and pulmonary pathology changes after infection.411 Therefore, differences in virus strain, dose, and route of challenge might cause significant differences in the clinical signs of infection in macaques.425 In addition, a head-to-head study showed that SARS-CoV-2-challenged cynomolgus macaques and rhesus macaques did not exhibit significant differences in weight loss or body temperature changes. In addition, these two species exhibited similar histopathological changes, including alveolar necrosis, type II pneumocyte hyperplasia, and interstitial lymphoid infiltrates.426 Overall, these two species responded similarly to SARS-CoV-2 infection.

The severity of SARS-CoV-2 infection in cynomolgus macaques was age-associated. After exposure to SARS-CoV-2, aged cynomolgus macaques presented greater viral RNA levels and longer infection periods than young animals. After inoculation with SARS-CoV-2 via IT or IN route, viral RNA was detected in nasal or throat swab samples, respectively, and the levels peaked at 1 and 2 dpi, respectively, in young cynomolgus macaques, whereas both types of RNA peaked at 4 dpi in aged animals. Additionally, a greater level of viral RNA in nasal swabs were observed in aged animals than in young animals.422 Decreased white blood cell and platelet counts were observed in both young and aged cynomolgus macaques. However, significant weight loss was not observed in these two groups.427 Moreover, proteomic and metabolomic analyses revealed that neutrophilia, lymphopenia and cytokine storms were significantly weakened in SARS-CoV-2-infected cynomolgus macaques, which was consistent with reports of clinical symptoms in patients with moderate COVID-19.428

In SARS-CoV-2-challenged African green monkeys, transient fever, decreased appetite, hypercapnia, lymphocytopenia and thrombocytopenia, elevated liver-related enzymes, and increased monocytes were observed.424,429,430 Like in other NHPs, viral pneumonia, severe pulmonary consolidation with hemorrhage and infiltration, extensive pulmonary lesions and gastrointestinal abnormalities were also observed in infected animals. Common histopathological lesions included pulmonary discoloration, opacity, bronchiolization, hyperemia, and pleural adhesions.429 Compared to rhesus macaques, African green monkeys exhibited more severe consolidation and edema in the lung lobes.424 In particular, ARDS, a common and often fatal characteristic that is difficult to replicate in other NHPs, was sustainably observed in aged African green monkeys. African green monkeys, especially aged animals, are useful models for severe COVID-19.430

Baboons

Compared with macaques, baboons are more susceptible to SARS-CoV-2 infection and exhibit more severe histopathological lesions, prolonged viral RNA shedding and substantially more lung inflammation.431 In contrast, marmosets are less susceptible to severe acute respiratory syndrome 2 (SARS-CoV-2) than macaques or baboons.431 Preclinical studies in the NHPs of patients with COVID-19 revealed immune correlates of protection and simultaneously provided remarkable predictive value for the outcome of clinical efficacy studies of COVID-19 vaccines.432–434 Moreover, studies in NHPs accurately reflected that protection against symptomatic COVID-19 infection would be easier to achieve than protection against viral replication in the upper respiratory tract.435 According to the NHP model, more viral breakthroughs were observed following beta VOC challenge than following homologous WA1/2020 challenge.436 Overall, rhesus macaques are the most common NHPs for COVID-19 infection because they are commercially available and manifest clinical symptoms quite well. Cynomolgus macaques usually exhibit pulmonary consolidation but show weak clinical symptoms. In contrast, African green monkeys generally exhibit severe symptoms, but their scarcity greatly limits their use. Nevertheless, natural protective immunity, such as innate, humoral, and cellular immune responses, can be induced in these NHPs.

Medical countermeasures for beta-coronavirus diseases

Globally, no vaccines or therapies have been approved for SARS-CoV or MERS-CoV. Approved COVID-19 vaccines are based on both traditional and novel techniques. Here we provide insights into advanced vaccines and approved therapies for COVID-19, especially antibodies and small molecule drugs (Table 7).Table 7 Representative medical countermeasures for beta-coronaviruses

Classification	Manufacturer	Name	Platform/Strategy	Stage	Efficacy/Benefic	References	
Vaccines	Sinopharm/Sinovac Biotech	CoronaVac/ BBIBP-CorV	Whole virus inactivated vaccines	Licensed	50% protective efficacy	903–905	
CanSinoBIO	Convidecia	Encoding the S of SARS-CoV-2 based on Ad5	Licensed	57.5% protective efficacy; aerosolized	476–478	
Wantai Biological	dNS1-RBD	Encoding the RBD of SARS-CoV-2 based on IFV	Licensed	28.2% protective efficacy and applicable in boosting	473	
Johnson	Ad26-S	Encoding the RBD of SARS-CoV-2 based on Ad26 vector	Licensed	52.9% protective efficacy	432,455,479	
Russia	Ad26 + Ad5-S (SPUTNIK V)	Prime-boost strategy of two viral vector vaccines	Licensed	91.4% protective efficacy	456	
AstraZeneca	ChAdOx1-S	Encoding the S gene of SARS-CoV-2 based on ChAdOx1 vector	Licensed	70.4% protection protective efficacy	456	
Modena/BioNTech	mRNA-1273/ BNT162b2	Encoding the S gene of SARS-CoV-2 based on mRNA platform	Licensed	90% protective efficacy	490,492,906,907	
Clover Biopharmaceuticals	SCB-2019	S-Trimer	Licensed	67·2% protective efficacy	443	
Novavax	NVX-CoV2373	S-Trimer	Licensed	90.4% protective efficacy	445,908,909	
Zhifei Longcom	ZF2001	RBD-dimer	Licensed	75.7% protective efficacy	449,450	
Antibodies	Genentech	Tocilizumab (Actemra)	Humanized mAb targeting IL-6R and inhibit subsequent signal transduction	Licensed	Improve survival and other clinical outcomes	501,502	
Eli Liliy and AbCellera	LY-CoV555 (bamlanivimab)	Human antibodies targeting S1	Licensed	Reduces viral load, disease symptoms, and hospitalization and emergency treatment risks	505,910	
Junshi Biosciences	LY-JS016 (LY-CoV016)	
Regeneron Pharmaceuticals	REGN-COV2	RBD-targeting antibody cocktail	Licensed	Reduces the viral load and alleviates symptoms in non-hospitalized COVID-19 patients	506,509,510	
BriiBio	Amubarvimab/Romlusevimab	Human antibodies targeting S1	Licensed	Reduced the hospitalization and mortality risk by 80%	515	
China	4A8	nAbs targeting the NTD	Clinical	Did not compete with antibodies targeting other regions of the S protein	517	
Small molecule drugs	Gilead technology	Remdesivir (GS-5734)	RdRp inhibitor	Licensed	Not sure efficacy of remdesivir in treating COVID-19	532,533	
Merck	Molnupiravir	RdRp inhibitor	Licensed	Higher proportion of viral RNA clearance and infectious virus elimination in clinical trials	537	
Junshi Biosciences	VV116	RdRp inhibitor	Licensed	Clinical benefits	539	
Pfizer	Paxlovid (Nirmatrelvir+Ritonavir)	Mpro inhibitor	Licensed	Reduce hospitalization and mortality rates in patients	542	
Incyte	Baricitinib	JAK signal pathways inhibitor	Licensed	Reduced mortality in hospitalized patients	545	
Kintor Pharmaceutical	Proxalutamide	Androgen receptor antagonist	Licensed	Higher recovery rate and lower all-cause mortality rate; reduced the rate of hospitalization by 91%	548,549	
S spike, SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2, Ad5 Adenovirus type 5, RBD Receptor binding domain, IFV Influenza virus, Ad26 Adenovirus type 26, ChAdOx1 Chimpanzee adenovirus type 1, mAb Monoclonal antibody, IL-6R IL-6 receptor, NTD N-terminal domain, RdRp RNA dependent RNA polymerase, Mpro Main protease, JAK Janus kinase

Preventive vaccines for beta-coronavirus diseases

Inactivated vaccines

Inactivated vaccines are traditional platforms that use radiation or chemical substances to inactivate pathogens of interest under eligible biosafety conditions. More than three inactivated COVID-19 vaccines have been approved. These vaccines are immunogenic, capable of inducing S protein or N protein-specific antibodies and nAbs and are safe in clinical trials.437–439 Inactivated vaccine platforms provide timely choices for safe vaccines during emergencies. Exposure to complete antigen epitopes of coronaviruses enables the inducing of immune responses other than those involving S protein. However, inactivated viruses lack pathogen-associated molecular patterns (PAMC) and therefore can not simulate the natural process of viral infection. Also, inactivated viruses cannot arouse mucosal immune response and thus show limited ability to block transmission.

Protein subunit vaccines

Subunit vaccines were developed by obtaining immunogenic proteins or peptides from pathogens. Compared with traditional approaches that obtain monomeric immunogenic proteins from eukaryotic expression system, novel techniques have facilitated antigen assembly and display in various forms.440 For example, the S protein with a stabilized trimeric form (S-Trimer) has been widely investigated in vaccine designs for SARS-CoV and MERS-CoV and has been proven to be safe and immunogenic.441,442 Clover Biopharmaceuticals developed an S-Trimer subunit vaccine named SCB-2019.443 Coupled with CpG/Alum adjuvants, an overall protective efficacy of 67·2% was reported in phase III clinical trials.444 NVX-CoV2373, which was developed by Novavax, is another S trimers-based COVID-19 vaccine tha has been approved.445 To develop a universal vaccine for both beta-CoVs. A dimeric form of MERS-CoV RBD was described, which significantly increased NAb titers compared to conventional subunit vaccine approaches. The structure guided design enabled the RBD dimer to fully expose receptor-binding motifs and yielded a stable version of RBD-dimer.446 Similarly, another tandem-repeat dimeric RBD protein-based COVID-19 vaccine, known as ZF2001, was developed and approved.447 In subsequent attempts, it was proven that antigens from novel variants, for example, the delta-omicron chimeric RBD-dimer, could better adapt to prevalent variants and elicite broader serum neutralization of SARS-CoV-2 variants.448 Additionally, these RBD-Dimer vaccines, such as, BQ.1, BQ.1.1, an XBB, have been shown to have broad neutralizing effects on SARS-CoV-2 variants. In clinical trials, a three-dose regimen of ZF2001 was found to be safe and responsible for a protective efficacy of 75.7% for at least 6 months.449,450 There are also reports of structure-based nanoparticle vaccines that display 60 copies of the SARS-CoV-2 RBD in a highly immunogenic array.451 Compared with inactivated vaccines, protein subunit vaccines are also safe, simultaneously, they repeatedly and adequately display of immunogenic proteins, which promises a broader spectrum of protection. However, these vaccines are also weak inducers of mucosal immune response.

Viral vector vaccines

Viral vector vaccines are replication-competent/deficient viral particles whose genomes have been modified to carry foreign genes encoding the targeted antigens for infectious disease without the involvement of hazardous pathogens. Viral vector vaccines can simulate the natural infection process of specific pathogens, thus triggering robust innate, mucosal, humoral and cellular immunity against infectious diseases and providing choices for pathogens that hamper control efforts using conventional vaccine approaches.452 Notably, due to the expression of diverse PAMPs, viral vectors have intrinsic adjuvant properties that effectively activate innate immunity in the absence of adjuvants.453 Several viral vector-based prophylactic vaccines have entered Phase III clinical trials or have been approved for use against beta-CoVs.454–458

In attempts to use a VSV vector for Beta-CoVs, single dose-vaccination with VSV-based vaccines induced robust and long-lasting immune responses.459–462 Notably, VSVΔG-based vaccine designs exhibit altered tropism, which enables mucosal delivery routes such as oral and intranasal vaccination and induces a mucosal immune response. Parainfluenza viruses (PIVs) were also hopeful viral vectors for Beta-CoVs. Several PIV vectors have been investigated, including human parainfluenza virus type 2 (hPIV2), human parainfluenza virus type 3 (HPIV3), parainfluenza virus type 5 (PIV5) and chimeric bovine/human PIV consisting of the bovine PIV3 (BPIV3) strain Kansas, in which the BPIV3 HN and F glycoproteins have been replaced by those of the human PIV3 strain JS (B/HPIV3).463,464 PIV-based vaccines were designed to expressing full-length prefusion-stabilized or conventional S protein of Beta-CoVs.465,466 A single IN dose vaccination of these replication-defective/competent constructs induced high levels of S-specific IgG and mucosal IgA antibodies in animal models.467–470 Several live-attenuated influenza virus (IFV) vectored COVID-19 vaccines have been developed. dNS1-RBD is an approved COVID-19 vaccine, in which the SARS-CoV-2 RBD gene was inserted in place of IFV NS1 by gene reassortment.471,472 dNS1-RBD induced rapid, long-term, and broad-spectrum immune responses, particularly local resident memory T cells in the respiratory tract.472 In clinical trials, IN inoculation of dNS1-RBD was tolerated in healthy adults;457 however, humoral and mucosal immune responses against SARS-CoV-2 were weak. The overall protective efficacy of dNS1-RBD was 28.2%.473

The Ad5-nCoV vaccine was designed to deliver the S gene of SARS-CoV-2, which is well tolerated in humans and induces S-specific antibodies and nAbs, and a T-cell response.474,475 In further attempts, heterologous boost immunization with aerosolized Ad5-nCoV following two-dose priming with an inactivated COVID-19 vaccine was proven to be safe and highly immunogenic compared to the homologous prime-boost strategy.476–478 Similarly, Harvard Medical School and Russia constructed an Ad26-vectored and Ad26 plus Ad5 vector COVID-19 vaccine.432,455,479 The University of Oxford developed a ChAdOx1-vectored COVID-19 vaccine.480,481 The protective efficacy of these Adv based COVID-19 vaccines is 50–70.4%.456,458,482 For adenovirus vector-based vaccines, preexisting antiviral immunity is the main obstacle to address. Poxvirus vectors have attracted increasing attention for their ability to induce long-lasting T-cell immune responses.483 One of the most paramount poxvirus vectors is modified vaccinia virus Ankara (MVA). Single-dose vaccination of MVA-vectored coronavirus vaccines expressing the S protein induced high levels of NAbs.484–486

Nucleic acid vaccines

Nucleic acid vaccines can be further divided into DNA vaccines and mRNA vaccines. mRNA vaccines are more popular due to their simple production process/industrialization, flexibility to be edited, and ability to induce a better immune response.487 mRNA-1273 and BNT162b2 were wildly distributed during the COVID-19 pandemic. These mRNA vaccines are modified and delivered via lipid nanoparticle systems. Compared with traditional vaccines, mRNA vaccines efficiently translate the encoded mRNA in-vivo, and enable cell-free and scalable productions.488 Both mRNA-1273 and BNT162b2 encode the perfusion-stabilized S protein, which induces robust SARS-CoV-2 nAbs and achieves protection in airways in animal models.433,489–491 In clinical trials, they were highly immunogenic and offered a protective efficacy of more than 90%.490,492 Lipid nanoparticle-encapsulated mRNA (mRNA-LNP) encoding the RBD of SARS-CoV-2 was also developed (termed ARCoV).493 In Phase I clinical trial, ARCoV was shown to be safe and immunogenic, which warrants further large scale clinical testing.494

Therapies for Beta-coronavirus diseases

Passive serum therapy

Passive serum therapy has been clinically applied for treating SARS, MERS, and SARS-CoV-2.495 Prior to the successful development of effective drugs, CPT has become an active clinical intervention method for the treatment of COVID-19. There have been reports of COVID-19 patients with a good prognosis who underwent CPT. CPT showed ability in antiviral, immunomodulatory, anti-inflammatory, and antithrombotic, making it a potentially effective approach for treating viral infections. On the other hand, it should be noted that CPT can cause moderate to severe transfusion-related reactions, including fever, allergies, life-threatening bronchospasm, acute lung injury, and increased circulatory load, in patients with kidney and cardiovascular disease. Patients undergoing CPT should be continuously monitored to ensure a timely response to possible adverse reactions.496 Additionally, there are still administrative and technical barriers to the application of CPT, including the availability, screening, approval, collection and monitoring of blood donors and the allocation of a sufficient number of laboratory facilities.

Neutralizing antibodies

Compared with plasma therapy, neutralizing antibodies show better specificity and safety, and can be applied in both prevention and treatment.497,498 Antibodies can be classified according to their source, structure, and method of acquisition. Neutralizing antibodies are important therapeutic approaches for treating COVID-19, particularly severe cases of COVID-19 in clinical. Antibodies bind to antigens through Fab, blocking the entry of pathogens into cells. Fc can also cause ADCC, ADCP, and complement-dependent cytotoxicity (CDC), and in some cases, induce antibody-dependent enhancement (ADE). There are also antibodies that target dysregulated immune responses, termed nontargeted monoclonal antibodies.

Nontargeting mAb drugs usually act as immune modulators in the treatment of severe cases. Potential targets, including interleukin-6 receptor (IL-6R)/IL-6, tumor necrosis factor, and human epidermal receptor 2 (HER2) have been described. Previous studies have shown that IL-6 is a proinflammatory cytokine, and its release can induce a series of downstream proinflammatory responses, which serve as an important pathway for inducing cytokine storms in COVID-19 patients.499,500 In response, tocilizumab was designed to alleviate cytokine storms in COVID-19 patients. Tocilizumab is a recombinant humanized mAb that can specifically bind to the interleukin-6 receptor (IL-6R), thus inhibiting subsequent signal transduction.501 The FDA approved tocilizumab because of its potential benefits in clinical trials to improve survival and other clinical outcomes.502 However, the therapeutic efficacy of tocilizumab is controversial, since some clinical trials have suggest that tocilizumab does not result in a significantly better clinical outcome or lower mortality.503,504

SARS-CoV-2 specific NAbs mainly target four regions within the S protein, including the N-terminal domain (NTD), RBD, stem helix region and fusion peptide region.497 S1-targeting NAbs work by blocking receptor-ligand recognition. LY-CoV555 (bamlanivimab) was the first FDA-approved NAb developed by Eli Liliy and AbCellera. Compared to placebo, a single intravenous injection of LY-CoV555 was associated with limited benefits. In another study, combination therapy with LY-CoV555 and LY-CoV016 (JS016) significantly reduced the viral load, disease symptoms, and hospitalization and emergency treatment risks in mild and moderate COVID-19 patients.505 REGN-COV2 is another RBD-targeting antibody cocktail developed by Regeneron, that is composed of the REGN10987 and REGN10933 antibodies. REGN-COV2 was obtained by matching the antibody genes from the VelocImmune mice with those from the convalescent patients.506 REGN10933 and REGN10987 which are ideal partners against the development of escaped virus mutants in response to selective pressure from a single antibody, which were selected as non-competing highly-potent binding to the RBD of SARS-CoV-2,.507 Preclinical studies have shown that REGN-COV2 can reduce the viral load and associated damage in the lungs of nonhuman primates in rhesus monkeys and golden hamsters.508 According to Phase III clinical trials, REGN-COV2 reduces the viral load and alleviates symptoms in nonhospitalized COVID-19 patients.509,510 JS016 (etesevimab) was developed by Junshipharma. Initially, CA1 and CB6 were isolated from COVID-19 convalescent patients.511 Among them, CB6-LALA, also known as JS016 mAb, showed stronger neutralizing activity, and L234A and L235A were introduced into the Fc segment to remove the ADCC effect. In rhesus monkeys, CB6-LALA showed therapeutic and preventive effects. In this phase 3 trial among high-risk ambulatory patients, bamlanivimab plus etesevimab led to a lower incidence of hospitalization and death and accelerated the decline in the SARS-CoV-2 viral load.512,513 Amubarvimab/Romlusevimab (BRII-196 plus BRII-198) are mAbs approved for the treatment of COVID-19 by the National Medical Products Administration of China.514 In Phase III clinical trial, BRII-196 plus BRII-198 treatment reduced the hospitalization and mortality risk by 80%.515 However, the results of the phase III clinical trial of the ACTIV-3 clinical study showed that there was no significant difference between the protection rate of the combination therapy of mAb and the placebo for severe hospitalized patients with COVID-19, and this result was the same as that of GlaxoSmithKline’s neutralizing antibody against COVID-19. However, BRII-196 plus BRII-198 showed no efficacy in improving clinical outcomes among adults hospitalized with COVID-19.516

4A8 is one of the earliest identified nAbs targeting the NTD.517 Among the five structural loops in the NTD (N1–N5), 4A8N3 interacted with N3 and N5. Similarly, other NTD-targeting mAbs, such as COV2-2676, COV2-2489, 4–8, and 5–24, also recognize structural loops.518,519 Importantly, since NTD-targeting antibodies do not compete with antibodies targeting other regions of the S protein, antibody cocktails combining NTD-targeting antibodies with non-NTD-targeting antibodies are feasible. Interestingly, it has been reported that potent NTD-directed neutralizing antibodies appear to target a single supersite, which is defined as the strongly positively charged epitope in the NTD.520,521

In contrast to those in the S1 subunit, neutralizing epitopes in the S2 subunit are more conserved. S2-targeting NAbs can inhibit SARS-CoV-2 infection by preventing fusion mediated by S protein. Representatively, S2P6 is a humanized S2 subunit-targeting mAb that exhibits broad-spectrum neutralization of beta-CoVs.522 S2P6 bound to 14 residues in the S2 stem helix (SH) region, and these epitopes were conserved across beta-CoVs. The Fc effector functions of S2P6 also play a critical role in virus clearance. S2P6 can broadly neutralize beta-CoVs, with IC50 values of 1.4 μg ml−1 for SARS-CoV-2, 2.4 μg ml−1 for SARS-CoV, and 17.1 μg ml−1 for MERS-CoV. Apart from the SH region, S2 fusion peptides (FPs) are also highly conserved among coronavirus genera and corresponding NAbs, such as VN01H1 and VP12E7, have also been developed.523 Interestingly, this type of antibody binds S2 FPs without competition with S2 SH-targeting antibodies, highlighting the possibility of combining S2 SH and S2 FP bispecific antibodies.523 The synergistic effects of S2 FP-targeting and RBD-targeting nAbs have also been confirmed.524 Although S2-targeting NAbs showed inferior neutralizing potency compared with that of RBD-targeting antibodies, S2 has the potential to be a broad-spectrum neutralizing.525

Overall, NAb treatment significantly reduced the risk of hospitalization and/or death among nonhospitalized adults with mild to moderate SARS-CoV-2 infection at high risk for progression to severe disease, but showing limited efficacy in treating severe cases. Another concern for developing neutralizing antibodies is escape by variants. Representatively, the Omicron variant of SARS-CoV-2 escapes more than 85% of 247 human SARS-CoV-2 neutralizing antibodies.526

In addition to the use of antibody cocktails, another promising method is to engineer them into bispecific or even multispecific antibodies, which confer synergistic neutralization. In addition to increasing the threshold for the generation of neutralization escape mutants, the dual antibody has a cost advantage over the mAb cocktail strategy, and the complex formulation of the mAb cocktail usually increases production costs and affects yield. For example, different RBD class antibodies or RBD-targeting antibodies can be combined with NTD-targeting and/or S2-targeting antibodies. Such attempts have already shown the ability to avoid escape and enhance neutralizing ability.527 Overall, antibodies in RBD class 1 and class 2 in the NTD supersite are more prone to mutation and consequently lose their neutralizing activity. In contrast, antibodies targeting S2 epitopes are more conserved. Therefore, balance between the breadth and potency of nAbs is needed. On the other hand, comprehending the characteristics of these bnAbs could provide guidance for devising more effective vaccines focused on conserved viral epitopes for the development of broad-spectrum antibody therapies. However, clinical research on antibody drugs has focused mainly on preventive efficacy, while therapeutic applications are limited due to the lack of animal models that accurately simulate human infection.

Bispecific nanobodies against SARS-CoV-2 have also been reported.365 These nanobodies could reach the conserved and cryptic epitope of SARS-CoV-2. This small volume of bispecific nanoantibodies has a molecular size of only 27 kDa. Compared to traditional mAb drugs, which target the internal region of S trimer, nobodies can enter and bind tightly to the hidden epitope.528 Together with their high tissue penetration ability, bispecific nanobodies can be formulated as an inhalable preparation that shows improved lung targeting.

Small molecule drugs

Compared to monoclonal antibodies, small molecule drugs are more flexible in binding to target molecules.529 Antiviral strategies against SARS-CoV-2 were explored in several aspects, including direct inhibition of key viral proteins such as RdRp and Mpro, interference with host enzymes such as ACE2 and proteases, and blocking relevant immunoregulatory pathways.530

Targeting RdRp

Remdesivir was previously developed for the prevention of EBOV. It is the first FDA-approved drug for COVID-19, it functions as a nonobligate and inhibits RNA-dependent RNA polymerase (RdRp).531 Structurally, the RNA template is inserted into the central channel of the RdRp, where remdesivir mimics a nucleotide. It is covalently incorporated into the replicating RNA at the first replicated base pair, and terminates chain elongation, thus blocking further synthesis of SARS-CoV-2 RNA.532 In clinical, there is some controversy over the efficacy of remdesivir in treating COVID-19.533 In nonhospitalized patients, a 3-day course given of remdesivir were proven to be safe and was responsible for an 87% lower risk than a placebo.534 In COVID-19 patients with or without or conventional oxygen support, remdesivir reduced mortality. For patients with more respiratory support or acquired immunity, the cost-effectiveness of remdesivir remains to be further elucidated.535 Like remdesivir, molnupiravir is another RdRp inhibitor developed by Merck that was approved for the treatment of patients with mild to moderate COVID-19.536 As a mutagenesis inducer, Molnupiravir was associated with increased proportion of viral RNA clearance and infectious virus elimination in clinical trials.537 In another clinical study, early treatment with molnupiravir after the onset of symptoms reduced the risk of hospitalization.538 VV116 is an oral antiviral agent with potent activity against COVID-19 that has been approved in China. Among adults with mild to moderate COVID-19 who were at risk for progression, VV116 showed efficacy comparable to that of nirmatrelvir-ritonavir, with fewer safety concerns.539 Three other RdRp inhibitor drugs, favipiravir (AVIFAVIR), and azvudine have also been approved.540,541 Moreover, far more RdRp-targeting small molecules are under investigation.

Targeting Mpro

Paxlovid is a popular oral small molecule COVID-19 drug that is composed of PF-07321332 (nirmatrelvir) and ritonavir. Wherein nirmatrelvir corresponds to Mpro inhibition, while ritonavir further improves efficacy by slowing the metabolism of Nirmatrelvir and maximizing its therapeutic benefits. Compared to placebo, paxlovid can significantly reduce hospitalization and mortality in high-risk patients with moderate to severe COVID-19 by 89 and 88%, respectively, within 3 or 5 days of symptom onset.542

Targeting proinflammatory signal pathways

Baricitinib is an approved oral selective inhibitor of JAK signaling pathways. It blocks cytokine-induced JAK/STAT/APOL1 signaling.543 Baricitinib improved the clinical outcomes of patients with COVID-19, reshaped the immune landscape, and alleviated the immunosuppressive effects in myeloid cells, consequently restraining the immune dysregulation.544 In Phase III clinical trials, treatment with baricitinib in addition to standard of care reduced mortality in hospitalized COVID-19 patients although not significantly.545 In clinical practice, remdesivir has been approved by FDA for the treatment of mild to moderate COVID-19 patients while Baricitinib, was approved for the treatment of severe hospitalized patients with COVID-19.546,547 Combination treatment with the baricitinib and remdesivir was safe and superior to remdesivir alone for the treatment of hospitalized COVID-19 patients. In addition to the JAK-STAT pathway, other COVID-19 associated proinflammatory signaling pathways, such as the BTK, NF-κB and NLRP3 pathways, have also been identified as targets.530

Receptor antagonist

Proxalutamide is an approved androgen receptor antagonist against SARS-CoV-2.548 Compared with the placebo, proxalutamide was associated with a greater recovery rate and lower all-cause mortality at day 14 and day 28, respectively.548 In another study, proxalutamide treatment reduced the rate of hospitalization by 91%.549 Furthermore, the anti-COVID-19 effect of proxalutamine remains to be verified by clinical trials in other countries because it has not been widely accepted.

Currently, there are more than 30 small molecule candidates in the phase III/IV clinical trial stages that target distinct viral proteins, host cell components, and immunoregulatory pathways. To better guide the development of small molecule drugs, a better understanding of SARS-CoV-2 pathogenesis, viral replication/life cycle and key viral components involved should be obtained. Additionally, further insights into virus-host interactions, or host immune system dysregulation by viruses are needed. Notably, the COVID-19 pandemic has encouraged the discovery of more compounds from natural products, and these attempts have enriched pools of the natural backbones of potential small molecule drugs for beta-CoVs.

Bunyavirus diseases

Etiology, epidemiology, and pathogenesis of Bunyavirus diseases

CCHF is caused by Crimean-Congo hemorrhagic fever virus (CCHFV), which is a widespread tick-borne viral zoonotic disease with a human mortality rate ranging from 9% to 50%.550 CCHFV is a member of the genus Nairovirus in the Bunyaviridae. CCHFV has spherical viral particles with a diameter of approximately 80–100 nm, and its spikes consist of glycoproteins GN and GC, which are located on the surface of the cell membrane and are responsible for binding the viral particles to cellular receptors. The virions contain negative-sense small (S), medium (M), and large (L) genomic fragments enveloped by NP and RdRp that initiate transcription and genome replication in host cells.551 In addition, secreted glycoprotein 38 (GP38), which corresponds to the maturation of CCHFV particles, could also be a potential of therapeutic target.552,553 The first CCHF outbreak occurred in Crimea in 1944.554 Subsequently, CCHF disseminated in the Congo, Africa, the Balkans, the Middle East, and Asia.555 CCHFV is transmitted mainly through direct contact with infectious blood, tissue and mucous membranes; through the bite of infected Hyalomma species ticks; or through contact with livestock with viremia.556 CCHF patients go through four stages of the disease: latent, prehemorrhagic, hemorrhagic, and recovery. The prehemorrhagic phase presents fever, muscle aches, chills, photophobia, headache, and nausea; mild cases recover from this phase, while severe cases progress to a bleeding phase involving petechiae, internal organs, gastrointestinal tract, gums, and nose bleeding; fatal patients suffer from multiorgan failure.557 Leucopenia, thrombocytopenia and elevated liver enzymes are hallmarks of this disease. After the virus entry, a series of events, including a decrease in white blood cells, thrombocytopenia, and a decreased hemoglobin levels are induced.558 Moreover, coagulation abnormalities, characterized by prolonged prothrombin time (PT) and activated partial thromboplastin time (aPTT), detectable fibrin degradation products, and D-dimers appeared. Elevated levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) indicate hepatic injury.559 Patients with severe CCHF develop lethal infections, including vascular leakage, multiorgan failure, shock, and hemorrhage. More recently, LDLR has been identified as an entry receptor for CCHFV. However, the pathogenesis of CCHFV is not well understood.560

Rift Valley fever virus (RVFV) is a mosquito-borne phlebovirus that causes febrile or hemorrhagic illness in ruminants and humans. RVFV is a single-stranded negative-sense RNA virus belonging to the genus Phlebovirus of the Bunyaviridae family. RVFV is a quasisymmetrical, icosahedral lattice with a diameter of 100 nm and an envelope decorated with surface glycoproteins.561 The glycoprotein precursors Gc and Gn, encoded by the M segment, are the primary targets for viral binding to cellular receptors and cell entry. The interaction of Gn with cell entry factors triggers endocytosis, and the low pH in the endosome enables Gc-mediated fusion of the virus with the membrane.562,563 Since its identification in Kenya in 1931, the disease has been repeatedly endemic in eastern and southern Africa and the Arabian Peninsula, causing enormous economic losses to society and posing a serious public health risk.564 The most recent RVF outbreak occurred in Kenya in 2020, resulting in 11 deaths. In human infections, the incubation period is approximately 2–6 days, followed by the sudden onset of fever, headache and muscle and joint pain. In human RVF, manifestations usually range from asymptomatic or self-limiting febrile illness; however, liver damage, hemorrhagic disease, encephalitis and neurological disorders are also observed in severe cases.565 Most patients recover quickly, but in severe cases, hemorrhagic fever and hepatic injury develop. Newborn lambs and goats are the most susceptible to RVFV, with a mortality rate of up to 90%. Rift Valley fever infection is first transmitted in livestock through mosquito bites but can also be transmitted vertically between animals. Human transmission occurs mainly through direct contact with the blood, excrement, meat, or secretions of infected animals and through the consumption of raw milk.566 RVFV infection leads to a remarked inflammatory response, including elevated proinflammatory factor levels, lymphocytic infiltration, neutrophilic infiltration, and a wide range of tissue damage and necrosis.567,568 Currently, no preventive or therapeutic approaches have been approved for CCHFV or RVFV. Preclinical attempts are ongoing and some of them have shown efficacy in animal models.

Animal models for Bunyavirus diseases

The study of CCHF has been hampered by the lack of ideal animal models. Most animal models exhibit viremia but no clinical signs after CCHFV infection. To address this issue, neonatal mice, immunodeficient mice and mouse-adapted models were generated and shown to be susceptible to CCHFV infection (Table 8). IFNAR−/− mice typically develop a rapid-onset fatal disease at 2–5 dpi prior to the development of adaptive immune responses. Additionally, CCHFV caused severe disease in STAT-1−/− mice and in mice lacking both the IFN-I receptor and type II interferon (IFNAGR−/−). Additionally, the IFN-I receptor was blocked with the specific antibody MAR1-5A3.569 Administration of MAR1-5A3 produced transient IFN-I blockade in mice and resulted in consistent lethal/severe CCHFV infection.570,571 This model provides a convenient choice as an IFN-I receptor knockout animal in virtually any wild-type or transgenic mouse without the need for crossbreeding. Compared to genetically KO animals, the antibody-mediated IFN-I blockade model exhibited identical symptoms and mean time to death. A humanized mouse model was also generated by transferring human CD34+ stem cells into NOD-SCID-gamma (NSG)-SGM3 mice. These immunodeficient mice lack mature T cells, B cells, and NK cells and exhibit defects in cytokine signaling due to the lack of a common gamma chain. The infection of these mice with CCHFV produced neurological disease, prolonged infection time, and led to death at 13–23 dpi.572 A mouse-adapted CCHFV strain (MA-CCHFV) was generated via serial passages of CCHFV-Hoti in Rag2−/− mice (deficient in adaptive immunity, recombination-activating-gene) and C57BL/6J mice. MA-CCHFV causes severe disease in WT mice through viral replication in multiple tissues, liver injury, and severe inflammation. Gender and age-associated disease severity were noted; female mice were largely resistant to severe disease, while young animals progressed to fatal outcomes. Both innate and adaptive immune responses have been proven to be necessary for protection.573Table 8 Animal models of CCHFV

Species	Animal model	Pathogens	Max. Dose	Route	Lethality	Signs of disease	Strengths/weaknesses	References	
Mice	Neonatal mice	IbAr 10200	50 LD50	IP	100%	Viraemia and death	Obvious symptoms/Lacking of full immune function	911	
IFNAR−/− C57BL/6 mice	IbAr 10200	104 TCID50	IP/IN/IM/SC	100%	Weight loss, ruffled hair, hunchback and lethargy	Highly susceptible to CCHFV and clinical signs similar to human patients/Lacking of important innate immune pathways	569,570,912	
STAT-1 knockout mice	IbAr 10200	103 PFU	IP	100%	Lethargy, piloerection, and hunched posture, fever	913	
IFNα/β/γR−/− mice	Ank-2 strain	100 TCID50	IP	100%	Weight loss, ruffled fur, depression and nasal/ocular discharge	914	
SGM3 humanized mice	Oman-199809166	104 TCID50	IP	0	Minimal weight loss and recovered	Disease process similar to humans/Time consuming and expensive	572	
Turkey-200406546	104 TCID50	IP	100%	Weight loss and severe neurological disease	
Mice adapted, Male mice	Hoti	104 TCID50	IP	0–100% (age-dependent)	Weight loss, piloerection, hunched posture, and lethargy	Immunocompetent animal model, gender and age-associated disease severity/Additional mutants introduced by virus adaptation	573	
Hamsters	STAT-2 knockout hamsters	IbAr10200	104 TCID50	IP/IM/SC	100%	Petechial rash, blood coagulation dysfunction, and biochemistry and blood cell count abnormalities	Applicable for pathogenesis study and recapitulated hallmarks of human disease/Immunodeficient and inapplicable for evaluating immune correlates	915	
Nonhuman primates	Cynomolgus macaques	Afghan09-2990	106.2 PFU	IV	0	Largely uniform and mild disease state	Immunocompetent animal model, similar to human transmission, organ pathology, and disease progression/not consistently lethal, inaccessibility and ethical issues	576,916	
Kosova Hoti	105 TCID50	IV/SC/SC + IV	0–75%	Thrombocytopenia, hypoproteinemia, edema and epistaxis	
IP intraperitoneal, SC subcutaneous, IV intravenous, IM intramuscular, IN intranasal, PFU plaque-forming units, TCID50 median tissue culture infective dose, CCHF Crimean-Congo hemorrhagic fever, CCHFV Crimean-Congo hemorrhagic fever virus, – not applicable

Overall, the mouse models above reliably succumb to CCHFV challenge but poorly reflect disease hallmarks in humans. Therefore, a STAT-2 knockout hamster model, which presented as systemic infection and lethal disease, was established. Typical signs of disease, including petechial rash, orbital bleeding, coagulation dysfunction, and abnormal biochemistry and blood parameters, are observed in humans. Among the NHP models used in CCHFV studies, African green monkeys, baboons, and patas monkeys were not susceptible to CCHFV and presented no clinical signs or fulminant disease.574 However, CCHFV-infected cynomolgus macaques exhibit piloerection, anorexia, a hunched posture, fever, rashes and orchitis, as well as thrombocytopenia, hypoproteinaemia, edema and epistaxis, manifesting as a clinical shock syndrome accompanied by elevated liver enzymes ALT and AST. In addition, prolonged CCHFV infection in the testes of monkeys was noted. Concurrent latent tuberculosis (TB) in the lungs and liver granulomas were also observed in some CCHFV-infected macaques, which highlights the public health implications of these emerging pathogens in overlapping endemic regions.575,576

In BALB/c mice, peripheral infection with RVFV triggers signs of disease, including coat coarsening, lethargy, weight loss and death (Table 9).577 These clinical signs appeared within 7 dpi, and some mice even died at 3 dpi.578 RVFV-infected mice exhibited acute hepatitis and encephalitis. As in humans, RVFV primarily injures the liver in mice, triggering extensive hepatocellular damage.577,579 The condition of the infected mice rapidly deteriorated. Surviving mice exhibited liver injury and encephalitis.580,581 Disease in the central nervous system was alleviated in mice that received vaccine prophylaxis and effective drug treatment.578 Aerosol infection of BALB/c mice with virulent RVFV ZH501 increased the mean time to death from an average of 3 days to 5 days or even longer.582,583 After viral invasion into the brain, mice develop neurological symptoms such as hind limb paralysis or cage circling. Taken together, these findings can be used to investigate the mechanism of RVFV invasion into the nervous system while providing a basis for evaluating the development of vaccines and drugs that prevent RVFV from triggering neurological diseases and encephalitis. In rats, initial RVFV replication occurs in macrophages of the draining lymph nodes, after which the virus is transferred to the liver, where it becomes infected and leads to high viraemia.584 After experimental infection with RVFV-ZH501, Wistar-Furth and Brown Norway rats were sensitive, with an LD50 of 1–5 pfu given by the SC or aerosol route.585,586 Infected rats succumbed at 3–5 dpi due to severe fulminant hepatitis.587 Total hepatic necrosis is a typical lesion. Compared to those of Wistar-Furth rats, the mortality of ACI and MAXX rats after IP or SC infection is approximately 50% with high doses of RVFV.588 Neurological symptoms and encephalitis were observed. Clinical signs include hind limb paralysis, circling, weakness, head tilt, head tremors, and ataxis.586Table 9 Animal models of RVFV

Species	Animal model	Strains	Max. Dose	Route	Lethality	Signs of disease	Strengths/Weaknesses	References	
Mice	BALB/c mice	ZH501	103 PFU	SC/IP	100%	Scuffled fur, lethargy, shivers, weight loss, hepatitis/hepatic necrosis, meningoencephalitis	Typical clinical symptoms/No hemorrhagic fever and ocular diseases	577,578	
ZH548	2 × 104 PFU	IP	<100%	579	
Rat	Sprague Dawley rats	ZH501	103 PFU	SC/Aerosol/Conjunctival	70%	Uvea, retina, and optic nerve infection, inflammation in the posterior eye	Mimicking ocular disease, encephalitis, hepatic necrosis and pneumonia in human RVF/-	917	
Wistar-Furth	ZH501	105.7 PFU	SC	100%	Hepatic necrosis, pneumonia, lethal encephalitis	918	
Lewis	ZH501	105.7 PFU	SC	16%	
MAXX rats	44%	
Hamster	Syrian hamsters	ZH501	5×103 PFU	IP	100%	Progressive viremia and hepatic necrosis	Highly susceptible to RVFV/Lack of encephalitis	590	
Ferret	Ferret	ZH501	106 TCID50	IN/ID	IN: >70%

ID: 0

	Mild self-limited febrile illness and later-onset severe encephalitis.	Mimicking RVFV CNS disease in humans/No hepatitis	564	
Nonhuman primates	Rhesus monkeys	ZH501	105 PFU	IV	18%	Lethal hemorrhagic fever, anorexia, sadness, vomiting, and weakness	Highly susceptible to RVFV/Disease ranged from clinically inapparent to death	919	
Marmosets	ZH501	107 PFU	SC/IV/IN/Aerosol	25–100%	Acute hepatitis, delayed encephalitis, and hemorrhagic illness	More closely resembles severe human RVF disease/Symptoms of disease are related to challenge route	920	
African green monkeys	ZH501	105.86 PFU	Aerosol	80%	Viral meningitis, formed blood clots, and death	Mimic natural human infections/inaccessibility, ethical issues	920	
Cynomolgus macaques	ZH501	105.18 PFU	Aerosol	0/18%	Fever	Insensitive to RVFV	920	
Ruminants	Sheep	ZH501	–	SC	0–30%	Acute hepatic necrosis, ocular lesions, abortion in pregnant ewes	Natural hosts and susceptible animal, applicable to transmission study/Nonstandardized animal models	921	
Calves (<1 month)	ZH501	–	SC	10–70%	Acute hepatic necrosis, meningoencephalitis	921,922	
ID intradermal, IN intranasal, SC subcutaneous, IP intraperitoneal, IV intravenous, CNS central nervous system, RVF rift valley fever, RVFV rift valley fever virus, PFU plaque formation unit, TCID50 median tissue culture infective dose, – not applicable

Ferrets infected with RVFV-ZH501 exhibited weight loss, hyperpyrexia, lymphopenia, hypoalbuminemia, and CNS diseases such as seizures and ataxia, which are associated with high viral RNA loads in the brain. In addition, mild increases in the AST, ALT, and total protein levels were observed in infected animals.564,589 Syrian hamsters are susceptible to RVFV infection, and even with minimal doses of the virus, susceptible animals die within 2-3 days. Niklasson et al. studied the protective effects of immunization in Syrian hamsters following IP infection with 5000 PFU RVFV; actively immunized hamsters and controls died within 4 days of virus attack, whereas passively immunized hamsters died 11 days after virus attack. Deaths are associated with massive hepatic necrosis, whereas late deaths are caused by encephalitis.590 The hamster model is applicable for evaluating the diagnosis, transmission, and medical countermeasures used against RVFV.591

Ruminants are natural hosts of RVFV and the severity of the disease varies between young and adult animals.592 RVFV infection in ruminants leads to abortion and death. Sheep are highly susceptible to RVFV, depending on the virus strain, breed, and age of the animals.593 Hepatic lesions developed in neonatal lambs infected with RVFV. Horizontal transmission to noninfected sentinel lambs was also observed. In adult lambs, RVFV infection causes transient pyrexia. Notably, RVFV infection led to uveitis in the Lambs, which progressed to lymphoplasmacytic endotheliitis and anterior uveitis that lasted 1 to 5 days. Hence, lambs may be a good model for studying RVFV-associated ocular pathology in humans.

Medical countermeasures for Bunyavirus diseases

Preventive vaccines for Bunyavirus diseases

Platforms engaged in CCHFV and RVFV vaccine development include inactivated vaccines,594 subunit vaccines,595 virus-like particle vaccines (VLPs),596,597 viral vector vaccines598–600 and nucleic acid vaccines23,57–60 (Table 10). Compared with tissue-derived vaccines, cell culture-based vaccines are more immunogenic.601,602 Several live attenuated RVFV vaccines are used in livestock and have been shown to be immunogenic, but these vaccines are of great safety concern.603 Subunit vaccines for RVFV were developed using baculovirus system expressing the Gn ectostructural domain (eGn) and full-length Gc, which protected animals against viral infections when an ISA-25 VG adjuvant was applied.604,605 When ectodomains of Gn and Gc were produced using a Drosophila insect cell-based expression system, this subunit vaccine induced high levels of NAbs but showed no protective efficacy in STAT1 knockout Mice. This result suggested that NAbs were not sufficient to confer protection.595 This phenomenon was also observed for mRNA, DNA, and VLP vaccines, which suggests that cell-mediated Th1 response and a balanced Th2 response are responsible to the protection.597,606 VLPs for RVFV were constructed using the Drosophila Insect protein expression system. When RVFV was used in combination with the Stimune adjuvant, protection against RVFV was achieved in BALB/c mice.607Table 10 Representative medical countermeasures for bunyaviruses

Classification	Name	Platform/Strategy	Stage	Efficacy/Benefic	References	
Vaccines	Live attenuated vaccine	Live attenuated RVFV	Licensed (Veterinary)	Immunogenic but are of safety concerns	601,603,923–927	
Subunit vaccine	Expressing the eGn and full-length Gc of RVFV	Preclinical	Protect sheep	604,605	
Viral like particles	Formulate VLPs of RVFV based on Insect Protein Expression System	Preclinical	Complete protection in mice	607	
DNA vaccine	Encoding the M-segment GPC gene or expressing GPC and the NP of CCHFV	Preclinical	Immunogenic and protect mice and NHPs	570,597,609	
Encoding the Gn and Gc glycoproteins of RVFV	Preclinical	612	
mRNA vaccine	Encoding for the CCHFV N or glycoproteins (GcGn)	Preclinical	Complete protection against mice	606	
CAdVax-GnGc	Expressing RVFV GnGc based on complex adenovirus-vectored	Preclinical	Immunogenic and protect animals	611	
MVA/Adv-N	Deliver the N gene of CCHFV based on MVA or Adv vector	Preclinical	Partially protection in mice	599,613	
Replicon RNA	Expressing CCHFV N or GPC	Preclinical	Complete protection in mice	614	
Antibodies	8A1, 11E7, and 30F7	Mouse antibodies targeting CCHFV Gn/Gc	Preclinical	Protect neonatal mice	553,623	
mAb-13G8	Mouse antibodies targeting CCHFV GP38	Preclinical	Protect IFNAR−/− mice	552,624	
c13G8	Chimeric human-mouse antibody	Preclinical		
ADI-37801/ 36121/36145	Human antibodies targeting CCHFV Gc	Preclinical	Complete protection in mice	626	
RVFV-268	Human antibodies targeting RVFV Gn	Preclinical	Prevents vertical transmission in rat/sterilizing immunity	630,633	
RVFV-268 + RVFV-140	Human antibodies targeting RVFV Gn	Preclinical	Effective at minimal doses and blocking both attachment and fusion	632	
R4, R12, R13, R16, R17, R19 and R22	Human antibodies targeting RVFV Gn/Gc	Preclinical	Complete protection in mice	634	
Small molecular drugs	Ribavirin	Broad spectrum antiviral drug	Preclinical	Controversial efficacy	616,617,913,915	
Favipiravir or derivative (H44)	RdRp inhibitor	Preclinical	Reduced mortality rate and decreased viral loads in mice/NHPs	616,618,619	
Fluorocytidine and molnupiravir	RdRp inhibitor	Preclinical	Favorable therapeutic effects in vitro	618,620	
RVFV Rift valley virus, eGn Gn ectostructural domain, VLPs Viral like particles, GPC Glycoprotein precursor, NP Nucleocapsid protein, CCHFV Crimean Congo hemorrhagic fever virus, Adv Adenovirus, MVA Modified vaccinia virus Ankara, RdRp RNA dependent RNA polymerase, NHPs nonhuman primates

A DNA vaccine expressing the M-segment glycoprotein precursor gene of CCHFV was developed, termed CCHFV-M10200. In both IFNAR−/− mice and IS mice, M-segment DNA vaccine elicited strong humoral immune responses after three doses of vaccination. Animals were protected from weight loss against CCHFV challenge, with a protective rate of 60%.570 Further studies suggested that increasing the dose of CCHFV-M10200 improved the protective efficacy, with 100% protection against homologous CCHFV and 80% protection from heterologous strain. Additionally, they showed that nonstructural M-segment protein GP38 is an important immunogen that plays a role in protect against homologous CCHFV challenge.608 Two plasmids DNA vaccine expressing both GPC and NP was also reported. In mice and cynomolgus macaques, the GPC + NP DNA vaccine induced potent antibody and T-cell responses. Vaccinated animals were protected from viraemia and disease.597,609 A DNA replicon that encoding the N gene of CCHFV was constructed based on the Sindbis virus vector, and the resulting plasmid was named pSinCCHF-52S. pSinCCHF-52S generated a Th1 response in mice. However, the protective efficacy was not certain.610 These DNA vaccines are promising candidates, however, DNA vaccines require the in vivo electroporation-assisted delivery, and at least 3 doses are needed to confer a potent immune response/protection. The CAdVax-GnGc vaccine was found to elicit strong GP-specific IgG antibodies with 100% protection.611 A DNA vaccine encoding the Gn and Gc glycoproteins (pWRG7077-RVFV-NSm) was found to be highly immunogenic in BALB/c mice.612

In attempts to use the MVA and Adv vectors to deliver the N gene of CCHFV, no protection or partial protection was reported in mice.599,613 Alphavirus-based replicon RNA vaccines expressing either CCHFV N or GPC were constructed. Vaccination with RNA expressing the N alone could confer complete protection against clinical disease, and a combination of N and GPC afforded robust protection against disease and viral replication.614 Nucleoside-modified mRNA-lipid nanoparticles (mRNA LNPs), encoding CCHFV N or glycoproteins (GcGn) were constructed, both of them induced strong humoral and cellular immune responses and protected 100% of IFNAR−/−mice against lethal CCHFV infection, particularly hepatic injury. A comparison of the immune responses induced by CCHFV Gc and Gn antigens revealed that Gc protein was more immunogenic than Gn protein. Overall, genetic immunization is an attractive approach for CCHFV. Compared to DNA vaccines, mRNA-LNP vaccines combine the ability to induce an effective immune response, the safety of transient carriers, and the flexibility of genetic vaccines. These results support the development of a mRNA-LNP based vaccine against CCHFV.606

Therapies for bunyavirus

Ribavirin is an antiviral drug that has been used in patients with CCHF.615 However, the efficacy of ribavirin in animal models is controversial; it protected STAT−/− mice and STAT2−/− hamsters but failed to protect IFNAR−/− mice.616,617 Compared with ribavirin, favipiravir or its derivative (H44) was protective in IFNAR−/− mice, as indicated by a reduced mortality rate and decreased viral load.616,618 Similarly, favipiravir attenuated viremia and the viral load in tissues in an NHP model.619 Furthermore, the therapeutic efficacy of favipiravir in patients needs to be investigated. 2′-Deoxy-2′-fluorocytidine and molnupiravir showed favorable therapeutic effects in vitro, suggesting that these may be effective antiviral agents.618,620 In severe cases, patients experience dysregulation of the inflammatory response and cytokine storms; therefore, corticosteroids can be used at this stage.558

In the early stages, CPT is used for the treatment of CCHF patients.621,622 Although several successful cases have been reported, only a limited number of people have been treated with convalescent serum; thus substantial therapeutic efficacy is difficult to document. Both pre-GN and GC-specific mouse mAbs have been reported.623 Among them, GC-targeting mAbs have shown cross-neutralizing activity against multiple strains.553 Both nonneutralizing and neutralizing mAbs protect neonatal mice. Interesting, only nonneutralizing pre-GN(GP38)-specific mAbs, known as mAb-13G8, efficiently protected IFNAR−/− mice, and IFN-I activity blocked mice.624 These findings suggested that GP38 is a potential target for CCHFV immunotherapy and demonstrated the role of ADCC and complement-mediated functions in protection against CCHF.625 However, this protection seems to be strain-limited, as passive protection by mAb-13G8 against heterologous CCHFV strains is poor.

Furthermore, several human anti-GP38 mAbs were isolated from a CCHFV survivor.552 These mAbs bind to other antigenic sites on GP38 compared to mAb-13G8. Using fluorescence-activated cell sorting, a panel of 361 rGn/Gc-reactive mAbs bound to six distinct antigenic sites in the Gc subunit. Neutralizing ability was associated with binding sites, of which fusion-loop targeting (Site 1) and domain II-targeting (Site 3) nAbs displayed the highest median potencies of approximately 70–80% against CCHFV clade IV.626 Pairwise screening revealed that combinations of the non-competing nAbs, ADI-37801 and ADI-36121/ADI-36145, afforded synergistic neutralization. By linking variable domains of synergistic nAbs, a bispecific antibody (bsAb) was obtained, which exhibited enhanced neutralization breadth and potency and in vivo antiviral potency. Notably, a single therapeutic dose of bsAb provided protection even when administered 24 h after the challenge. Subsequently, structural basis of pre-fusion Gc bound to the above synergistic neutralizing antibodies was resolved.627 ADI-36121 targets fusion loops while ADI-37801 binds to the host-membrane insertion surface (HMIS) and blocks Gc trimer formation. Together, they blocked membrane fusion. Structural information revealed the neutralization mechanism of anti-CCHFV antibodies and provided the molecular basis for developing CCHFV-specific medical countermeasures.

Allen et al. revealed a molecular basis for antibody-mediated neutralization of RVFV. The authors characterized a distinct region, the membrane-distal head domain of RVFV Gn, as a key site of vulnerability, and identified a class of rabbit monoclonal antibodies that protect RVFV in an animal model.628 These antibodies are predicted to prevent exposure to viral fusion loops and have shown protective efficacy in a murine model of RVFV infection. Based on single memory B-cell screening, two Gn-specific NAbs were isolated from a rhesus monkey immunized with recombinant human adenovirus type 4 expressing RVFV Gn and Gc.629 Both NAbs protected host cells from RVFV infection. According to docking models, these two NAbs might preclude RVFV glycoprotein rearrangement, thus hindering the exposure of fusion loops in Gc to endosomal membranes during virus invasion. A previous study reported the generation of glycoprotein Gn-specific neutralizing antibodies in individuals naturally infected with RVFV in Kenya.630 One typical mAb, RVFV-268, displayed excellent neutralization of RVFV and was mapped to the surface exposed residues of domain A on the Gn surface. After intraperitoneal injection, RVFV-268 rapidly reaches placental and fetal tissue, and prevents maternal and fetal infection in a dose-dependent manner. In vitro, RVFV-268 reduced viral replication in placenta explant cultures, and in vivo, RVFV-268 prevented vertical transmission in a rat model of congenital RVF. Passive transfer of the RVFV-268 mAb from parent to fetus 2 h prior to RVFV challenge or 24 h post challenge protected dams and offspring from RVFV infection. These results support the use of RVFV-268 mAb as a prophylaxis and post infection therapy to prevent RVFV infection and vertical transmission, thus protecting mothers and offspring.

In another study, two synergistic monoclonal antibodies targeting the glycoprotein Gn were identified.631 In therapeutic attempts, the neutralizing mAb Gn3 alone showed a moderate efficacy of approximately 58.3% when given pre or postchallenge. In contrast, combination therapy with nonneutralizing mAb Gn32 conferred complete protection when applied 30 min after the lethal challenge dose. The enhanced protective efficacy is probably attributed to cooperative neutralization effects, which warrants further study. More recently, a combination of dual-mechanism human monoclonal antibodies conferred protection against RVFV at low doses.632 Structural analysis and characterization revealed a prototypical potent Gn domain-A binding antibody that blocks attachment and an antibody that inhibits infection by abrogating the fusion process. Interestingly, according to a competitive assay, the Gn domain-A antibody does not directly block the receptor-ligand interaction of RVFV Gn. This study provides insights into combination therapy using representative mAbs from distinct classes of neutralizing mechanisms that act via both attachment and fusion to accomplish protection in low doses of this antibody.

Chapman, et al. isolated a total of 20 monoclonal antibodies (mAbs), including Gn-specific mAbs, hetero-oligomer glycoprotein complex (Gc+Gn)-specific mAbs and Gc-specific mAbs from human B cells.633 Gc-specific mAbs exhibited relatively lower neutralizing capacity than their counterparts. mAbs that bind to coexpressed full-length Gc-Gn proteins and Gn domain A-specific mAbs can inhibit the exposure of the fusion loop in Gc, thus inhibiting RVFV fusion to cells. Competition binding analysis with coexpressed Gc/Gn and mutagenesis library screening indicated that four competition groups for binding to viral antigen on the RVFV surface were recognized by neutralizing antibodies, with two sites of vulnerability for neutralization on Gn. Since mAbs targeting domain A caused partial inhibition of fusion while Gc+Gn-specific mAbs caused complete inhibition of fusion, a representative mAb, RVFV-268 was tested in a mouse model. RVFV-268 recognized three of the antigenic sites and reduced the rate of lethal hepatic disease in adult mice when it was prophylactically delivered or treated 2 or 4 days after infection. Sterilizing immunity against RVFV infection was achieved when the mAb was delivered 2 h prior to inoculation. Similarly, Wang et al. reported the isolation of monoclonal antibodies from antigen-specific single memory B cells in a convalescent patient.634 Among these antibodies targeting the RVFV envelope proteins Gn or Gc, Gn-specific monoclonal antibodies exhibited much greater in vitro neutralizing activity and protective efficacy in mice against RVFV infection. In cell interactions, they provided evidence that Gn monoclonal antibodies interfere with soluble Gn binding to cells, thus blocking the binding of Gn on virions to susceptible cells. Structural analysis of Gn complexed with Gn-specific monoclonal antibodies revealed two potential neutralizing hotspots on Gn domain I. These results highlight the potential of human antibody-based therapeutics and provide a structure-based immune-determining region against RVFV.

Interestingly, there is also evidence that isotype-specific Fc effectors enhance antibody-mediated protection in vivo.635 In a proof-of-concept study, compared with IgG1 mAbs, IgG2a mAbs had an increased capacity to induce effector functions and conferred better protection against RVFV challenge in a lethal mouse model. Overall, this study showed that Fc mediated functions are a critical component of humoral protection from RVFV.

An equine immunoglobulin F(ab’)2 fragment demonstrated an in vitro neutralization effect and reduced mortality in infected mice.636 Another study revealed that llama-derived single-domain antibody (VHH) building blocks were assembled into highly efficient neutralizing complexes using bacterial superglue technology, and this multimeric complex showed protective effects in mice.637

Nipah virus disease

Etiology, epidemiology, and pathogenesis of Nipah virus disease

Nipah virus (NiV) is a viral zoonotic pathogen that was first reported in Singapore and Malaysia in 1998.638 NiV is a member of the genus Henipavirus, family Paramyxoviridae, it is a negative-sense, single-strand, nonsegmented, enveloped RNA virus possessing helical symmetry.10 The fusion glycoprotein (F) and the attachment glycoprotein (G) of the genome are responsible for the cellular attachment of virus particles and subsequent entry into the host cell.639,640 Several species of fruit bats are natural hosts of NiV, while pigs are intermediate hosts of NiV.641,642 NiV is transmitted to humans by direct contact or through contaminated food.643 In humans, NiV infection results in severe and often fatal respiratory and neurological manifestations, presented as interstitial pneumonia, systemic vasculitis, and meningitis.644 A human mortality rate of Nipah virus disease was up to 75% have been reported.645 The outbreak of NiV has been reported in South and Southeast Asia, including Bangladesh, Cambodia, Timor-Leste, Indonesia, India, Malaysia, Papua New Guinea, Vietnam and Thailand, and poses a potential threat to global health security.646 Sporadic NiV outbreaks, human-to-human transmission and zoonotic transmission have been associated with hundreds of deaths over the past decades, posing a significant threat to domestic animals and humans. At disease onset, NiV is first detected in bronchial epithelial cells. Respiratory epithelial cells are also infected thereby triggering dysregulation of the levels of inflammatory factors, leading to the recruitment of immune cells and ultimately resulting in the development of acute respiratory distress syndrome (ARDS)-like disease.647 Later in the disease, the virus spreads from respiratory epithelial cells to lung endothelial cells. Subsequently, the virus enters the blood and spreads to the target organ either by free transmission or by binding to host leukocytes, leading to multiorgan failure.648 Viruses can enter the central nervous system through two routes: the hematogenous route and/or the olfactory route.649 Symptoms of NiV disease include fever, difficulty breathing, cough and headache. Encephalitis and seizures are associated complications.650

Animal models for Nipah virus disease

Animal models for Nipah virus disease have been established in mice, hamsters, guinea pigs, ferrets, pigs, dogs, cats and NHPs. (Table 11) Wild-type mice were insensitive to NiV infection by IN or IP inoculation, whereas mice intracerebrally injected with 105 PFU of NiV died within 6 days.651 In contrast, the pathogenesis of NiV was studied in IFNAR-KO mice, which are highly susceptible to NiV infection regardless of the route of administration.651 Intraperitoneally infected IFNAR-KO mice exhibited weight loss, agitation, impatience, dyskinesia, head tilt, and paralysis. Moreover, IFNAR-KO mice developed vasculitis, meningitis, and bronchial interstitial pneumonia. NiV was detected in multiple organs, including the brain, lungs, spleen, and liver, with the highest titers detected in the brain and lungs.651 Consequently, IFNAR-KO mice are a suitable small animal model for treating NiV. Other innate signaling immunodeficient mice were also used in pathogenesis studies, which highlighted the role of pathogen recognition in sensing NiV infection and protection. Specifically, the host adapter mitochondrial antiviral signaling protein (MAVS) and myeloid differentiation primary response 88 (MyD88) mediate the control of NiV infection. Moreover, the cGAS/STING pathway plays synergistic roles in host protection.652,653 To investigate the molecular mechanisms of NiV-associated ALI in humans, a human lung xenograft humanized mouse model was developed.654 NiV replicated efficiently in transplanted mice, targeting both the endothelium and epithelium and triggering inflammatory cytokines and chemokines in lung tissue. Unfortunately, this model did not present obvious signs of disease.Table 11 Animal models of NiV

Animal species	Animal model	Strains	Max. Dose	Route	Lethality	Signs of disease	Strengths/Weaknesses	References	
Mouse	C57BL/6 mice	UMMC1	105 PFU	IP	0	No	Challenge route dependent lethality/Inability to mimic natural infection routes	651	
IC	100%	–	
IFNAR-KO mice	106 PFU	IP	100%	Weight loss, agitation, impatience, dyskinesia, head tilt, paralysis, vasculitis, meningitis, bronchial interstitial pneumonia	Lethal encephalitis similarly to human infections/Inability to mimic natural infection routes	
IC	100%	
IN	60%	Neuronal signs, breath difficulties	
MyD88/TRIF/MAVS/STING KO mice	Malaysia	106 PFU	IP	100%	Posture, prostration, and paralysis	Applicable to the study of pathogenesis and immune correlates/In applicable to extensive usage	652	
MyD88/MAVS-KO mice	66%	Posture, prostration, and paralysis	653	
Human Lung Xenograft	Malaysia	105 TCID50	Intragraft injection	0	No	Facilitate study of pathogenesis and virus-host interactions/No obvious signs of disease	654	
Hamster	Syrian hamsters	Malaysia/Bangladesh	107 PFU	IP/IN	100%	Hyperreflexia, ataxia, irregular breathing	Suitable animal model for acute NiV infection/Differential time to death in different challenge routes and no parenchymal fibrinoid necrosis in the lungs	910	
Malaysia	6 × 105 PFU	IN	100%	Imbalance, paralysis of limbs, lethargy, muscle twitching and respiratory distress	
Cambodian	13500 PFU	SC	100%	Paralysis, limb tremors, respiratory distress, unsteady gait; weight loss, hypothermia	660	
Guinea pig	Guinea pig	Malaysia	107 PFU	IP	0	Brief fever and weight loss but recovered.	Reproductive infection model/Variable clinical symptoms between different NiV isolates and routes	659	
6 × 104 PFU	IP	100%	Vascular necrosis and inflammation, bladder and female reproductive tract infections evident	660	
Ferret	Ferret	Malaysia	5 × 104 TCID50	IN	100%	Fever, depression, lethargy, loss of appetite, difficulty breathing	Ability to exhibit complex behaviors for clinical assessment/-	662,674,681	
Pig	Pig	Malaysia	5 × 103 TCID50	SC	66%	Fever, unconsciousness, coughing, and ataxia	Marked respiratory and neurological features, age-associate lethality/Ununiform lethality	663,928	
IN/OR	0–31%	No	
Dog	Dog	Malaysia	5 × 103 TCID50	SC/OR	0–100%	Fever, respiratory distress, nasal discharge and conjunctivitis	Similar pathological changes to those in human patients/In applicable to study dissemination mechanisms	664	
Cat	Cat	Malaysia	50–100%	Fever, increased respiratory rate, inappetence, depression	High susceptibility to NiV/In applicable to study dissemination mechanisms	665,666,929	
Nonhuman primates	African green monkey	Malaysia	1.3 × 106 PFU	IT/IN/Aerosol	100%	Fever, anorexia, respiratory disease, lethargy, rash, depression, behavioral changes, vasculitis, hemorrhage, edema, thrombocytopenia, meningitis	Mimic serious clinical diseases in humans/inaccessibility and ethical issues	667,668,930	
Bangladesh	5 × 105 PFU	IT/IN/Aerosol	100%	668,669,671	
Squirrel Monkey	Malaysia	107 PFU	IN	0	Anorexia, weight loss, depression, respiratory disease, uncoordinated motor movements, acute neurologic illness	673	
IV	75%	
Cynomolgus Monkeys	Bangladesh/Malaysia	5× 105 PFU	IT/IN	0	Self-limiting/asymptomatic	Study of the immune response and organism after infection/mild or asymptomatic infection	672	
IN intranasal, IP intraperitoneal, IC intracerebral, SC subcutaneous, IT intratracheal, IV intravenous, NiV Nipah virus, PFUs plaque-forming units, TCID50 median tissue culture infective dose, MyD88 myeloid differentiation primary response 88 (MyD88), TRIF TIR-domain-containing adapter-inducing interferon-b, MAVS mitochondrial antiviral-signaling protein, STING stimulator of interferon genes, – not applicable

The Syrian hamster is another small animal model for treating NiV. After NiV infection, the Syrian hamsters exhibited pathological changes and died of acute encephalitis.655,656 IP infection in hamsters was associated with the rapid onset of symptoms within a day, and the animals died at 5–9 dpi.657 In contrast, hamsters infected by the IN route showed progressive deterioration of disease; animals developed disequilibrium, limb paralysis, lethargy, muscle twitching, and respiratory distress; and died in 9–15 days.657,658 Compared to other organs, the brain is the most severely affected organ in terms of vascular and parenchymal lesions. In addition, NiV-infected hamsters develop myocardial infarcts similar to those observed in humans.659 Animals infected with high doses of NiV died of acute episodes of severe respiratory distress.660 In contrast, animals infected with low doses of NiV developed respiratory disease and neurological signs.647,661 In guinea pigs, intraperitoneal inoculation of 6 × 104 PFU of NiV resulted in a mortality rate of 92.86%, the majority of which died at 4–8 dpi.660 The spleen, lymph nodes, bladder, ovaries, uterus, and brain were the most extensively infected organs. Pathology revealed mild to severe histiocytosis, lymphocytic meningitis, meningeal vasculitis, and lymphohistiocytic meningoencephalitis. NiV-infected ferrets presented fever, depression, lethargy, loss of appetite, and labored breathing and eventually succumbed to infection. The gross pathology results included thrombocytopenia, lymphopenia, rash, severe congestion and hemorrhage in the lungs, and liver and spleen damage.662

Pigs are natural hosts of NiV. NiV-infected pigs exhibit acute and self-limiting clinical disease, including barking cough and, occasionally, muscle spasms, myoclonus, trembling, fever, and respiratory and neurological features, and typically do not result in fatal outcomes.641 The lethality of NiV infection in pigs was challenge route-related, SC challenge resulted in 66% mortality, while oral and IN infection caused asymptomatic or mild infections. Young pigs were relatively more susceptible to NiV.663 Overall, NiV induced respiratory and neurological syndrome consistent with that observed in Malaysian pigs.

Domestic dogs and cats were also included as models of NiV infection. In dogs, NiV infection results in respiratory distress, fever, nasal discharge and conjunctivitis. Pathology revealed findings resembling those of infected humans, including heavy lungs with visible congestion, mottling, and consolidation of all lobes in addition to reddening of the renal capsules and cortices.664 Experimentally, it has been demonstrated that NiV is not transmitted between dogs.664 For domestic cats, NiV infection via SC challenge resulted in 100% lethality, while NiV infection via nasal challenge caused 50% lethality. Clinical symptoms included fever, tachypnea, anorexia, and depression. Histopathological lesions in the lungs included bronchitis and alveolar hemorrhage, as did meningitis. Horizontal transmission of NiV between cats has not been recorded, while vertical transmission of NiV has been noted in pregnant cats.665,666

NiV-infected African green monkeys developed neurological disease, severe respiratory lesions, and systemic vasculitis.667–669 A uniform severe ARDS-like disease developed.670 To mimic the natural infection route, African green monkeys were infected with NiV-Bangladesh via the IN route, which resulted in uniform lethality.668 Under the same conditions, NiV-Bangladesh was more pathogenic than was NiV-Malaysia in the AGM.671 In contrast to African green monkeys, Cynomolgus monkeys were asymptomatic or had mild symptoms of NiV infection.672 Similarly, squirrel monkeys intravenously infected with NiV developed acute neurologic and respiratory illnesses, whereas monkeys infected intranasally exhibited milder clinical signs and recovered from the disease at 3–7 dpi.673

Medical countermeasures for Nipah virus disease

Several vaccine candidates for Nipah virus disease have been tested in preclinical studies (Table 12). A VSV based vaccine protected nonhuman primates and hamsters against NiV infection.674 Another recombinant vaccine was produced using the vaccinia virus strain LC16m8 expressing the NiV glycoprotein (G) or fusion protein (F). It was also demonstrated that this recombinant vaccine protects hamsters from lethal NiV infection and generates high levels of neutralizing antibodies in hamsters.675 One VLP vaccine consisting of three NiV proteins, G, F and M, was shown to induce a neutralizing antibody response in mice.676 In addition, an APC-targeting vaccine has also been developed by fusing humanized anti-CD40 mAbs with conserved peptides. It showed positive immunogenicity, cross-neutralization of NiV and Hendra virus (HeV), and promising protection in an African green monkey model.677 A novel approach is to add a cholesterol moiety to the C-terminal heptapeptide repeat sequence (HRC) of F proteins to facilitate membrane targeting and fusion of the peptide, increasing the antiviral effect.678 Favipiravir has been shown to be effective in treating Nipah virus in hamster models.679 The National Institute of Allergy and Infectious Diseases launched an early clinical trial to evaluate the mRNA-1215 Nipah virus vaccine produced and developed by Moderna Corporation, which has entered phase I clinical trials. The VSV-NIVG vaccine developed by public health vaccines has also entered Phase I clinical trials. The vaccine is a multivalent vaccine that expresses glycoproteins of Nipah virus and Ebola virus. Phylex BioSciences announced the second-generation nanoparticle mRNA vaccine technology will be directly used in the development of Nipah virus vaccines. The expected advantages of nanoparticle vaccines are excellent immune responses, long-term protection against cell-mediated immunity, and prevention of virus transmission in the brain.680Table 12 Representative medical countermeasures for Nipah

Classification	Name	Platform/Strategy	Stage	Efficacy/Benefic	References	
Vaccines	VSV-F/G	Vesicular stomatitis virus vectors expressing NiV F or/and G	Clinical	Immunogenic and protected ferrets	674,680	
LC16m8-F/G	Vaccinia virus LC16m8 expressing NiV F/G	Preclinical	Protects hamsters	675	
Viral like particles	Formulate VLPs of NIV by expressing G, F and M protein	Preclinical	Immunogenic in mice	676	
CD40 vaccine	Fusing a humanized anti-CD40 monoclonal antibody with conserved peptides	Preclinical	Protect African green monkey	677	
mRNA-1215	/	Clinical	/	/	
Antibodies	m102.4	Human monoclonal antibody targeting G	Clinical	Effective in NHPs and ferrets	681–683	
Hu1F5	Human monoclonal antibody targeting F	Preclinical	Effective in NHPs	931	
NiV41	Human monoclonal antibody targeting F	Preclinical	Cross-reactive to NiV and Hendra virus and protect hamsters	684	
Small molecular drugs	Fapiravir	RdRp inhibitor	Preclinical	Effective in hamsters	679	
Ribavirin	Broad spectrum antiviral drug	Preclinical	Used in clinical in Kerala in South India	649	
NiV Nipah virus, G glycoprotein, F fusion protein, M matrix protein, VLPs viral like particles, RdRp RNA dependent RNA polymerase, NHPs nonhuman primates

No specific drug is currently approved for the treatment of NiV disease. However, ribavirin was used as an anti-Niv drug in Kerala, South India.649 Several mAb therapies have been evaluated in animal models. A fully humanized mAb targeting the viral G protein, m102.4, has shown protective effects in ferret model of Niv disease.681 Furthermore, m102.4 was also evaluated in a nonhuman primate model and showed positive therapeutic effects.682 Recent studies have shown that a mAb against the prefusion conformation of the F glycoprotein protects AGMs from severe NiV attacks more effectively than m102.4.{Zeitlin, 2024 #6503} In Phase I clinical trial, m102.4 was tolerated and safe.683 Based on a naïve human phage-displayed Fab library, two neutralizing antibodies targeting G proteins, NiV41 and NiV42, were screened. One of them, NiV41, is cross-reactive to NiV and HeV and protects hamsters from lethal NiV infection.684 Existing treatments are targeted at the early stages of viral infection, including the use of neutralizing virus-specific antibodies and blocking the fusion of membranes with peptides binding the fusion protein of the virus.685

Zika virus disease

Etiology, epidemiology, and pathogenesis of Zika virus disease

Zika virus (ZIKV) is the causative agent of Zika virus disease and is a mosquito-transmitted RNA virus with an 11 kb single-stranded genome.686 The viral genomic RNA is composed of a single open reading frame that encodes a long polyprotein that is cleaved by host and viral proteases into 10 proteins. These proteins included three structural proteins, capsid (C), premembrane/membrane (pr-M/M), and envelope (E), as well as seven nonstructural proteins (NS1, NS2A, NS2B, NS3, NS4A NS4B, and NS5).687 Structural proteins play a role in the viral entry to target cells, virus assembly, and virion secretion.688 Nonstructural proteins play a crucial role in the replication of viral RNA, the assembly and release of virions, and the evasion of innate immunity.689,690 Previous studies have shown that ZIKV NS4A and NS4B induce autophagy by suppressing multiple target proteins in signaling pathways including the PI3K-AKT pathway. However, the inhibition of ZIKV in this pathway could result in defective neurogenesis.691,692 Furthermore, ZIKV NS1, NS2A, NS2B, NS4A, NS4B, and NS5 can target important factors to interfere with signaling pathways and IFN induction to evade the innate immune response.693–695 Moreover, NS1 contributes to the pathophysiology of disease by causing vascular leakage and endothelial cell injury, as well as by generating autoimmune reactions.696 It also functions as an immune evasion factor by delaying complement-dependent lysis of infected cells.697 Researchers have shown that the ubiquitin E3 ligase HRD1 can directly interact with NS4A and ubiquitinate a conserved lysine residue for ER-associated degradation to prevent the excessive accumulation of NS4A and balance the homeostasis of viral proteins.698

In 1969–1983, ZIKV was detected in India, Indonesia, Malaysia, and Pakistan. The virus also caused epidemics in French Polynesia, Easter Island, the Cook Islands, and New Caledonia in 2013–2014.699 The ZIKV outbreak in French Polynesia caused more than 30,000 cases. An outbreak caused by infection with African strain of Zika virus in Cape Verde in 2015–2016 involved thousands of cases. In the following year, mosquito-borne ZIKV transmission was documented in 84 countries or territories worldwide, including 61 countries or territories where ZIKV was firstly introduced in 2015.700 The WHO has declared it a global health emergency.701 Zika can be transmitted through mosquito bites, blood transfusion, sex, and from pregnant woman to fetus.702,703 Zika virus is transmitted to humans by the bite of an infected mosquito from the Aedes genus, primarily Aedes aegypti, in tropical climates. This mosquito spreads dengue, chikungunya, and yellow fever. The majority of Zika virus infections result in either no symptoms at all or very minor symptoms. The most typical Zika symptoms include fever, rash, headache, joint pain, red eyes, and muscle pain, which can last for several days to a week. However, pregnancy-related ZIKV infection can have negative effects, including fetal death, congenital microcephaly, or other severe brain abnormalities.704 In addition, ZIKV infection has also been associated with Guillain-Barré syndrome (GBS), encephalopathy, meningoencephalitis, myelitis, uveitis, paresthesia, and severe thrombocytopenia.705 Currently, no vaccines or drugs are approved for treating Zika virus infection.

Animal models of Zika virus disease

Mice

Wild-type mice are insensitive to ZIKV (Table 13).706,707 ZIKV can antagonize the type I interferon response; more precisely, the NS5 protein of ZIKV promotes the degradation of STAT2, a transcription factor that mediates signaling through the type I interferon receptor IFNAR.708,709 However, NS5 was unable to promote the degradation of STAT2 in mice, which may explain the insusceptibility of mice to ZIKV.708Table 13 Animal models of Zika virus infection

Animal Species	Animal model	Pathogens	Max. Dose	Route	Lethality	Signs of Disease	Strengths/Weaknesses	References	
Mice	Neonatal mice	ZIKV	–	IC or SC	–	Lethargy, ataxia, and paralysis	Neurological manifestations/Pathological changes confined to nervous system	710,711	
PRVABC59	2 × 103 PFU	SC	20%	Ataxia, and seizures	
IFN-α/βR−/− mice	MP1751	106 PFU	SC	100%	Weight loss, elevated temperature	Systemic symptoms/No reproductive lesions	713	
ZIKV	103 FFU	Retro-orbital	–	Ruffled fur, and lethargy	Obvious neurological manifestations/Lack of typical clinical features	714	
DAK AR D41525	6.4 log10 PFU	SC	40%	Weight loss, and severe neuropathologic changes	Obvious brain lesions/Need IFN I blockade	715	
IP	100%	
ZIKV	105 PFU	FP/IP	100%	Weight loss, lethargy, hunched posture	Brain pathology/Lack reproductive symptoms	716	
H/PF/2013	103 FFU	SC	–	Fetal demise, IUGR, and microcephaly,	In utero transmission/No neurological signs in survived animals	722	
BALB/c mice	PRVABC59	6×106 TCID50	IP	66.7/100%	Weight loss, dyspnea, lethargy, and ruffled fur	Immunosuppressed mice for studying long-term infection/Need dexamethasone for immunosuppression	719	
C57BL/6 mice	H/PF/2013	103 FFU	SC	–	No	Obvious male reproductive tissue injury/Antibody treatment needed	717	
ma Dakar 41519	106 FFU	SC	–	
H/PF/2013	103 FFU	SC	–	IUGR	In utero transmission model/Antibody blockade of Ifnar1 signaling	722	
SZ01	3×105 PFU	IP	–	Fetal mice exhibited a reduced cavity of lateral ventricles and a discernable decrease in surface areas of the cortex	Vertical transmission model/Ventricular changes are contrary to that in human disease	932	
SJL mice	ZIKV	2×102/8×109/2×1011 PFU	IV	–	Weight loss, whole-body growth delay or IUGR	Presenting brain malformations/-	723	
Syrian golden hamsters	–	ZIKV	500 TCID50	SC	37%	Weight loss	Vertical transmission/Lack of typical clinical features	724	
50 TCID50	42%	
ArD 41525	5.4 log10 PFU	SC	–	Lethargy	-/Mild signs of disease	725	
IP	
Guinea pigs	–	ZIKV	105/106 PFU	SC or IN	–	Fever, lethargy, hunched posture, ruffled fur, and decrease in mobility	Contact transmission model, Viral replication in brain/No observed signs of disease	726	
728	
Ferrets	Ferrets	PRVABC59	106 TCID50	SC	28%	Fever, brains deformities, and hypertrophied vessels.	Neurological symptoms/Presenting inconsistent symptoms	731	
NHPs	Rhesus monkey	Rio U-1/2016	104 PFU	SC	–	Fetal loss and demise	-/Inconsistent signs of disease	933	
PRABC59	105 FFU	SC	–	Decreased fetal- placental weight ratio, malaise, ataxia, and deficits in visual, cardiomyopathy, seizure activity	Uteroplacental pathology/No obvious fetal signs of disease	934	
746	
742,748	
ZIKV	300 TCID50	IR	–	Lymphoid- and neuro-tropism and histopathologic abnormalities	High incidence (78%) of spontaneous pregnancy loss/Lack of other typical symptoms	739	
DAK	108 PFU	SC	–	Fetal loss	Vertical transmission/Dose dependent	740	
Brazil	103 PFU	SC	–	Fetal loss, smaller brain size, and histopathologic brain lesions	Presenting the hallmarks including vascular compromise and neuroprogenitor cell dysfunction.	743	
Brazil	5.0 log10 PFU	IV and IA	–	Fetal death	Developing gross neuroanatomical abnormalities/No gross microcephaly	744,747	
Cynomolgus macaque	ZIKV PRVABC59	2×106 FFU	IV	–	Marginal change in blood cells, including PLT, RBC, and WBC counts	Intravaginal inoculation model/No detectable viremia or clinical symptoms	759	
BeH815744/PF13/251013–18/ZKA-16-291	5×106 PFU	IV/SC	–	Fever/Weight loss	Systemic inflammation/Lack of neurological symptoms	754	
African green monkey	ArD 41525	4.5 log10 PFU	SC, IV, or IA	–	Lymphadenopathy	Sexual transmission model/No clinical symptoms	760	
Marmoset monkey	MR766	104 PFU	IM	–	Drowsiness, and weight loss	Viral transmission by the oral route/Lack of apparent clinical symptoms	764	
SPH2015	2.5×105 PFU	IM	–	Spontaneous pregnancy loss, and fetal neurocellular disorganization	Vertical transmission/Lack of apparent clinical symptoms	767	
Baboon	ZIKV	106 PFU	SC	–	Rash, conjunctivitis	Similar to human ZIKV infection/No obvious neurological symptoms	769	
French	104 FFU	SC	–	Fetal death, weight loss, rash and conjunctivitis	Vertical transmission model/No gross microcephaly	770,772	
106 FFU	SC	–	
ZIKV	107 PFU	SC	–	Intermittent rectal bleeding, rash	Substantial injury to fetal brain/Subtle injury pattern without microcephaly	762	
FSS13025	10 PFU	SC	–	Abnormal fetal autopsy	–	763	
ZIKV Zika virus, SC subcutaneous, IC intracutaneous, PFU plaque-forming unit, FFU focus-forming unit, TCID50 50% tissue culture infective dose, IP intraperitoneal, FP foot pad, IUGR intrauterine growth restriction, IV intravenous, IN intranasal, IR intrarectal, IA intraarterial, IM intramuscular, – not applicable

Neonatal mice

Neonatal mice are susceptible to ZIKV due to their immature immune system. ZIKV infection in 7- to 8-day-old mice damages the central nervous system and triggers tremors, ataxia, and epilepsy, ultimately leading to lethal infection.706,710,711 In a proof-of-concept study, ZIKV infections were induced in four different species of mice.712 The results showed that neonatal Kunming, ICR and C57BL/6 mice were fatally susceptible to ZIKV infection while BALB/c mice were resistant to ZIKV infection. In C57BL/6 neonates, a dose-dependent viral infection pattern was observed. In these susceptible mouse species, microcephaly and neuronal symptoms were observed. According to pathologic and immunofluorescent results, ZIKV infected different areas of the CNS and replicated in multiple organs, including the liver and testis. Thus, ZIKV infection in newborn mice can be used to determine pathogenesis and assess long-term neurodevelopmental factors and behavioral sequelae associated with ZIKV infection during brain maturation.

Immunodeficient mice

Mice genetically deficient in the type I interferon signaling pathway exhibited increased susceptibility to flavivirus infection. After ZIKV infection, mice deficient in the IFNAR1 gene develop severe disease, including hind limb weakness, paralysis, and death.713–715 Blocking with an anti-IFNAR1 mAb had similar effects. ZIKV-infected IFNAR1−/− mice developed disease in an age-dependent manner, and aged ZIKV-infected IFNAR1−/− mice exhibited greater survival than young ZIKV-infected mice.706,707,713 Mice lacking both type I and type II IFNRs were more susceptible to ZIKV.707,716 ZIKV caused uniform lethality in AG129 mice, even at doses as low as 1 PFU.713 In addition, immunodeficient mice exhibit some of the typical symptoms of ZIKV infection in humans, including conjunctivitis, uveitis, and abnormal manifestations in the reproductive system, such as hematospermia and prostatitis.717,718 Immunodeficient mice can be used to study the pathogenesis of ocular and reproductive diseases associated with ZIKV infection.

Mice with acquired immunodeficiency are also susceptible to ZIKV infection.719 When mice were given the immunosuppressive steroid dexamethasone before and after ZIKV challenge, the infected mice exhibited weight loss, viremia, and disseminated infection, with viral RNA and antigens detected in many tissues. The discontinuation of dexamethasone after 9 days of infection resulted in rapid deterioration of the mice. This study demonstrated that exogenous type I interferons improve clinical outcomes, and a dexamethasone-induced immunosuppression model could be used to investigate the mechanisms of host immune response-related damage and countermeasures against ZIKV infection.

Much attention has been given to ZIKV infection in pregnant women and the corresponding fetal microcephaly and other associated diseases.720,721 IV or SC infection of ZIKV-infected pregnant IFNAR1−/− C57BL/6 mice caused placental infection, fetal brain injury, and fetal death.722 When IFNAR1 female mice were mated with WT sires, the resulting fetuses were considered IFNAR1 heterozygotes. Severe consequences were observed despite the ability of the fetus to respond to type I interferon, suggesting that the type I interferon response in the fetus was not sufficient to protect the fetus from ZIKV-induced damage. Likewise, pregnant wtC57BL/6 mice were infected with ZIKV after receiving the anti-IFNAR1 mAb. The fetus exhibited intrauterine growth restriction with high levels of ZIKV infection in the placenta and fetal head.722 Thus, a gestational fetal ZIKV pathogenic model was successfully established in mice, which could be exploited to determine the cellular tropism and mechanisms of transplacental transmission of ZIKV to the fetus. IV inoculation of pregnant WT mice with the ZIKV strain caused fetal abnormalities,723 which enabled us to investigate the mechanisms of ZIKV teratogenicity in more immunocompetent animals. Direct injection of ZIKV into the cerebroventricular space of fetuses developing in WT ICR or C57BL/6 mice resulted in decreased brain size, thinning of cortical layers, reduced numbers of cortical neural progenitors, and death of immature and mature neurons within 3 to 5 dpi.

Syrian golden hamsters

ZIKV infection of STAT2 knockout hamsters resulted in morbidity and mortality rates of 37 and 42%, respectively. Viruses were observed in the uterus, placenta, brain, spinal cord, and testicles. ZIKV has been detected in several placentas and fetal brains of hamsters.724 However, immunocompetent hamsters inoculated intraperitoneally with the ArD 41525 strain did not exhibit any clinical signs other than viremia or ruffled fur.725

Guinea pigs

Guinea pigs are susceptible to ZIKV infection and harbor viral antigens in multiple tissues, including the brain and parotid glands.726 After inoculation with ZIKV, the guinea pigs developed clinical signs, including fever, lethargy, a hunched back, ruffled fur, and decreased mobility. ZIKV RNA was detected in the serum and whole blood at 2 dpi. Viremia and antigenaemia were observed in infected animals.727 No infectious virus was detected in any of the infected animals. ZIKV replication was observed in the spleen and brain, and the brain harbored the highest viral load. Increases in the levels of IL-5, IL-12 (p70), G-CSF, MCP-1, TNF-α, G-CSF, MCP-1, MIP-1α, LIX, fractalkine and VEGF were observed at 2 dpi.728,729 In pregnant guinea pigs, ZIKV was detected at low levels in reproductive and placental tissues and caused fetal infection.730

Ferrets

ZIKV infection has been investigated in pregnant ferrets. On the 21st day of pregnancy, the animals were infected with ZIKV-PRVABC59. Infected animals developed clinical signs such as fever, brain deformities, and hypertrophied vessels, and 28.57% (2/7) of the infected ferrets died. However, the outcomes were variable within and across litters and ranged from the absence of observable abnormalities to prominent changes.731

Nonhuman primates

Rhesus macaques

Rhesus macaques have shown susceptibility to ZIKV.732–734 Infected macaques developed rash, fever and conjunctivitis. ZIKV infection causes acute and chronic inflammatory and proliferative changes. The virus initially targets the intestinal tract, spleen, and parotid glands and persists in multiple tissues, such as neuronal, spleen, lymphoid, and joint/muscle tissues and reproductive tissues.735–737 ZIKV is vertically transmitted to macaque fetuses at a very low dose during pregnancy and causes maternal viremia, placental dysfunction, and fetal death in utero. ZIKV has been detected in a variety of brain regions, including the caudate nucleus, parietal lobe, cortex, and amygdala.738 ZIKV infection during pregnancy results in early pregnancy loss, fetal loss and fetal and neonatal developmental abnormalities; this disease is known as congenital Zika syndrome (CZS).739–741 Symptoms of CZS include cerebral and cranial abnormalities, neurodevelopmental delays, seizures, joint contractions, hearing loss and visual impairment.742 Histopathologic brain lesions included microcalcifications, hemorrhage, necrosis, vasculitis, gliosis, and apoptosis of neuroprogenitor cells.743 Central nervous system abnormalities associated with virus replication and local neuroinflammatory responses were also observed in ZIKV-infected fetal brains, and these abnormalities impacted brain development over time.744–748 In addition, ZIKV infection during early pregnancy impacts fetal retinal development and causes congenital ocular anomalies.749 ZIKV infection via a needle results in systemic symptoms and virus dissemination. Infection via mosquito bite causes mild or asymptomatic disease, which is similar to the disease observed in human patients; delayed ZIKV replication; and virus present only in hemolymphatic tissues, female reproductive tract tissues, the kidney, and the liver.750

Cynomolgus macaques

Cynomolgus macaques have been used to study the pathogenesis of and evaluate medical countermeasures for ZIKV infection.751,752 During mosquito bite infection, ZIKV RNA loads peak at 4~8 dpi and range from 3 × 103–6.4 × 105 copies/mL in cynomolgus macaques.753 After infection, sole fever and mild weight loss were observed.736,754 Animals infected with ZIKV-FSS13025 developed peak viremia at 3–4 dpi but showed a limited ability to spread the virus to mosquitoes, even during peak viremia.755 The clinical manifestations of ZIKV infection in cynomolgus macaques were strain- and challenge route-dependent. Macaques infected with ZIKV IBH30656 (of the African lineage) develop mild erythema or even asymptomatic lesions. Compared to animals challenged with Asian lineage strains, African lineage strain-inoculated animals did not produce productive virus in serum. Moderate viral loads of less than 300 copies/mL were detected in saliva and urine samples of animals challenged with Asian lineage strains. In addition, the highest viral loads were detected in testis samples, which supported the transmission of ZIKV by sexual contact.756 Peak viral RNA titers were significantly greater in macaques infected with ZIKV-SG than in those infected with ZIKV-Brazil or ZIKV-FP, whereas the ZIKV-Brazil and ZIKV-FP strains elicited more innate immune cells.754 SC challenge decreased the level of the growth factor VEGF in colorectal and cervicovaginal tissues.757 ZIKV infection via the intravaginal or intrarectal route was high in cynomolgus macaques, in which 3.5 log10 PFU/mL and 4.8 log10 PFU/mL of ZIKV, respectively, were detected; moreover, ZIKV infection significantly changed clinical laboratory parameters such as blood urea nitrogen (BUN), aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP), erythrocytes, monocytes, and eosinophils. When mosquito–human transmission is absent, ZIKV transmission through sexual intercourse can serve as a virus maintenance mechanism and may increase the likelihood of ZIKV establishment and transmission in areas that are free of the virus.758 Furthermore, repeated intravaginal inoculations of ZIKV induced potent protective neutralizing antibodies in cynomolgus macaques.759 Vaginal challenge causes proinflammatory responses in all mucosal tissues in the later stage of chronic infection.757 Compared with SC infection, ZIKV infection via the IV route induced greater serum viremia and cytokine and chemokine responses.754

Other NHPs

Other NHPs have also been applied for ZIKV infection.760 In male pigtail macaques, ZIKV replicates efficiently and shows broad tissue tropism.761 Intermittent rectal bleeding and rash developed in some individuals, while other typical symptoms were absent.761 In the absence of microcephaly, ZIKV induces substantial brain injury.762 Peripheral ventricular lesions developed within 10 dpi, with asymmetric changes in the occipital parietal lobe. Fetal autopsies revealed ZIKV in the brain, hypoplasia of white matter in the brain, hypergliosis of the periventricular white matter, and axonal and outdoor injuries.762,763

In marmoset monkeys, ZIKV causes rapid, high, acute viremia with neuroinvasion in peripheral and central nervous tissue but developed no observable lesions or clinical symptoms.764–766 After infection, the virus persists in lymphoid, neurological and reproductive tissues and body fluids such as semen and saliva for a long period of time.764–766 The virus can invade the placenta and fetal neural tissue, and viremia is detected in pregnant marmosets, causing spontaneous fetal loss and neurodevelopmental abnormalities.767 There are also reports that fetal brain damage is associated with a high maternal antibody titer, which underlines the potential pathogenesis of fetal brain damage.768

In baboons, ZIKV infection can cause viremia, rash and conjunctivitis. Viral shedding was detected in the mucosa and cerebrospinal fluid. High levels of ZIKV-specific IgM and IgG antibodies and increased IL2, IL6, IL7, IL15, and IL16 were observed in infected animals.769 ZIKV has been detected in the fetal cerebral cortex and other tissues and can be transferred from maternal to fetal through the placenta,.770 Placental pathology includes disruption of syncytiotrophoblast layers, delayed villous maturation, partially or fully thrombosed vessels, calcium mineralization and fibrin deposits.771 ZIKV infection caused fetal CNS lesions in pregnant baboons. The reproductive organs of male baboons can also be infected, characterized by the presence of ZIKV in sperm progenitor cells, penetration of spermatogenic tubular macrophages, and an increase in tumor necrosis factor alpha (TNF-α), especially in the vascular wall.772 Viruses can be transmitted by semen and are detected in the lymph nodes of pregnant animals.

Medical countermeasures for treating Zika virus disease

Several ZIKV vaccines, including inactivated vaccines, DNA vaccines, mRNA vaccines, and protein subunit vaccines, have entered clinical trials. In addition, live attenuated virus vaccines and AdV-, MVA- and MeV-based viral vector vaccines were also under preclinical investigation (Table 14). Representatively, the Walter Reed Army Institute of Research developed a purified formalin-inactivated Zika virus vaccine (ZPIV), which was safe in mice and NHPs.773 In Phase I clinical trial, ZPIV was found to be safe and immunogenic when coupled with an aluminum hydroxide adjuvant.774Table 14 Representative medical countermeasures for treating Zika virus infection

Classification	Name	Platform/Strategy	Stage	Efficacy/Benefic	References	
Vaccines	Inactivated vaccines	Formalin-inactivated Zika virus	Clinical	Safe and immunogenic in humans	774	
GLS5700	DNA vaccine encoding prM-E sequence of African and Asian/American strains	Clinical	Immunogenic in mice and NHPs	775	
VRC5288/VRC5283	DNA vaccine encoding chimeric prM-E or prM-E	Clinical	Safe, tolerate and immunogenic	776,777	
mRNA vaccine	Non-self-amplified mRNA and nonintegrated vectors	Preclinical	Protect mice and NHPs	778,779	
Self-amplified mRNA	Preclinical	Immunogenic in mice	780	
MeV-prM-ENV	Measles virus vector expressing prM-ENV	Clinical	Immunogenic in mice and NHPs	781,782	
RHAd52-prM-ENV	RHAd52 vector expressing prM-ENV	Preclinical	Immunogenic in NHPs	774	
Antibodies	ZIKV-117	Human monoclonal antibody targeting a unique quaternary epitope on the E protein	Preclinical	Broadly neutralized ZIKV African and Asian-American lineages and effective in mice	784	
ZKA78	Human monoclonal antibody targeting EDIII	Preclinical	Protect mice	785	
Small molecular drugs	BCX 4430	RdRp inhibitor	Preclinical	Effective in mice	789	
The following acronyms are used: membrane and envelope proteins (prM-E); rhesus monkey adenovirus serotype 52 (RHAd52); envelop protein domain III(EDIII); RNA dependent RNA polymerase (RdRp); nonhuman primates (NHPs)

Three DNA vaccines are in clinical trials. GLS5700 was developed by Inovio Company while VRC5288/VRC5283 was developed by NIAID. GLS5700 is designed to express prM-E sequences from African and Asian/American strains. GLS5700 was immunogenic in mice and NHPs.775 A Phase II clinical trial of GLS5700 is ongoing. Based on French Polynesia and early Brazilian ZIKV isolates, VRC5288 is designed by exchanging 98 amino acids from transmembrane and stem regions in the Japanese encephalitis virus (JEV) envelope protein with corresponding regions in the ZIKV E protein and expressing codon-modified ZIKV/JEV chimeric prM-E. In addition, VRC5283 contains an optimized complete ZIKV prM-E gene structure. Both VRC5288 and VRC5283 vaccines were immunogenic in mice and NHPs. VRC5283 is more effective than VRC5288 in preventing viremia and can produce a strong neutralizing antibody and T-cell immune response.776 In Phase II clinical trials, both vaccines were safe, well tolerated, and immunogenic.777

At least two strategies have been involved in the development of ZIKV mRNA vaccines. In one case, modified nucleotides and codon optimization were performed using non-self-amplified mRNA and nonintegrated vectors. This method increases the scale and duration of vaccine production by improving the stability of the ZIKV RNA vaccine and reducing the detection of intracellular innate immune sensors.778 In this manner, the ZIKV mRNA vaccine combined with lipid nanoparticles efficiently protected mice and NHPs after a single dose of vaccination.779 In other cases, self-amplified mRNA was applied, which enables the rapid production of a large number of transcripts and vaccine antigens and significantly activates innate sensors.780

Measles virus-vectored ZIKV vaccine expressing prM-ENV has entered Phase I clinical trial. It has been proven to be immunogenic in mice and NHPs.781,782 Using Rhesus monkey adenovirus serotype 52 (RHAd52) as a vector, a recombinant vaccine was developed by expressing prM-ENV of ZIKV, namely RHAd52-prM-ENV. It was immunogenic in rhesus monkeys and provided effective protection after a single dose of vaccination.774 One study compared four replication defective gorilla adenovirus (Chadox1) vector based ZIKV vaccine candidates. The results showed that the defective adenovirus vaccine expressing both prM and E without the transmembrane region, which obtained 100% protection and a lasting anti-envelope immune response in mice immunized without adjuvants.783

A panel of human mAbs was isolated from recovered ZIKV patients. A subset of antibodies recognizes diverse epitopes on the envelope (E) protein and exhibits potent neutralizing activity. One of the most effective antibodies, ZIKV-117, which broadly neutralizes African and Asian-American ZIKV lineages, was selected. ZIKV-117 recognized a unique quaternary epitope on the E protein dimer-dimer interface. In pregnant and non-pregnant mice, ZIKV-117 treatment markedly reduced tissue pathology, placental and fetal infection, and mortality.784 In another study, antibodies against E protein domain I/II (EDI/II) were shown to cross react between ZIKV and DENV but were less effective. The most potent neutralizing antibodies were ZIKV-specific and targeted EDIII or quaternary epitopes on infectious viruses. An EDIII-specific antibody, ZKA78, protected mice from lethal ZIKV infection.785 Interestingly, a subset of antibodies isolated from dengue virus infected patients also potently neutralizes Zika virus. These mAbs are complex with the conserved epitope in the envelope protein of Zika virus.786

Drugs for ZIKV have been developed based on the following directions: repurposing clinically approved drugs, viral replication-based phenotypic screening for inhibitors, and targeted drug discovery of viral proteins.787,788 Emricasan targets caspase 3 (caspase-3) to prevent cell death. The Z2 peptide targets ZIKV for entry into cells. 25-Hydroxycholesterol and chloroquine interfere with lipid homeostasis and autophagy, thus destroying the release of viral particles after endocytosis. Temoporfin, nitazoxanide, niclosamide and viperin block the activity of the NS2B/NS3 protease to prevent viral replication. Sofosbuvir, Merimepodib, N-(4-hydroxyphenyl) retinamide, 7-deaza2’-C-methyladenosine, NITD008, BCX4430 and ribavarin block the activity of ZIKV NS5 polymerase to prevent virus replication. Ribavarin and merimepodib block hypoxanthine nucleotide dehydrogenase. Niclosamide, EGCG, and cavinafungin block CDKs to prevent virus replication. For example, BCX 4430 is a selective inhibitor of viral RdRp. It acted on NS5 polymerase and promoted the synthesis of viral RNA. In AG129 mice BCX 4430 significantly reduced viremia and protected 87.5% of the mice.789 The compound is currently in the Phase I clinical trial.

Gaps, directions, and prospects

While remarkable progress has been made in the prevention and control of WHO high priority pathogens, much more issues need to be noted and addressed. The most direct bottleneck in studying WHO high priority diseases is the availability of animal models, as currently available animal models suffer from several limitations and challenges. In addition, the selection of animal models is a critical step, and may even determine the direction of the outcomes. To obtain effective prophylactic and therapeutic approaches, a prerequisite is the clarification of immune correlates of protection. Preferably, to accomplish a better connection between correlates of protection across animal experiments and clinical studies. Similarly, accurate and targeted therapies require a better understanding of disease mechanisms. Given the abundance of subtypes and variants, as well as the different levels of disease severity, comorbidities, and sequelae involved in WHO high priority diseases, corresponding countermeasures should be taken. Novel technologies may aid and accelerate breakthroughs in the prevention and control of infectious diseases. Here, we discuss these aspects of gaps, directions, and prospects in detail.

Limitations and challenges of currently available animal models

One of the paramount challenges in acquiring animal models is the differences in physiology, genome and immune system between animals and humans. These differences contribute to the varied pattern of host interactions, which hinders research into pathogenesis and immune-based prevention and treatment strategies.790 Moreover, susceptibility to specific pathogens is determined by functional receptors. For WHO high-priority pathogens, NHPs, in some cases ferrets, are naturally susceptible animals.15–18 However, most if not all, accessible, economically abundant experimental animals, such as guinea pigs, hamsters, and mice, are insusceptible to these pathogens. Therefore, additional techniques, including immunodeficiency, virus adaptation, receptor knock-in, and humanization, should be adapted to establish effective infections and diseases.15–18 Although the aforementioned approaches have enabled lethal infections and recapitulation of certain aspects of WHO high-priority disease in rodents, there are significant differences. For instance, most rodent models are solely susceptible to EBOV via the IP route, which differs from what has been observed in humans, indicating a distinct pattern of infection, immune response, and disease progression.15 Hence these rodent models may lead to misleading medical countermeasures. For example, due to differences in the function and distribution of the ACE2 receptor, the efficacy of viral vector-based mucosal COVID-19 vaccines tested in mice was opposite to that of NHPs or humans.460,791–794 These results underscore the significance of selecting appropriate animal models under specific conditions.

Another challenge in extrapolating human clinical conditions from animal models is complex genetic and environmental factors in humans.795 Generally, experimental animals have a clear genetic background, are raised in a barrier environment, and are free from pathogenic microorganisms. However, there are significant racial, genetic, and environmental differences between populations. In addition, factors such as the economy, region, and climate further exacerbate these differences. Humans are constantly exposed to microbial environments, and the immune system is tightly regulated.796 These issues complicate the interpretation of preclinical data in animal models. In preclinical studies, abundant vaccines and antibodies have been proven to be effective and offer potential benefits. However, only a limited number of products have entered human clinical trials, and few have been approved.797 This could be largely attributed to the poor connection between preclinical data and clinical outcomes. To address this issue, immune correlates of protection against specific pathogens should be established between animal models and humans. Ideally, the establishment of immune correlates of protection in animal models would allow for immune bridging, which would improve the prediction and interpretation of the target product in humans.798 However, animal models that provide early warning signs of VAED and ADE effects are also urgently needed. This would be significant for timely responses to potential side effects or hazards caused by medical countermeasures.

To accomplish effective infection, novel sensitization strategies are involved, which may introduce additional concerns. Specifically, immunodeficient animals are expensive and need to be maintained in a barrier environment. These animal models are inapplicable for vaccine evaluation and corresponding immune correlates of protection. According to the virus adaptation model, the adaptation process may introduce additional mutant sites than the original virus, which hinders the translation and predictability of the virus for the treatment of the corresponding human disease.353–358,799 In addition, despite the transgene model enabling the knock-in of functional receptors, the precision and distribution of receptors should be carefully explained.333–337 In contrast, several naturally susceptible small animal models of WHO high-priority pathogens, such as ferrets of filoviruses, beta-coronavirus infections, and minks/hamsters of beta-coronaviruses, were found. These small animal models present promising alternatives to NHPs, given the adequate characterization of simulated human diseases. NHPs are the only animal species available that can recapitulate the stated aspects and are thus considered the gold standard. Unfortunately, NHPs are expensive, inaccessible and associated with ethical issues. Most of the major works in animal ethics strongly oppose the current use of NHP animals for research, ranging from advocating a restrictive stance to advocating abolition.800 Four key issues that come to the core in animal ethics are autonomy or self-determination, harm and benefit, justice, and vulnerability. Moreover, delicate differences between NHP species should be sufficiently documented in terms of specific pathogens.

Moreover, there are abundant subtypes or variants of WHO high-priority pathogens. These subtypes or variants exhibit distinct pathogenicity, transmission capacity, and clinical disease severities in humans.1,801 However, no animal models fully recapitulate the subtype or variant-associated disease severity in humans. In this regard, resource imbalances exist, and models for some viruses are more developed than those of others.15 For example, animal models for EBOV infection have been fully investigated, but limited models are available for TAFV infection. In the near future, the development and characterization of animal models for less known filovirus subtypes is needed.

Overall, accurate animal models and their indications are used to clarify the correlates of protection, subtypes or variants, possible adverse effects, disease severity, duration and recovery period, risk of reinfection, and complications. The above aspects have important implications for patient management, serotherapy, vaccine design, and drug administration during recovery.802 Here, we dissect these aspects of the application and deployment of animal models.

Selection of animal models

According to the “two-animal rule” guidlines of the FDA, to better support the approval or licensure of medical countermeasures, the efficacy of a candidate product should be tested in “more than one animal species expected to react with a response predictive for humans”.803 Therefore, any candidate product should have potential benefits in at least two animal models, preferably a small animal model in addition to an NHP model, to determine the overall outlook for the safety and efficacy of the target product. More specifically, there is some evidence and data needed to demonstrate the effectiveness of a product when human efficacy studies are not ethical or feasible. I. A reasonable understanding of the pathological and physiological mechanisms of biological substances and prevention or significant reduction effectiveness of products. II. Animal study endpoints are obviously related to the expected benefits to humans, usually to improve survival or reduce the major incidence rate. Product kinetics and pharmacodynamics data or information should allow the selection of effective doses for humans. III. Animal efficacy studies should substitute for human efficacy trials, following the practice of adequate and well-controlled human efficacy studies, and their endpoints prove to have important clinical benefits. The effect is demonstrated in more than one animal species expected to react with a response predictive for humans, unless the effect is demonstrated in a single animal species that represents a sufficiently well-characterized animal model (meaning the model has been adequately evaluated for its responsiveness) for predicting the response in humans. Owing to the balance between susceptibility, cost, accessibility, and feasibility, mice, hamsters, and guinea pigs often serve as preliminary animal models for initial experiments. These small rodent models are available and can be easily manipulated. Subsequently, NHPs could be used as secondary animal models, which would provide further insights into the candidate product.

Consequently, the choice of preliminary or secondary model largely depends on the purpose of the study, carefully weighing accessibility, economy, and the provided conditions (Fig. 2). Overall, naturally susceptible animal models have contributed to the exploration of pathogenesis, transmission, and clinical manifestations, while receptor-transduced models help clarify receptor-ligand interactions and interspecies transmission. Other models established by novel approaches also reproduce aspects of pathogen-specific issues, which warrant further definitions.Fig. 2 Choice of animal model. Animal models for filoviruses are taken as examples, and the susceptibility, cost, accessibility, and feasibility of nonhuman primates (NHPs), ferrets, guinea pigs, hamsters, and mice are presented. (Created in BioRender)

Clarification of correlates of immune protection

The concept of immuno-bridging requires standardized immunological assays to quantify correlates of protection across animal experiments and clinical studies. Immunobridging would simplify and expedite the expansion of approved vaccines to larger groups of people without costly or lengthy efficacy studies. It will also assist in determining other aspects of the immunization program, drug administration and prognosis. In fact, correlates of protection are always more complicated than expected, rendering a universal correlate of protection difficult to achieve.804 In this process, animal models are valuable for validating correlations of protection through depletion or passive transfer studies of antibodies or T cells, which offer an in-depth examination of immune parameters (Fig. 3).Fig. 3 The determination of immune correlates in animal models and immune correlates in COVID-19 patients are taken as examples. a In animal models and coronavirus disease 2019 (COVID-19) patients, a positive correlation between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was confirmed. b, c In COVID-19 convalescent animals, passive transfer of serum IgG protects naïve animals in a dose-dependent manner, while CD8+ T-cell depletion abolishes this protective effect to some extent. d SARS-CoV-2 rechallenge in convalescent animals increased neutralizing antibody (NAb), virus-specific binding antibody and IFN-γ responses. e In large-scale human clinical trials, a negative correlation between NAb titers and viral loads was noted. Taken together, these findings suggest that NAbs and virus-specific IgG are responsible for improved protection against COVID-19, while cellular immunity partially contributes to this protection. (Created in BioRender)

Representatively, animal models of beta-CoV infection have fostered the understanding of immune correlates. It has been described in an animal model that neutralizing antibodies, which are positively correlated with virus-specific IgG, are responsible for a better prognosis and protection in patients with COVID-19.433,805–808 Moreover, CD8+ T cells may also contribute to protection if antibody responses are suboptimal.804 However, a dysregulated cellular immune response, particularly cytokine storms, contributes to lethal outcomes.809 Similarly, in EBOV infection, massive lymphocyte apoptosis has been proven to be a marker of poor prognosis in mice, NHPs, and humans and is characterized by actively activated proinflammatory cytokines.66,67,139,810,811 In both mice and NHPs, lymphocyte activation, increased CD44+ T cells, and increased lymphocyte numbers were biomarkers observed at later stages of infection. That is, mice and NHPs infected with EBOV have obviously similar immunoreactive characteristics to those of humans. These results help to elucidate disease progression, biomarkers, and immune parameters, and help validate correlates of protection or dysregulated immunity that correspond to severe disease in humans. Furthermore, when data from large-scale clinical trials are well excavated, connected and modeled with results from preclinical studies, animal models could better predict the clinical efficacy of candidate medical interventions.

Better understanding of disease mechanisms

One of the basic considerations in developing animal models is their potential to recapitulate disease pathogenesis. In this regard, the biases of each model should be fully considered. To a large extent, diseases caused by WHO high-priority pathogens are attributed to virus-host interactions, overwhelming viral multiplication, followed by dysregulation of immune parameters and subsequent acute injury and multiorgan failure.13,812 In cases that immunodeficient animals facilitate and enable sensitive infection and symptom onset, these models may provide a better understanding of disease mechanisms in terms of antiviral signaling pathways. On the other hand, naturally susceptible animal models can provide an overall profile of disease mechanisms in humans. In contrast, transgenic and humanized models offer insights into functional receptor-associated virus-host interactions, as well as comprehensive immune systems and patterns comparable to those of humans. For instance, to determine the physiological expression of a series of immune components with regard to quantity, location and time in humans, MISTRG629 mice were engineered based on homologous gene replacement approaches between humans and mice.813–819 When engrafted with human hematopoietic stem/progenitor cells (HSPCs), these mice have a comprehensive immune system comparable to that of humans.817,820 For humanized mice, implantation of human tissue could further expand the tropism of human pathogens. When lung-implanted mouse was incorporated into bone marrow/liver/thymus humanized mice, this model supported infection with a broad range of human pathogens and enabled robust adaptive immunity following pathogen infection.821

Vaccine-associated enhanced disease (VAED) and antibody-dependent enhancement (ADE) are two major issues of concern in the development of medical responses to infectious diseases. These adverse events severely affect individuals infected with a pathogen after receiving a prior vaccine or infection-induced antibodies, resulting in enhanced infection via FcγR-expressing cells.822,823 There has been in vitro evidence of ADE for EBOV, MARV and beta-coronavirus.824–826 ADE was also observed for EBOV mAbs at subneutralizing concentrations, and this effect was not epitope restricted or independent of the neutralizing capacity or subclass of the mAbs.827 Fcγ receptor blockade reduced but did not abolish the ADE. A mAb that interacts with Fc receptors at a low dose partially protects mice. These results suggest that ADE disturbs antibody-mediated protection and facilitates the dissemination of filovirus infections. Some studies with NHPs suggest the possibility of ADE. Treatment of EBOV-infected macaques with macaque-origin convalescent serum failed to protect the animals and resulted in greater viral titers at the time of death/moribund conditions.828,829 Although protection with extremely high doses of antibodies was achieved, the failure of EBOV treatments with moderate antibody doses and increased viral loads suggest the possibility of ADE.830,831

Several studies have noted that RBD-specific SARS-CoV-2 monoclonal antibodies can cause ADE in vitro, which enhances Fcγ-mediated entry of SARS-CoV-2 into cell lines. The ADE effects could be eliminated by introducing an LALA mutation at the FC end.832,833 In addition to RBD-specific antibodies, N-terminal domain (NTD)-specific antibodies also have ADE effects in vitro via a mechanism different from that of RBD-specific antibodies. NTD-specific antibodies do not depend on the FCγR. Instead, the “open” conformation of the RBD is increased by affecting the NTD-RBD interaction, which facilitates the binding of the S protein to ACE2.834 The above results collectively showed that the adverse effects of the SARS-CoV-2 antibody involved at least two mechanisms: FC-FCγRII and S-ACE2 interaction-dependent. Interestingly, neither RBD nor NTD-specific antibodies, such as those against increased viral load or inflammation, had obvious adverse effects on mice or NHPs. In contrast, these antibodies had certain protective effects, indicating that in vitro ADE results cannot represent comprehensive clinical results in vivo.835 Although SARS-CoV-2 may enter macrophages through FC-mediated ADE antibodies in vivo, it may not replicate effectively in macrophages. In addition, FC mediated effector functions may also play a protective role, but the specific mechanism involved is still unclear.

Preclinical data indicating increased eosinophilic infiltration and pulmonary response in mice after treatment with SARS-CoV and MERS-CoV inactivated vaccines.836,837 In a ferret model, immunization with a modified vaccinia virus Ankara-based SARS-CoV vaccine led to enhanced hepatitis in ferrets.390 To avoid these effects, strong T-helper 1 (Th1) CD4-mediated responses are preferable.838 Moreover, alum-adjuvanted and formaldehyde-inactivated whole-virus vaccines were utilized to address evidence of VAED. In rhesus macaques, there was no evidence of enhanced lung pathology, and a rapid increase in NAbs was observed after challenge with SARS-CoV-2 following formalin-inactivated vaccine inoculation.839 In hamsters and ferrets, mild transient enhanced disease was observed at 7 dpi, which was resolved by day 15. Notably, hamsters showed suboptimal NAb levels and protection against challenge because formaldehyde treatment of SARS-CoV-2 reduces exposure of the RBD, and their lung cytokines were markedly skewed toward Th2 cells.839 Moreover, in K18-hACE2 mice immunized with a very impure formalin-inactivated SARS-CoV-2 preparation and an aluminum hydroxide-based adjuvant, the onset of SARS-CoV-2 replication and disease occurred earlier than that in naïve control groups or mRNA-vaccinated animals.840

Taken together, these results on ADE and VADE highlight that a tight combination should be achieved between in vitro results and in vivo performance in animal models (Fig. 4). Together with a thorough dissection of the underlying mechanism, these adverse effects could be better handled during the R&D process for WHO high-priority pathogens.Fig. 4 Validation of potential vaccine-associated adverse effects (VADEs) and antibody-dependent enhancement (ADE) in animal models. a Antibodies at subconcentrations facilitate virus entry through Fc-FcR recognition. b Fcγ receptor blockade reduced virus entry and endocytosis. c Deposition of the complement cascade (C1q) facilitates virus entry and endocytosis. (Created in BioRender)

Concerns of WHO high-priority pathogen subtypes and variants

WHO high-priority pathogens include a large group of viruses of the genus Filovirus, coronavirus, bunyavirus, etc., which can be further divided into several subtypes. For example, the Ebola virus family consists of six members.1,841,842 They exhibit varied clinical signs of disease and severity in humans and NHPs. Moreover, beta-CoVs are highly susceptible to the accumulation of mutants. For SARS-CoV-2, more than five variants of concern (VOCs) have been noted.842 Additionally, these variants exhibited altered transmission transmissibility and pathogenicity. To distinguish between these subtypes and variants, specialized animal models are needed.

As a natural model of Ebola virus infection, members of the Ebola virus family were evaluated in ferrets. EBOV- and SUDV-infected ferrets exhibit symptoms and lesions typical of humans.96–98,100 Compared with EBOV- and SUDV-infected animals, ferrets infected with BDBV exhibit a prolonged disease course, which is consistent with what has been observed in humans.96,98 However, despite asymptomatic infection in humans, RESTV is highly lethal to ferrets, humanized mice, and NHPs.77,101,102 Like those of EBOV and SUDV, the symptoms of RESTV infection in ferrets showed similar signs of disease and outcomes.103 Additionally, RESTV-infected macaques were similar to those infected with EBOV or SUDV and died at 8–10 dpi.146–148 Notably, RESTV even caused an outbreak in cynomolgus macaques in 1996 in the Philippines.145 In contrast to lethal infections in humans and NHPs,149 TAFV infection can be mild or nonlethal in ferrets.104 Additionally, infections with MARV or the ravn virus (RAVV) did not cause obvious signs in either adult or naïve ferrets.105,106 The above results suggested that disease severity is altered in ferrets and even in NHPs for some filoviruses. Fortunately, humanized mice may help address this issue, as case fatality rates of different Ebolavirus subtypes in humans have been recapitulated. As described, huNSG-A2 mice were significantly less susceptible to Makona virus than to Mayinga virus. These results suggest that humanized mice are a putative model for distinguishing the pathogenicity of various filovirus subtypes.77

For SARS-CoV-2, VOCs show enhanced transmission ability in comparison with the original SARS-CoV-2 strain in hamsters, ferrets, and white-tailed deer, which is similar to what has been observed in humans.801,843,844 This could be attributed, at least partially, to the presence of key substitutions in the spike protein, such as N501Y, which improve the receptor‒ligand affinity. This aromatic N501Y substitution is associated with increased transmission in humans but also allows infection in wild-type mice via the mouse ACE2 receptor, which was confirmed in SARS-CoV-2-adapted mouse models.845 These results open the possibility of using wild-type mice as a potential animal model of SARS-CoV-2 infection, as these mice are insusceptible to the original SARS-CoV-2 strains. Moreover, the possibility of interspecies transmission should be closely monitored since emerging variants may expand their tropism toward other animal species and eventually become resistant to ancestral viral strains, becoming novel secondary viral reservoirs.846 Fortunately, none of these variants seemed to show enhanced virulence in hamsters or NHPs, although increased proinflammatory cytokines were observed in hamsters infected with the alpha strain.847 In rhesus macaques and African green monkeys, beta-strain infection resulted in milder symptoms than infection with the ancestral B.1 and alpha strains.413 Conversely, studies in nonnaturally susceptible animals, such as K18-huACE2, revealed that infection with the beta VOC resulted in enhanced infectivity and quicker disease progression than infection with one of the ancestral variants (B.1). This increase in infectivity could be largely due to increased expression of interferon antagonist proteins induced by some VOCs.848 One study showed reduced fitness in response to beta VOCs in mice in competition trials. The increase in mutations leading to increased processing and fusion by the S protein of SARS-CoV-2 may be attributed to these differences.849 Overall, animal models of VOCs mimicked the characteristics of VOCs in humans and helped reveal associated mutation sites and potential mechanisms for enhanced transmissibility. Similarly, animal models will be essential for evaluating variant-associated pathogenicity and transmissibility and for dissecting and warning of potential risk. Currently available SARS-CoV-2 animal models show a limited duration of virus replication; therefore, we explored whether, in particularly, drug-resistant variants may emerge with suboptimal doses of either mAb or small molecule antiviral. It will therefore be important to develop SARS-CoV-2 infection models in which the virus replicates sufficiently high titers for extended periods of time without causing severe pathology, allowing for the assessment of the emergence of resistant variants against vaccines or therapies.

A concern with COVID-19 is reinfection with VOCs and virus shedding, which increases the possibility of asymptomatic infection and transmission. In this regard, hamsters reinfected with VOCs were indeed shown to shed SARS-CoV-2 for a number of days.850–852 However, infected cats do not shed enough virus for transmission to cohoused naïve animals.853 These results are in agreement with the clinical findings that although breakthrough infection could occur in vaccinated individuals, the transmission of delta VOCs from these individuals may be substantially reduced in comparison with that in nonvaccinated individuals. Importantly, virus shedding in hamsters, ferrets, and NHPs was reduced by IN vaccination,854,855 suggesting the potential value of mucosal vaccines for controlling VOC expansion.101,102

Focusing different levels of disease severity, comorbidities, and sequelae

In the clinic, WHO high-priority pathogens present different degrees of disease severity, which are determined by the virus strain involved, host genetics and environmental factors. For example, the clinical course of COVID-19 can range from asymptomatic to severe.842 Pending the identification of animal models, one of the main prerequisites remains the clarification of animal models that recapitulate a given degree of disease severity. Hamsters have been defined as mild to moderate models of COVID-19 in humans; these individuals develop respiratory disease and display some important clinical hallmarks, such as anosmia, neurotropism, and vascular inflammation, after SARS-CoV-2 infection.856–858 However, there are disconnections between pathological examination and clinical signs. Severe interstitial pneumonia but mild to moderate clinical signs were observed in SARS-CoV-2-infected hamsters. Moreover, male hamsters exhibit more severe lung lesions than females and less efficient antibody responses.378,859 Indeed, male COVID-19 patients exhibit greater levels of proinflammatory cytokines and reduced T-cell-mediated immunity than female patients.860 Mouse-adapted SARS-CoV-2 and ACE2 transgenic mice also develop pathological signs of pneumonia that range from mild to severe. In some instances, mice also develop anosmia, a common manifestation of human COVID-19. SARS-CoV-2 is highly transmissible among minks via direct contact and respiratory droplets.401–403 Importantly, SARS-CoV-2 variants have emerged in minks, and relevant transmission from minks to humans has been confirmed.404 Among all COVID-19 animal models, minks are the most susceptible due to their functional receptor ACE2.405,406 The original SARS-CoV-2 strain replicates extensively in both the upper and lower respiratory tracts, leading to severe pathological injury and causing up to 20% weight loss.403 Additionally, mink intratracheally challenged with 106 TCID50 of SARS-CoV-2 Omic mimicked the pathological features of severe COVID-19. Surprisingly, the amount of viral RNA reached 7.15 log10 RNA copies/mL in nasal lavage fluid and 6.73 log10 RNA copies/mL in throat swabs at 1–2 dpi.408

Defining animal models for different levels of disease severity caused by other pathogens is also needed. These models could accurately support preclinical research into prophylaxis and therapy for different groups of people, guide administration in clinical practice, and uncover disease mechanisms and biomarkers.

WHO high-priority pathogens are always coupled with typical signs of disease, comorbidities, and sequelae. For instance, LASV causes SNHL, while ZIKV leads to congenital microcephaly. In response, animal models recapitulating these comorbidities/sequelae would provide benefits in terms of uncovering potential underlying mechanisms and evaluating medical interventions. STAT1−/−129Sv mice infected with LASV presented typical SNHL, similar to the clinical outcome of patients infected with LASV/LF2384 and LASV/LF2350.241,245 The STAT1−/− model is the only small animal model of SNHL available. Histological examination revealed severe damage to the inner ear with a marked reduction in the number of outer hair cells. The inner hair cells remained intact. Hearing-bearing mice also exhibit impairment of the auditory nerve, while the nearby facial nerve remains intact. There was marked vacuolization of the spiral ganglion, thinning of the stria vascularis, expansion of Reissner’s membrane, and blood cell infiltration into the iliac crest. Viral antigens are present in vascular-rich areas where there is also significant infiltration of CD3+ lymphocytes, suggesting an immunopathological mechanism of hearing loss.245

For COVID-19, aged people are more vulnerable to SARS-CoV-2 infection, which correlates with immune senescence characterized by suppressed type I IFN responses, antigen presentation, and reduced T-cell responses, which leads to delayed viral clearance.500,861 There are abundant animal models that reflect age-dependent COVID-19 in humans. The severity of mouse-adapted SARS-CoV-2 infection in C57BL/6 and BALB/c mice is age dependent.357 Young mice are resistant to SARS-CoV infection, which is regulated by a STAT1-dependent but interferon receptor-independent mechanism, while aged mice exhibit greater weight loss, clinical signs, and pathology under the same conditions.357,862 The positive age-dependent severity of SARS-CoV infection was attributed to, at least to a large extent, increased inflammation in the lung, which has also been observed in humans.863,864 In ferrets, aged animals exhibit prolonged fever and more obvious weight loss than do their young counterparts.400 More severe lung pathology, higher viral titers, and a higher risk of transmission were observed. These phenomena were confirmed with findings in older patients. Age-related COVID-19 was also observed in rhesus macaques, baboons and cynomolgus macaques and presented as persistent viral pneumonia, impacting antibody responses.431 Consequently, there is increased viral shedding, more severe lung pathology, greater levels of proinflammatory cytokines, and greater body weight loss.430 Due to the high degree of biological similarity between NHPs and humans, NHPs could be powerful tools for revealing the mechanism by which age results in delayed or impaired antiviral immune responses and deficiency in immune homeostasis.865 Cardiovascular disease (CVD) and diabetes mellitus (DM) are the two most common chronic comorbidities that increase the severity and mortality of COVID-19. To better understand the potential underlying mechanism and assist corresponding countermeasures, animal models that recapitulate comorbidities of COVID-19 were established. After hACE2 transduction and SARS-CoV-2 infection, preexisting CVD development results in enhanced inflammation, viral invasion, and apoptotic pathway activation. Viral infection increased fasting blood glucose levels and reduced the insulin response in a DM model.866 There are also approaches to induce comorbidities, such as diabetes and obesity, through changes in diet. Diet-induced obesity in mice resulted in more severe disease upon SARS-CoV-2 infection.845 Finally, to respond to groups of people with comorbidities who are at high risk of severe disease, animal models with comorbidities are needed to dissect the role of infection versus comorbidity in disease severity. These efforts focus on multiple directions based on clinical needs and ultimately expedite timely and adequate responses to public health emergencies.

Emerging technologies for prevention and control of infectious disease

Classic animal models are always concerned with ethical issues and lack the ability to replicate human genetic variation or study human-specific pathogens. On the other hand, in vitro standards, cell lines, do not recapitulate the complex microenvironment or disease process that occurs throughout the organism or at multiple organ levels.867 Therefore, novel models have been developed to bridge the gap between transformed cell lines and animal models based on the principle of “reduction, replacement and refinement”. Derived from pluripotent and tissue stem cells, organoid models provide ex vivo insights into pathogenesis, the host response, and the features necessary to develop preventive and therapeutic treatments.867 Currently, organoid models recapitulate many characteristics of respiratory, gastrointestinal, and neuronal host–microbe interactions.868–870 Studies of receptor identification and distribution, tropism, and local epithelial response in SARS-CoV-2-infected lung organoids have been performed. The lung organoid model is permissive to SARS-CoV-2 infection and shows robust induction of chemokines upon SARS-CoV-2 infection.868 Colonic organoids that express ACE2 and are susceptible to SARS-CoV-2 infection have also been developed. These organoid models enabled high throughput screening of FDA-approved drugs and identified entry inhibitors of SARS-CoV-2. Organoids also help reveal CNS targeting of ZIKV and the connection between infection and clinical manifestations of microencephaly. Using neurospheres and brain organoids, it has been shown that ZIKV targets human brain cells, reducing their viability and consequently abrogating neurogenesis during human brain development.871 In another study, forebrain organoids, which showed preferential, productive infection in neural progenitors, were used to model ZIKV exposure.872 Increased cell death and reduced proliferation resulted in decreased neuronal cell layer volume, which resembles microcephaly. Subsequently, Watanabe et al. described more susceptibility receptors for ZIKV and screened various compounds for ZIKV infection using organoid methods.873 Interestingly, the neuroinvasive capacity of SARS-CoV-2 was confirmed in brain organoids, characterized by clear infection of neuronal and neural stem cells, followed by neuronal cell death in both target cells and neighboring cells.874 These versatile platforms are essential for modeling human organ development and disease, and for compound testing including potential antiviral drugs against WHO high-priority disease. However, there are still many challenges facing the use of organoids. Since the human body is an integrated organism, all organs are regulated by network-like activities through signaling through hormones, cytokines, and other signaling molecules. However, in independent organoids, it is difficult to simulate active in vivo conditions although increasing cultural complexity has already been accomplished by adding stroma, interorgan communication, and the microbiome.875 In addition, high cost, variability and tissue heterogeneity further complicate the in vitro manipulation of organoids.

Concerted interdisciplinary efforts would be another direction for disease models. More recently, AI has been actively involved in screening antiviral drugs, diagnostics and synthetic biology.876,877 Additionally, AI has been used in the field of infection biology in infectious diseases. Viral pathogens trigger a complex host reactions, in which the viral load, host immunity, intervention methods, and other factors determin the progression of infection.878 In this regard, supervised machine learning models have been used to analyze structured and unstructured datasets of nucleic acids, proteins, carbohydrates, and cell phenotypes to identify key features and molecular networks involved in host pathogen interactions and immune responses.879–881 Both supervised and unsupervised machine learning models, including random forest classifiers and complex language models, have been applied to identify gene and protein interactions related to host cell changes, predict immunogenicity, evaluate pathogen eradication ability, and evaluate host cell adaptation. Interestingly, a conceptual bridge between natural language and viral evolution has been reported, which modeled viral escape with machine learning algorithms originally developed for human natural language. In this model, potential escape mutations of the SARS-CoV-2 S protein were identified using sequence data alone.879 Overall, machine learning has made significant contributions to the analysis of large and often complex datasets in infectious disease research.876 By integrating high-throughput datasets with detailed mechanistic studies, experiments, and infection models, the problems of low throughput and limited universality of AI guidance methods can be solved. For example, experiments that systematically obtain and analyze large-scale datasets in different infection backgrounds through comprehensive CRISPR screening, RNA sequencing, and mass spectrometry techniques will promote the development of AI models that go beyond data analysis tools and can propose generalizable hypotheses and reasoning. Parameterizing these efforts with biological sequences or chemical structures will provide adjustable methods for studying infections. In addition, machine learning has effectively processed microscopic datasets related to infection biology. Similarly, AI can improve and optimize the selection and design of experimental animal models by analyzing large amounts of data, such as predicting the response of disease models under specific genetic backgrounds or phenotypes, and guiding the construction of more accurate humanized models.

The use of AI in vaccine and drug design were more extensive. The core role of AI in vaccine design is to dissect immunogenic viral proteins by examining their complex structure, followed by determination of components that are most likely to trigger a robust and broad-spectrum immune response.882,883 Among them, immune negative selection is an important algorithm. It does not require prior knowledge and can effectively defend against unknown human invasion patterns. For drug design, AI has enabled the discovery and validation of molecular targets. The deep knowledge of coding can be designed and evaluated using machine learning algorithms, which can be fully applied to the traditional single target drug discovery project. For drug mining, AI has integrated independent professional knowledge in the fields of medicine, physics, or material science.884 Through deep learning optimization, rapid and pertinent organization and connection to this knowledge were accomplished. AI can automatically identify correlations and propose corresponding drug candidates and further screen molecular structures effective for some diseases, thus facilitating the development of new drugs. Compound screening refers to the method of selecting compounds with high activity for specific targets from a large group of compounds through standardized experimental methods, which has proven to be time consuming.885 Atomwise, an AI company in Silicon Valley, has developed the artificial intelligence molecular screening (AIMS) project, which aims to accelerate drug screening.886 The atomnet system was developed based on convolutional neural networks, which have learned a lot of chemical knowledge and research data. This system analyzes the structure-activity relationship of compounds, determines the basic modules in medicinal chemistry, and is used for new drug discovery and new drug risk assessment. At present, atomic systems have mastered much chemical knowledge and research data. In 2015, Atomnet simulated two promising compounds for Ebola virus treatment in only one week. In addition, the absorption, distribution, metabolism, excretion and toxicity (ADMET) property is the most important reference index for measuring the drug properties of compounds.887 Compound ADMET prediction is important in contemporary drug design and drug screening. The early ADMET properties of drugs mainly involved the use of human or humanized tissue functional proteins as drug targets. In vitro research combined with computer simulation was used to study the interaction between drugs and biophysical and biochemical barrier factors in vivo. To further improve the accuracy of ADMET property prediction, some enterprises have explored the effective extraction of structural features through deep neural network algorithms, which accelerated the early detection and screening process of drugs and greatly reduced the R&D investment and risk.888 Polymorphism is a phenomenon in which a substance can exist in two or more different crystal structures.889 For chemical drugs, almost all solid drugs have polymorphisms. Because changes in the crystal form can change many physical and chemical properties of solid chemical drugs, several drugs fail to be marketed due to crystal form problems. Therefore, crystal form prediction is of great significance in the pharmaceutical industry. With AI, the effective dynamic configuration of drug crystal forms can be used to predict all possible crystal forms of small molecule drugs. In addition, crystal form prediction technology greatly shortens the development cycle of crystals and more effectively selects the appropriate drug crystal form. Drug repositioning was deemed to be an effective strategy for improving the efficacy of existing drugs, finding new indications and using them to treat other diseases.890 Based on the powerful literature reading and cognitive reasoning ability of AI, the best matching order could be selected and ranked in a few minutes from large pools of drugs. Taken together, these novel technologies may complement or replace traditional animal models in the future, which could facilitate the development of more effective countermeasures against these infectious diseases.

Conclusion remarks

Given the urgent circumstances of potential social and economic impacts caused by WHO high-priority pathogens, a timely response should be adopted in terms of pathogenesis, transmission mechanisms, and medical countermeasures. More importantly, “Disease X”, an infectious disease caused by unknown pathogens that could lead to a global pandemic, highlights the urgent need for preparations. In this process, the establishment of accurate animal models that reflect the authentic situation in humans is a prerequisite. Traditional approaches, together with novel technologies such as CRISPR and surrogate models, would provide and enrich the choices of animal models. However, many more issues need to be addressed in the future due to the scarcity and ethics of NHPs, the scarcity of BSL-3/4, the insusceptibility of common laboratory animals to WHO high-priority pathogens, and the discrepancy between humans and other species. Similarly, for their prevention and control, vaccines, antibodies, small molecular drugs, and other therapies have been developed based on existing and emerging technologies, and benefit from interdisciplinary cooperation. For example, organoid models offer humanized three-dimensional structures and functions for infection that are similar to those of organs in vivo. This would replace, reduce and in some cases, refine the use of traditional animal models in the study of WHO high-priority diseases. In addition, AI and machine learning can be used to build high-throughput databases for host-pathogen interactions, which can further optimize model selection, vaccine design, drug discovery, and antibody screening. Consequently, further technological advances, applied innovations and interdisciplinary cooperation are needed to gain better knowledge and consolidate the line of defence against WHO high-priority pathogens.

Author contributions

C.S., F.Y. and X.X. conceptualized and supervised. S.W. and W.L. developed Methodology. S.W., Z.W., W.Y., and E.L. wrote original draft. S.W. drew the figures. All authors have read and approved this article.

Competing interests

The authors declare no competing interests.

These authors contributed equally: Shen Wang, Wujian Li, Zhenshan Wang, Wanying Yang
==== Refs
References

1. Jacob ST Ebola virus disease Nat. Rev. Dis. Prim. 2020 6 13 10.1038/s41572-020-0147-3 32080199
Jacob, S. T. et al. Ebola virus disease. Nat. Rev. Dis. Prim. 6, 13 (2020).32080199
2. Kortepeter MG Dierberg K Shenoy ES Cieslak TJ Marburg virus disease: A summary for clinicians Int. J. Infect. Dis. 2020 99 233 242 10.1016/j.ijid.2020.07.042 32758690
Kortepeter, M. G., Dierberg, K., Shenoy, E. S. & Cieslak, T. J. Marburg virus disease: A summary for clinicians. Int. J. Infect. Dis. 99, 233–242 (2020).32758690
3. Garry RF Lassa fever - the road ahead Nat. Rev. Microbiol 2023 21 87 96 10.1038/s41579-022-00789-8 36097163
Garry, R. F. Lassa fever - the road ahead. Nat. Rev. Microbiol 21, 87–96 (2023).36097163
4. Raabe V Mehta AK Evans JD Lassa Virus Infection: a Summary for Clinicians Int. J. Infect. Dis. 2022 119 187 200 10.1016/j.ijid.2022.04.004 35395384
Raabe, V., Mehta, A. K. & Evans, J. D. Lassa Virus Infection: a Summary for Clinicians. Int. J. Infect. Dis. 119, 187–200 (2022).35395384
5. Hawman DW Feldmann H Crimean-Congo haemorrhagic fever virus Nat. Rev. Microbiol 2023 21 463 477 10.1038/s41579-023-00871-9 36918725
Hawman, D. W. & Feldmann, H. Crimean-Congo haemorrhagic fever virus. Nat. Rev. Microbiol 21, 463–477 (2023).36918725
6. Connors KA Hartman AL Advances in Understanding Neuropathogenesis of Rift Valley Fever Virus Annu. Rev. Virol. 2022 9 437 450 10.1146/annurev-virology-091919-065806 36173701
Connors, K. A. & Hartman, A. L. Advances in Understanding Neuropathogenesis of Rift Valley Fever Virus. Annu. Rev. Virol. 9, 437–450 (2022).36173701
7. Zhang XY Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2 Infect. Dis. Poverty 2020 9 99 10.1186/s40249-020-00691-6 32690096
Zhang, X. Y. et al. Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2. Infect. Dis. Poverty 9, 99 (2020).32690096
8. Hui DSC Zumla A Severe Acute Respiratory Syndrome: Historical, Epidemiologic, and Clinical Features Infect. Dis. Clin. North Am. 2019 33 869 889 10.1016/j.idc.2019.07.001 31668196
Hui, D. S. C. & Zumla, A. Severe Acute Respiratory Syndrome: Historical, Epidemiologic, and Clinical Features. Infect. Dis. Clin. North Am. 33, 869–889 (2019).31668196
9. de Wit E van Doremalen N Falzarano D Munster VJ SARS and MERS: recent insights into emerging coronaviruses Nat. Rev. Microbiol. 2016 14 523 534 10.1038/nrmicro.2016.81 27344959
de Wit, E., van Doremalen, N., Falzarano, D. & Munster, V. J. SARS and MERS: recent insights into emerging coronaviruses. Nat. Rev. Microbiol. 14, 523–534 (2016).27344959
10. Ang BSP Lim TCC Wang L Nipah Virus Infection J. Clin. Microbiol. 2018 56 e01875 01817 10.1128/JCM.01875-17 29643201
Ang, B. S. P., Lim, T. C. C. & Wang, L. Nipah Virus Infection. J. Clin. Microbiol. 56, e01875–01817 (2018).29643201
11. Musso D Gubler DJ Zika Virus Clin. Microbiol. Rev. 2016 29 487 524 10.1128/CMR.00072-15 27029595
Musso, D. & Gubler, D. J. Zika Virus. Clin. Microbiol. Rev. 29, 487–524 (2016).27029595
12. Fathi A Dahlke C Addo MM Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens Hum. Vaccin Immunother. 2019 15 2269 2285 10.1080/21645515.2019.1649532 31368826
Fathi, A., Dahlke, C. & Addo, M. M. Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens. Hum. Vaccin Immunother. 15, 2269–2285 (2019).31368826
13. Friedrich MJ WHO’s Blueprint List of Priority Diseases JAMA 2018 319 1973 29800221
Friedrich, M. J. WHO’s Blueprint List of Priority Diseases. JAMA 319, 1973 (2018).29800221
14. Mehand MS Al-Shorbaji F Millett P Murgue B The WHO R&D Blueprint: 2018 review of emerging infectious diseases requiring urgent research and development efforts Antivir. Res. 2018 159 63 67 10.1016/j.antiviral.2018.09.009 30261226
Mehand, M. S., Al-Shorbaji, F., Millett, P. & Murgue, B. The WHO R&D Blueprint: 2018 review of emerging infectious diseases requiring urgent research and development efforts. Antivir. Res. 159, 63–67 (2018).30261226
15. Siragam V Wong G Qiu XG Animal models for filovirus infections Zool. Res. 2018 39 15 24 10.24272/j.issn.2095-8137.2017.053 29511141
Siragam, V., Wong, G. & Qiu, X. G. Animal models for filovirus infections. Zool. Res. 39, 15–24 (2018).29511141
16. Fan C Animal models for COVID-19: advances, gaps and perspectives Signal Transduct. Target Ther. 2022 7 220 10.1038/s41392-022-01087-8 35798699
Fan, C. et al. Animal models for COVID-19: advances, gaps and perspectives. Signal Transduct. Target Ther. 7, 220 (2022).35798699
17. Muñoz-Fontela C Animal models for COVID-19 Nature 2020 586 509 515 10.1038/s41586-020-2787-6 32967005
Muñoz-Fontela, C. et al. Animal models for COVID-19. Nature 586, 509–515 (2020).32967005
18. Banadyga L Wong G Qiu X Small Animal Models for Evaluating Filovirus Countermeasures ACS Infect. Dis. 2018 4 673 685 10.1021/acsinfecdis.7b00266 29457711
Banadyga, L., Wong, G. & Qiu, X. Small Animal Models for Evaluating Filovirus Countermeasures. ACS Infect. Dis. 4, 673–685 (2018).29457711
19. Feldmann H Sprecher A Geisbert TW Ebola N. Engl. J. Med. 2020 382 1832 1842 10.1056/NEJMra1901594 32441897
Feldmann, H., Sprecher, A. & Geisbert, T. W. Ebola. N. Engl. J. Med. 382, 1832–1842 (2020).32441897
20. Ghosh S Saha A Samanta S Saha RP Genome structure and genetic diversity in the Ebola virus Curr. Opin. Pharm. 2021 60 83 90 10.1016/j.coph.2021.06.010
Ghosh, S., Saha, A., Samanta, S. & Saha, R. P. Genome structure and genetic diversity in the Ebola virus. Curr. Opin. Pharm. 60, 83–90 (2021).
21. Milligan JC Asymmetric and non-stoichiometric glycoprotein recognition by two distinct antibodies results in broad protection against ebolaviruses Cell 2022 185 995 1007.e18 10.1016/j.cell.2022.02.023 35303429
Milligan, J. C. et al. Asymmetric and non-stoichiometric glycoprotein recognition by two distinct antibodies results in broad protection against ebolaviruses. Cell 185, 995–1007.e18 (2022).35303429
22. Bär S Takada A Kawaoka Y Alizon M Detection of cell-cell fusion mediated by Ebola virus glycoproteins J. Virol. 2006 80 2815 2822 10.1128/JVI.80.6.2815-2822.2006 16501090
Bär, S., Takada, A., Kawaoka, Y. & Alizon, M. Detection of cell-cell fusion mediated by Ebola virus glycoproteins. J. Virol. 80, 2815–2822 (2006).16501090
23. Beniac DR Booth TF Structure of the Ebola virus glycoprotein spike within the virion envelope at 11Å resolution Sci. Rep. 2017 7 46374 10.1038/srep46374 28397863
Beniac, D. R. & Booth, T. F. Structure of the Ebola virus glycoprotein spike within the virion envelope at 11Å resolution. Sci. Rep. 7, 46374 (2017).28397863
24. Kuroda M Interaction between TIM-1 and NPC1 Is Important for Cellular Entry of Ebola Virus J. Virol. 2015 89 6481 6493 10.1128/JVI.03156-14 25855742
Kuroda, M. et al. Interaction between TIM-1 and NPC1 Is Important for Cellular Entry of Ebola Virus. J. Virol. 89, 6481–6493 (2015).25855742
25. Alvarez CP C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans J. Virol. 2002 76 6841 6844 10.1128/JVI.76.13.6841-6844.2002 12050398
Alvarez, C. P. et al. C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans. J. Virol. 76, 6841–6844 (2002).12050398
26. Shimojima M Tyro3 family-mediated cell entry of Ebola and Marburg viruses J. Virol. 2006 80 10109 10116 10.1128/JVI.01157-06 17005688
Shimojima, M. et al. Tyro3 family-mediated cell entry of Ebola and Marburg viruses. J. Virol. 80, 10109–10116 (2006).17005688
27. Geisbert TW Hensley LE Ebola virus: new insights into disease aetiopathology and possible therapeutic interventions Expert Rev. Mol. Med. 2004 6 1 24 10.1017/S1462399404008300 15383160
Geisbert, T. W. & Hensley, L. E. Ebola virus: new insights into disease aetiopathology and possible therapeutic interventions. Expert Rev. Mol. Med. 6, 1–24 (2004).15383160
28. Geisbert TW Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection Am. J. Pathol. 2003 163 2347 2370 10.1016/S0002-9440(10)63591-2 14633608
Geisbert, T. W. et al. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am. J. Pathol. 163, 2347–2370 (2003).14633608
29. Lin G Differential N-linked glycosylation of human immunodeficiency virus and Ebola virus envelope glycoproteins modulates interactions with DC-SIGN and DC-SIGNR J. Virol. 2003 77 1337 1346 10.1128/JVI.77.2.1337-1346.2003 12502850
Lin, G. et al. Differential N-linked glycosylation of human immunodeficiency virus and Ebola virus envelope glycoproteins modulates interactions with DC-SIGN and DC-SIGNR. J. Virol. 77, 1337–1346 (2003).12502850
30. Takada A Human macrophage C-type lectin specific for galactose and N-acetylgalactosamine promotes filovirus entry J. Virol. 2004 78 2943 2947 10.1128/JVI.78.6.2943-2947.2004 14990712
Takada, A. et al. Human macrophage C-type lectin specific for galactose and N-acetylgalactosamine promotes filovirus entry. J. Virol. 78, 2943–2947 (2004).14990712
31. Aleksandrowicz P Ebola virus enters host cells by macropinocytosis and clathrin-mediated endocytosis J. Infect. Dis. 2011 204 S957 S967 10.1093/infdis/jir326 21987776
Aleksandrowicz, P. et al. Ebola virus enters host cells by macropinocytosis and clathrin-mediated endocytosis. J. Infect. Dis. 204, S957–S967 (2011).21987776
32. Nanbo A Ebolavirus is internalized into host cells via macropinocytosis in a viral glycoprotein-dependent manner PLoS Pathog. 2010 6 e1001121 10.1371/journal.ppat.1001121 20886108
Nanbo, A. et al. Ebolavirus is internalized into host cells via macropinocytosis in a viral glycoprotein-dependent manner. PLoS Pathog. 6, e1001121 (2010).20886108
33. Saeed MF Kolokoltsov AA Albrecht T Davey RA Cellular entry of ebola virus involves uptake by a macropinocytosis-like mechanism and subsequent trafficking through early and late endosomes PLoS Pathog. 2010 6 e1001110 10.1371/journal.ppat.1001110 20862315
Saeed, M. F., Kolokoltsov, A. A., Albrecht, T. & Davey, R. A. Cellular entry of ebola virus involves uptake by a macropinocytosis-like mechanism and subsequent trafficking through early and late endosomes. PLoS Pathog. 6, e1001110 (2010).20862315
34. Wang H Ebola Viral Glycoprotein Bound to Its Endosomal Receptor Niemann-Pick C1 Cell 2016 164 258 268 10.1016/j.cell.2015.12.044 26771495
Wang, H. et al. Ebola Viral Glycoprotein Bound to Its Endosomal Receptor Niemann-Pick C1. Cell 164, 258–268 (2016).26771495
35. Carette JE Ebola virus entry requires the cholesterol transporter Niemann-Pick C1 Nature 2011 477 340 343 10.1038/nature10348 21866103
Carette, J. E. et al. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature 477, 340–343 (2011).21866103
36. Olson MA Lee MS Yeh IC Membrane insertion of fusion peptides from Ebola and Marburg viruses studied by replica-exchange molecular dynamics simulations J. Comput. Chem. 2017 38 1342 1352 10.1002/jcc.24717 28130780
Olson, M. A., Lee, M. S. & Yeh, I. C. Membrane insertion of fusion peptides from Ebola and Marburg viruses studied by replica-exchange molecular dynamics simulations. J. Comput. Chem. 38, 1342–1352 (2017).28130780
37. Noyori O Suppression of Fas-mediated apoptosis via steric shielding by filovirus glycoproteins Biochem. Biophys. Res. Commun. 2013 441 994 998 10.1016/j.bbrc.2013.11.018 24239546
Noyori, O. et al. Suppression of Fas-mediated apoptosis via steric shielding by filovirus glycoproteins. Biochem. Biophys. Res. Commun. 441, 994–998 (2013).24239546
38. Noyori O Differential potential for envelope glycoprotein-mediated steric shielding of host cell surface proteins among filoviruses Virology 2013 446 152 161 10.1016/j.virol.2013.07.029 24074577
Noyori, O. et al. Differential potential for envelope glycoprotein-mediated steric shielding of host cell surface proteins among filoviruses. Virology 446, 152–161 (2013).24074577
39. Cao Z Ebola virus VP35 perturbs type I interferon signaling to facilitate viral replication Virol. Sin. 2023 38 922 930 10.1016/j.virs.2023.10.004 37839549
Cao, Z. et al. Ebola virus VP35 perturbs type I interferon signaling to facilitate viral replication. Virol. Sin. 38, 922–930 (2023).37839549
40. Martines RB Tissue and cellular tropism, pathology and pathogenesis of Ebola and Marburg viruses J. Pathol. 2015 235 153 174 10.1002/path.4456 25297522
Martines, R. B. et al. Tissue and cellular tropism, pathology and pathogenesis of Ebola and Marburg viruses. J. Pathol. 235, 153–174 (2015).25297522
41. Sanchez A Biochemical analysis of the secreted and virion glycoproteins of Ebola virus J. Virol. 1998 72 6442 6447 10.1128/JVI.72.8.6442-6447.1998 9658086
Sanchez, A. et al. Biochemical analysis of the secreted and virion glycoproteins of Ebola virus. J. Virol. 72, 6442–6447 (1998).9658086
42. Ito H Watanabe S Takada A Kawaoka Y Ebola virus glycoprotein: proteolytic processing, acylation, cell tropism, and detection of neutralizing antibodies J. Virol. 2001 75 1576 1580, 10.1128/JVI.75.3.1576-1580.2001 11152533
Ito, H., Watanabe, S., Takada, A. & Kawaoka, Y. Ebola virus glycoprotein: proteolytic processing, acylation, cell tropism, and detection of neutralizing antibodies. J. Virol. 75, 1576–1580, (2001).11152533
43. Kindzelskii AL Ebola virus secretory glycoprotein (sGP) diminishes Fc gamma RIIIB-to-CR3 proximity on neutrophils J. Immunol. 2000 164 953 958 10.4049/jimmunol.164.2.953 10623844
Kindzelskii, A. L. et al. Ebola virus secretory glycoprotein (sGP) diminishes Fc gamma RIIIB-to-CR3 proximity on neutrophils. J. Immunol. 164, 953–958 (2000).10623844
44. Wahl-Jensen VM Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function J. Virol. 2005 79 10442 10450 10.1128/JVI.79.16.10442-10450.2005 16051836
Wahl-Jensen, V. M. et al. Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function. J. Virol. 79, 10442–10450 (2005).16051836
45. Suzuki Y Gojobori T The origin and evolution of Ebola and Marburg viruses Mol. Biol. Evol. 1997 14 800 806, 10.1093/oxfordjournals.molbev.a025820 9254917
Suzuki, Y. & Gojobori, T. The origin and evolution of Ebola and Marburg viruses. Mol. Biol. Evol. 14, 800–806, (1997).9254917
46. Barrette RW Discovery of swine as a host for the Reston ebolavirus Science 2009 325 204 206 10.1126/science.1172705 19590002
Barrette, R. W. et al. Discovery of swine as a host for the Reston ebolavirus. Science 325, 204–206 (2009).19590002
47. Pan Y Reston virus in domestic pigs in China Arch. Virol. 2014 159 1129 1132 10.1007/s00705-012-1477-6 22996641
Pan, Y. et al. Reston virus in domestic pigs in China. Arch. Virol. 159, 1129–1132 (2014).22996641
48. Swanepoel R Studies of reservoir hosts for Marburg virus Emerg. Infect. Dis. 2007 13 1847 1851 10.3201/eid1312.071115 18258034
Swanepoel, R. et al. Studies of reservoir hosts for Marburg virus. Emerg. Infect. Dis. 13, 1847–1851 (2007).18258034
49. Towner JS Isolation of genetically diverse Marburg viruses from Egyptian fruit bats PLoS Pathog. 2009 5 e1000536 10.1371/journal.ppat.1000536 19649327
Towner, J. S. et al. Isolation of genetically diverse Marburg viruses from Egyptian fruit bats. PLoS Pathog. 5, e1000536 (2009).19649327
50. Gowen BB Holbrook MR Animal models of highly pathogenic RNA viral infections: hemorrhagic fever viruses Antivir. Res. 2008 78 79 90 10.1016/j.antiviral.2007.10.002 18036672
Gowen, B. B. & Holbrook, M. R. Animal models of highly pathogenic RNA viral infections: hemorrhagic fever viruses. Antivir. Res. 78, 79–90 (2008).18036672
51. Towner JS Marburgvirus genomics and association with a large hemorrhagic fever outbreak in Angola J. Virol. 2006 80 6497 6516 10.1128/JVI.00069-06 16775337
Towner, J. S. et al. Marburgvirus genomics and association with a large hemorrhagic fever outbreak in Angola. J. Virol. 80, 6497–6516 (2006).16775337
52. Mahanty S Bray M Pathogenesis of filoviral haemorrhagic fevers Lancet Infect. Dis. 2004 4 487 498, 10.1016/S1473-3099(04)01103-X 15288821
Mahanty, S. & Bray, M. Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect. Dis. 4, 487–498, (2004).15288821
53. Robinson JE Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits Nat. Commun. 2016 7 11544 10.1038/ncomms11544 27161536
Robinson, J. E. et al. Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits. Nat. Commun. 7, 11544 (2016).27161536
54. Brauburger K Hume AJ Mühlberger E Olejnik J Forty-five years of Marburg virus research Viruses 2012 4 1878 1927 10.3390/v4101878 23202446
Brauburger, K., Hume, A. J., Mühlberger, E. & Olejnik, J. Forty-five years of Marburg virus research. Viruses 4, 1878–1927 (2012).23202446
55. Shifflett K Marzi A Marburg virus pathogenesis - differences and similarities in humans and animal models Virol. J. 2019 16 165 10.1186/s12985-019-1272-z 31888676
Shifflett, K. & Marzi, A. Marburg virus pathogenesis - differences and similarities in humans and animal models. Virol. J. 16, 165 (2019).31888676
56. Geisbert TW Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys Lancet 2003 362 1953 1958 10.1016/S0140-6736(03)15012-X 14683653
Geisbert, T. W. et al. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet 362, 1953–1958 (2003).14683653
57. Warfield KL Development and characterization of a mouse model for Marburg hemorrhagic fever J. Virol. 2009 83 6404 6415 10.1128/JVI.00126-09 19369350
Warfield, K. L. et al. Development and characterization of a mouse model for Marburg hemorrhagic fever. J. Virol. 83, 6404–6415 (2009).19369350
58. Bray M The role of the Type I interferon response in the resistance of mice to filovirus infection J. Gen. Virol. 2001 82 1365 1373 10.1099/0022-1317-82-6-1365 11369881
Bray, M. The role of the Type I interferon response in the resistance of mice to filovirus infection. J. Gen. Virol. 82, 1365–1373 (2001).11369881
59. Hofmann H Kunz C [A strain of “Marburg virus” (Rhabdovirus simiae) pathogenic to mice] Arch. Gesamt. Virusforsch. 1970 32 244 248, 10.1007/BF01249960
Hofmann, H. & Kunz, C. [A strain of “Marburg virus” (Rhabdovirus simiae) pathogenic to mice]. Arch. Gesamt. Virusforsch. 32, 244–248, (1970).
60. Moe JB Lambert RD Lupton HW Plaque assay for Ebola virus J. Clin. Microbiol 1981 13 791 793 10.1128/jcm.13.4.791-793.1981 7014628
Moe, J. B., Lambert, R. D. & Lupton, H. W. Plaque assay for Ebola virus. J. Clin. Microbiol 13, 791–793 (1981).7014628
61. Banadyga L Dolan MA Ebihara H Rodent-Adapted Filoviruses and the Molecular Basis of Pathogenesis J. Mol. Biol. 2016 428 3449 3466 10.1016/j.jmb.2016.05.008 27189922
Banadyga, L., Dolan, M. A. & Ebihara, H. Rodent-Adapted Filoviruses and the Molecular Basis of Pathogenesis. J. Mol. Biol. 428, 3449–3466 (2016).27189922
62. Bray M A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever J. Infect. Dis. 1999 179 S248 S258 10.1086/514292 9988191
Bray, M. et al. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J. Infect. Dis. 179, S248–S258 (1999).9988191
63. Ebihara H Molecular determinants of Ebola virus virulence in mice PLoS Pathog. 2006 2 e73 10.1371/journal.ppat.0020073 16848640
Ebihara, H. et al. Molecular determinants of Ebola virus virulence in mice. PLoS Pathog. 2, e73 (2006).16848640
64. Ramanan P Filoviral immune evasion mechanisms Viruses 2011 3 1634 1649 10.3390/v3091634 21994800
Ramanan, P. et al. Filoviral immune evasion mechanisms. Viruses 3, 1634–1649 (2011).21994800
65. Gibb TR Pathogenesis of experimental Ebola Zaire virus infection in BALB/c mice J. Comp. Pathol. 2001 125 233 242 10.1053/jcpa.2001.0502 11798240
Gibb, T. R. et al. Pathogenesis of experimental Ebola Zaire virus infection in BALB/c mice. J. Comp. Pathol. 125, 233–242 (2001).11798240
66. Geisbert TW Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event J. Infect. Dis. 2003 188 1618 1629 10.1086/379724 14639531
Geisbert, T. W. et al. Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J. Infect. Dis. 188, 1618–1629 (2003).14639531
67. Villinger F Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection J. Infect. Dis. 1999 179 S188 S191 10.1086/514283 9988183
Villinger, F. et al. Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection. J. Infect. Dis. 179, S188–S191 (1999).9988183
68. Baize S Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients Nat. Med. 1999 5 423 426 10.1038/7422 10202932
Baize, S. et al. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat. Med. 5, 423–426 (1999).10202932
69. Raymond J Bradfute S Bray M Filovirus infection of STAT-1 knockout mice J. Infect. Dis. 2011 204 S986 S990 10.1093/infdis/jir335 21987780
Raymond, J., Bradfute, S. & Bray, M. Filovirus infection of STAT-1 knockout mice. J. Infect. Dis. 204, S986–S990 (2011).21987780
70. Lever MS Lethality and pathogenesis of airborne infection with filoviruses in A129 α/β −/− interferon receptor-deficient mice J. Med. Microbiol. 2012 61 8 15 10.1099/jmm.0.036210-0 21852521
Lever, M. S. et al. Lethality and pathogenesis of airborne infection with filoviruses in A129 α/β −/− interferon receptor-deficient mice. J. Med. Microbiol. 61, 8–15 (2012).21852521
71. Escaffre O STAT-1 Knockout Mice as a Model for Wild-Type Sudan Virus (SUDV) Viruses 2021 13 1388 10.3390/v13071388 34372594
Escaffre, O. et al. STAT-1 Knockout Mice as a Model for Wild-Type Sudan Virus (SUDV). Viruses 13, 1388 (2021).34372594
72. Warfield KL Development of a model for marburgvirus based on severe-combined immunodeficiency mice Virol. J. 2007 4 108 10.1186/1743-422X-4-108 17961252
Warfield, K. L. et al. Development of a model for marburgvirus based on severe-combined immunodeficiency mice. Virol. J. 4, 108 (2007).17961252
73. Qiu X Establishment and characterization of a lethal mouse model for the Angola strain of Marburg virus J. Virol. 2014 88 12703 12714 10.1128/JVI.01643-14 25142608
Qiu, X. et al. Establishment and characterization of a lethal mouse model for the Angola strain of Marburg virus. J. Virol. 88, 12703–12714 (2014).25142608
74. Wei H Deep-sequencing of Marburg virus genome during sequential mouse passaging and cell-culture adaptation reveals extensive changes over time Sci. Rep. 2017 7 3390 10.1038/s41598-017-03318-3 28611428
Wei, H. et al. Deep-sequencing of Marburg virus genome during sequential mouse passaging and cell-culture adaptation reveals extensive changes over time. Sci. Rep. 7, 3390 (2017).28611428
75. Valmas C Basler CF Marburg virus VP40 antagonizes interferon signaling in a species-specific manner J. Virol. 2011 85 4309 4317 10.1128/JVI.02575-10 21325424
Valmas, C. & Basler, C. F. Marburg virus VP40 antagonizes interferon signaling in a species-specific manner. J. Virol. 85, 4309–4317 (2011).21325424
76. Bird BH Humanized Mouse Model of Ebola Virus Disease Mimics the Immune Responses in Human Disease J. Infect. Dis. 2016 213 703 711 10.1093/infdis/jiv538 26582961
Bird, B. H. et al. Humanized Mouse Model of Ebola Virus Disease Mimics the Immune Responses in Human Disease. J. Infect. Dis. 213, 703–711 (2016).26582961
77. Escudero-Pérez B Comparative pathogenesis of Ebola virus and Reston virus infection in humanized mice JCI Insight 2019 4 e126070 10.1172/jci.insight.126070 31550241
Escudero-Pérez, B. et al. Comparative pathogenesis of Ebola virus and Reston virus infection in humanized mice. JCI Insight 4, e126070 (2019).31550241
78. Rasmussen AL Host genetic diversity enables Ebola hemorrhagic fever pathogenesis and resistance Science 2014 346 987 991 10.1126/science.1259595 25359852
Rasmussen, A. L. et al. Host genetic diversity enables Ebola hemorrhagic fever pathogenesis and resistance. Science 346, 987–991 (2014).25359852
79. Lavender KJ Pathogenicity of Ebola and Marburg Viruses Is Associated With Differential Activation of the Myeloid Compartment in Humanized Triple Knockout-Bone Marrow, Liver, and Thymus Mice J. Infect. Dis. 2018 218 S409 s417 10.1093/infdis/jiy269 30085162
Lavender, K. J. et al. Pathogenicity of Ebola and Marburg Viruses Is Associated With Differential Activation of the Myeloid Compartment in Humanized Triple Knockout-Bone Marrow, Liver, and Thymus Mice. J. Infect. Dis. 218, S409–s417 (2018).30085162
80. Bradfute SB Lymphocyte death in a mouse model of Ebola virus infection J. Infect. Dis. 2007 196 S296 S304 10.1086/520602 17940964
Bradfute, S. B. et al. Lymphocyte death in a mouse model of Ebola virus infection. J. Infect. Dis. 196, S296–S304 (2007).17940964
81. Bradfute SB Mechanisms and consequences of ebolavirus-induced lymphocyte apoptosis J. Immunol. 2010 184 327 335 10.4049/jimmunol.0901231 20028660
Bradfute, S. B. et al. Mechanisms and consequences of ebolavirus-induced lymphocyte apoptosis. J. Immunol. 184, 327–335 (2010).20028660
82. Ebihara H A Syrian golden hamster model recapitulating ebola hemorrhagic fever J. Infect. Dis. 2013 207 306 318 10.1093/infdis/jis626 23045629
Ebihara, H. et al. A Syrian golden hamster model recapitulating ebola hemorrhagic fever. J. Infect. Dis. 207, 306–318 (2013).23045629
83. Ebihara H Host response dynamics following lethal infection of rhesus macaques with Zaire ebolavirus J. Infect. Dis. 2011 204 S991 S999 10.1093/infdis/jir336 21987781
Ebihara, H. et al. Host response dynamics following lethal infection of rhesus macaques with Zaire ebolavirus. J. Infect. Dis. 204, S991–S999 (2011).21987781
84. Atkins C Natural History and Pathogenesis of Wild-Type Marburg Virus Infection in STAT2 Knockout Hamsters J. Infect. Dis. 2018 218 S438 s447 30192975
Atkins, C. et al. Natural History and Pathogenesis of Wild-Type Marburg Virus Infection in STAT2 Knockout Hamsters. J. Infect. Dis. 218, S438–s447 (2018).30192975
85. Marzi A A hamster model for Marburg virus infection accurately recapitulates Marburg hemorrhagic fever Sci. Rep. 2016 6 39214 10.1038/srep39214 27976688
Marzi, A. et al. A hamster model for Marburg virus infection accurately recapitulates Marburg hemorrhagic fever. Sci. Rep. 6, 39214 (2016).27976688
86. Bowen ET Viral haemorrhagic fever in southern Sudan and northern Zaire. Preliminary studies on the aetiological agent Lancet 1977 1 571 573 10.1016/S0140-6736(77)92001-3 65662
Bowen, E. T. et al. Viral haemorrhagic fever in southern Sudan and northern Zaire. Preliminary studies on the aetiological agent. Lancet 1, 571–573 (1977).65662
87. Connolly BM Pathogenesis of experimental Ebola virus infection in guinea pigs J. Infect. Dis. 1999 179 S203 S217 10.1086/514305 9988186
Connolly, B. M. et al. Pathogenesis of experimental Ebola virus infection in guinea pigs. J. Infect. Dis. 179, S203–S217 (1999).9988186
88. Ryabchikova E Ebola virus infection in guinea pigs: presumable role of granulomatous inflammation in pathogenesis Arch. Virol. 1996 141 909 921 10.1007/BF01718165 8678836
Ryabchikova, E. et al. Ebola virus infection in guinea pigs: presumable role of granulomatous inflammation in pathogenesis. Arch. Virol. 141, 909–921 (1996).8678836
89. Subbotina E Dadaeva A Kachko A Chepurnov A Genetic factors of Ebola virus virulence in guinea pigs Virus Res. 2010 153 121 133 10.1016/j.virusres.2010.07.015 20654661
Subbotina, E., Dadaeva, A., Kachko, A. & Chepurnov, A. Genetic factors of Ebola virus virulence in guinea pigs. Virus Res. 153, 121–133 (2010).20654661
90. Cross RW Modeling the Disease Course of Zaire ebolavirus Infection in the Outbred Guinea Pig J. Infect. Dis. 2015 212 S305 S315 10.1093/infdis/jiv237 26038397
Cross, R. W. et al. Modeling the Disease Course of Zaire ebolavirus Infection in the Outbred Guinea Pig. J. Infect. Dis. 212, S305–S315 (2015).26038397
91. Wong G Development and Characterization of a Guinea Pig-Adapted Sudan Virus J. Virol. 2016 90 392 399 10.1128/JVI.02331-15 26491156
Wong, G. et al. Development and Characterization of a Guinea Pig-Adapted Sudan Virus. J. Virol. 90, 392–399 (2016).26491156
92. Simpson DI Zlotnik I Rutter DA Vervet monkey disease. Experiment infection of guinea pigs and monkeys with the causative agent Br. J. Exp. Pathol. 1968 49 458 464 5727750
Simpson, D. I., Zlotnik, I. & Rutter, D. A. Vervet monkey disease. Experiment infection of guinea pigs and monkeys with the causative agent. Br. J. Exp. Pathol. 49, 458–464 (1968).5727750
93. Cross RW Comparison of the Pathogenesis of the Angola and Ravn Strains of Marburg Virus in the Outbred Guinea Pig Model J. Infect. Dis. 2015 212 S258 S270 10.1093/infdis/jiv182 26092858
Cross, R. W. et al. Comparison of the Pathogenesis of the Angola and Ravn Strains of Marburg Virus in the Outbred Guinea Pig Model. J. Infect. Dis. 212, S258–S270 (2015).26092858
94. Hevey M Antigenicity and vaccine potential of Marburg virus glycoprotein expressed by baculovirus recombinants Virology 1997 239 206 216 10.1006/viro.1997.8883 9426460
Hevey, M. et al. Antigenicity and vaccine potential of Marburg virus glycoprotein expressed by baculovirus recombinants. Virology 239, 206–216 (1997).9426460
95. Fenollar F Mink, SARS-CoV-2, and the Human-Animal Interface Front. Microbiol. 2021 12 663815 10.3389/fmicb.2021.663815 33868218
Fenollar, F. et al. Mink, SARS-CoV-2, and the Human-Animal Interface. Front. Microbiol. 12, 663815 (2021).33868218
96. Cross RW The Domestic Ferret (Mustela putorius furo) as a Lethal Infection Model for 3 Species of Ebolavirus J. Infect. Dis. 2016 214 565 569 10.1093/infdis/jiw209 27354371
Cross, R. W. et al. The Domestic Ferret (Mustela putorius furo) as a Lethal Infection Model for 3 Species of Ebolavirus. J. Infect. Dis. 214, 565–569 (2016).27354371
97. Wong G The Makona Variant of Ebola Virus Is Highly Lethal to Immunocompromised Mice and Immunocompetent Ferrets J. Infect. Dis. 2018 218 S466 S470 29878131
Wong, G. et al. The Makona Variant of Ebola Virus Is Highly Lethal to Immunocompromised Mice and Immunocompetent Ferrets. J. Infect. Dis. 218, S466–S470 (2018).29878131
98. Kozak R Ferrets Infected with Bundibugyo Virus or Ebola Virus Recapitulate Important Aspects of Human Filovirus Disease J. Virol. 2016 90 9209 9223 10.1128/JVI.01033-16 27489269
Kozak, R. et al. Ferrets Infected with Bundibugyo Virus or Ebola Virus Recapitulate Important Aspects of Human Filovirus Disease. J. Virol. 90, 9209–9223 (2016).27489269
99. Brasel T Mucosal Challenge Ferret Models of Ebola Virus Disease Pathogens 2021 10 292 10.3390/pathogens10030292 33806375
Brasel, T. et al. Mucosal Challenge Ferret Models of Ebola Virus Disease. Pathogens 10, 292 (2021).33806375
100. Kroeker A Characterization of Sudan Ebolavirus infection in ferrets Oncotarget 2017 8 46262 46272 10.18632/oncotarget.17694 28545034
Kroeker, A. et al. Characterization of Sudan Ebolavirus infection in ferrets. Oncotarget 8, 46262–46272 (2017).28545034
101. Burk R Neglected filoviruses FEMS Microbiol. Rev. 2016 40 494 519 10.1093/femsre/fuw010 27268907
Burk, R. et al. Neglected filoviruses. FEMS Microbiol. Rev. 40, 494–519 (2016).27268907
102. Geisbert TW Jahrling PB Use of immunoelectron microscopy to show Ebola virus during the 1989 United States epizootic J. Clin. Pathol. 1990 43 813 816 10.1136/jcp.43.10.813 2229429
Geisbert, T. W. & Jahrling, P. B. Use of immunoelectron microscopy to show Ebola virus during the 1989 United States epizootic. J. Clin. Pathol. 43, 813–816 (1990).2229429
103. Yan F Characterization of Reston virus infection in ferrets Antivir. Res. 2019 165 1 10 10.1016/j.antiviral.2019.03.001 30836107
Yan, F. et al. Characterization of Reston virus infection in ferrets. Antivir. Res. 165, 1–10 (2019).30836107
104. Schiffman Z Taï Forest Virus Does Not Cause Lethal Disease in Ferrets Microorganisms 2021 9 213 10.3390/microorganisms9020213 33494199
Schiffman, Z. et al. Taï Forest Virus Does Not Cause Lethal Disease in Ferrets. Microorganisms 9, 213 (2021).33494199
105. Cross RW Marburg and Ravn Viruses Fail to Cause Disease in the Domestic Ferret (Mustela putorius furo) J. Infect. Dis. 2018 218 S448 S452 29955887
Cross, R. W. et al. Marburg and Ravn Viruses Fail to Cause Disease in the Domestic Ferret (Mustela putorius furo). J. Infect. Dis. 218, S448–S452 (2018).29955887
106. Wong G Marburg and Ravn Virus Infections Do Not Cause Observable Disease in Ferrets J. Infect. Dis. 2018 218 S471 S474 10.1093/infdis/jiy245 29889278
Wong, G. et al. Marburg and Ravn Virus Infections Do Not Cause Observable Disease in Ferrets. J. Infect. Dis. 218, S471–S474 (2018).29889278
107. Liu DX Ebola Virus Disease Features Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome in the Rhesus Macaque Model J. Infect. Dis. 2023 228 371 382 10.1093/infdis/jiad203 37279544
Liu, D. X. et al. Ebola Virus Disease Features Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome in the Rhesus Macaque Model. J. Infect. Dis. 228, 371–382 (2023).37279544
108. Warren T Characterization of Ebola Virus Disease (EVD) in Rhesus Monkeys for Development of EVD Therapeutics Viruses 2020 12 92 10.3390/v12010092 31941095
Warren, T. et al. Characterization of Ebola Virus Disease (EVD) in Rhesus Monkeys for Development of EVD Therapeutics. Viruses 12, 92 (2020).31941095
109. Worwa G Persistent intraocular Ebola virus RNA is associated with severe uveitis in a convalescent rhesus monkey Commun. Biol. 2022 5 1204 10.1038/s42003-022-04158-2 36352100
Worwa, G. et al. Persistent intraocular Ebola virus RNA is associated with severe uveitis in a convalescent rhesus monkey. Commun. Biol. 5, 1204 (2022).36352100
110. Geisbert TW Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses Lab. Invest. 2000 80 171 186 10.1038/labinvest.3780021 10701687
Geisbert, T. W. et al. Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab. Invest. 80, 171–186 (2000).10701687
111. Fisher-Hoch SP Haematological and biochemical monitoring of Ebola infection in rhesus monkeys: implications for patient management Lancet 1983 2 1055 1058 10.1016/S0140-6736(83)91041-3 6138602
Fisher-Hoch, S. P. et al. Haematological and biochemical monitoring of Ebola infection in rhesus monkeys: implications for patient management. Lancet 2, 1055–1058 (1983).6138602
112. Kortepeter MG Real-time monitoring of cardiovascular function in rhesus macaques infected with Zaire ebolavirus J. Infect. Dis. 2011 204 S1000 S1010 10.1093/infdis/jir337 21987736
Kortepeter, M. G. et al. Real-time monitoring of cardiovascular function in rhesus macaques infected with Zaire ebolavirus. J. Infect. Dis. 204, S1000–S1010 (2011).21987736
113. Baskerville A Fisher-Hoch SP Neild GH Dowsett AB Ultrastructural pathology of experimental Ebola haemorrhagic fever virus infection J. Pathol. 1985 147 199 209 10.1002/path.1711470308 4067737
Baskerville, A., Fisher-Hoch, S. P., Neild, G. H. & Dowsett, A. B. Ultrastructural pathology of experimental Ebola haemorrhagic fever virus infection. J. Pathol. 147, 199–209 (1985).4067737
114. Hensley LE Young HA Jahrling PB Geisbert TW Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily Immunol. Lett. 2002 80 169 179 10.1016/S0165-2478(01)00327-3 11803049
Hensley, L. E., Young, H. A., Jahrling, P. B. & Geisbert, T. W. Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. Immunol. Lett. 80, 169–179 (2002).11803049
115. Bennett RS Nonhuman Primate Models of Ebola Virus Disease Curr. Top. Microbiol. Immunol. 2017 411 171 193 28643203
Bennett, R. S. et al. Nonhuman Primate Models of Ebola Virus Disease. Curr. Top. Microbiol. Immunol. 411, 171–193 (2017).28643203
116. Woolsey C Natural history of infection in rhesus and cynomolgus macaques Emerg. Microbes Infect. 2022 11 1635 1646 10.1080/22221751.2022.2086072 35657325
Woolsey, C. et al. Natural history of infection in rhesus and cynomolgus macaques. Emerg. Microbes Infect. 11, 1635–1646 (2022).35657325
117. Zumbrun EE A characterization of aerosolized Sudan virus infection in African green monkeys, cynomolgus macaques, and rhesus macaques Viruses 2012 4 2115 2136 10.3390/v4102115 23202456
Zumbrun, E. E. et al. A characterization of aerosolized Sudan virus infection in African green monkeys, cynomolgus macaques, and rhesus macaques. Viruses 4, 2115–2136 (2012).23202456
118. Gilchuk P Efficacy of Human Monoclonal Antibody Monotherapy Against Bundibugyo Virus Infection in Nonhuman Primates J. Infect. Dis. 2018 218 S565 S573 10.1093/infdis/jiy295 29982718
Gilchuk, P. et al. Efficacy of Human Monoclonal Antibody Monotherapy Against Bundibugyo Virus Infection in Nonhuman Primates. J. Infect. Dis. 218, S565–S573 (2018).29982718
119. Woolsey C Bundibugyo ebolavirus Survival Is Associated with Early Activation of Adaptive Immunity and Reduced Myeloid-Derived Suppressor Cell Signaling mBio 2021 12 e0151721 10.1128/mBio.01517-21 34372693
Woolsey, C. et al. Bundibugyo ebolavirus Survival Is Associated with Early Activation of Adaptive Immunity and Reduced Myeloid-Derived Suppressor Cell Signaling. mBio 12, e0151721 (2021).34372693
120. Nicholas VV Distinct Biological Phenotypes of Marburg and Ravn Virus Infection in Macaques J. Infect. Dis. 2018 218 S458 S465 10.1093/infdis/jiy456 30215737
Nicholas, V. V. et al. Distinct Biological Phenotypes of Marburg and Ravn Virus Infection in Macaques. J. Infect. Dis. 218, S458–S465 (2018).30215737
121. Lin KL Temporal Characterization of Marburg Virus Angola Infection following Aerosol Challenge in Rhesus Macaques J. Virol. 2015 89 9875 9885 10.1128/JVI.01147-15 26202230
Lin, K. L. et al. Temporal Characterization of Marburg Virus Angola Infection following Aerosol Challenge in Rhesus Macaques. J. Virol. 89, 9875–9885 (2015).26202230
122. Hensley LE Pathogenesis of Marburg hemorrhagic fever in cynomolgus macaques J. Infect. Dis. 2011 204 S1021 S1031 10.1093/infdis/jir339 21987738
Hensley, L. E. et al. Pathogenesis of Marburg hemorrhagic fever in cynomolgus macaques. J. Infect. Dis. 204, S1021–S1031 (2011).21987738
123. Glaze ER Roy MJ Dalrymple LW Lanning LL A Comparison of the Pathogenesis of Marburg Virus Disease in Humans and Nonhuman Primates and Evaluation of the Suitability of These Animal Models for Predicting Clinical Efficacy under the ‘Animal Rule’ Comp. Med. 2015 65 241 259 26141449
Glaze, E. R., Roy, M. J., Dalrymple, L. W. & Lanning, L. L. A Comparison of the Pathogenesis of Marburg Virus Disease in Humans and Nonhuman Primates and Evaluation of the Suitability of These Animal Models for Predicting Clinical Efficacy under the ‘Animal Rule’. Comp. Med. 65, 241–259 (2015).26141449
124. Speranza E A conserved transcriptional response to intranasal Ebola virus exposure in nonhuman primates prior to onset of fever Sci. Transl. Med. 2018 10 eaaq1016 10.1126/scitranslmed.aaq1016 29593102
Speranza, E. et al. A conserved transcriptional response to intranasal Ebola virus exposure in nonhuman primates prior to onset of fever. Sci. Transl. Med. 10, eaaq1016 (2018).29593102
125. Jankeel A Early Transcriptional Changes within Liver, Adrenal Gland, and Lymphoid Tissues Significantly Contribute to Ebola Virus Pathogenesis in Cynomolgus Macaques J. Virol. 2020 94 e00250 20 10.1128/JVI.00250-20 32213610
Jankeel, A. et al. Early Transcriptional Changes within Liver, Adrenal Gland, and Lymphoid Tissues Significantly Contribute to Ebola Virus Pathogenesis in Cynomolgus Macaques. J. Virol. 94, e00250–20 (2020).32213610
126. Pinski AN Maroney KJ Marzi A Messaoudi I Distinct transcriptional responses to fatal Ebola virus infection in cynomolgus and rhesus macaques suggest species-specific immune responses Emerg. Microbes Infect. 2021 10 1320 1330 10.1080/22221751.2021.1942229 34112056
Pinski, A. N., Maroney, K. J., Marzi, A. & Messaoudi, I. Distinct transcriptional responses to fatal Ebola virus infection in cynomolgus and rhesus macaques suggest species-specific immune responses. Emerg. Microbes Infect. 10, 1320–1330 (2021).34112056
127. Stefan CP Transcriptomic Analysis Reveals Host miRNAs Correlated with Immune Gene Dysregulation during Fatal Disease Progression in the Ebola Virus Cynomolgus Macaque Disease Model Microorganisms 2021 9 665 10.3390/microorganisms9030665 33806942
Stefan, C. P. et al. Transcriptomic Analysis Reveals Host miRNAs Correlated with Immune Gene Dysregulation during Fatal Disease Progression in the Ebola Virus Cynomolgus Macaque Disease Model. Microorganisms 9, 665 (2021).33806942
128. Alfson KJ Development of a Lethal Intranasal Exposure Model of Ebola Virus in the Cynomolgus Macaque Viruses 2017 9 319 10.3390/v9110319 29109373
Alfson, K. J. et al. Development of a Lethal Intranasal Exposure Model of Ebola Virus in the Cynomolgus Macaque. Viruses 9, 319 (2017).29109373
129. Johnston SC Delayed Disease in Cynomolgus Macaques Exposed to Ebola Virus by an Intranasal Route Front. Immunol. 2021 12 709772 10.3389/fimmu.2021.709772 34484210
Johnston, S. C. et al. Delayed Disease in Cynomolgus Macaques Exposed to Ebola Virus by an Intranasal Route. Front. Immunol. 12, 709772 (2021).34484210
130. Sullivan NJ Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates Nature 2003 424 681 684 10.1038/nature01876 12904795
Sullivan, N. J. et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 424, 681–684 (2003).12904795
131. Reed DS Aerosol exposure to Zaire ebolavirus in three nonhuman primate species: differences in disease course and clinical pathology Microbes Infect. 2011 13 930 936 10.1016/j.micinf.2011.05.002 21651988
Reed, D. S. et al. Aerosol exposure to Zaire ebolavirus in three nonhuman primate species: differences in disease course and clinical pathology. Microbes Infect. 13, 930–936 (2011).21651988
132. Mire CE Oral and Conjunctival Exposure of Nonhuman Primates to Low Doses of Ebola Makona Virus J. Infect. Dis. 2016 214 S263 S267 10.1093/infdis/jiw149 27284090
Mire, C. E. et al. Oral and Conjunctival Exposure of Nonhuman Primates to Low Doses of Ebola Makona Virus. J. Infect. Dis. 214, S263–S267 (2016).27284090
133. Johnson DM Characterization of Ebola Virus Mucosal Challenge Routes in Cynomolgus Macaques J. Virol. 2023 97 e0188822 10.1128/jvi.01888-22 36975793
Johnson, D. M. et al. Characterization of Ebola Virus Mucosal Challenge Routes in Cynomolgus Macaques. J. Virol. 97, e0188822 (2023).36975793
134. Marzi A Delayed Disease Progression in Cynomolgus Macaques Infected with Ebola Virus Makona Strain Emerg. Infect. Dis. 2015 21 1777 1783 10.3201/eid2110.150259 26402165
Marzi, A. et al. Delayed Disease Progression in Cynomolgus Macaques Infected with Ebola Virus Makona Strain. Emerg. Infect. Dis. 21, 1777–1783 (2015).26402165
135. Wong G Pathogenicity Comparison Between the Kikwit and Makona Ebola Virus Variants in Rhesus Macaques J. Infect. Dis. 2016 214 S281 S289 10.1093/infdis/jiw267 27651412
Wong, G. et al. Pathogenicity Comparison Between the Kikwit and Makona Ebola Virus Variants in Rhesus Macaques. J. Infect. Dis. 214, S281–S289 (2016).27651412
136. Alfson KJ Development of a Well-Characterized Cynomolgus Macaque Model of Sudan Virus Disease for Support of Product Development Vaccines 2022 10 1723 10.3390/vaccines10101723 36298588
Alfson, K. J. et al. Development of a Well-Characterized Cynomolgus Macaque Model of Sudan Virus Disease for Support of Product Development. Vaccines 10, 1723 (2022).36298588
137. Geisbert TW Strong JE Feldmann H Considerations in the Use of Nonhuman Primate Models of Ebola Virus and Marburg Virus Infection J. Infect. Dis. 2015 212 S91 S97 10.1093/infdis/jiv284 26063223
Geisbert, T. W., Strong, J. E. & Feldmann, H. Considerations in the Use of Nonhuman Primate Models of Ebola Virus and Marburg Virus Infection. J. Infect. Dis. 212, S91–S97 (2015).26063223
138. McElroy AK Ebola hemorrhagic Fever: novel biomarker correlates of clinical outcome J. Infect. Dis. 2014 210 558 566 10.1093/infdis/jiu088 24526742
McElroy, A. K. et al. Ebola hemorrhagic Fever: novel biomarker correlates of clinical outcome. J. Infect. Dis. 210, 558–566 (2014).24526742
139. Wauquier N Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis PLoS Negl. Trop. Dis. 2010 4 e837 10.1371/journal.pntd.0000837 20957152
Wauquier, N. et al. Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis. PLoS Negl. Trop. Dis. 4, e837 (2010).20957152
140. Henn V The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40 Blood 2001 98 1047 1054 10.1182/blood.V98.4.1047 11493450
Henn, V. et al. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 98, 1047–1054 (2001).11493450
141. Alfson KJ Intramuscular Exposure of to Low Doses of Low Passage- or Cell Culture-Adapted Sudan Virus or Ebola Virus Viruses 2018 10 642 10.3390/v10110642 30453499
Alfson, K. J. et al. Intramuscular Exposure of to Low Doses of Low Passage- or Cell Culture-Adapted Sudan Virus or Ebola Virus. Viruses 10, 642 (2018).30453499
142. Trefry JC Ebola Virus Infections in Nonhuman Primates Are Temporally Influenced by Glycoprotein Poly-U Editing Site Populations in the Exposure Material Viruses 2015 7 6739 6754 10.3390/v7122969 26703716
Trefry, J. C. et al. Ebola Virus Infections in Nonhuman Primates Are Temporally Influenced by Glycoprotein Poly-U Editing Site Populations in the Exposure Material. Viruses 7, 6739–6754 (2015).26703716
143. Alfson KJ Development of a Well-Characterized Cynomolgus Macaque Model of Marburg Virus Disease for Support of Vaccine and Therapy Development Vaccines 2022 10 1314 10.3390/vaccines10081314 36016203
Alfson, K. J. et al. Development of a Well-Characterized Cynomolgus Macaque Model of Marburg Virus Disease for Support of Vaccine and Therapy Development. Vaccines 10, 1314 (2022).36016203
144. Hensley LE Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species PLoS Pathog. 2010 6 e1000904 10.1371/journal.ppat.1000904 20502688
Hensley, L. E. et al. Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species. PLoS Pathog. 6, e1000904 (2010).20502688
145. Jahrling PB Experimental infection of cynomolgus macaques with Ebola-Reston filoviruses from the 1989-1990 U.S. epizootic Arch. Virol. Suppl. 1996 11 115 134 8800793
Jahrling, P. B. et al. Experimental infection of cynomolgus macaques with Ebola-Reston filoviruses from the 1989-1990 U.S. epizootic. Arch. Virol. Suppl. 11, 115–134 (1996).8800793
146. Taniguchi S Analysis of the humoral immune responses among cynomolgus macaque naturally infected with Reston virus during the 1996 outbreak in the Philippines BMC Vet. Res. 2012 8 189 10.1186/1746-6148-8-189 23057674
Taniguchi, S. et al. Analysis of the humoral immune responses among cynomolgus macaque naturally infected with Reston virus during the 1996 outbreak in the Philippines. BMC Vet. Res. 8, 189 (2012).23057674
147. Hutchinson KL Multiplex analysis of cytokines in the blood of cynomolgus macaques naturally infected with Ebola virus (Reston serotype) J. Med. Virol. 2001 65 561 566 10.1002/jmv.2073 11596094
Hutchinson, K. L. et al. Multiplex analysis of cytokines in the blood of cynomolgus macaques naturally infected with Ebola virus (Reston serotype). J. Med. Virol. 65, 561–566 (2001).11596094
148. Ikegami T Histopathology of natural Ebola virus subtype Reston infection in cynomolgus macaques during the Philippine outbreak in 1996 Exp. Anim. 2002 51 447 455 10.1538/expanim.51.447 12451705
Ikegami, T. et al. Histopathology of natural Ebola virus subtype Reston infection in cynomolgus macaques during the Philippine outbreak in 1996. Exp. Anim. 51, 447–455 (2002).12451705
149. Geisbert TW Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus J. Virol. 2009 83 7296 7304 10.1128/JVI.00561-09 19386702
Geisbert, T. W. et al. Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. J. Virol. 83, 7296–7304 (2009).19386702
150. Comer JE Natural History of Marburg Virus Infection to Support Medical Countermeasure Development Viruses 2022 14 2291 10.3390/v14102291 36298846
Comer, J. E. et al. Natural History of Marburg Virus Infection to Support Medical Countermeasure Development. Viruses 14, 2291 (2022).36298846
151. Ryabchikova EI Kolesnikova LV Luchko SV An analysis of features of pathogenesis in two animal models of Ebola virus infection J. Infect. Dis. 1999 179 S199 S202 10.1086/514293 9988185
Ryabchikova, E. I., Kolesnikova, L. V. & Luchko, S. V. An analysis of features of pathogenesis in two animal models of Ebola virus infection. J. Infect. Dis. 179, S199–S202 (1999).9988185
152. Carrion R A small nonhuman primate model for filovirus-induced disease Virology 2011 420 117 124 10.1016/j.virol.2011.08.022 21959017
Carrion, R. et al. A small nonhuman primate model for filovirus-induced disease. Virology 420, 117–124 (2011).21959017
153. Smither SJ Experimental Respiratory Infection of Marmosets (Callithrix jacchus) With Ebola Virus Kikwit J. Infect. Dis. 2015 212 S336 S345 10.1093/infdis/jiv371 26209682
Smither, S. J. et al. Experimental Respiratory Infection of Marmosets (Callithrix jacchus) With Ebola Virus Kikwit. J. Infect. Dis. 212, S336–S345 (2015).26209682
154. Perry DL Bollinger L White GL The Baboon (Papio spp.) as a model of human Ebola virus infection Viruses 2012 4 2400 2416 10.3390/v4102400 23202470
Perry, D. L., Bollinger, L. & White, G. L. The Baboon (Papio spp.) as a model of human Ebola virus infection. Viruses 4, 2400–2416 (2012).23202470
155. Ignatiev GM Dadaeva AA Luchko SV Chepurnov AA Immune and pathophysiological processes in baboons experimentally infected with Ebola virus adapted to guinea pigs Immunol. Lett. 2000 71 131 140 10.1016/S0165-2478(99)00169-8 10714441
Ignatiev, G. M., Dadaeva, A. A., Luchko, S. V. & Chepurnov, A. A. Immune and pathophysiological processes in baboons experimentally infected with Ebola virus adapted to guinea pigs. Immunol. Lett. 71, 131–140 (2000).10714441
156. McWilliams IL Pseudovirus rVSVΔG-ZEBOV-GP Infects Neurons in Retina and CNS, Causing Apoptosis and Neurodegeneration in Neonatal Mice Cell Rep. 2019 26 1718 1726.e4 10.1016/j.celrep.2019.01.069 30759384
McWilliams, I. L. et al. Pseudovirus rVSVΔG-ZEBOV-GP Infects Neurons in Retina and CNS, Causing Apoptosis and Neurodegeneration in Neonatal Mice. Cell Rep. 26, 1718–1726.e4 (2019).30759384
157. Yang W Establishment and application of a surrogate model for human Ebola virus disease in BSL-2 laboratory Virol. Sin. 2024 39 434 446 10.1016/j.virs.2024.03.010 38556051
Yang, W. et al. Establishment and application of a surrogate model for human Ebola virus disease in BSL-2 laboratory. Virol. Sin. 39, 434–446 (2024).38556051
158. Lee H-N Characterization of the therapeutic effect of antibodies targeting the Ebola glycoprotein using a novel BSL2-compliant rVSVΔG-EBOV-GP infection model Emerg. Microbes Infect. 2021 10 2076 2089 10.1080/22221751.2021.1997075 34674613
Lee, H.-N. et al. Characterization of the therapeutic effect of antibodies targeting the Ebola glycoprotein using a novel BSL2-compliant rVSVΔG-EBOV-GP infection model. Emerg. Microbes Infect. 10, 2076–2089 (2021).34674613
159. Saito T A Surrogate Animal Model for Screening of Ebola and Marburg Glycoprotein-Targeting Drugs Using Pseudotyped Vesicular Stomatitis Viruses Viruses 2020 12 923 10.3390/v12090923 32842671
Saito, T. et al. A Surrogate Animal Model for Screening of Ebola and Marburg Glycoprotein-Targeting Drugs Using Pseudotyped Vesicular Stomatitis Viruses. Viruses 12, 923 (2020).32842671
160. Jones SM Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses Nat. Med. 2005 11 786 790 10.1038/nm1258 15937495
Jones, S. M. et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat. Med. 11, 786–790 (2005).15937495
161. Qiu X Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses PLoS One 2009 4 e5547 10.1371/journal.pone.0005547 19440245
Qiu, X. et al. Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses. PLoS One 4, e5547 (2009).19440245
162. Menicucci AR Antiviral Innate Responses Induced by VSV-EBOV Vaccination Contribute to Rapid Protection mBio 2019 10 e00597 00519 10.1128/mBio.00597-19 31138743
Menicucci, A. R. et al. Antiviral Innate Responses Induced by VSV-EBOV Vaccination Contribute to Rapid Protection. mBio 10, e00597–00519 (2019).31138743
163. Huttner A Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study Lancet Infect. Dis. 2018 18 738 748 10.1016/S1473-3099(18)30165-8 29627147
Huttner, A. et al. Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study. Lancet Infect. Dis. 18, 738–748 (2018).29627147
164. Agnandji ST Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe N. Engl. J. Med. 2016 374 1647 1660, 10.1056/NEJMoa1502924 25830326
Agnandji, S. T. et al. Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe. N. Engl. J. Med. 374, 1647–1660, (2016).25830326
165. Regules JA A Recombinant Vesicular Stomatitis Virus Ebola Vaccine N. Engl. J. Med. 2017 376 330 341 10.1056/NEJMoa1414216 25830322
Regules, J. A. et al. A Recombinant Vesicular Stomatitis Virus Ebola Vaccine. N. Engl. J. Med. 376, 330–341 (2017).25830322
166. Henao-Restrepo AM Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!) Lancet 2017 389 505 518 10.1016/S0140-6736(16)32621-6 28017403
Henao-Restrepo, A. M. et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!). Lancet 389, 505–518 (2017).28017403
167. Callaway E Make Ebola a thing of the past’: first vaccine against deadly virus approved Nature 2019 575 425 426 10.1038/d41586-019-03490-8 31745354
Callaway, E. Make Ebola a thing of the past’: first vaccine against deadly virus approved. Nature 575, 425–426 (2019).31745354
168. Wu S An Adenovirus Vaccine Expressing Ebola Virus Variant Makona Glycoprotein Is Efficacious in Guinea Pigs and Nonhuman Primates J. Infect. Dis. 2016 214 S326 S332 10.1093/infdis/jiw250 27493239
Wu, S. et al. An Adenovirus Vaccine Expressing Ebola Virus Variant Makona Glycoprotein Is Efficacious in Guinea Pigs and Nonhuman Primates. J. Infect. Dis. 214, S326–S332 (2016).27493239
169. Zhu FC Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial Lancet 2015 385 2272 2279 10.1016/S0140-6736(15)60553-0 25817373
Zhu, F. C. et al. Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet 385, 2272–2279 (2015).25817373
170. Lihua W Open-label phase I clinical trial of Ad5-EBOV in Africans in China Hum. Vaccin Immunother. 2017 13 2078 2085 10.1080/21645515.2017.1342021 28708962
Lihua, W. et al. Open-label phase I clinical trial of Ad5-EBOV in Africans in China. Hum. Vaccin Immunother. 13, 2078–2085 (2017).28708962
171. Li JX Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial Lancet Glob. Health 2017 5 e324 e334 10.1016/S2214-109X(16)30367-9 28017642
Li, J. X. et al. Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Glob. Health 5, e324–e334 (2017).28017642
172. Zhu F-C Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial Lancet 2017 389 621 628 10.1016/S0140-6736(16)32617-4 28017399
Zhu, F.-C. et al. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 389, 621–628 (2017).28017399
173. Stanley DA Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge Nat. Med. 2014 20 1126 1129 10.1038/nm.3702 25194571
Stanley, D. A. et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat. Med. 20, 1126–1129 (2014).25194571
174. Ledgerwood JE Chimpanzee Adenovirus Vector Ebola Vaccine N. Engl. J. Med. 2017 376 928 938 10.1056/NEJMoa1410863 25426834
Ledgerwood, J. E. et al. Chimpanzee Adenovirus Vector Ebola Vaccine. N. Engl. J. Med. 376, 928–938 (2017).25426834
175. Ewer K A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA N. Engl. J. Med. 2016 374 1635 1646, 10.1056/NEJMoa1411627 25629663
Ewer, K. et al. A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. N. Engl. J. Med. 374, 1635–1646, (2016).25629663
176. Tapia MD Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial Lancet Infect. Dis. 2016 16 31 42 10.1016/S1473-3099(15)00362-X 26546548
Tapia, M. D. et al. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. Lancet Infect. Dis. 16, 31–42 (2016).26546548
177. Dolzhikova IV Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia Hum. Vaccin Immunother. 2017 13 613 620 10.1080/21645515.2016.1238535 28152326
Dolzhikova, I. V. et al. Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia. Hum. Vaccin Immunother. 13, 613–620 (2017).28152326
178. Sullivan NJ Development of a preventive vaccine for Ebola virus infection in primates Nature 2000 408 605 609 10.1038/35046108 11117750
Sullivan, N. J. et al. Development of a preventive vaccine for Ebola virus infection in primates. Nature 408, 605–609 (2000).11117750
179. Kennedy SB Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia N. Engl. J. Med. 2017 377 1438 1447 10.1056/NEJMoa1614067 29020589
Kennedy, S. B. et al. Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia. N. Engl. J. Med. 377, 1438–1447 (2017).29020589
180. Agua-Agum J Ebola virus disease among children in West Africa N. Engl. J. Med. 2015 372 1274 1277 10.1056/NEJMc1415318 25806936
Agua-Agum, J. et al. Ebola virus disease among children in West Africa. N. Engl. J. Med. 372, 1274–1277 (2015).25806936
181. Sullivan NJ CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates Nat. Med. 2011 17 1128 1131 10.1038/nm.2447 21857654
Sullivan, N. J. et al. CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat. Med. 17, 1128–1131 (2011).21857654
182. Reynolds P Marzi A Ebola and Marburg virus vaccines Virus Genes 2017 53 501 515 10.1007/s11262-017-1455-x 28447193
Reynolds, P. & Marzi, A. Ebola and Marburg virus vaccines. Virus Genes 53, 501–515 (2017).28447193
183. Martin JE A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial Clin. Vaccin. Immunol. 2006 13 1267 1277 10.1128/CVI.00162-06
Martin, J. E. et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin. Vaccin. Immunol. 13, 1267–1277 (2006).
184. Falzarano D Geisbert TW Feldmann H Progress in filovirus vaccine development: evaluating the potential for clinical use Expert Rev. Vaccines 2011 10 63 77 10.1586/erv.10.152 21162622
Falzarano, D., Geisbert, T. W. & Feldmann, H. Progress in filovirus vaccine development: evaluating the potential for clinical use. Expert Rev. Vaccines 10, 63–77 (2011).21162622
185. Geisbert TW Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates J. Virol. 2010 84 10386 10394 10.1128/JVI.00594-10 20660192
Geisbert, T. W. et al. Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates. J. Virol. 84, 10386–10394 (2010).20660192
186. Marzi A Vesicular stomatitis virus-based vaccines against Lassa and Ebola viruses Emerg. Infect. Dis. 2015 21 305 307 10.3201/eid2102.141649 25625358
Marzi, A. et al. Vesicular stomatitis virus-based vaccines against Lassa and Ebola viruses. Emerg. Infect. Dis. 21, 305–307 (2015).25625358
187. Cross RW Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death J. Clin. Invest 2019 130 539 551 10.1172/JCI131958
Cross, R. W. et al. Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death. J. Clin. Invest 130, 539–551 (2019).
188. Furuyama W Marzi A Ebola Virus: Pathogenesis and Countermeasure Development Annu. Rev. Virol. 2019 6 435 458 10.1146/annurev-virology-092818-015708 31567063
Furuyama, W. & Marzi, A. Ebola Virus: Pathogenesis and Countermeasure Development. Annu. Rev. Virol. 6, 435–458 (2019).31567063
189. Wong G Ebola-specific therapeutic antibodies from lab to clinic: The example of ZMapp Antivir. Res. 2024 226 105873 10.1016/j.antiviral.2024.105873 38580170
Wong, G. et al. Ebola-specific therapeutic antibodies from lab to clinic: The example of ZMapp. Antivir. Res. 226, 105873 (2024).38580170
190. Nakkazi E Randomised controlled trial begins for Ebola therapeutics Lancet 2018 392 2338 10.1016/S0140-6736(18)33011-3 30527603
Nakkazi, E. Randomised controlled trial begins for Ebola therapeutics. Lancet 392, 2338 (2018).30527603
191. Qiu X Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp Nature 2014 514 47 53 10.1038/nature13777 25171469
Qiu, X. et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514, 47–53 (2014).25171469
192. Pascal KE Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates J. Infect. Dis. 2018 218 S612 S626 10.1093/infdis/jiy285 29860496
Pascal, K. E. et al. Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates. J. Infect. Dis. 218, S612–S626 (2018).29860496
193. Lyon GM Clinical care of two patients with Ebola virus disease in the United States N. Engl. J. Med. 2014 371 2402 2409 10.1056/NEJMoa1409838 25390460
Lyon, G. M. et al. Clinical care of two patients with Ebola virus disease in the United States. N. Engl. J. Med. 371, 2402–2409 (2014).25390460
194. Fausther-Bovendo H Kobinger G The road to effective and accessible antibody therapies against Ebola virus Curr. Opin. Virol. 2022 54 101210 10.1016/j.coviro.2022.101210 35287095
Fausther-Bovendo, H. & Kobinger, G. The road to effective and accessible antibody therapies against Ebola virus. Curr. Opin. Virol. 54, 101210 (2022).35287095
195. Rayaprolu V Structure of the Inmazeb cocktail and resistance to Ebola virus escape Cell Host Microbe 2023 31 260 272.e7 10.1016/j.chom.2023.01.002 36708708
Rayaprolu, V. et al. Structure of the Inmazeb cocktail and resistance to Ebola virus escape. Cell Host Microbe 31, 260–272.e7 (2023).36708708
196. Levine MM Monoclonal Antibody Therapy for Ebola Virus Disease N. Engl. J. Med. 2019 381 2365 2366 10.1056/NEJMe1915350 31774948
Levine, M. M. Monoclonal Antibody Therapy for Ebola Virus Disease. N. Engl. J. Med. 381, 2365–2366 (2019).31774948
197. Gaudinski MR Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study Lancet 2019 393 889 898 10.1016/S0140-6736(19)30036-4 30686586
Gaudinski, M. R. et al. Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study. Lancet 393, 889–898 (2019).30686586
198. Markham A REGN-EB3: First Approval Drugs 2021 81 175 178 10.1007/s40265-020-01452-3 33432551
Markham, A. REGN-EB3: First Approval. Drugs 81, 175–178 (2021).33432551
199. Mulangu S A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics N. Engl. J. Med. 2019 381 2293 2303 10.1056/NEJMoa1910993 31774950
Mulangu, S. et al. A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. N. Engl. J. Med. 381, 2293–2303 (2019).31774950
200. Mullard A FDA approves antibody cocktail for Ebola virus Nat. Rev. Drug Discov. 2020 19 827 33144717
Mullard, A. FDA approves antibody cocktail for Ebola virus. Nat. Rev. Drug Discov. 19, 827 (2020).33144717
201. Flyak AI Mechanism of human antibody-mediated neutralization of Marburg virus Cell 2015 160 893 903 10.1016/j.cell.2015.01.031 25723164
Flyak, A. I. et al. Mechanism of human antibody-mediated neutralization of Marburg virus. Cell 160, 893–903 (2015).25723164
202. Mire CE Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody Sci. Transl. Med. 2017 9 eaai8711 10.1126/scitranslmed.aai8711 28381540
Mire, C. E. et al. Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody. Sci. Transl. Med. 9, eaai8711 (2017).28381540
203. Cross RW Mire CE Feldmann H Geisbert TW Post-exposure treatments for Ebola and Marburg virus infections Nat. Rev. Drug Discov. 2018 17 413 434 10.1038/nrd.2017.251 29375139
Cross, R. W., Mire, C. E., Feldmann, H. & Geisbert, T. W. Post-exposure treatments for Ebola and Marburg virus infections. Nat. Rev. Drug Discov. 17, 413–434 (2018).29375139
204. Sissoko D Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea PLoS Med. 2016 13 e1001967 10.1371/journal.pmed.1001967 26930627
Sissoko, D. et al. Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. PLoS Med. 13, e1001967 (2016).26930627
205. Bixler SL Efficacy of favipiravir (T-705) in nonhuman primates infected with Ebola virus or Marburg virus Antivir. Res. 2018 151 97 104 10.1016/j.antiviral.2017.12.021 29289666
Bixler, S. L. et al. Efficacy of favipiravir (T-705) in nonhuman primates infected with Ebola virus or Marburg virus. Antivir. Res. 151, 97–104 (2018).29289666
206. Jacobs M Late Ebola virus relapse causing meningoencephalitis: a case report Lancet 2016 388 498 503 10.1016/S0140-6736(16)30386-5 27209148
Jacobs, M. et al. Late Ebola virus relapse causing meningoencephalitis: a case report. Lancet 388, 498–503 (2016).27209148
207. Dörnemann J First Newborn Baby to Receive Experimental Therapies Survives Ebola Virus Disease J. Infect. Dis. 2017 215 171 174 28073857
Dörnemann, J. et al. First Newborn Baby to Receive Experimental Therapies Survives Ebola Virus Disease. J. Infect. Dis. 215, 171–174 (2017).28073857
208. Porter DP Remdesivir (GS-5734) Is Efficacious in Cynomolgus Macaques Infected With Marburg Virus J. Infect. Dis. 2020 222 1894 1901 10.1093/infdis/jiaa290 32479636
Porter, D. P. et al. Remdesivir (GS-5734) Is Efficacious in Cynomolgus Macaques Infected With Marburg Virus. J. Infect. Dis. 222, 1894–1901 (2020).32479636
209. Iversen PL Discovery and early development of AVI-7537 and AVI-7288 for the treatment of Ebola virus and Marburg virus infections Viruses 2012 4 2806 2830 10.3390/v4112806 23202506
Iversen, P. L. et al. Discovery and early development of AVI-7537 and AVI-7288 for the treatment of Ebola virus and Marburg virus infections. Viruses 4, 2806–2830 (2012).23202506
210. Heald AE AVI-7288 for Marburg Virus in Nonhuman Primates and Humans N. Engl. J. Med. 2015 373 339 348 10.1056/NEJMoa1410345 26200980
Heald, A. E. et al. AVI-7288 for Marburg Virus in Nonhuman Primates and Humans. N. Engl. J. Med. 373, 339–348 (2015).26200980
211. Heald AE Safety and pharmacokinetic profiles of phosphorodiamidate morpholino oligomers with activity against ebola virus and marburg virus: results of two single-ascending-dose studies Antimicrob. Agents Chemother. 2014 58 6639 6647 10.1128/AAC.03442-14 25155593
Heald, A. E. et al. Safety and pharmacokinetic profiles of phosphorodiamidate morpholino oligomers with activity against ebola virus and marburg virus: results of two single-ascending-dose studies. Antimicrob. Agents Chemother. 58, 6639–6647 (2014).25155593
212. Ursic-Bedoya R Protection against lethal Marburg virus infection mediated by lipid encapsulated small interfering RNA J. Infect. Dis. 2014 209 562 570 10.1093/infdis/jit465 23990568
Ursic-Bedoya, R. et al. Protection against lethal Marburg virus infection mediated by lipid encapsulated small interfering RNA. J. Infect. Dis. 209, 562–570 (2014).23990568
213. Thi EP Marburg virus infection in nonhuman primates: Therapeutic treatment by lipid-encapsulated siRNA Sci. Transl. Med. 2014 6 250ra116 10.1126/scitranslmed.3009706 25143366
Thi, E. P. et al. Marburg virus infection in nonhuman primates: Therapeutic treatment by lipid-encapsulated siRNA. Sci. Transl. Med. 6, 250ra116 (2014).25143366
214. Monath TP Lassa virus isolation from Mastomys natalensis rodents during an epidemic in Sierra Leone Science 1974 185 263 265 10.1126/science.185.4147.263 4833828
Monath, T. P. et al. Lassa virus isolation from Mastomys natalensis rodents during an epidemic in Sierra Leone. Science 185, 263–265 (1974).4833828
215. Oldstone MB Arenaviruses. I. The epidemiology molecular and cell biology of arenaviruses. Introduction Curr. Top. Microbiol Immunol. 2002 262 V xii 11987810
Oldstone, M. B. Arenaviruses. I. The epidemiology molecular and cell biology of arenaviruses. Introduction. Curr. Top. Microbiol Immunol. 262, V–xii (2002).11987810
216. Hastie KM Structure of the Lassa virus nucleoprotein reveals a dsRNA-specific 3’ to 5’ exonuclease activity essential for immune suppression Proc. Natl Acad. Sci. USA 2011 108 2396 2401 10.1073/pnas.1016404108 21262835
Hastie, K. M. et al. Structure of the Lassa virus nucleoprotein reveals a dsRNA-specific 3’ to 5’ exonuclease activity essential for immune suppression. Proc. Natl Acad. Sci. USA 108, 2396–2401 (2011).21262835
217. Hastie KM Crystal structure of the Lassa virus nucleoprotein-RNA complex reveals a gating mechanism for RNA binding Proc. Natl Acad. Sci. USA 2011 108 19365 19370 10.1073/pnas.1108515108 22084115
Hastie, K. M. et al. Crystal structure of the Lassa virus nucleoprotein-RNA complex reveals a gating mechanism for RNA binding. Proc. Natl Acad. Sci. USA 108, 19365–19370 (2011).22084115
218. Katz M Structure and receptor recognition by the Lassa virus spike complex Nature 2022 603 174 179 10.1038/s41586-022-04429-2 35173332
Katz, M. et al. Structure and receptor recognition by the Lassa virus spike complex. Nature 603, 174–179 (2022).35173332
219. Li S Acidic pH-Induced Conformations and LAMP1 Binding of the Lassa Virus Glycoprotein Spike PLoS Pathog. 2016 12 e1005418 10.1371/journal.ppat.1005418 26849049
Li, S. et al. Acidic pH-Induced Conformations and LAMP1 Binding of the Lassa Virus Glycoprotein Spike. PLoS Pathog. 12, e1005418 (2016).26849049
220. Israeli H Mapping of the Lassa virus LAMP1 binding site reveals unique determinants not shared by other old world arenaviruses PLoS Pathog. 2017 13 e1006337 10.1371/journal.ppat.1006337 28448640
Israeli, H. et al. Mapping of the Lassa virus LAMP1 binding site reveals unique determinants not shared by other old world arenaviruses. PLoS Pathog. 13, e1006337 (2017).28448640
221. Kouba T Conformational changes in Lassa virus L protein associated with promoter binding and RNA synthesis activity Nat. Commun. 2021 12 7018 10.1038/s41467-021-27305-5 34857749
Kouba, T. et al. Conformational changes in Lassa virus L protein associated with promoter binding and RNA synthesis activity. Nat. Commun. 12, 7018 (2021).34857749
222. Hastie KM Crystal Structure of the Oligomeric Form of Lassa Virus Matrix Protein Z J. Virol. 2016 90 4556 4562 10.1128/JVI.02896-15 26912609
Hastie, K. M. et al. Crystal Structure of the Oligomeric Form of Lassa Virus Matrix Protein Z. J. Virol. 90, 4556–4562 (2016).26912609
223. Andersen KG Clinical Sequencing Uncovers Origins and Evolution of Lassa Virus Cell 2015 162 738 750 10.1016/j.cell.2015.07.020 26276630
Andersen, K. G. et al. Clinical Sequencing Uncovers Origins and Evolution of Lassa Virus. Cell 162, 738–750 (2015).26276630
224. Pinneo L Pinneo R Mystery virus from Lassa Am. J. Nurs. 1971 71 1352 1355, 4996954
Pinneo, L. & Pinneo, R. Mystery virus from Lassa. Am. J. Nurs. 71, 1352–1355, (1971).4996954
225. Ehichioya, D. U. et al. Phylogeography of Lassa Virus in Nigeria. J Virol. 93, e00929-19 (2019).
226. Bowen MD Genetic diversity among Lassa virus strains J. Virol. 2000 74 6992 7004 10.1128/JVI.74.15.6992-7004.2000 10888638
Bowen, M. D. et al. Genetic diversity among Lassa virus strains. J. Virol. 74, 6992–7004 (2000).10888638
227. Whitmer SLM New Lineage of Lassa Virus, Togo, 2016 Emerg. Infect. Dis. 2018 24 599 602 10.3201/eid2403.171905 29460758
Whitmer, S. L. M. et al. New Lineage of Lassa Virus, Togo, 2016. Emerg. Infect. Dis. 24, 599–602 (2018).29460758
228. Macher AM Wolfe MS Historical Lassa fever reports and 30-year clinical update Emerg. Infect. Dis. 2006 12 835 837, 10.3201/eid1205.050052 16704848
Macher, A. M. & Wolfe, M. S. Historical Lassa fever reports and 30-year clinical update. Emerg. Infect. Dis. 12, 835–837, (2006).16704848
229. Ehlkes L Management of a Lassa fever outbreak, Rhineland-Palatinate, Germany, 2016 Eur. Surveill. 2017 22 16 00728 10.2807/1560-7917.ES.2017.22.39.16-00728
Ehlkes, L. et al. Management of a Lassa fever outbreak, Rhineland-Palatinate, Germany, 2016. Eur. Surveill. 22, 16–00728 (2017).
230. Njuguna C A challenging response to a Lassa fever outbreak in a non endemic area of Sierra Leone in 2019 with export of cases to The Netherlands Int. J. Infect. Dis. 2022 117 295 301 10.1016/j.ijid.2022.02.020 35167968
Njuguna, C. et al. A challenging response to a Lassa fever outbreak in a non endemic area of Sierra Leone in 2019 with export of cases to The Netherlands. Int. J. Infect. Dis. 117, 295–301 (2022).35167968
231. Brosh-Nissimov T Lassa fever: another threat from West Africa Disaster Mil. Med. 2016 2 8 10.1186/s40696-016-0018-3 28265442
Brosh-Nissimov, T. Lassa fever: another threat from West Africa. Disaster Mil. Med. 2, 8 (2016).28265442
232. Hastie KM Bale S Kimberlin CR Saphire EO Hiding the evidence: two strategies for innate immune evasion by hemorrhagic fever viruses Curr. Opin. Virol. 2012 2 151 156, 10.1016/j.coviro.2012.01.003 22482712
Hastie, K. M., Bale, S., Kimberlin, C. R. & Saphire, E. O. Hiding the evidence: two strategies for innate immune evasion by hemorrhagic fever viruses. Curr. Opin. Virol. 2, 151–156, (2012).22482712
233. Günther S Lassa fever encephalopathy: Lassa virus in cerebrospinal fluid but not in serum J. Infect. Dis. 2001 184 345 349 10.1086/322033 11443561
Günther, S. et al. Lassa fever encephalopathy: Lassa virus in cerebrospinal fluid but not in serum. J. Infect. Dis. 184, 345–349 (2001).11443561
234. Mahanty S Low levels of interleukin-8 and interferon-inducible protein-10 in serum are associated with fatal infections in acute Lassa fever J. Infect. Dis. 2001 183 1713 1721 10.1086/320722 11372023
Mahanty, S. et al. Low levels of interleukin-8 and interferon-inducible protein-10 in serum are associated with fatal infections in acute Lassa fever. J. Infect. Dis. 183, 1713–1721 (2001).11372023
235. Mahanty S Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses J. Immunol. 2003 170 2797 2801 10.4049/jimmunol.170.6.2797 12626527
Mahanty, S. et al. Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J. Immunol. 170, 2797–2801 (2003).12626527
236. Baize S Lassa virus infection of human dendritic cells and macrophages is productive but fails to activate cells J. Immunol. 2004 172 2861 2869 10.4049/jimmunol.172.5.2861 14978087
Baize, S. et al. Lassa virus infection of human dendritic cells and macrophages is productive but fails to activate cells. J. Immunol. 172, 2861–2869 (2004).14978087
237. Pannetier D Human dendritic cells infected with the nonpathogenic Mopeia virus induce stronger T-cell responses than those infected with Lassa virus J. Virol. 2011 85 8293 8306 10.1128/JVI.02120-10 21632749
Pannetier, D. et al. Human dendritic cells infected with the nonpathogenic Mopeia virus induce stronger T-cell responses than those infected with Lassa virus. J. Virol. 85, 8293–8306 (2011).21632749
238. Walker DH Wulff H Lange JV Murphy FA Comparative pathology of Lassa virus infection in monkeys, guinea-pigs, and Mastomys natalensis Bull. World Health Organ. 1975 52 523 534 821625
Walker, D. H., Wulff, H., Lange, J. V. & Murphy, F. A. Comparative pathology of Lassa virus infection in monkeys, guinea-pigs, and Mastomys natalensis. Bull. World Health Organ. 52, 523–534 (1975).821625
239. Uckun FM Stampidine prevents mortality in an experimental mouse model of viral hemorrhagic fever caused by lassa virus BMC Infect. Dis. 2004 4 1 10.1186/1471-2334-4-1 14720304
Uckun, F. M. et al. Stampidine prevents mortality in an experimental mouse model of viral hemorrhagic fever caused by lassa virus. BMC Infect. Dis. 4, 1 (2004).14720304
240. Rieger T Merkler D Günther S Infection of type I interferon receptor-deficient mice with various old world arenaviruses: a model for studying virulence and host species barriers PLoS One 2013 8 e72290 10.1371/journal.pone.0072290 23991083
Rieger, T., Merkler, D. & Günther, S. Infection of type I interferon receptor-deficient mice with various old world arenaviruses: a model for studying virulence and host species barriers. PLoS One 8, e72290 (2013).23991083
241. Yun NE Mice lacking functional STAT1 are highly susceptible to lethal infection with Lassa virus J. Virol. 2013 87 10908 10911 10.1128/JVI.01433-13 23903830
Yun, N. E. et al. Mice lacking functional STAT1 are highly susceptible to lethal infection with Lassa virus. J. Virol. 87, 10908–10911 (2013).23903830
242. Oestereich L Chimeric Mice with Competent Hematopoietic Immunity Reproduce Key Features of Severe Lassa Fever PLoS Pathog. 2016 12 e1005656 10.1371/journal.ppat.1005656 27191716
Oestereich, L. et al. Chimeric Mice with Competent Hematopoietic Immunity Reproduce Key Features of Severe Lassa Fever. PLoS Pathog. 12, e1005656 (2016).27191716
243. Yun NE Functional interferon system is required for clearance of lassa virus J. Virol. 2012 86 3389 3392 10.1128/JVI.06284-11 22238311
Yun, N. E. et al. Functional interferon system is required for clearance of lassa virus. J. Virol. 86, 3389–3392 (2012).22238311
244. Oestereich L Efficacy of Favipiravir Alone and in Combination With Ribavirin in a Lethal, Immunocompetent Mouse Model of Lassa Fever J. Infect. Dis. 2016 213 934 938 10.1093/infdis/jiv522 26531247
Oestereich, L. et al. Efficacy of Favipiravir Alone and in Combination With Ribavirin in a Lethal, Immunocompetent Mouse Model of Lassa Fever. J. Infect. Dis. 213, 934–938 (2016).26531247
245. Yun NE Animal Model of Sensorineural Hearing Loss Associated with Lassa Virus Infection J. Virol. 2015 90 2920 2927 10.1128/JVI.02948-15 26719273
Yun, N. E. et al. Animal Model of Sensorineural Hearing Loss Associated with Lassa Virus Infection. J. Virol. 90, 2920–2927 (2015).26719273
246. Flatz L T cell-dependence of Lassa fever pathogenesis PLoS Pathog. 2010 6 e1000836 10.1371/journal.ppat.1000836 20360949
Flatz, L. et al. T cell-dependence of Lassa fever pathogenesis. PLoS Pathog. 6, e1000836 (2010).20360949
247. Buchmeier MJ Rawls WE Variation between strains of hamsters in the lethality of Pichinde virus infections Infect. Immun. 1977 16 413 421 10.1128/iai.16.2.413-421.1977 193786
Buchmeier, M. J. & Rawls, W. E. Variation between strains of hamsters in the lethality of Pichinde virus infections. Infect. Immun. 16, 413–421 (1977).193786
248. Xiao SY Zhang H Yang Y Tesh RB Pirital virus (Arenaviridae) infection in the syrian golden hamster, Mesocricetus auratus: a new animal model for arenaviral hemorrhagic fever Am. J. Trop. Med. Hyg. 2001 64 111 118 10.4269/ajtmh.2001.64.111 11442204
Xiao, S. Y., Zhang, H., Yang, Y. & Tesh, R. B. Pirital virus (Arenaviridae) infection in the syrian golden hamster, Mesocricetus auratus: a new animal model for arenaviral hemorrhagic fever. Am. J. Trop. Med. Hyg. 64, 111–118 (2001).11442204
249. Lukashevich IS The search for animal models for Lassa fever vaccine development Expert Rev. Vaccines 2013 12 71 86 10.1586/erv.12.139 23256740
Lukashevich, I. S. The search for animal models for Lassa fever vaccine development. Expert Rev. Vaccines 12, 71–86 (2013).23256740
250. Cashman KA Evaluation of Lassa antiviral compound ST-193 in a guinea pig model Antivir. Res. 2011 90 70 79 10.1016/j.antiviral.2011.02.012 21371508
Cashman, K. A. et al. Evaluation of Lassa antiviral compound ST-193 in a guinea pig model. Antivir. Res. 90, 70–79 (2011).21371508
251. Gary JM Lassa Virus Targeting of Anterior Uvea and Endothelium of Cornea and Conjunctiva in Eye of Guinea Pig Model Emerg. Infect. Dis. 2019 25 865 874 10.3201/eid2505.181254 31002065
Gary, J. M. et al. Lassa Virus Targeting of Anterior Uvea and Endothelium of Cornea and Conjunctiva in Eye of Guinea Pig Model. Emerg. Infect. Dis. 25, 865–874 (2019).31002065
252. Stein DR A recombinant vesicular stomatitis-based Lassa fever vaccine elicits rapid and long-term protection from lethal Lassa virus infection in guinea pigs NPJ Vaccines 2019 4 8 10.1038/s41541-019-0104-x 30774999
Stein, D. R. et al. A recombinant vesicular stomatitis-based Lassa fever vaccine elicits rapid and long-term protection from lethal Lassa virus infection in guinea pigs. NPJ Vaccines 4, 8 (2019).30774999
253. Stein DR Differential pathogenesis of closely related 2018 Nigerian outbreak clade III Lassa virus isolates PLoS Pathog. 2021 17 e1009966 10.1371/journal.ppat.1009966 34634087
Stein, D. R. et al. Differential pathogenesis of closely related 2018 Nigerian outbreak clade III Lassa virus isolates. PLoS Pathog. 17, e1009966 (2021).34634087
254. Liu DX Persistence of Lassa Virus Associated With Severe Systemic Arteritis in Convalescing Guinea Pigs (Cavia porcellus) J. Infect. Dis. 2019 219 1818 1822 30517671
Liu, D. X. et al. Persistence of Lassa Virus Associated With Severe Systemic Arteritis in Convalescing Guinea Pigs (Cavia porcellus). J. Infect. Dis. 219, 1818–1822 (2019).30517671
255. Huynh T Lassa virus antigen distribution and inflammation in the ear of infected strain 13/N Guinea pigs Antivir. Res. 2020 183 104928 10.1016/j.antiviral.2020.104928 32898586
Huynh, T. et al. Lassa virus antigen distribution and inflammation in the ear of infected strain 13/N Guinea pigs. Antivir. Res. 183, 104928 (2020).32898586
256. Jahrling PB Smith S Hesse RA Rhoderick JB Pathogenesis of Lassa virus infection in guinea pigs Infect. Immun. 1982 37 771 778, 10.1128/iai.37.2.771-778.1982 6749685
Jahrling, P. B., Smith, S., Hesse, R. A. & Rhoderick, J. B. Pathogenesis of Lassa virus infection in guinea pigs. Infect. Immun. 37, 771–778, (1982).6749685
257. Sattler RA Paessler S Ly H Huang C Animal Models of Lassa Fever Pathogens 2020 9 197 10.3390/pathogens9030197 32155851
Sattler, R. A., Paessler, S., Ly, H. & Huang, C. Animal Models of Lassa Fever. Pathogens 9, 197 (2020).32155851
258. Safronetz D The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset Sci. Rep. 2015 5 14775 10.1038/srep14775 26456301
Safronetz, D. et al. The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset. Sci. Rep. 5, 14775 (2015).26456301
259. Maruyama J Lethal Infection of Lassa Virus Isolated from a Human Clinical Sample in Outbred Guinea Pigs without Adaptation mSphere 2019 4 e00428 00419 10.1128/mSphere.00428-19 31554720
Maruyama, J. et al. Lethal Infection of Lassa Virus Isolated from a Human Clinical Sample in Outbred Guinea Pigs without Adaptation. mSphere 4, e00428–00419 (2019).31554720
260. Warner BM Safronetz D Stein DR Current research for a vaccine against Lassa hemorrhagic fever virus Drug Des. Devel Ther. 2018 12 2519 2527 10.2147/DDDT.S147276 30147299
Warner, B. M., Safronetz, D. & Stein, D. R. Current research for a vaccine against Lassa hemorrhagic fever virus. Drug Des. Devel Ther. 12, 2519–2527 (2018).30147299
261. Warner BM Siragam V Stein DR Assessment of antiviral therapeutics in animal models of Lassa fever Curr. Opin. Virol. 2019 37 84 90 10.1016/j.coviro.2019.06.010 31357140
Warner, B. M., Siragam, V. & Stein, D. R. Assessment of antiviral therapeutics in animal models of Lassa fever. Curr. Opin. Virol. 37, 84–90 (2019).31357140
262. Walker DH Experimental infection of rhesus monkeys with Lassa virus and a closely related arenavirus, Mozambique virus J. Infect. Dis. 1982 146 360 368 10.1093/infdis/146.3.360 6286795
Walker, D. H. et al. Experimental infection of rhesus monkeys with Lassa virus and a closely related arenavirus, Mozambique virus. J. Infect. Dis. 146, 360–368 (1982).6286795
263. Fisher-Hoch SP Physiological and immunologic disturbances associated with shock in a primate model of Lassa fever J. Infect. Dis. 1987 155 465 474 10.1093/infdis/155.3.465 3543155
Fisher-Hoch, S. P. et al. Physiological and immunologic disturbances associated with shock in a primate model of Lassa fever. J. Infect. Dis. 155, 465–474 (1987).3543155
264. Yun NE Walker DH Pathogenesis of Lassa fever Viruses 2012 4 2031 2048 10.3390/v4102031 23202452
Yun, N. E. & Walker, D. H. Pathogenesis of Lassa fever. Viruses 4, 2031–2048 (2012).23202452
265. Baillet N Systemic viral spreading and defective host responses are associated with fatal Lassa fever in macaques Commun. Biol. 2021 4 27 10.1038/s42003-020-01543-7 33398113
Baillet, N. et al. Systemic viral spreading and defective host responses are associated with fatal Lassa fever in macaques. Commun. Biol. 4, 27 (2021).33398113
266. Hensley LE Pathogenesis of Lassa fever in cynomolgus macaques Virol. J. 2011 8 205 10.1186/1743-422X-8-205 21548931
Hensley, L. E. et al. Pathogenesis of Lassa fever in cynomolgus macaques. Virol. J. 8, 205 (2011).21548931
267. Mateo M Pathogenesis of recent Lassa virus isolates from lineages II and VII in cynomolgus monkeys Virulence 2022 13 654 669 10.1080/21505594.2022.2060170 35437094
Mateo, M. et al. Pathogenesis of recent Lassa virus isolates from lineages II and VII in cynomolgus monkeys. Virulence 13, 654–669 (2022).35437094
268. Safronetz D A recently isolated Lassa virus from Mali demonstrates atypical clinical disease manifestations and decreased virulence in cynomolgus macaques J. Infect. Dis. 2013 207 1316 1327 10.1093/infdis/jit004 23303805
Safronetz, D. et al. A recently isolated Lassa virus from Mali demonstrates atypical clinical disease manifestations and decreased virulence in cynomolgus macaques. J. Infect. Dis. 207, 1316–1327 (2013).23303805
269. Downs IL Natural History of Aerosol Induced Lassa Fever in Non‑Human Primates Viruses 2020 12 593 10.3390/v12060593 32485952
Downs, I. L. et al. Natural History of Aerosol Induced Lassa Fever in Non‑Human Primates. Viruses 12, 593 (2020).32485952
270. Baize S Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys J. Virol. 2009 83 5890 5903 10.1128/JVI.01948-08 19297492
Baize, S. et al. Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys. J. Virol. 83, 5890–5903 (2009).19297492
271. Carrion R Jr. Lassa virus infection in experimentally infected marmosets: liver pathology and immunophenotypic alterations in target tissues J. Virol. 2007 81 6482 6490 10.1128/JVI.02876-06 17409137
Carrion, R. Jr. et al. Lassa virus infection in experimentally infected marmosets: liver pathology and immunophenotypic alterations in target tissues. J. Virol. 81, 6482–6490 (2007).17409137
272. Trapido H Sanmartín C Pichindé virus, a new virus of the Tacaribe group from Colombia Am. J. Trop. Med. Hyg. 1971 20 631 641 10.4269/ajtmh.1971.20.631 4998616
Trapido, H. & Sanmartín, C. Pichindé virus, a new virus of the Tacaribe group from Colombia. Am. J. Trop. Med. Hyg. 20, 631–641 (1971).4998616
273. Walker DH Wulff H Murphy FA Experimental Lassa virus infection in the squirrel monkey Am. J. Pathol. 1975 80 261 278 1163630
Walker, D. H., Wulff, H. & Murphy, F. A. Experimental Lassa virus infection in the squirrel monkey. Am. J. Pathol. 80, 261–278 (1975).1163630
274. Jahrling PB Pathogenesis of a pichinde virus strain adapted to produce lethal infections in guinea pigs Infect. Immun. 1981 32 872 880 10.1128/iai.32.2.872-880.1981 6265367
Jahrling, P. B. et al. Pathogenesis of a pichinde virus strain adapted to produce lethal infections in guinea pigs. Infect. Immun. 32, 872–880 (1981).6265367
275. Connolly BM Pathogenesis of Pichinde virus infection in strain 13 guinea pigs: an immunocytochemical, virologic, and clinical chemistry study Am. J. Trop. Med. Hyg. 1993 49 10 24 10.4269/ajtmh.1993.49.10 8394659
Connolly, B. M. et al. Pathogenesis of Pichinde virus infection in strain 13 guinea pigs: an immunocytochemical, virologic, and clinical chemistry study. Am. J. Trop. Med. Hyg. 49, 10–24 (1993).8394659
276. Cosgriff TM Studies of the coagulation system in arenaviral hemorrhagic fever: experimental infection of strain 13 guinea pigs with Pichinde virus Am. J. Trop. Med. Hyg. 1987 36 416 423 10.4269/ajtmh.1987.36.416 3030150
Cosgriff, T. M. et al. Studies of the coagulation system in arenaviral hemorrhagic fever: experimental infection of strain 13 guinea pigs with Pichinde virus. Am. J. Trop. Med. Hyg. 36, 416–423 (1987).3030150
277. Zhang L Marriott KA Harnish DG Aronson JF Reassortant analysis of guinea pig virulence of pichinde virus variants Virology 2001 290 30 38 10.1006/viro.2001.1127 11883003
Zhang, L., Marriott, K. A., Harnish, D. G. & Aronson, J. F. Reassortant analysis of guinea pig virulence of pichinde virus variants. Virology 290, 30–38 (2001).11883003
278. Lan S Development of infectious clones for virulent and avirulent pichinde viruses: a model virus to study arenavirus-induced hemorrhagic fevers J. Virol. 2009 83 6357 6362 10.1128/JVI.00019-09 19386714
Lan, S. et al. Development of infectious clones for virulent and avirulent pichinde viruses: a model virus to study arenavirus-induced hemorrhagic fevers. J. Virol. 83, 6357–6362 (2009).19386714
279. Campo A Impairment in auditory and visual function follows perinatal viral infection in the rat Int. J. Neurosci. 1985 27 85 90 10.3109/00207458509149137 4019065
Campo, A. et al. Impairment in auditory and visual function follows perinatal viral infection in the rat. Int. J. Neurosci. 27, 85–90 (1985).4019065
280. Lukashevich IS Arenavirus-mediated liver pathology: acute lymphocytic choriomeningitis virus infection of rhesus macaques is characterized by high-level interleukin-6 expression and hepatocyte proliferation J. Virol. 2003 77 1727 1737 10.1128/JVI.77.3.1727-1737.2003 12525606
Lukashevich, I. S. et al. Arenavirus-mediated liver pathology: acute lymphocytic choriomeningitis virus infection of rhesus macaques is characterized by high-level interleukin-6 expression and hepatocyte proliferation. J. Virol. 77, 1727–1737 (2003).12525606
281. Uwishema O Lassa fever amidst the COVID-19 pandemic in Africa: A rising concern, efforts, challenges, and future recommendations J. Med. Virol. 2021 93 6433 6436 10.1002/jmv.27219 34289134
Uwishema, O. et al. Lassa fever amidst the COVID-19 pandemic in Africa: A rising concern, efforts, challenges, and future recommendations. J. Med. Virol. 93, 6433–6436 (2021).34289134
282. Abreu-Mota T Non-neutralizing antibodies elicited by recombinant Lassa–Rabies vaccine are critical for protection against Lassa fever Nat. Commun. 2018 9 4223 10.1038/s41467-018-06741-w 30310067
Abreu-Mota, T. et al. Non-neutralizing antibodies elicited by recombinant Lassa–Rabies vaccine are critical for protection against Lassa fever. Nat. Commun. 9, 4223 (2018).30310067
283. Galan-Navarro C Oxidation-sensitive polymersomes as vaccine nanocarriers enhance humoral responses against Lassa virus envelope glycoprotein Virology 2017 512 161 171 10.1016/j.virol.2017.09.013 28963882
Galan-Navarro, C. et al. Oxidation-sensitive polymersomes as vaccine nanocarriers enhance humoral responses against Lassa virus envelope glycoprotein. Virology 512, 161–171 (2017).28963882
284. Cai Y A Lassa Virus Live-Attenuated Vaccine Candidate Based on Rearrangement of the Intergenic Region mBio 2020 11 e00186 20 10.1128/mBio.00186-20 32209677
Cai, Y. et al. A Lassa Virus Live-Attenuated Vaccine Candidate Based on Rearrangement of the Intergenic Region. mBio 11, e00186–20 (2020).32209677
285. Cai Y A Lassa Fever Live-Attenuated Vaccine Based on Codon Deoptimization of the Viral Glycoprotein Gene mBio 2020 11 e00039 20 10.1128/mBio.00039-20 32098811
Cai, Y. et al. A Lassa Fever Live-Attenuated Vaccine Based on Codon Deoptimization of the Viral Glycoprotein Gene. mBio 11, e00039–20 (2020).32098811
286. Wulff H McIntosh BM Hamner DB Johnson KM Isolation of an arenavirus closely related to Lassa virus from Mastomys natalensis in south-east Africa B World Health Organ. 1977 55 441 444
Wulff, H., McIntosh, B. M., Hamner, D. B. & Johnson, K. M. Isolation of an arenavirus closely related to Lassa virus from Mastomys natalensis in south-east Africa. B World Health Organ. 55, 441–444 (1977).
287. Salami K A review of Lassa fever vaccine candidates Curr. Opin. Virol. 2019 37 105 111 10.1016/j.coviro.2019.07.006 31472333
Salami, K. et al. A review of Lassa fever vaccine candidates. Curr. Opin. Virol. 37, 105–111 (2019).31472333
288. Zapata JC Genetic variation in vitro and in vivo of an attenuated Lassa vaccine candidate J. Virol. 2014 88 3058 3066 10.1128/JVI.03035-13 24335292
Zapata, J. C. et al. Genetic variation in vitro and in vivo of an attenuated Lassa vaccine candidate. J. Virol. 88, 3058–3066 (2014).24335292
289. Carrion R A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity Vaccine 2007 25 4093 4102 10.1016/j.vaccine.2007.02.038 17360080
Carrion, R. et al. A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity. Vaccine 25, 4093–4102 (2007).17360080
290. Lukashevich IS Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates Vaccine 2008 26 5246 5254 10.1016/j.vaccine.2008.07.057 18692539
Lukashevich, I. S. et al. Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates. Vaccine 26, 5246–5254 (2008).18692539
291. Carnec X A Vaccine Platform against Arenaviruses Based on a Recombinant Hyperattenuated Mopeia Virus Expressing Heterologous Glycoproteins J. Virol. 2018 92 e02230 17 10.1128/JVI.02230-17 29593043
Carnec, X. et al. A Vaccine Platform against Arenaviruses Based on a Recombinant Hyperattenuated Mopeia Virus Expressing Heterologous Glycoproteins. J. Virol. 92, e02230–17 (2018).29593043
292. Geisbert TW Development of a new vaccine for the prevention of Lassa fever PLoS Med. 2005 2 e183 10.1371/journal.pmed.0020183 15971954
Geisbert, T. W. et al. Development of a new vaccine for the prevention of Lassa fever. PLoS Med. 2, e183 (2005).15971954
293. Safronetz D A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses PLoS Negl. Trop. Dis. 2015 9 e0003736 10.1371/journal.pntd.0003736 25884628
Safronetz, D. et al. A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses. PLoS Negl. Trop. Dis. 9, e0003736 (2015).25884628
294. Bredenbeek PJ A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins Virology 2006 345 299 304 10.1016/j.virol.2005.12.001 16412488
Bredenbeek, P. J. et al. A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins. Virology 345, 299–304 (2006).16412488
295. Jiang X Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs Vaccine 2011 29 1248 1257 10.1016/j.vaccine.2010.11.079 21145373
Jiang, X. et al. Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs. Vaccine 29, 1248–1257 (2011).21145373
296. Lukashevich IS Pushko P Vaccine platforms to control Lassa fever Expert Rev. Vaccines 2016 15 1135 1150, 10.1080/14760584.2016.1184575 27136941
Lukashevich, I. S. & Pushko, P. Vaccine platforms to control Lassa fever. Expert Rev. Vaccines 15, 1135–1150, (2016).27136941
297. Frantz PN Teeravechyan S Tangy F Measles-derived vaccines to prevent emerging viral diseases Microbes Infect. 2018 20 493 500 10.1016/j.micinf.2018.01.005 29410084
Frantz, P. N., Teeravechyan, S. & Tangy, F. Measles-derived vaccines to prevent emerging viral diseases. Microbes Infect. 20, 493–500 (2018).29410084
298. Mateo, M. et al. One-shot immunization using a Measles/Lassa vaccine fully protects cynomolgus monkeys against Lassa fever. Int J Infect Dis. 79, 6 (2019).
299. Clegg JC Lloyd G Vaccinia recombinant expressing Lassa-virus internal nucleocapsid protein protects guineapigs against Lassa fever Lancet 1987 2 186 188, 10.1016/S0140-6736(87)90767-7 2885642
Clegg, J. C. & Lloyd, G. Vaccinia recombinant expressing Lassa-virus internal nucleocapsid protein protects guineapigs against Lassa fever. Lancet 2, 186–188, (1987).2885642
300. Fisher-Hoch SP Hutwagner L Brown B McCormick JB Effective vaccine for lassa fever J. Virol. 2000 74 6777 6783 10.1128/JVI.74.15.6777-6783.2000 10888616
Fisher-Hoch, S. P., Hutwagner, L., Brown, B. & McCormick, J. B. Effective vaccine for lassa fever. J. Virol. 74, 6777–6783 (2000).10888616
301. Salvato MS A Single Dose of Modified Vaccinia Ankara Expressing Lassa Virus-like Particles Protects Mice from Lethal Intra-cerebral Virus Challenge Pathogens 2019 8 133 10.3390/pathogens8030133 31466243
Salvato, M. S. et al. A Single Dose of Modified Vaccinia Ankara Expressing Lassa Virus-like Particles Protects Mice from Lethal Intra-cerebral Virus Challenge. Pathogens 8, 133 (2019).31466243
302. Pushko P Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses J. Virol. 2001 75 11677 11685 10.1128/JVI.75.23.11677-11685.2001 11689649
Pushko, P. et al. Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. J. Virol. 75, 11677–11685 (2001).11689649
303. Wang M Alphavirus vector-based replicon particles expressing multivalent cross-protective Lassa virus glycoproteins Vaccine 2018 36 683 690 10.1016/j.vaccine.2017.12.046 29287681
Wang, M. et al. Alphavirus vector-based replicon particles expressing multivalent cross-protective Lassa virus glycoproteins. Vaccine 36, 683–690 (2018).29287681
304. Maruyama J Adenoviral vector-based vaccine is fully protective against lethal Lassa fever challenge in Hartley guinea pigs Vaccine 2019 37 6824 6831 10.1016/j.vaccine.2019.09.030 31561999
Maruyama, J. et al. Adenoviral vector-based vaccine is fully protective against lethal Lassa fever challenge in Hartley guinea pigs. Vaccine 37, 6824–6831 (2019).31561999
305. Cashman KA Enhanced Efficacy of a Codon-Optimized DNA Vaccine Encoding the Glycoprotein Precursor Gene of Lassa Virus in a Guinea Pig Disease Model When Delivered by Dermal Electroporation Vaccines 2013 1 262 277 10.3390/vaccines1030262 26344112
Cashman, K. A. et al. Enhanced Efficacy of a Codon-Optimized DNA Vaccine Encoding the Glycoprotein Precursor Gene of Lassa Virus in a Guinea Pig Disease Model When Delivered by Dermal Electroporation. Vaccines 1, 262–277 (2013).26344112
306. Cashman KA A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against Lassa fever Hum. Vaccin Immunother. 2017 13 2902 2911 10.1080/21645515.2017.1356500 29045192
Cashman, K. A. et al. A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against Lassa fever. Hum. Vaccin Immunother. 13, 2902–2911 (2017).29045192
307. Jiang J Immunogenicity of a protective intradermal DNA vaccine against lassa virus in cynomolgus macaques Hum. Vaccin Immunother. 2019 15 2066 2074 10.1080/21645515.2019.1616499 31071008
Jiang, J. et al. Immunogenicity of a protective intradermal DNA vaccine against lassa virus in cynomolgus macaques. Hum. Vaccin Immunother. 15, 2066–2074 (2019).31071008
308. Kotturi MF A multivalent and cross-protective vaccine strategy against arenaviruses associated with human disease PLoS Pathog. 2009 5 e1000695 10.1371/journal.ppat.1000695 20019801
Kotturi, M. F. et al. A multivalent and cross-protective vaccine strategy against arenaviruses associated with human disease. PLoS Pathog. 5, e1000695 (2009).20019801
309. Botten J A multivalent vaccination strategy for the prevention of Old World arenavirus infection in humans J. Virol. 2010 84 9947 9956 10.1128/JVI.00672-10 20668086
Botten, J. et al. A multivalent vaccination strategy for the prevention of Old World arenavirus infection in humans. J. Virol. 84, 9947–9956 (2010).20668086
310. Leifer E Gocke DJ Bourne H Lassa fever, a new virus disease of man from West Africa. II. Report of a laboratory-acquired infection treated with plasma from a person recently recovered from the disease Am. J. Trop. Med. Hyg. 1970 19 677 679 10.4269/ajtmh.1970.19.677 4987546
Leifer, E., Gocke, D. J. & Bourne, H. Lassa fever, a new virus disease of man from West Africa. II. Report of a laboratory-acquired infection treated with plasma from a person recently recovered from the disease. Am. J. Trop. Med. Hyg. 19, 677–679 (1970).4987546
311. Jahrling PB Protection of Lassa virus-infected guinea pigs with Lassa-immune plasma of guinea pig, primate, and human origin J. Med. Virol. 1983 12 93 102 10.1002/jmv.1890120203 6619814
Jahrling, P. B. Protection of Lassa virus-infected guinea pigs with Lassa-immune plasma of guinea pig, primate, and human origin. J. Med. Virol. 12, 93–102 (1983).6619814
312. Frame JD Verbrugge GP Gill RG Pinneo L The use of Lassa fever convalescent plasma in Nigeria Trans. R. Soc. Trop. Med. Hyg. 1984 78 319 324 10.1016/0035-9203(84)90107-X 6464130
Frame, J. D., Verbrugge, G. P., Gill, R. G. & Pinneo, L. The use of Lassa fever convalescent plasma in Nigeria. Trans. R. Soc. Trop. Med. Hyg. 78, 319–324 (1984).6464130
313. McCormick JB Clinical, epidemiologic, and therapeutic aspects of Lassa fever Med. Microbiol. Immunol. 1986 175 153 155 10.1007/BF02122438 3724661
McCormick, J. B. Clinical, epidemiologic, and therapeutic aspects of Lassa fever. Med. Microbiol. Immunol. 175, 153–155 (1986).3724661
314. Jahrling PB Lassa virus infection of rhesus monkeys: pathogenesis and treatment with ribavirin J. Infect. Dis. 1980 141 580 589 10.1093/infdis/141.5.580 6768812
Jahrling, P. B. et al. Lassa virus infection of rhesus monkeys: pathogenesis and treatment with ribavirin. J. Infect. Dis. 141, 580–589 (1980).6768812
315. Ter Meulen J Hunting of peridomestic rodents and consumption of their meat as possible risk factors for rodent-to-human transmission of Lassa virus in the Republic of Guinea Am. J. Trop. Med. Hyg. 1996 55 661 666 10.4269/ajtmh.1996.55.661 9025695
Ter Meulen, J. et al. Hunting of peridomestic rodents and consumption of their meat as possible risk factors for rodent-to-human transmission of Lassa virus in the Republic of Guinea. Am. J. Trop. Med. Hyg. 55, 661–666 (1996).9025695
316. Houlihan C Behrens R Lassa fever BMJ 2017 358 j2986 10.1136/bmj.j2986 28701331
Houlihan, C. & Behrens, R. Lassa fever. BMJ 358, j2986 (2017).28701331
317. Carrillo-Bustamante P Determining Ribavirin’s mechanism of action against Lassa virus infection Sci. Rep. 2017 7 11693 10.1038/s41598-017-10198-0 28916737
Carrillo-Bustamante, P. et al. Determining Ribavirin’s mechanism of action against Lassa virus infection. Sci. Rep. 7, 11693 (2017).28916737
318. Madu IG A potent Lassa virus antiviral targets an arenavirus virulence determinant PLoS Pathog. 2018 14 e1007439 10.1371/journal.ppat.1007439 30576397
Madu, I. G. et al. A potent Lassa virus antiviral targets an arenavirus virulence determinant. PLoS Pathog. 14, e1007439 (2018).30576397
319. Ruo SL Antigenic relatedness between arenaviruses defined at the epitope level by monoclonal antibodies J. Gen. Virol. 1991 72 549 555 10.1099/0022-1317-72-3-549 1706408
Ruo, S. L. et al. Antigenic relatedness between arenaviruses defined at the epitope level by monoclonal antibodies. J. Gen. Virol. 72, 549–555 (1991).1706408
320. Cross RW A human monoclonal antibody combination rescues nonhuman primates from advanced disease caused by the major lineages of Lassa virus Proc. Natl Acad. Sci. USA 2023 120 e2304876120 10.1073/pnas.2304876120 37590417
Cross, R. W. et al. A human monoclonal antibody combination rescues nonhuman primates from advanced disease caused by the major lineages of Lassa virus. Proc. Natl Acad. Sci. USA 120, e2304876120 (2023).37590417
321. Zhong NS Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People’s Republic of China, in February, 2003 Lancet 2003 362 1353 1358 10.1016/S0140-6736(03)14630-2 14585636
Zhong, N. S. et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People’s Republic of China, in February, 2003. Lancet 362, 1353–1358 (2003).14585636
322. Zhou P A pneumonia outbreak associated with a new coronavirus of probable bat origin Nature 2020 579 270 273 10.1038/s41586-020-2012-7 32015507
Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273 (2020).32015507
323. Zaki AM Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia N. Engl. J. Med. 2012 367 1814 1820 10.1056/NEJMoa1211721 23075143
Zaki, A. M. et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 367, 1814–1820 (2012).23075143
324. Rabaan AA SARS-CoV-2, SARS-CoV, and MERS-COV: A comparative overview Le. Infez. Med. 2020 28 174 184
Rabaan, A. A. et al. SARS-CoV-2, SARS-CoV, and MERS-COV: A comparative overview. Le. Infez. Med. 28, 174–184 (2020).
325. Cui J Li F Shi ZL Origin and evolution of pathogenic coronaviruses Nat. Rev. Microbiol 2019 17 181 192 10.1038/s41579-018-0118-9 30531947
Cui, J., Li, F. & Shi, Z. L. Origin and evolution of pathogenic coronaviruses. Nat. Rev. Microbiol 17, 181–192 (2019).30531947
326. Walls AC Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein Cell 2020 181 281 292.e286 10.1016/j.cell.2020.02.058 32155444
Walls, A. C. et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 181, 281–292.e286 (2020).32155444
327. Li W Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus Nature 2003 426 450 454 10.1038/nature02145 14647384
Li, W. et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426, 450–454 (2003).14647384
328. Wang Q Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2 Cell 2020 181 894 904.e899 10.1016/j.cell.2020.03.045 32275855
Wang, Q. et al. Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. Cell 181, 894–904.e899 (2020).32275855
329. Arabi YM Middle East Respiratory Syndrome N. Engl. J. Med. 2017 376 584 594 10.1056/NEJMsr1408795 28177862
Arabi, Y. M. et al. Middle East Respiratory Syndrome. N. Engl. J. Med. 376, 584–594 (2017).28177862
330. Cron RQ Caricchio R Chatham WW Calming the cytokine storm in COVID-19 Nat. Med. 2021 27 1674 1675 10.1038/s41591-021-01500-9 34480126
Cron, R. Q., Caricchio, R. & Chatham, W. W. Calming the cytokine storm in COVID-19. Nat. Med. 27, 1674–1675 (2021).34480126
331. Shang J Structural basis of receptor recognition by SARS-CoV-2 Nature 2020 581 221 224 10.1038/s41586-020-2179-y 32225175
Shang, J. et al. Structural basis of receptor recognition by SARS-CoV-2. Nature 581, 221–224 (2020).32225175
332. Jiang R-D Pathogenesis of SARS-CoV-2 in transgenic mice expressing human angiotensin-converting enzyme 2 Cell 2020 182 50 58 10.1016/j.cell.2020.05.027 32516571
Jiang, R.-D. et al. Pathogenesis of SARS-CoV-2 in transgenic mice expressing human angiotensin-converting enzyme 2. Cell 182, 50–58 (2020).32516571
333. McCray PB Jr. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus J. Virol. 2007 81 813 821 10.1128/JVI.02012-06 17079315
McCray, P. B. Jr. et al. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J. Virol. 81, 813–821 (2007).17079315
334. Li K Middle East Respiratory Syndrome Coronavirus Causes Multiple Organ Damage and Lethal Disease in Mice Transgenic for Human Dipeptidyl Peptidase 4 J. Infect. Dis. 2016 213 712 722 10.1093/infdis/jiv499 26486634
Li, K. et al. Middle East Respiratory Syndrome Coronavirus Causes Multiple Organ Damage and Lethal Disease in Mice Transgenic for Human Dipeptidyl Peptidase 4. J. Infect. Dis. 213, 712–722 (2016).26486634
335. Zheng J COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice Nature 2021 589 603 607 10.1038/s41586-020-2943-z 33166988
Zheng, J. et al. COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice. Nature 589, 603–607 (2021).33166988
336. Yinda CK K18-hACE2 mice develop respiratory disease resembling severe COVID-19 PLoS Pathog. 2021 17 e1009195 10.1371/journal.ppat.1009195 33465158
Yinda, C. K. et al. K18-hACE2 mice develop respiratory disease resembling severe COVID-19. PLoS Pathog. 17, e1009195 (2021).33465158
337. Winkler ES SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function Nat. Immunol. 2020 21 1327 1335 10.1038/s41590-020-0778-2 32839612
Winkler, E. S. et al. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat. Immunol. 21, 1327–1335 (2020).32839612
338. Sun SH A Mouse Model of SARS-CoV-2 Infection and Pathogenesis Cell Host Microbe 2020 28 124 133.e124 10.1016/j.chom.2020.05.020 32485164
Sun, S. H. et al. A Mouse Model of SARS-CoV-2 Infection and Pathogenesis. Cell Host Microbe 28, 124–133.e124 (2020).32485164
339. Hong W A mouse model for SARS-CoV-2-induced acute respiratory distress syndrome Signal Transduct. Target Ther. 2021 6 1 10.1038/s41392-020-00451-w 33384407
Hong, W. et al. A mouse model for SARS-CoV-2-induced acute respiratory distress syndrome. Signal Transduct. Target Ther. 6, 1 (2021).33384407
340. Agrawal AS Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease J. Virol. 2015 89 3659 3670 10.1128/JVI.03427-14 25589660
Agrawal, A. S. et al. Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease. J. Virol. 89, 3659–3670 (2015).25589660
341. Zhao G Multi-Organ Damage in Human Dipeptidyl Peptidase 4 Transgenic Mice Infected with Middle East Respiratory Syndrome-Coronavirus PLoS One 2015 10 e0145561 10.1371/journal.pone.0145561 26701103
Zhao, G. et al. Multi-Organ Damage in Human Dipeptidyl Peptidase 4 Transgenic Mice Infected with Middle East Respiratory Syndrome-Coronavirus. PLoS One 10, e0145561 (2015).26701103
342. Tao X Characterization and Demonstration of the Value of a Lethal Mouse Model of Middle East Respiratory Syndrome Coronavirus Infection and Disease J. Virol. 2016 90 57 67 10.1128/JVI.02009-15 26446606
Tao, X. et al. Characterization and Demonstration of the Value of a Lethal Mouse Model of Middle East Respiratory Syndrome Coronavirus Infection and Disease. J. Virol. 90, 57–67 (2016).26446606
343. Pascal KE Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection Proc. Natl Acad. Sci. USA 2015 112 8738 8743 10.1073/pnas.1510830112 26124093
Pascal, K. E. et al. Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection. Proc. Natl Acad. Sci. USA 112, 8738–8743 (2015).26124093
344. Cockrell AS A mouse model for MERS coronavirus-induced acute respiratory distress syndrome Nat. Microbiol 2016 2 16226 10.1038/nmicrobiol.2016.226 27892925
Cockrell, A. S. et al. A mouse model for MERS coronavirus-induced acute respiratory distress syndrome. Nat. Microbiol 2, 16226 (2016).27892925
345. Kim J Yang YL Jeong Y Jang YS Middle East Respiratory Syndrome-Coronavirus Infection into Established hDPP4-Transgenic Mice Accelerates Lung Damage Via Activation of the Pro-Inflammatory Response and Pulmonary Fibrosis J. Microbiol. Biotechnol. 2020 30 427 438 10.4014/jmb.1910.10055 31838832
Kim, J., Yang, Y. L., Jeong, Y. & Jang, Y. S. Middle East Respiratory Syndrome-Coronavirus Infection into Established hDPP4-Transgenic Mice Accelerates Lung Damage Via Activation of the Pro-Inflammatory Response and Pulmonary Fibrosis. J. Microbiol. Biotechnol. 30, 427–438 (2020).31838832
346. Hassan AO A SARS-CoV-2 infection model in mice demonstrates protection by neutralizing antibodies Cell 2020 182 744 753.e744 10.1016/j.cell.2020.06.011 32553273
Hassan, A. O. et al. A SARS-CoV-2 infection model in mice demonstrates protection by neutralizing antibodies. Cell 182, 744–753.e744 (2020).32553273
347. Sun J Generation of a Broadly Useful Model for COVID-19 Pathogenesis Vaccination, and Treatment Cell 2020 182 734 743.e735 10.1016/j.cell.2020.06.010 32643603
Sun, J. et al. Generation of a Broadly Useful Model for COVID-19 Pathogenesis Vaccination, and Treatment. Cell 182, 734–743.e735 (2020).32643603
348. Zhao J Rapid generation of a mouse model for Middle East respiratory syndrome Proc. Natl Acad. Sci. USA 2014 111 4970 4975 10.1073/pnas.1323279111 24599590
Zhao, J. et al. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc. Natl Acad. Sci. USA 111, 4970–4975 (2014).24599590
349. Israelow B Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling J. Exp. Med. 2020 217 e20201241 10.1084/jem.20201241 32750141
Israelow, B. et al. Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling. J. Exp. Med. 217, e20201241 (2020).32750141
350. Yang MS Non-invasive administration of AAV to target lung parenchymal cells and develop SARS-CoV-2-susceptible mice Mol. Ther. 2022 30 1994 2004 10.1016/j.ymthe.2022.01.010 35007757
Yang, M. S. et al. Non-invasive administration of AAV to target lung parenchymal cells and develop SARS-CoV-2-susceptible mice. Mol. Ther. 30, 1994–2004 (2022).35007757
351. Sefik E A humanized mouse model of chronic COVID-19 Nat. Biotechnol. 2022 40 906 920 10.1038/s41587-021-01155-4 34921308
Sefik, E. et al. A humanized mouse model of chronic COVID-19. Nat. Biotechnol. 40, 906–920 (2022).34921308
352. Sefik E Inflammasome activation in infected macrophages drives COVID-19 pathology Nature 2022 606 585 593 10.1038/s41586-022-04802-1 35483404
Sefik, E. et al. Inflammasome activation in infected macrophages drives COVID-19 pathology. Nature 606, 585–593 (2022).35483404
353. Roberts A A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice PLoS Pathog. 2007 3 e5 10.1371/journal.ppat.0030005 17222058
Roberts, A. et al. A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice. PLoS Pathog. 3, e5 (2007).17222058
354. Li K Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice Proc. Natl Acad. Sci. USA 2017 114 E3119 e3128 28348219
Li, K. et al. Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice. Proc. Natl Acad. Sci. USA 114, E3119–e3128 (2017).28348219
355. Gu, H. et al. Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy. Science, 369, 1603–1607 (2020).
356. Wang Mouse-adapted SARS-CoV-2 replicates efficiently in the upper and lower respiratory tract of BALB/c and C57BL/6J mice Protein Cell 2020 11 776 782 10.1007/s13238-020-00767-x 32749592
Wang et al. Mouse-adapted SARS-CoV-2 replicates efficiently in the upper and lower respiratory tract of BALB/c and C57BL/6J mice. Protein Cell 11, 776–782 (2020).32749592
357. Leist SR A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice Cell 2020 183 1070 1085.e1012 10.1016/j.cell.2020.09.050 33031744
Leist, S. R. et al. A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice. Cell 183, 1070–1085.e1012 (2020).33031744
358. Yan F Characterization of Two Heterogeneous Lethal Mouse-Adapted SARS-CoV-2 Variants Recapitulating Representative Aspects of Human COVID-19 Front. Immunol. 2022 13 821664 10.3389/fimmu.2022.821664 35197985
Yan, F. et al. Characterization of Two Heterogeneous Lethal Mouse-Adapted SARS-CoV-2 Variants Recapitulating Representative Aspects of Human COVID-19. Front. Immunol. 13, 821664 (2022).35197985
359. Ng DL Clinicopathologic, Immunohistochemical, and Ultrastructural Findings of a Fatal Case of Middle East Respiratory Syndrome Coronavirus Infection in the United Arab Emirates, April 2014 Am. J. Pathol. 2016 186 652 658 10.1016/j.ajpath.2015.10.024 26857507
Ng, D. L. et al. Clinicopathologic, Immunohistochemical, and Ultrastructural Findings of a Fatal Case of Middle East Respiratory Syndrome Coronavirus Infection in the United Arab Emirates, April 2014. Am. J. Pathol. 186, 652–658 (2016).26857507
360. Iwata-Yoshikawa N Acute Respiratory Infection in Human Dipeptidyl Peptidase 4-Transgenic Mice Infected with Middle East Respiratory Syndrome Coronavirus J. Virol. 2019 93 e01818 e01818 10.1128/JVI.01818-18 30626685
Iwata-Yoshikawa, N. et al. Acute Respiratory Infection in Human Dipeptidyl Peptidase 4-Transgenic Mice Infected with Middle East Respiratory Syndrome Coronavirus. J. Virol. 93, e01818–e01818 (2019).30626685
361. Coleman, C. M. et al. CD8+ T Cells and Macrophages Regulate Pathogenesis in a Mouse Model of Middle East Respiratory Syndrome. J. Virol. 91, e01825-16 (2017).
362. Singh A A Comprehensive Review of Animal Models for Coronaviruses: SARS-CoV-2, SARS-CoV, and MERS-CoV Virol. Sin. 2020 35 290 304 10.1007/s12250-020-00252-z 32607866
Singh, A. et al. A Comprehensive Review of Animal Models for Coronaviruses: SARS-CoV-2, SARS-CoV, and MERS-CoV. Virol. Sin. 35, 290–304 (2020).32607866
363. Liu YH Functional and genetic analysis of viral receptor ACE2 orthologs reveals a broad potential host range of SARS-CoV-2 Proc. Natl Acad. Sci. USA 2021 118 e2025373118 10.1073/pnas.2025373118 33658332
Liu, Y. H. et al. Functional and genetic analysis of viral receptor ACE2 orthologs reveals a broad potential host range of SARS-CoV-2. Proc. Natl Acad. Sci. USA 118, e2025373118 (2021).33658332
364. Zhao XS Broad and Differential Animal Angiotensin-Converting Enzyme 2 Receptor Usage by SARS-CoV-2 J. Virol. 2020 94 e00940 00920 10.1128/JVI.00940-20 32661139
Zhao, X. S. et al. Broad and Differential Animal Angiotensin-Converting Enzyme 2 Receptor Usage by SARS-CoV-2. J. Virol. 94, e00940–00920 (2020).32661139
365. Ma H A bispecific nanobody dimer broadly neutralizes SARS-CoV-1 & 2 variants of concern and offers substantial protection against Omicron via low-dose intranasal administration Cell Discov. 2022 8 132 10.1038/s41421-022-00497-w 36494344
Ma, H. et al. A bispecific nanobody dimer broadly neutralizes SARS-CoV-1 & 2 variants of concern and offers substantial protection against Omicron via low-dose intranasal administration. Cell Discov. 8, 132 (2022).36494344
366. Lu G Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26 Nature 2013 500 227 231 10.1038/nature12328 23831647
Lu, G. et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 500, 227–231 (2013).23831647
367. Roberts A Severe Acute Respiratory Syndrome Coronavirus Infection of Golden Syrian Hamsters J. Virol. 2005 79 503 511 10.1128/JVI.79.1.503-511.2005 15596843
Roberts, A. et al. Severe Acute Respiratory Syndrome Coronavirus Infection of Golden Syrian Hamsters. J. Virol. 79, 503–511 (2005).15596843
368. Roberts A Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters J. Infect. Dis. 2006 193 685 692 10.1086/500143 16453264
Roberts, A. et al. Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters. J. Infect. Dis. 193, 685–692 (2006).16453264
369. Schaecher SR An immunosuppressed Syrian golden hamster model for SARS-CoV infection Virology 2008 380 312 321 10.1016/j.virol.2008.07.026 18760437
Schaecher, S. R. et al. An immunosuppressed Syrian golden hamster model for SARS-CoV infection. Virology 380, 312–321 (2008).18760437
370. Sia SF Pathogenesis and transmission of SARS-CoV-2 in golden hamsters Nature 2020 583 834 838 10.1038/s41586-020-2342-5 32408338
Sia, S. F. et al. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. Nature 583, 834–838 (2020).32408338
371. Chan JF Simulation of the Clinical and Pathological Manifestations of Coronavirus Disease 2019 (COVID-19) in a Golden Syrian Hamster Model: Implications for Disease Pathogenesis and Transmissibility Clin. Infect. Dis. 2020 71 2428 2446 10.1093/cid/ciaa644 32215622
Chan, J. F. et al. Simulation of the Clinical and Pathological Manifestations of Coronavirus Disease 2019 (COVID-19) in a Golden Syrian Hamster Model: Implications for Disease Pathogenesis and Transmissibility. Clin. Infect. Dis. 71, 2428–2446 (2020).32215622
372. Imai M Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development Proc. Natl Acad. Sci. USA 2020 117 16587 16595 10.1073/pnas.2009799117 32571934
Imai, M. et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc. Natl Acad. Sci. USA 117, 16587–16595 (2020).32571934
373. Bakoyiannis I Cardiovascular effects of SARS-CoV-2 in hamster Lab. Anim. 2022 51 77
Bakoyiannis, I. Cardiovascular effects of SARS-CoV-2 in hamster. Lab. Anim. 51, 77 (2022).
374. Rizvi ZA Golden Syrian hamster as a model to study cardiovascular complications associated with SARS-CoV-2 infection Elife 2022 11 e73522 10.7554/eLife.73522 35014610
Rizvi, Z. A. et al. Golden Syrian hamster as a model to study cardiovascular complications associated with SARS-CoV-2 infection. Elife 11, e73522 (2022).35014610
375. Yuan L Infection, pathology and interferon treatment of the SARS-CoV-2 Omicron BA.1 variant in juvenile, adult and aged Syrian hamsters Cell. Mol. Immunol. 2022 19 1392 1399 10.1038/s41423-022-00923-9 36258005
Yuan, L. et al. Infection, pathology and interferon treatment of the SARS-CoV-2 Omicron BA.1 variant in juvenile, adult and aged Syrian hamsters. Cell. Mol. Immunol. 19, 1392–1399 (2022).36258005
376. Osterrieder N Age-Dependent Progression of SARS-CoV-2 Infection in Syrian Hamsters Viruses 2020 12 779 10.3390/v12070779 32698441
Osterrieder, N. et al. Age-Dependent Progression of SARS-CoV-2 Infection in Syrian Hamsters. Viruses 12, 779 (2020).32698441
377. Ohno M Abnormal Blood Coagulation and Kidney Damage in Aged Hamsters Infected with Severe Acute Respiratory Syndrome Coronavirus 2 Viruses 2021 13 2137 10.3390/v13112137 34834944
Ohno, M. et al. Abnormal Blood Coagulation and Kidney Damage in Aged Hamsters Infected with Severe Acute Respiratory Syndrome Coronavirus 2. Viruses 13, 2137 (2021).34834944
378. Santosh D Sex Differences in Lung Imaging and SARS-CoV-2 Antibody Responses in a COVID-19 Golden Syrian Hamster Model mBio. 2021 12 e0097421 10.1128/mBio.00974-21 34253053
Santosh, D. et al. Sex Differences in Lung Imaging and SARS-CoV-2 Antibody Responses in a COVID-19 Golden Syrian Hamster Model. mBio. 12, e0097421 (2021).34253053
379. Li C Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection by Intranasal or Intratesticular Route Induces Testicular Damage Clin. Infect. Dis. 2022 75 e974 e990 10.1093/cid/ciac142 35178548
Li, C. et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection by Intranasal or Intratesticular Route Induces Testicular Damage. Clin. Infect. Dis. 75, e974–e990 (2022).35178548
380. Yuan L Persisting lung pathogenesis and minimum residual virus in hamster after acute COVID-19 Protein Cell 2022 13 72 77 10.1007/s13238-021-00874-3 34491552
Yuan, L. et al. Persisting lung pathogenesis and minimum residual virus in hamster after acute COVID-19. Protein Cell 13, 72–77 (2022).34491552
381. Golden JW Hamsters Expressing Human Angiotensin-Converting Enzyme 2 Develop Severe Disease following Exposure to SARS-CoV-2 mBio 2022 13 e0290621 10.1128/mbio.02906-21 35073750
Golden, J. W. et al. Hamsters Expressing Human Angiotensin-Converting Enzyme 2 Develop Severe Disease following Exposure to SARS-CoV-2. mBio 13, e0290621 (2022).35073750
382. Zhai C Roborovski hamster (Phodopus roborovskii) strain SH101 as a systemic infection model of SARS-CoV-2 Virulence 2021 12 2430 2442 10.1080/21505594.2021.1972201 34517779
Zhai, C. et al. Roborovski hamster (Phodopus roborovskii) strain SH101 as a systemic infection model of SARS-CoV-2. Virulence 12, 2430–2442 (2021).34517779
383. Trimpert J The Roborovski Dwarf Hamster Is A Highly Susceptible Model for a Rapid and Fatal Course of SARS-CoV-2 Infection Cell Rep. 2020 33 108488 10.1016/j.celrep.2020.108488 33271063
Trimpert, J. et al. The Roborovski Dwarf Hamster Is A Highly Susceptible Model for a Rapid and Fatal Course of SARS-CoV-2 Infection. Cell Rep. 33, 108488 (2020).33271063
384. Bertzbach LD SARS-CoV-2 infection of Chinese hamsters (Cricetulus griseus) reproduces COVID-19 pneumonia in a well-established small animal model Transbound. Emerg. Dis. 2021 68 1075 1079 10.1111/tbed.13837 32946664
Bertzbach, L. D. et al. SARS-CoV-2 infection of Chinese hamsters (Cricetulus griseus) reproduces COVID-19 pneumonia in a well-established small animal model. Transbound. Emerg. Dis. 68, 1075–1079 (2021).32946664
385. Rosenke, K. et al. Defining the Syrian hamster as a highly susceptible preclinical model for SARS-CoV-2 infection. Emerg. Microbes Infect. 9, 2673-2684, (2020).
386. Boudewijns R STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters Nat. Commun. 2020 11 5838 10.1038/s41467-020-19684-y 33203860
Boudewijns, R. et al. STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters. Nat. Commun. 11, 5838 (2020).33203860
387. Brocato RL Disruption of Adaptive Immunity Enhances Disease in SARS-CoV-2-Infected Syrian Hamsters J. Virol. 2020 94 e01683 01620 10.1128/JVI.01683-20 32900822
Brocato, R. L. et al. Disruption of Adaptive Immunity Enhances Disease in SARS-CoV-2-Infected Syrian Hamsters. J. Virol. 94, e01683–01620 (2020).32900822
388. van Doremalen N Host species restriction of Middle East respiratory syndrome coronavirus through its receptor, dipeptidyl peptidase 4 J. Virol. 2014 88 9220 9232 10.1128/JVI.00676-14 24899185
van Doremalen, N. et al. Host species restriction of Middle East respiratory syndrome coronavirus through its receptor, dipeptidyl peptidase 4. J. Virol. 88, 9220–9232 (2014).24899185
389. Martina BEE Virology: SARS virus infection of cats and ferrets Nature 2003 425 915 10.1038/425915a 14586458
Martina, B. E. E. et al. Virology: SARS virus infection of cats and ferrets. Nature 425, 915 (2003).14586458
390. Weingartl H Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets J. Virol. 2004 78 12672 12676 10.1128/JVI.78.22.12672-12676.2004 15507655
Weingartl, H. et al. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J. Virol. 78, 12672–12676 (2004).15507655
391. Darnell MER Severe acute respiratory syndrome coronavirus infection in vaccinated ferrets J. Infect. Dis. 2007 196 1329 1338 10.1086/522431 17922397
Darnell, M. E. R. et al. Severe acute respiratory syndrome coronavirus infection in vaccinated ferrets. J. Infect. Dis. 196, 1329–1338 (2007).17922397
392. Chu Y-K The SARS-CoV ferret model in an infection-challenge study Virology 2008 374 151 163 10.1016/j.virol.2007.12.032 18234270
Chu, Y.-K. et al. The SARS-CoV ferret model in an infection-challenge study. Virology 374, 151–163 (2008).18234270
393. Kim YI Infection and Rapid Transmission of SARS-CoV-2 in Ferrets Cell Host Microbe 2020 27 704 709 e702 10.1016/j.chom.2020.03.023 32259477
Kim, Y. I. et al. Infection and Rapid Transmission of SARS-CoV-2 in Ferrets. Cell Host Microbe 27, 704–709 e702 (2020).32259477
394. Monchatre-Leroy E Hamster and ferret experimental infection with intranasal low dose of a single strain of SARS-CoV-2 J. Gen. Virol. 2021 102 001567 10.1099/jgv.0.001567 33612147
Monchatre-Leroy, E. et al. Hamster and ferret experimental infection with intranasal low dose of a single strain of SARS-CoV-2. J. Gen. Virol. 102, 001567 (2021).33612147
395. Kutter JS SARS-CoV and SARS-CoV-2 are transmitted through the air between ferrets over more than one meter distance Nat. Commun. 2021 12 1653 10.1038/s41467-021-21918-6 33712573
Kutter, J. S. et al. SARS-CoV and SARS-CoV-2 are transmitted through the air between ferrets over more than one meter distance. Nat. Commun. 12, 1653 (2021).33712573
396. Everett HE Intranasal Infection of Ferrets with SARS-CoV-2 as a Model for Asymptomatic Human Infection Viruses 2021 13 113 10.3390/v13010113 33467732
Everett, H. E. et al. Intranasal Infection of Ferrets with SARS-CoV-2 as a Model for Asymptomatic Human Infection. Viruses 13, 113 (2021).33467732
397. Pulit-Penaloza JA Comparative Assessment of Severe Acute Respiratory Syndrome Coronavirus 2 Variants in the Ferret Model mBio 2022 13 e0242122 10.1128/mbio.02421-22 36135377
Pulit-Penaloza, J. A. et al. Comparative Assessment of Severe Acute Respiratory Syndrome Coronavirus 2 Variants in the Ferret Model. mBio 13, e0242122 (2022).36135377
398. Ryan KA Dose-dependent response to infection with SARS-CoV-2 in the ferret model and evidence of protective immunity Nat. Commun. 2021 12 81 10.1038/s41467-020-20439-y 33398055
Ryan, K. A. et al. Dose-dependent response to infection with SARS-CoV-2 in the ferret model and evidence of protective immunity. Nat. Commun. 12, 81 (2021).33398055
399. Martins M Fernandes MHV Joshi LR Diel DG Age-Related Susceptibility of Ferrets to SARS-CoV-2 Infection J. Virol. 2022 96 e0145521 10.1128/jvi.01455-21 34817200
Martins, M., Fernandes, M. H. V., Joshi, L. R. & Diel, D. G. Age-Related Susceptibility of Ferrets to SARS-CoV-2 Infection. J. Virol. 96, e0145521 (2022).34817200
400. Kim Y-I Age-dependent pathogenic characteristics of SARS-CoV-2 infection in ferrets Nat. Commun. 2022 13 21 10.1038/s41467-021-27717-3 35013229
Kim, Y.-I. et al. Age-dependent pathogenic characteristics of SARS-CoV-2 infection in ferrets. Nat. Commun. 13, 21 (2022).35013229
401. Shi Z Hu Z A review of studies on animal reservoirs of the SARS coronavirus Virus Res. 2008 133 74 87 10.1016/j.virusres.2007.03.012 17451830
Shi, Z. & Hu, Z. A review of studies on animal reservoirs of the SARS coronavirus. Virus Res. 133, 74–87 (2008).17451830
402. Oreshkova N SARS-CoV-2 infection in farmed minks, the Netherlands, April and May 2020 Eur. Surveill. 2020 25 2001005 10.2807/1560-7917.ES.2020.25.23.2001005
Oreshkova, N. et al. SARS-CoV-2 infection in farmed minks, the Netherlands, April and May 2020. Eur. Surveill. 25, 2001005 (2020).
403. Shuai L Replication, pathogenicity, and transmission of SARS-CoV-2 in minks Natl Sci. Rev. 2021 8 nwaa291 10.1093/nsr/nwaa291 34676095
Shuai, L. et al. Replication, pathogenicity, and transmission of SARS-CoV-2 in minks. Natl Sci. Rev. 8, nwaa291 (2021).34676095
404. Hammer AS SARS-CoV-2 Transmission between Mink (Neovison vison) and Humans, Denmark Emerg. Infect. Dis. 2021 27 547 551 10.3201/eid2702.203794 33207152
Hammer, A. S. et al. SARS-CoV-2 Transmission between Mink (Neovison vison) and Humans, Denmark. Emerg. Infect. Dis. 27, 547–551 (2021).33207152
405. Adney DR Severe acute respiratory disease in American mink experimentally infected with SARS-CoV-2 JCI Insight 2022 7 e159573 10.1172/jci.insight.159573 36509288
Adney, D. R. et al. Severe acute respiratory disease in American mink experimentally infected with SARS-CoV-2. JCI Insight 7, e159573 (2022).36509288
406. Ritter JM Histopathology and localization of SARS-CoV-2 and its host cell entry receptor ACE2 in tissues from naturally infected US-farmed mink (Neovison vison) Vet. Pathol. 2022 59 681 695 10.1177/03009858221079665 35229669
Ritter, J. M. et al. Histopathology and localization of SARS-CoV-2 and its host cell entry receptor ACE2 in tissues from naturally infected US-farmed mink (Neovison vison). Vet. Pathol. 59, 681–695 (2022).35229669
407. Virtanen J Experimental Infection of Mink with SARS-COV-2 Omicron Variant and Subsequent Clinical Disease Emerg. Infect. Dis. 2022 28 1286 1288 10.3201/eid2806.220328 35608951
Virtanen, J. et al. Experimental Infection of Mink with SARS-COV-2 Omicron Variant and Subsequent Clinical Disease. Emerg. Infect. Dis. 28, 1286–1288 (2022).35608951
408. Song Z Integrated histopathological, lipidomic, and metabolomic profiles reveal mink is a useful animal model to mimic the pathogenicity of severe COVID-19 patients Signal Transduct. Target Ther. 2022 7 29 10.1038/s41392-022-00891-6 35091528
Song, Z. et al. Integrated histopathological, lipidomic, and metabolomic profiles reveal mink is a useful animal model to mimic the pathogenicity of severe COVID-19 patients. Signal Transduct. Target Ther. 7, 29 (2022).35091528
409. de Wit E Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques Proc. Natl Acad. Sci. USA 2013 110 16598 16603 10.1073/pnas.1310744110 24062443
de Wit, E. et al. Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques. Proc. Natl Acad. Sci. USA 110, 16598–16603 (2013).24062443
410. Falzarano D Infection with MERS-CoV causes lethal pneumonia in the common marmoset PLoS Pathog. 2014 10 e1004250 10.1371/journal.ppat.1004250 25144235
Falzarano, D. et al. Infection with MERS-CoV causes lethal pneumonia in the common marmoset. PLoS Pathog. 10, e1004250 (2014).25144235
411. Lu S Comparison of nonhuman primates identified the suitable model for COVID-19 Signal Transduct. Target Ther. 2020 5 157 10.1038/s41392-020-00269-6 32814760
Lu, S. et al. Comparison of nonhuman primates identified the suitable model for COVID-19. Signal Transduct. Target Ther. 5, 157 (2020).32814760
412. Tong D Single-dose AAV-based vaccine induces a high level of neutralizing antibodies against SARS-CoV-2 in rhesus macaques Protein Cell 2023 14 69 73 36726759
Tong, D. et al. Single-dose AAV-based vaccine induces a high level of neutralizing antibodies against SARS-CoV-2 in rhesus macaques. Protein Cell 14, 69–73 (2023).36726759
413. Munster VJ Subtle differences in the pathogenicity of SARS-CoV-2 variants of concern B.1.1.7 and B.1.351 in rhesus macaques Sci. Adv. 2021 7 eabj3627 10.1126/sciadv.abj3627 34678071
Munster, V. J. et al. Subtle differences in the pathogenicity of SARS-CoV-2 variants of concern B.1.1.7 and B.1.351 in rhesus macaques. Sci. Adv. 7, eabj3627 (2021).34678071
414. Haagmans BL Osterhaus ADME Nonhuman primate models for SARS PLoS Med. 2006 3 e194 10.1371/journal.pmed.0030194 16608385
Haagmans, B. L. & Osterhaus, A. D. M. E. Nonhuman primate models for SARS. PLoS Med. 3, e194 (2006).16608385
415. Rowe T Macaque model for severe acute respiratory syndrome J. Virol. 2004 78 11401 11404 10.1128/JVI.78.20.11401-11404.2004 15452262
Rowe, T. et al. Macaque model for severe acute respiratory syndrome. J. Virol. 78, 11401–11404 (2004).15452262
416. McAuliffe J Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys Virology 2004 330 8 15 10.1016/j.virol.2004.09.030 15527829
McAuliffe, J. et al. Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys. Virology 330, 8–15 (2004).15527829
417. Lawler JV Cynomolgus macaque as an animal model for severe acute respiratory syndrome PLoS Med. 2006 3 e149 10.1371/journal.pmed.0030149 16605302
Lawler, J. V. et al. Cynomolgus macaque as an animal model for severe acute respiratory syndrome. PLoS Med. 3, e149 (2006).16605302
418. Rockx B Comparative pathogenesis of three human and zoonotic SARS-CoV strains in cynomolgus macaques PLoS One 2011 6 e18558 10.1371/journal.pone.0018558 21533129
Rockx, B. et al. Comparative pathogenesis of three human and zoonotic SARS-CoV strains in cynomolgus macaques. PLoS One 6, e18558 (2011).21533129
419. de Lang A Functional genomics highlights differential induction of antiviral pathways in the lungs of SARS-CoV-infected macaques PLoS Pathog. 2007 3 e112 10.1371/journal.ppat.0030112 17696609
de Lang, A. et al. Functional genomics highlights differential induction of antiviral pathways in the lungs of SARS-CoV-infected macaques. PLoS Pathog. 3, e112 (2007).17696609
420. Smits SL Distinct severe acute respiratory syndrome coronavirus-induced acute lung injury pathways in two different nonhuman primate species J. Virol. 2011 85 4234 4245 10.1128/JVI.02395-10 21325418
Smits, S. L. et al. Distinct severe acute respiratory syndrome coronavirus-induced acute lung injury pathways in two different nonhuman primate species. J. Virol. 85, 4234–4245 (2011).21325418
421. Nagata N Pathology and virus dispersion in cynomolgus monkeys experimentally infected with severe acute respiratory syndrome coronavirus via different inoculation routes Int. J. Exp. Pathol. 2007 88 403 414 10.1111/j.1365-2613.2007.00567.x 18039277
Nagata, N. et al. Pathology and virus dispersion in cynomolgus monkeys experimentally infected with severe acute respiratory syndrome coronavirus via different inoculation routes. Int. J. Exp. Pathol. 88, 403–414 (2007).18039277
422. Rockx B Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model Science 2020 368 1012 1015 10.1126/science.abb7314 32303590
Rockx, B. et al. Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model. Science 368, 1012–1015 (2020).32303590
423. Baek SH Cynomolgus Macaque Model for COVID-19 Delta Variant Immune Netw. 2022 22 e48 10.4110/in.2022.22.e48 36627939
Baek, S. H. et al. Cynomolgus Macaque Model for COVID-19 Delta Variant. Immune Netw. 22, e48 (2022).36627939
424. Johnston SC Development of a coronavirus disease 2019 nonhuman primate model using airborne exposure PLoS One 2021 16 e0246366 10.1371/journal.pone.0246366 33529233
Johnston, S. C. et al. Development of a coronavirus disease 2019 nonhuman primate model using airborne exposure. PLoS One 16, e0246366 (2021).33529233
425. Dabisch PA Seroconversion and fever are dose-dependent in a nonhuman primate model of inhalational COVID-19 PLoS Pathog. 2021 17 e1009865 10.1371/journal.ppat.1009865 34424943
Dabisch, P. A. et al. Seroconversion and fever are dose-dependent in a nonhuman primate model of inhalational COVID-19. PLoS Pathog. 17, e1009865 (2021).34424943
426. Salguero FJ Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19 Nat. Commun. 2021 12 1260 10.1038/s41467-021-21389-9 33627662
Salguero, F. J. et al. Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19. Nat. Commun. 12, 1260 (2021).33627662
427. Urano E COVID-19 cynomolgus macaque model reflecting human COVID-19 pathological conditions Proc. Natl Acad. Sci. USA 2021 118 e2104847118 10.1073/pnas.2104847118 34625475
Urano, E. et al. COVID-19 cynomolgus macaque model reflecting human COVID-19 pathological conditions. Proc. Natl Acad. Sci. USA 118, e2104847118 (2021).34625475
428. Wang T Proteomic and Metabolomic Characterization of SARS-CoV-2-Infected Cynomolgus Macaque at Early Stage Front. Immunol. 2022 13 954121 10.3389/fimmu.2022.954121 35903092
Wang, T. et al. Proteomic and Metabolomic Characterization of SARS-CoV-2-Infected Cynomolgus Macaque at Early Stage. Front. Immunol. 13, 954121 (2022).35903092
429. Woolsey C Establishment of an African green monkey model for COVID-19 and protection against re-infection Nat. Immunol. 2021 22 86 98 10.1038/s41590-020-00835-8 33235385
Woolsey, C. et al. Establishment of an African green monkey model for COVID-19 and protection against re-infection. Nat. Immunol. 22, 86–98 (2021).33235385
430. Blair RV Acute Respiratory Distress in Aged, SARS-CoV-2-Infected African Green Monkeys but Not Rhesus Macaques Am. J. Pathol. 2021 191 274 282 10.1016/j.ajpath.2020.10.016 33171111
Blair, R. V. et al. Acute Respiratory Distress in Aged, SARS-CoV-2-Infected African Green Monkeys but Not Rhesus Macaques. Am. J. Pathol. 191, 274–282 (2021).33171111
431. Singh DK Responses to acute infection with SARS-CoV-2 in the lungs of rhesus macaques, baboons and marmosets Nat. Microbiol 2021 6 73 86 10.1038/s41564-020-00841-4 33340034
Singh, D. K. et al. Responses to acute infection with SARS-CoV-2 in the lungs of rhesus macaques, baboons and marmosets. Nat. Microbiol 6, 73–86 (2021).33340034
432. Mercado NB Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques Nature 2020 590 E25 10.1038/s41586-020-03100-y
Mercado, N. B. et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature 590, E25 (2020).
433. Corbett KS Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates N. Engl. J. Med. 2020 383 1544 1555 10.1056/NEJMoa2024671 32722908
Corbett, K. S. et al. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. N. Engl. J. Med. 383, 1544–1555 (2020).32722908
434. Vogel AB BNT162b vaccines protect rhesus macaques from SARS-CoV-2 Nature 2021 592 283 289 10.1038/s41586-021-03275-y 33524990
Vogel, A. B. et al. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature 592, 283–289 (2021).33524990
435. Muñoz-Fontela C Advances and gaps in SARS-CoV-2 infection models PLoS Pathog. 2022 18 e1010161 10.1371/journal.ppat.1010161 35025969
Muñoz-Fontela, C. et al. Advances and gaps in SARS-CoV-2 infection models. PLoS Pathog. 18, e1010161 (2022).35025969
436. Chandrashekar A Prior infection with SARS-CoV-2 WA1/2020 partially protects rhesus macaques against reinfection with B.1.1.7 and B.1.351 variants Sci. Transl. Med. 2021 13 eabj2641 10.1126/scitranslmed.abj2641 34546094
Chandrashekar, A. et al. Prior infection with SARS-CoV-2 WA1/2020 partially protects rhesus macaques against reinfection with B.1.1.7 and B.1.351 variants. Sci. Transl. Med. 13, eabj2641 (2021).34546094
437. Gao Q Development of an inactivated vaccine candidate for SARS-CoV-2 Science 2020 369 77 81 10.1126/science.abc1932 32376603
Gao, Q. et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science 369, 77–81 (2020).32376603
438. Wu, Z. et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 21, 803–812 (2021).
439. Wang H Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2 Cell 2020 182 713 721 10.1016/j.cell.2020.06.008 32778225
Wang, H. et al. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell 182, 713–721 (2020).32778225
440. Graham RL Donaldson EF Baric RS A decade after SARS: strategies for controlling emerging coronaviruses Nat. Rev. Microbiol. 2013 11 836 848 10.1038/nrmicro3143 24217413
Graham, R. L., Donaldson, E. F. & Baric, R. S. A decade after SARS: strategies for controlling emerging coronaviruses. Nat. Rev. Microbiol. 11, 836–848 (2013).24217413
441. Zhou Y Jiang S Du L Prospects for a MERS-CoV spike vaccine Expert Rev. Vaccines 2018 17 677 686 10.1080/14760584.2018.1506702 30058403
Zhou, Y., Jiang, S. & Du, L. Prospects for a MERS-CoV spike vaccine. Expert Rev. Vaccines 17, 677–686 (2018).30058403
442. He Y Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines J. Immunol. 2004 173 4050 4057 10.4049/jimmunol.173.6.4050 15356154
He, Y. et al. Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines. J. Immunol. 173, 4050–4057 (2004).15356154
443. Richmond P Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial Lancet 2021 397 682 694 10.1016/S0140-6736(21)00241-5 33524311
Richmond, P. et al. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial. Lancet 397, 682–694 (2021).33524311
444. Bravo L Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial Lancet 2022 399 461 472 10.1016/S0140-6736(22)00055-1 35065705
Bravo, L. et al. Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial. Lancet 399, 461–472 (2022).35065705
445. Dunkle LM Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico N. Engl. J. Med. 2022 386 531 543 10.1056/NEJMoa2116185 34910859
Dunkle, L. M. et al. Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico. N. Engl. J. Med. 386, 531–543 (2022).34910859
446. Dai L A universal design of betacoronavirus vaccines against COVID-19, MERS and SARS Cell 2020 182 722 733.e11 10.1016/j.cell.2020.06.035 32645327
Dai, L. et al. A universal design of betacoronavirus vaccines against COVID-19, MERS and SARS. Cell 182, 722–733.e11 (2020).32645327
447. Yang S Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials Lancet Infect. Dis. 2021 21 1107 1119 10.1016/S1473-3099(21)00127-4 33773111
Yang, S. et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect. Dis. 21, 1107–1119 (2021).33773111
448. Xu K Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2 Cell 2022 185 2265 2278.e2214 10.1016/j.cell.2022.04.029 35568034
Xu, K. et al. Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2. Cell 185, 2265–2278.e2214 (2022).35568034
449. Dai L Efficacy and Safety of the RBD-Dimer-Based Covid-19 Vaccine ZF2001 in Adults N. Engl. J. Med. 2022 386 2097 2111 10.1056/NEJMoa2202261 35507481
Dai, L. et al. Efficacy and Safety of the RBD-Dimer-Based Covid-19 Vaccine ZF2001 in Adults. N. Engl. J. Med. 386, 2097–2111 (2022).35507481
450. Gao L Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial Lancet Child Adolesc. Health 2023 7 269 279 10.1016/S2352-4642(22)00376-5 36803632
Gao, L. et al. Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial. Lancet Child Adolesc. Health 7, 269–279 (2023).36803632
451. Walls AC Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2 Cell 2020 183 1367 1382.e17 10.1016/j.cell.2020.10.043 33160446
Walls, A. C. et al. Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2. Cell 183, 1367–1382.e17 (2020).33160446
452. Travieso T The use of viral vectors in vaccine development NPJ Vaccines 2022 7 75 10.1038/s41541-022-00503-y 35787629
Travieso, T. et al. The use of viral vectors in vaccine development. NPJ Vaccines 7, 75 (2022).35787629
453. Ewer KJ Viral vectors as vaccine platforms: from immunogenicity to impact Curr. Opin. Immunol. 2016 41 47 54 10.1016/j.coi.2016.05.014 27286566
Ewer, K. J. et al. Viral vectors as vaccine platforms: from immunogenicity to impact. Curr. Opin. Immunol. 41, 47–54 (2016).27286566
454. Halperin SA Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial Lancet 2022 399 237 248 10.1016/S0140-6736(21)02753-7 34953526
Halperin, S. A. et al. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial. Lancet 399, 237–248 (2022).34953526
455. Sadoff J Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S N. Engl. J. Med. 2022 386 847 860 10.1056/NEJMoa2117608 35139271
Sadoff, J. et al. Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S. N. Engl. J. Med. 386, 847–860 (2022).35139271
456. Voysey M Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Lancet 2021 397 99 111 10.1016/S0140-6736(20)32661-1 33306989
Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397, 99–111 (2021).33306989
457. Zhu F Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials Lancet Respir. Med. 2022 10 749 760 10.1016/S2213-2600(22)00131-X 35644168
Zhu, F. et al. Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Respir. Med. 10, 749–760 (2022).35644168
458. Logunov DY Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia Lancet 2021 397 671 681 10.1016/S0140-6736(21)00234-8 33545094
Logunov, D. Y. et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 397, 671–681 (2021).33545094
459. Robbins JA Safety and immunogenicity of intramuscular, single-dose V590 (rVSV-SARS-CoV-2 Vaccine) in healthy adults: Results from a phase 1 randomised, double-blind, placebo-controlled, dose-ranging trial eBioMedicine 2022 82 104138 10.1016/j.ebiom.2022.104138 35809371
Robbins, J. A. et al. Safety and immunogenicity of intramuscular, single-dose V590 (rVSV-SARS-CoV-2 Vaccine) in healthy adults: Results from a phase 1 randomised, double-blind, placebo-controlled, dose-ranging trial. eBioMedicine 82, 104138 (2022).35809371
460. Wang S Characterization of Immune Response Diversity in Rodents Vaccinated with a Vesicular Stomatitis Virus Vectored COVID-19 Vaccine Viruses 2022 14 1127 10.3390/v14061127 35746599
Wang, S. et al. Characterization of Immune Response Diversity in Rodents Vaccinated with a Vesicular Stomatitis Virus Vectored COVID-19 Vaccine. Viruses 14, 1127 (2022).35746599
461. Wang S Oral delivery of a chitosan adjuvanted COVID-19 vaccine provides long-lasting and broad-spectrum protection against SARS-CoV-2 variants of concern in golden hamsters Antivir. Res. 2023 220 105765 10.1016/j.antiviral.2023.105765 38036065
Wang, S. et al. Oral delivery of a chitosan adjuvanted COVID-19 vaccine provides long-lasting and broad-spectrum protection against SARS-CoV-2 variants of concern in golden hamsters. Antivir. Res. 220, 105765 (2023).38036065
462. Kapadia SU Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine Virology 2005 340 174 182 10.1016/j.virol.2005.06.016 16043204
Kapadia, S. U. et al. Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology 340, 174–182 (2005).16043204
463. Schmidt AC Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates J. Virol. 2000 74 8922 8929 10.1128/JVI.74.19.8922-8929.2000 10982335
Schmidt, A. C. et al. Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates. J. Virol. 74, 8922–8929 (2000).10982335
464. Karron RA Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children Vaccine 2012 30 3975 3981 10.1016/j.vaccine.2011.12.022 22178099
Karron, R. A. et al. Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children. Vaccine 30, 3975–3981 (2012).22178099
465. Buchholz UJ Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity Proc. Natl Acad. Sci. USA 2004 101 9804 9809 10.1073/pnas.0403492101 15210961
Buchholz, U. J. et al. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc. Natl Acad. Sci. USA 101, 9804–9809 (2004).15210961
466. Ohtsuka J Non-propagative human parainfluenza virus type 2 nasal vaccine robustly protects the upper and lower airways against SARS-CoV-2 iScience 2021 24 103379 10.1016/j.isci.2021.103379 34805782
Ohtsuka, J. et al. Non-propagative human parainfluenza virus type 2 nasal vaccine robustly protects the upper and lower airways against SARS-CoV-2. iScience 24, 103379 (2021).34805782
467. An D Protection of K18-hACE2 mice and ferrets against SARS-CoV-2 challenge by a single-dose mucosal immunization with a parainfluenza virus 5-based COVID-19 vaccine Sci. Adv. 2021 7 eabi5246 10.1126/sciadv.abi5246 34215591
An, D. et al. Protection of K18-hACE2 mice and ferrets against SARS-CoV-2 challenge by a single-dose mucosal immunization with a parainfluenza virus 5-based COVID-19 vaccine. Sci. Adv. 7, eabi5246 (2021).34215591
468. Liu X A single intranasal dose of a live-attenuated parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in hamsters Proc. Natl Acad. Sci. USA 2021 118 e2109744118 10.1073/pnas.2109744118 34876520
Liu, X. et al. A single intranasal dose of a live-attenuated parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in hamsters. Proc. Natl Acad. Sci. USA 118, e2109744118 (2021).34876520
469. Le Nouën C Intranasal pediatric parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in monkeys Cell 2022 185 4811 4825.e4817 10.1016/j.cell.2022.11.006 36423629
Le Nouën, C. et al. Intranasal pediatric parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in monkeys. Cell 185, 4811–4825.e4817 (2022).36423629
470. Ilinykh PA A single intranasal dose of human parainfluenza virus type 3-vectored vaccine induces effective antibody and memory T cell response in the lungs and protects hamsters against SARS-CoV-2 NPJ Vaccines 2022 7 47 10.1038/s41541-022-00471-3 35468973
Ilinykh, P. A. et al. A single intranasal dose of human parainfluenza virus type 3-vectored vaccine induces effective antibody and memory T cell response in the lungs and protects hamsters against SARS-CoV-2. NPJ Vaccines 7, 47 (2022).35468973
471. Wang P Generation of DelNS1 Influenza Viruses: a Strategy for Optimizing Live Attenuated Influenza Vaccines mBio 2019 10 e02180 02119 10.1128/mBio.02180-19 31530680
Wang, P. et al. Generation of DelNS1 Influenza Viruses: a Strategy for Optimizing Live Attenuated Influenza Vaccines. mBio 10, e02180–02119 (2019).31530680
472. Chen J A live attenuated virus-based intranasal COVID-19 vaccine provides rapid, prolonged, and broad protection against SARS-CoV-2 Sci. Bull. 2022 67 1372 1387 10.1016/j.scib.2022.05.018
Chen, J. et al. A live attenuated virus-based intranasal COVID-19 vaccine provides rapid, prolonged, and broad protection against SARS-CoV-2. Sci. Bull. 67, 1372–1387 (2022).
473. Zhu F Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Lancet Respir. Med. 2023 11 1075 1088 10.1016/S2213-2600(23)00349-1 37979588
Zhu, F. et al. Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir. Med. 11, 1075–1088 (2023).37979588
474. Zhu F-C Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial Lancet 2020 395 1845 1854 10.1016/S0140-6736(20)31208-3 32450106
Zhu, F.-C. et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet 395, 1845–1854 (2020).32450106
475. Zhu F-C Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial Lancet 2020 396 479 488 10.1016/S0140-6736(20)31605-6 32702299
Zhu, F.-C. et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 396, 479–488 (2020).32702299
476. Li JX Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial Lancet Respir. Med. 2022 10 739 748 10.1016/S2213-2600(22)00087-X 35605625
Li, J. X. et al. Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial. Lancet Respir. Med. 10, 739–748 (2022).35605625
477. Li J Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial Nat. Med. 2022 28 401 409 10.1038/s41591-021-01677-z 35087233
Li, J. et al. Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial. Nat. Med. 28, 401–409 (2022).35087233
478. Jin L Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trial Emerg. Microbes Infect. 2023 12 2155251 10.1080/22221751.2022.2155251 36503413
Jin, L. et al. Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trial. Emerg. Microbes Infect. 12, 2155251 (2023).36503413
479. Tukhvatulin AI An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine “Sputnik Light” for prevention of coronavirus infection in healthy adults Lancet Reg. Health Eur. 2021 11 100241 10.1016/j.lanepe.2021.100241 34746910
Tukhvatulin, A. I. et al. An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine “Sputnik Light” for prevention of coronavirus infection in healthy adults. Lancet Reg. Health Eur. 11, 100241 (2021).34746910
480. Voysey M Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials Lancet 2021 397 881 891 10.1016/S0140-6736(21)00432-3 33617777
Voysey, M. et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet 397, 881–891 (2021).33617777
481. Jenkin D Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses Nat. Med. 2020 27 279 288 33335322
Jenkin, D. et al. Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nat. Med. 27, 279–288 (2020).33335322
482. Logunov DY Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia Lancet 2020 396 887 897 10.1016/S0140-6736(20)31866-3 32896291
Logunov, D. Y. et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet 396, 887–897 (2020).32896291
483. Weskamm LM Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine Cell Rep. Med. 2022 3 100685 10.1016/j.xcrm.2022.100685 35858586
Weskamm, L. M. et al. Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine. Cell Rep. Med. 3, 100685 (2022).35858586
484. Song F Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies J. Virol. 2013 87 11950 11954 10.1128/JVI.01672-13 23986586
Song, F. et al. Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies. J. Virol. 87, 11950–11954 (2013).23986586
485. Folegatti PM Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial Lancet Infect. Dis. 2020 20 816 826 10.1016/S1473-3099(20)30160-2 32325038
Folegatti, P. M. et al. Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. Lancet Infect. Dis. 20, 816–826 (2020).32325038
486. García-Arriaza J COVID-19 vaccine candidates based on modified vaccinia virus Ankara expressing the SARS-CoV-2 spike induce robust T- and B-cell immune responses and full efficacy in mice J. Virol. 2021 95 e02260 02220 10.1128/JVI.02260-20 33414159
García-Arriaza, J. et al. COVID-19 vaccine candidates based on modified vaccinia virus Ankara expressing the SARS-CoV-2 spike induce robust T- and B-cell immune responses and full efficacy in mice. J. Virol. 95, e02260–02220 (2021).33414159
487. Fang E Advances in COVID-19 mRNA vaccine development Signal Transduct. Target Ther. 2022 7 94 10.1038/s41392-022-00950-y 35322018
Fang, E. et al. Advances in COVID-19 mRNA vaccine development. Signal Transduct. Target Ther. 7, 94 (2022).35322018
488. Pardi N Hogan MJ Porter FW Weissman D mRNA vaccines - a new era in vaccinology Nat. Rev. Drug Discov. 2018 17 261 279 10.1038/nrd.2017.243 29326426
Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. mRNA vaccines - a new era in vaccinology. Nat. Rev. Drug Discov. 17, 261–279 (2018).29326426
489. Sahin, U. et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. medRxiv, https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1 (2020).
490. Polack FP Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine N. Engl. J. Med. 2020 383 2603 2615 10.1056/NEJMoa2034577 33301246
Polack, F. P. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 383, 2603–2615 (2020).33301246
491. Walsh EE Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates N. Engl. J. Med. 2020 383 2439 2450 10.1056/NEJMoa2027906 33053279
Walsh, E. E. et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N. Engl. J. Med. 383, 2439–2450 (2020).33053279
492. Widge AT Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination N. Engl. J. Med. 2021 384 80 82 10.1056/NEJMc2032195 33270381
Widge, A. T. et al. Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. N. Engl. J. Med. 384, 80–82 (2021).33270381
493. Zhang N-N A thermostable mRNA vaccine against COVID-19 Cell 2020 182 1271 1283.e1216 10.1016/j.cell.2020.07.024 32795413
Zhang, N.-N. et al. A thermostable mRNA vaccine against COVID-19. Cell 182, 1271–1283.e1216 (2020).32795413
494. Chen GL Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial Lancet Microbe 2022 3 e193 e202 10.1016/S2666-5247(21)00280-9 35098177
Chen, G. L. et al. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Microbe 3, e193–e202 (2022).35098177
495. Li L Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial JAMA 2020 324 460 470 10.1001/jama.2020.10044 32492084
Li, L. et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. JAMA 324, 460–470 (2020).32492084
496. Focosi D Anderson AO Tang JW Tuccori M Convalescent Plasma Therapy for COVID-19: State of the Art Clin. Microbiol. Rev. 2020 33 e00072 20 10.1128/CMR.00072-20 32792417
Focosi, D., Anderson, A. O., Tang, J. W. & Tuccori, M. Convalescent Plasma Therapy for COVID-19: State of the Art. Clin. Microbiol. Rev. 33, e00072–20 (2020).32792417
497. Chen Y Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses Nat. Rev. Immunol. 2023 23 189 199 10.1038/s41577-022-00784-3 36168054
Chen, Y. et al. Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses. Nat. Rev. Immunol. 23, 189–199 (2023).36168054
498. Taylor PC Neutralizing monoclonal antibodies for treatment of COVID-19 Nat. Rev. Immunol. 2021 21 382 393 10.1038/s41577-021-00542-x 33875867
Taylor, P. C. et al. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat. Rev. Immunol. 21, 382–393 (2021).33875867
499. Leisman DE Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes Lancet Respir. Med. 2020 8 1233 1244 10.1016/S2213-2600(20)30404-5 33075298
Leisman, D. E. et al. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir. Med. 8, 1233–1244 (2020).33075298
500. Giamarellos-Bourboulis EJ Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure Cell Host Microbe 2020 27 992 1000.e1003 10.1016/j.chom.2020.04.009 32320677
Giamarellos-Bourboulis, E. J. et al. Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure. Cell Host Microbe 27, 992–1000.e1003 (2020).32320677
501. Xu X Effective treatment of severe COVID-19 patients with tocilizumab Proc. Natl Acad. Sci. USA 2020 117 10970 10975 10.1073/pnas.2005615117 32350134
Xu, X. et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc. Natl Acad. Sci. USA 117, 10970–10975 (2020).32350134
502. Salama C Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia N. Engl. J. Med. 2021 384 20 30 10.1056/NEJMoa2030340 33332779
Salama, C. et al. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. N. Engl. J. Med. 384, 20–30 (2021).33332779
503. Rosas IO Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia N. Engl. J. Med. 2021 384 1503 1516 10.1056/NEJMoa2028700 33631066
Rosas, I. O. et al. Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. N. Engl. J. Med. 384, 1503–1516 (2021).33631066
504. Tatham KC Shankar-Hari M Arabi YM The REMDACTA trial: do interleukin receptor antagonists provide additional benefit in COVID-19? Intensive Care Med. 2021 47 1315 1318 10.1007/s00134-021-06540-w 34617150
Tatham, K. C., Shankar-Hari, M. & Arabi, Y. M. The REMDACTA trial: do interleukin receptor antagonists provide additional benefit in COVID-19? Intensive Care Med. 47, 1315–1318 (2021).34617150
505. Chen P SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 N. Engl. J. Med. 2021 384 229 237 10.1056/NEJMoa2029849 33113295
Chen, P. et al. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. N. Engl. J. Med. 384, 229–237 (2021).33113295
506. Hansen, J. et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science, 369, 1010–1014, (2020).
507. Baum, A. et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science, 369, 1014–1018 (2020).
508. Baum A REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters Science 2020 370 1110 1115 10.1126/science.abe2402 33037066
Baum, A. et al. REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. Science 370, 1110–1115 (2020).33037066
509. Weinreich DM REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 N. Engl. J. Med. 2021 384 238 251 10.1056/NEJMoa2035002 33332778
Weinreich, D. M. et al. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. N. Engl. J. Med. 384, 238–251 (2021).33332778
510. Weinreich DM REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19 N. Engl. J. Med. 2021 385 e81 10.1056/NEJMoa2108163 34587383
Weinreich, D. M. et al. REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19. N. Engl. J. Med. 385, e81 (2021).34587383
511. Shi R A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2 Nature 2020 584 120 124 10.1038/s41586-020-2381-y 32454512
Shi, R. et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature 584, 120–124 (2020).32454512
512. Dougan M Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19 N. Engl. J. Med. 2021 385 1382 1392 10.1056/NEJMoa2102685 34260849
Dougan, M. et al. Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19. N. Engl. J. Med. 385, 1382–1392 (2021).34260849
513. Gottlieb RL Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial JAMA 2021 325 632 644 10.1001/jama.2021.0202 33475701
Gottlieb, R. L. et al. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA 325, 632–644 (2021).33475701
514. Hoy SM Amubarvimab/Romlusevimab: First Approval Drugs 2022 82 1327 1331 10.1007/s40265-022-01759-3 35997943
Hoy, S. M. Amubarvimab/Romlusevimab: First Approval. Drugs 82, 1327–1331 (2022).35997943
515. Evering TH Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19 Ann. Intern. Med. 2023 176 658 666 10.7326/M22-3428 37068272
Evering, T. H. et al. Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19. Ann. Intern. Med. 176, 658–666 (2023).37068272
516. ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial. Lancet Infect. Dis. 22, 622–635, (2022).
517. Chi X A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2 Science 2020 369 650 655 10.1126/science.abc6952 32571838
Chi, X. et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science 369, 650–655 (2020).32571838
518. Suryadevara N Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein Cell 2021 184 2316 2331.e2315 10.1016/j.cell.2021.03.029 33773105
Suryadevara, N. et al. Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein. Cell 184, 2316–2331.e2315 (2021).33773105
519. Liu L Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike Nature 2020 584 450 456 10.1038/s41586-020-2571-7 32698192
Liu, L. et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584, 450–456 (2020).32698192
520. Lok SM An NTD supersite of attack Cell Host Microbe 2021 29 744 746 10.1016/j.chom.2021.04.010 33984277
Lok, S. M. An NTD supersite of attack. Cell Host Microbe 29, 744–746 (2021).33984277
521. Cerutti G Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite Cell Host Microbe 2021 29 819 833.e817 10.1016/j.chom.2021.03.005 33789084
Cerutti, G. et al. Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite. Cell Host Microbe 29, 819–833.e817 (2021).33789084
522. Pinto D Broad betacoronavirus neutralization by a stem helix-specific human antibody Science 2021 373 1109 1116 10.1126/science.abj3321 34344823
Pinto, D. et al. Broad betacoronavirus neutralization by a stem helix-specific human antibody. Science 373, 1109–1116 (2021).34344823
523. Dacon C Broadly neutralizing antibodies target the coronavirus fusion peptide Science 2022 377 728 735 10.1126/science.abq3773 35857439
Dacon, C. et al. Broadly neutralizing antibodies target the coronavirus fusion peptide. Science 377, 728–735 (2022).35857439
524. Sun X Neutralization mechanism of a human antibody with pan-coronavirus reactivity including SARS-CoV-2 Nat. Microbiol. 2022 7 1063 1074 10.1038/s41564-022-01155-3 35773398
Sun, X. et al. Neutralization mechanism of a human antibody with pan-coronavirus reactivity including SARS-CoV-2. Nat. Microbiol. 7, 1063–1074 (2022).35773398
525. Zhou P A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection Sci. Transl. Med. 2022 14 eabi9215 10.1126/scitranslmed.abi9215 35133175
Zhou, P. et al. A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection. Sci. Transl. Med. 14, eabi9215 (2022).35133175
526. Cao Y Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies Nature 2022 602 657 663 10.1038/s41586-021-04385-3 35016194
Cao, Y. et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature 602, 657–663 (2022).35016194
527. Zost SJ Potently neutralizing and protective human antibodies against SARS-CoV-2 Nature 2020 584 443 449 10.1038/s41586-020-2548-6 32668443
Zost, S. J. et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature 584, 443–449 (2020).32668443
528. Hanke L A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo Nat. Commun. 2022 13 155 10.1038/s41467-021-27610-z 35013189
Hanke, L. et al. A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo. Nat. Commun. 13, 155 (2022).35013189
529. Tian D An update review of emerging small-molecule therapeutic options for COVID-19 Biomed. Pharmacother. 2021 137 111313 10.1016/j.biopha.2021.111313 33556871
Tian, D. et al. An update review of emerging small-molecule therapeutic options for COVID-19. Biomed. Pharmacother. 137, 111313 (2021).33556871
530. Lei S Small molecules in the treatment of COVID-19 Signal Transduct. Target Ther. 2022 7 387 10.1038/s41392-022-01249-8 36464706
Lei, S. et al. Small molecules in the treatment of COVID-19. Signal Transduct. Target Ther. 7, 387 (2022).36464706
531. Kokic G Mechanism of SARS-CoV-2 polymerase stalling by remdesivir Nat. Commun. 2021 12 279 10.1038/s41467-020-20542-0 33436624
Kokic, G. et al. Mechanism of SARS-CoV-2 polymerase stalling by remdesivir. Nat. Commun. 12, 279 (2021).33436624
532. Yin W Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir Science 2020 368 1499 1504 10.1126/science.abc1560 32358203
Yin, W. et al. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science 368, 1499–1504 (2020).32358203
533. Rochwerg B Remdesivir for severe covid-19: a clinical practice guideline BMJ 2020 370 m2924 10.1136/bmj.m2924 32732352
Rochwerg, B. et al. Remdesivir for severe covid-19: a clinical practice guideline. BMJ 370, m2924 (2020).32732352
534. Gottlieb RL Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients N. Engl. J. Med. 2022 386 305 315 10.1056/NEJMoa2116846 34937145
Gottlieb, R. L. et al. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. N. Engl. J. Med. 386, 305–315 (2022).34937145
535. Amstutz A Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials Lancet Respir. Med. 2023 11 453 464 10.1016/S2213-2600(22)00528-8 36828006
Amstutz, A. et al. Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials. Lancet Respir. Med. 11, 453–464 (2023).36828006
536. Kabinger F Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis Nat. Struct. Mol. Biol. 2021 28 740 746 10.1038/s41594-021-00651-0 34381216
Kabinger, F. et al. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat. Struct. Mol. Biol. 28, 740–746 (2021).34381216
537. Fischer WA 2nd A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus Sci. Transl. Med. 2022 14 eabl7430 10.1126/scitranslmed.abl7430 34941423
Fischer, W. A. 2nd et al. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. Sci. Transl. Med. 14, eabl7430 (2022).34941423
538. Jayk Bernal A Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients N. Engl. J. Med. 2022 386 509 520 10.1056/NEJMoa2116044 34914868
Jayk Bernal, A. et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N. Engl. J. Med. 386, 509–520 (2022).34914868
539. Cao Z VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19 N. Engl. J. Med. 2023 388 406 417 10.1056/NEJMoa2208822 36577095
Cao, Z. et al. VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19. N. Engl. J. Med. 388, 406–417 (2023).36577095
540. Joshi S Role of favipiravir in the treatment of COVID-19 Int. J. Infect. Dis. 2021 102 501 508 10.1016/j.ijid.2020.10.069 33130203
Joshi, S. et al. Role of favipiravir in the treatment of COVID-19. Int. J. Infect. Dis. 102, 501–508 (2021).33130203
541. Qian HJ Safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog against SARS-CoV-2, in Chinese healthy subjects Acta Pharm. Sin. 2022 43 3130 3138 10.1038/s41401-022-00895-6
Qian, H. J. et al. Safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog against SARS-CoV-2, in Chinese healthy subjects. Acta Pharm. Sin. 43, 3130–3138 (2022).
542. Hammond J Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 N. Engl. J. Med. 2022 386 1397 1408 10.1056/NEJMoa2118542 35172054
Hammond, J. et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N. Engl. J. Med. 386, 1397–1408 (2022).35172054
543. Patel NM Inhibition of the JAK/STAT Pathway With Baricitinib Reduces the Multiple Organ Dysfunction Caused by Hemorrhagic Shock in Rats Ann. Surg. 2023 278 e137 e146 10.1097/SLA.0000000000005571 35837955
Patel, N. M. et al. Inhibition of the JAK/STAT Pathway With Baricitinib Reduces the Multiple Organ Dysfunction Caused by Hemorrhagic Shock in Rats. Ann. Surg. 278, e137–e146 (2023).35837955
544. Bronte V Baricitinib restrains the immune dysregulation in patients with severe COVID-19 J. Clin. Invest. 2020 130 6409 6416 10.1172/JCI141772 32809969
Bronte, V. et al. Baricitinib restrains the immune dysregulation in patients with severe COVID-19. J. Clin. Invest. 130, 6409–6416 (2020).32809969
545. Marconi VC Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial Lancet Respir. Med. 2021 9 1407 1418 10.1016/S2213-2600(21)00331-3 34480861
Marconi, V. C. et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir. Med. 9, 1407–1418 (2021).34480861
546. Lamb YN Remdesivir: First Approval Drugs 2020 80 1355 1363 10.1007/s40265-020-01378-w 32870481
Lamb, Y. N. Remdesivir: First Approval. Drugs 80, 1355–1363 (2020).32870481
547. Kalil AC Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 N. Engl. J. Med. 2021 384 795 807 10.1056/NEJMoa2031994 33306283
Kalil, A. C. et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N. Engl. J. Med. 384, 795–807 (2021).33306283
548. Cadegiani FA Final Results of a Randomized, Placebo-Controlled, Two-Arm, Parallel Clinical Trial of Proxalutamide for Hospitalized COVID-19 Patients: A Multiregional, Joint Analysis of the Proxa-Rescue AndroCoV Trial Cureus 2021 13 e20691 34976549
Cadegiani, F. A. et al. Final Results of a Randomized, Placebo-Controlled, Two-Arm, Parallel Clinical Trial of Proxalutamide for Hospitalized COVID-19 Patients: A Multiregional, Joint Analysis of the Proxa-Rescue AndroCoV Trial. Cureus 13, e20691 (2021).34976549
549. John M Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial Front. Med. 2022 9 964099 10.3389/fmed.2022.964099
John, M. et al. Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial. Front. Med. 9, 964099 (2022).
550. Mendoza EJ Warner B Safronetz D Ranadheera C Crimean-Congo haemorrhagic fever virus: Past, present and future insights for animal modelling and medical countermeasures Zoonoses Public Health 2018 65 465 480 10.1111/zph.12469 29676526
Mendoza, E. J., Warner, B., Safronetz, D. & Ranadheera, C. Crimean-Congo haemorrhagic fever virus: Past, present and future insights for animal modelling and medical countermeasures. Zoonoses Public Health 65, 465–480 (2018).29676526
551. Whitehouse CA Crimean-Congo hemorrhagic fever Antivir. Res. 2004 64 145 160 10.1016/j.antiviral.2004.08.001 15550268
Whitehouse, C. A. Crimean-Congo hemorrhagic fever. Antivir. Res. 64, 145–160 (2004).15550268
552. Durie IA Structural characterization of protective non-neutralizing antibodies targeting Crimean-Congo hemorrhagic fever virus Nat. Commun. 2022 13 7298 10.1038/s41467-022-34923-0 36435827
Durie, I. A. et al. Structural characterization of protective non-neutralizing antibodies targeting Crimean-Congo hemorrhagic fever virus. Nat. Commun. 13, 7298 (2022).36435827
553. Zivcec M Identification of broadly neutralizing monoclonal antibodies against Crimean-Congo hemorrhagic fever virus Antivir. Res. 2017 146 112 120 10.1016/j.antiviral.2017.08.014 28842265
Zivcec, M. et al. Identification of broadly neutralizing monoclonal antibodies against Crimean-Congo hemorrhagic fever virus. Antivir. Res. 146, 112–120 (2017).28842265
554. Casals J Antigenic similarity between the virus causing Crimean hemorrhagic fever and Congo virus Proc. Soc. Exp. Biol. Med. 1969 131 233 236 10.3181/00379727-131-33847 5770109
Casals, J. Antigenic similarity between the virus causing Crimean hemorrhagic fever and Congo virus. Proc. Soc. Exp. Biol. Med. 131, 233–236 (1969).5770109
555. Serretiello E The emerging tick-borne Crimean-Congo haemorrhagic fever virus: A narrative review Travel Med. Infect. Dis. 2020 37 101871 10.1016/j.tmaid.2020.101871 32891725
Serretiello, E. et al. The emerging tick-borne Crimean-Congo haemorrhagic fever virus: A narrative review. Travel Med. Infect. Dis. 37, 101871 (2020).32891725
556. Vorou R Pierroutsakos IN Maltezou HC Crimean-Congo hemorrhagic fever Curr. Opin. Infect. Dis. 2007 20 495 500 10.1097/QCO.0b013e3282a56a0a 17762783
Vorou, R., Pierroutsakos, I. N. & Maltezou, H. C. Crimean-Congo hemorrhagic fever. Curr. Opin. Infect. Dis. 20, 495–500 (2007).17762783
557. Shayan S Bokaean M Shahrivar MR Chinikar S Crimean-Congo Hemorrhagic Fever Lab. Med. 2015 46 180 189 10.1309/LMN1P2FRZ7BKZSCO 26199256
Shayan, S., Bokaean, M., Shahrivar, M. R. & Chinikar, S. Crimean-Congo Hemorrhagic Fever. Lab. Med. 46, 180–189 (2015).26199256
558. Dokuzoguz B Severity scoring index for Crimean-Congo hemorrhagic fever and the impact of ribavirin and corticosteroids on fatality Clin. Infect. Dis. 2013 57 1270 1274 10.1093/cid/cit527 23946218
Dokuzoguz, B. et al. Severity scoring index for Crimean-Congo hemorrhagic fever and the impact of ribavirin and corticosteroids on fatality. Clin. Infect. Dis. 57, 1270–1274 (2013).23946218
559. Cevik MA Clinical and laboratory features of Crimean-Congo hemorrhagic fever: predictors of fatality Int J. Infect. Dis. 2008 12 374 379 10.1016/j.ijid.2007.09.010 18063402
Cevik, M. A. et al. Clinical and laboratory features of Crimean-Congo hemorrhagic fever: predictors of fatality. Int J. Infect. Dis. 12, 374–379 (2008).18063402
560. Xu ZS LDLR is an entry receptor for Crimean-Congo hemorrhagic fever virus Cell Res. 2024 34 140 150 10.1038/s41422-023-00917-w 38182887
Xu, Z. S. et al. LDLR is an entry receptor for Crimean-Congo hemorrhagic fever virus. Cell Res. 34, 140–150 (2024).38182887
561. Freiberg AN Three-dimensional organization of Rift Valley fever virus revealed by cryoelectron tomography J. Virol. 2008 82 10341 10348 10.1128/JVI.01191-08 18715915
Freiberg, A. N. et al. Three-dimensional organization of Rift Valley fever virus revealed by cryoelectron tomography. J. Virol. 82, 10341–10348 (2008).18715915
562. Nair N Osterhaus A Rimmelzwaan GF Prajeeth CK Rift Valley Fever Virus-Infection, Pathogenesis and Host Immune Responses Pathogens 2023 12 1174 10.3390/pathogens12091174 37764982
Nair, N., Osterhaus, A., Rimmelzwaan, G. F. & Prajeeth, C. K. Rift Valley Fever Virus-Infection, Pathogenesis and Host Immune Responses. Pathogens 12, 1174 (2023).37764982
563. Halldorsson S Shielding and activation of a viral membrane fusion protein Nat. Commun. 2018 9 349 10.1038/s41467-017-02789-2 29367607
Halldorsson, S. et al. Shielding and activation of a viral membrane fusion protein. Nat. Commun. 9, 349 (2018).29367607
564. Himeidan YE Recent outbreaks of rift valley Fever in East Africa and the middle East Front. Public Health 2014 2 169 10.3389/fpubh.2014.00169 25340047
Himeidan, Y. E. et al. Recent outbreaks of rift valley Fever in East Africa and the middle East. Front. Public Health 2, 169 (2014).25340047
565. Gerken KN Paving the way for human vaccination against Rift Valley fever virus: A systematic literature review of RVFV epidemiology from 1999 to 2021 PLoS Negl. Trop. Dis. 2022 16 e0009852 10.1371/journal.pntd.0009852 35073355
Gerken, K. N. et al. Paving the way for human vaccination against Rift Valley fever virus: A systematic literature review of RVFV epidemiology from 1999 to 2021. PLoS Negl. Trop. Dis. 16, e0009852 (2022).35073355
566. Seufi AM Galal FH Role of Culex and Anopheles mosquito species as potential vectors of rift valley fever virus in Sudan outbreak, 2007 BMC Infect. Dis. 2010 10 65 10.1186/1471-2334-10-65 20222979
Seufi, A. M. & Galal, F. H. Role of Culex and Anopheles mosquito species as potential vectors of rift valley fever virus in Sudan outbreak, 2007. BMC Infect. Dis. 10, 65 (2010).20222979
567. Odendaal L Davis AS Venter EH Insights into the Pathogenesis of Viral Haemorrhagic Fever Based on Virus Tropism and Tissue Lesions of Natural Rift Valley Fever Viruses 2021 13 709 10.3390/v13040709 33923863
Odendaal, L., Davis, A. S. & Venter, E. H. Insights into the Pathogenesis of Viral Haemorrhagic Fever Based on Virus Tropism and Tissue Lesions of Natural Rift Valley Fever. Viruses 13, 709 (2021).33923863
568. Odendaal L Davis AS Fosgate GT Clift SJ Lesions and Cellular Tropism of Natural Rift Valley Fever Virus Infection in Young Lambs Vet. Pathol. 2020 57 66 81 10.1177/0300985819882633 31842723
Odendaal, L., Davis, A. S., Fosgate, G. T. & Clift, S. J. Lesions and Cellular Tropism of Natural Rift Valley Fever Virus Infection in Young Lambs. Vet. Pathol. 57, 66–81 (2020).31842723
569. Sheehan KC Blocking monoclonal antibodies specific for mouse IFN-alpha/beta receptor subunit 1 (IFNAR-1) from mice immunized by in vivo hydrodynamic transfection J. Interferon Cytokine Res. 2006 26 804 819 10.1089/jir.2006.26.804 17115899
Sheehan, K. C. et al. Blocking monoclonal antibodies specific for mouse IFN-alpha/beta receptor subunit 1 (IFNAR-1) from mice immunized by in vivo hydrodynamic transfection. J. Interferon Cytokine Res. 26, 804–819 (2006).17115899
570. Garrison AR A DNA vaccine for Crimean-Congo hemorrhagic fever protects against disease and death in two lethal mouse models PLoS Negl. Trop. Dis. 2017 11 e0005908 10.1371/journal.pntd.0005908 28922426
Garrison, A. R. et al. A DNA vaccine for Crimean-Congo hemorrhagic fever protects against disease and death in two lethal mouse models. PLoS Negl. Trop. Dis. 11, e0005908 (2017).28922426
571. Lindquist ME Exploring Crimean-Congo Hemorrhagic Fever Virus-Induced Hepatic Injury Using Antibody-Mediated Type I Interferon Blockade in Mice J. Virol. 2018 92 e01083 01018 10.1128/JVI.01083-18 30111561
Lindquist, M. E. et al. Exploring Crimean-Congo Hemorrhagic Fever Virus-Induced Hepatic Injury Using Antibody-Mediated Type I Interferon Blockade in Mice. J. Virol. 92, e01083–01018 (2018).30111561
572. Spengler JR Crimean-Congo Hemorrhagic Fever in Humanized Mice Reveals Glial Cells as Primary Targets of Neurological Infection J. Infect. Dis. 2017 216 1386 1397 10.1093/infdis/jix215 28482001
Spengler, J. R. et al. Crimean-Congo Hemorrhagic Fever in Humanized Mice Reveals Glial Cells as Primary Targets of Neurological Infection. J. Infect. Dis. 216, 1386–1397 (2017).28482001
573. Hawman DW Immunocompetent mouse model for Crimean-Congo hemorrhagic fever virus Elife 2021 8 e63906 10.7554/eLife.63906
Hawman, D. W. et al. Immunocompetent mouse model for Crimean-Congo hemorrhagic fever virus. Elife 8, e63906 (2021).
574. Fagbami AH Tomori O Fabiyi A Isoun TT Experimantal Congo virus (Ib -AN 7620) infection in primates Virologie 1975 26 33 37, 814708
Fagbami, A. H., Tomori, O., Fabiyi, A. & Isoun, T. T. Experimantal Congo virus (Ib -AN 7620) infection in primates. Virologie 26, 33–37, (1975).814708
575. Smith DR Persistent Crimean-Congo hemorrhagic fever virus infection in the testes and within granulomas of non-human primates with latent tuberculosis PLoS Pathog. 2019 15 e1008050 10.1371/journal.ppat.1008050 31557262
Smith, D. R. et al. Persistent Crimean-Congo hemorrhagic fever virus infection in the testes and within granulomas of non-human primates with latent tuberculosis. PLoS Pathog. 15, e1008050 (2019).31557262
576. Arnold CE Host response transcriptomic analysis of Crimean-Congo hemorrhagic fever pathogenesis in the cynomolgus macaque model Sci. Rep. 2021 11 19807 10.1038/s41598-021-99130-1 34615921
Arnold, C. E. et al. Host response transcriptomic analysis of Crimean-Congo hemorrhagic fever pathogenesis in the cynomolgus macaque model. Sci. Rep. 11, 19807 (2021).34615921
577. Smith DR The pathogenesis of Rift Valley fever virus in the mouse model Virology 2010 407 256 267 10.1016/j.virol.2010.08.016 20850165
Smith, D. R. et al. The pathogenesis of Rift Valley fever virus in the mouse model. Virology 407, 256–267 (2010).20850165
578. Mandell RB A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge Virology 2010 397 187 198 10.1016/j.virol.2009.11.001 19932911
Mandell, R. B. et al. A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge. Virology 397, 187–198 (2010).19932911
579. Näslund J Kinetics of Rift Valley Fever Virus in experimentally infected mice using quantitative real-time RT-PCR J. Virol. Methods 2008 151 277 282 10.1016/j.jviromet.2008.04.007 18514921
Näslund, J. et al. Kinetics of Rift Valley Fever Virus in experimentally infected mice using quantitative real-time RT-PCR. J. Virol. Methods 151, 277–282 (2008).18514921
580. van Velden DJ Rift Valley fever affecting humans in South Africa: a clinicopathological study S Afr. Med. J. 1977 51 867 871 561445
van Velden, D. J. et al. Rift Valley fever affecting humans in South Africa: a clinicopathological study. S Afr. Med. J. 51, 867–871 (1977).561445
581. Morrill JC Rapid accumulation of virulent rift valley Fever virus in mice from an attenuated virus carrying a single nucleotide substitution in the m RNA PLoS One 2010 5 e9986 10.1371/journal.pone.0009986 20376320
Morrill, J. C. et al. Rapid accumulation of virulent rift valley Fever virus in mice from an attenuated virus carrying a single nucleotide substitution in the m RNA. PLoS One 5, e9986 (2010).20376320
582. Anderson AO Snyder LF Pitt ML Wood OL Mucosal priming alters pathogenesis of Rift Valley fever Adv. Exp. Med. Biol. 1988 237 717 723 10.1007/978-1-4684-5535-9_107 3254072
Anderson, A. O., Snyder, L. F., Pitt, M. L. & Wood, O. L. Mucosal priming alters pathogenesis of Rift Valley fever. Adv. Exp. Med. Biol. 237, 717–723 (1988).3254072
583. Anderson GW Jr. Slone TW Jr. Peters CJ The gerbil, Meriones unguiculatus, a model for Rift Valley fever viral encephalitis Arch. Virol. 1988 102 187 196 10.1007/BF01310824 3060046
Anderson, G. W. Jr., Slone, T. W. Jr. & Peters, C. J. The gerbil, Meriones unguiculatus, a model for Rift Valley fever viral encephalitis. Arch. Virol. 102, 187–196 (1988).3060046
584. Anderson GW Jr. Peters CJ Viral determinants of virulence for Rift Valley fever (RVF) in rats Micro. Pathog. 1988 5 241 250 10.1016/0882-4010(88)90096-4
Anderson, G. W. Jr. & Peters, C. J. Viral determinants of virulence for Rift Valley fever (RVF) in rats. Micro. Pathog. 5, 241–250 (1988).
585. Anderson GW Jr. Efficacy of a Rift Valley fever virus vaccine against an aerosol infection in rats Vaccine 1991 9 710 714 10.1016/0264-410X(91)90285-E 1759489
Anderson, G. W. Jr. et al. Efficacy of a Rift Valley fever virus vaccine against an aerosol infection in rats. Vaccine 9, 710–714 (1991).1759489
586. Peters CJ Slone TW Inbred rat strains mimic the disparate human response to Rift Valley fever virus infection J. Med. Virol. 1982 10 45 54 10.1002/jmv.1890100107 7130966
Peters, C. J. & Slone, T. W. Inbred rat strains mimic the disparate human response to Rift Valley fever virus infection. J. Med. Virol. 10, 45–54 (1982).7130966
587. Bird BH Rift valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals J. Virol. 2008 82 2681 2691 10.1128/JVI.02501-07 18199647
Bird, B. H. et al. Rift valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals. J. Virol. 82, 2681–2691 (2008).18199647
588. Bales JM Choice of inbred rat strain impacts lethality and disease course after respiratory infection with Rift Valley Fever Virus Front. Cell Infect. Microbiol 2012 2 105 10.3389/fcimb.2012.00105 22919694
Bales, J. M. et al. Choice of inbred rat strain impacts lethality and disease course after respiratory infection with Rift Valley Fever Virus. Front. Cell Infect. Microbiol 2, 105 (2012).22919694
589. Ikegami T Makino S The pathogenesis of Rift Valley fever Viruses 2011 3 493 519 10.3390/v3050493 21666766
Ikegami, T. & Makino, S. The pathogenesis of Rift Valley fever. Viruses 3, 493–519 (2011).21666766
590. Niklasson BS Meadors GF Peters CJ Active and passive immunization against Rift Valley fever virus infection in Syrian hamsters Acta Pathol. Microbiol. Immunol. Scand. C 1984 92 197 200 6507105
Niklasson, B. S., Meadors, G. F. & Peters, C. J. Active and passive immunization against Rift Valley fever virus infection in Syrian hamsters. Acta Pathol. Microbiol. Immunol. Scand. C 92, 197–200 (1984).6507105
591. Westover JB Galidesivir limits Rift Valley fever virus infection and disease in Syrian golden hamsters Antivir. Res 2018 156 38 45 10.1016/j.antiviral.2018.05.013 29864447
Westover, J. B. et al. Galidesivir limits Rift Valley fever virus infection and disease in Syrian golden hamsters. Antivir. Res 156, 38–45 (2018).29864447
592. Sall AA Genetic reassortment of Rift Valley fever virus in nature J. Virol. 1999 73 8196 8200 10.1128/JVI.73.10.8196-8200.1999 10482570
Sall, A. A. et al. Genetic reassortment of Rift Valley fever virus in nature. J. Virol. 73, 8196–8200 (1999).10482570
593. Ross TM Animal models of Rift Valley fever virus infection Virus Res. 2012 163 417 423 10.1016/j.virusres.2011.10.023 22086058
Ross, T. M. et al. Animal models of Rift Valley fever virus infection. Virus Res. 163, 417–423 (2012).22086058
594. Pavel STI Yetiskin H Kalkan A Ozdarendeli A Evaluation of the cell culture based and the mouse brain derived inactivated vaccines against Crimean-Congo hemorrhagic fever virus in transiently immune-suppressed (IS) mouse model PLoS Negl. Trop. Dis. 2020 14 e0008834 10.1371/journal.pntd.0008834 33226988
Pavel, S. T. I., Yetiskin, H., Kalkan, A. & Ozdarendeli, A. Evaluation of the cell culture based and the mouse brain derived inactivated vaccines against Crimean-Congo hemorrhagic fever virus in transiently immune-suppressed (IS) mouse model. PLoS Negl. Trop. Dis. 14, e0008834 (2020).33226988
595. Kortekaas J Crimean-Congo Hemorrhagic Fever Virus Subunit Vaccines Induce High Levels of Neutralizing Antibodies But No Protection in STAT1 Knockout Mice Vector Borne Zoonotic Dis. 2015 15 759 764 10.1089/vbz.2015.1855 26684523
Kortekaas, J. et al. Crimean-Congo Hemorrhagic Fever Virus Subunit Vaccines Induce High Levels of Neutralizing Antibodies But No Protection in STAT1 Knockout Mice. Vector Borne Zoonotic Dis. 15, 759–764 (2015).26684523
596. Scholte FEM Single-dose replicon particle vaccine provides complete protection against Crimean-Congo hemorrhagic fever virus in mice Emerg. Microbes Infect. 2019 8 575 578 10.1080/22221751.2019.1601030 30947619
Scholte, F. E. M. et al. Single-dose replicon particle vaccine provides complete protection against Crimean-Congo hemorrhagic fever virus in mice. Emerg. Microbes Infect. 8, 575–578 (2019).30947619
597. Hinkula J Immunization with DNA Plasmids Coding for Crimean-Congo Hemorrhagic Fever Virus Capsid and Envelope Proteins and/or Virus-Like Particles Induces Protection and Survival in Challenged Mice J. Virol. 2017 91 e02076 16 10.1128/JVI.02076-16 28250124
Hinkula, J. et al. Immunization with DNA Plasmids Coding for Crimean-Congo Hemorrhagic Fever Virus Capsid and Envelope Proteins and/or Virus-Like Particles Induces Protection and Survival in Challenged Mice. J. Virol. 91, e02076–16 (2017).28250124
598. Buttigieg KR A novel vaccine against Crimean-Congo Haemorrhagic Fever protects 100% of animals against lethal challenge in a mouse model PloS One 2014 9 e91516 10.1371/journal.pone.0091516 24621656
Buttigieg, K. R. et al. A novel vaccine against Crimean-Congo Haemorrhagic Fever protects 100% of animals against lethal challenge in a mouse model. PloS One 9, e91516 (2014).24621656
599. Zivcec M Nucleocapsid protein-based vaccine provides protection in mice against lethal Crimean-Congo hemorrhagic fever virus challenge PLoS Neglected Tropical Dis. 2018 12 e0006628 10.1371/journal.pntd.0006628
Zivcec, M. et al. Nucleocapsid protein-based vaccine provides protection in mice against lethal Crimean-Congo hemorrhagic fever virus challenge. PLoS Neglected Tropical Dis. 12, e0006628 (2018).
600. Rodriguez SE Vesicular Stomatitis Virus-Based Vaccine Protects Mice against Crimean-Congo Hemorrhagic Fever Sci. Rep. 2019 9 7755 10.1038/s41598-019-44210-6 31123310
Rodriguez, S. E. et al. Vesicular Stomatitis Virus-Based Vaccine Protects Mice against Crimean-Congo Hemorrhagic Fever. Sci. Rep. 9, 7755 (2019).31123310
601. Faburay B Current Status of Rift Valley Fever Vaccine Development Vaccines 2017 5 29 10.3390/vaccines5030029 28925970
Faburay, B. et al. Current Status of Rift Valley Fever Vaccine Development. Vaccines 5, 29 (2017).28925970
602. Randall R The development of a formalin-killed Rift Valley fever virus vaccine for use in man J. Immunol. 1962 89 660 671 10.4049/jimmunol.89.5.660 13990748
Randall, R. et al. The development of a formalin-killed Rift Valley fever virus vaccine for use in man. J. Immunol. 89, 660–671 (1962).13990748
603. Sindato C Safety, Immunogenicity and Antibody Persistence of Rift Valley Fever Virus Clone 13 Vaccine in Sheep, Goats and Cattle in Tanzania Front. Vet. Sci. 2021 8 779858 10.3389/fvets.2021.779858 34977212
Sindato, C. et al. Safety, Immunogenicity and Antibody Persistence of Rift Valley Fever Virus Clone 13 Vaccine in Sheep, Goats and Cattle in Tanzania. Front. Vet. Sci. 8, 779858 (2021).34977212
604. Faburay B A glycoprotein subunit vaccine elicits a strong Rift Valley fever virus neutralizing antibody response in sheep Vector Borne Zoonotic Dis. 2014 14 746 756 10.1089/vbz.2014.1650 25325319
Faburay, B. et al. A glycoprotein subunit vaccine elicits a strong Rift Valley fever virus neutralizing antibody response in sheep. Vector Borne Zoonotic Dis. 14, 746–756 (2014).25325319
605. Faburay B A Recombinant Rift Valley Fever Virus Glycoprotein Subunit Vaccine Confers Full Protection against Rift Valley Fever Challenge in Sheep Sci. Rep. 2016 6 27719 10.1038/srep27719 27296136
Faburay, B. et al. A Recombinant Rift Valley Fever Virus Glycoprotein Subunit Vaccine Confers Full Protection against Rift Valley Fever Challenge in Sheep. Sci. Rep. 6, 27719 (2016).27296136
606. Appelberg S Nucleoside-Modified mRNA Vaccines Protect IFNAR(−/−) Mice against Crimean-Congo Hemorrhagic Fever Virus Infection J. Virol. 2022 96 e0156821 10.1128/jvi.01568-21 34817199
Appelberg, S. et al. Nucleoside-Modified mRNA Vaccines Protect IFNAR(−/−) Mice against Crimean-Congo Hemorrhagic Fever Virus Infection. J. Virol. 96, e0156821 (2022).34817199
607. de Boer SM Rift Valley fever virus subunit vaccines confer complete protection against a lethal virus challenge Vaccine 2010 28 2330 2339 10.1016/j.vaccine.2009.12.062 20056185
de Boer, S. M. et al. Rift Valley fever virus subunit vaccines confer complete protection against a lethal virus challenge. Vaccine 28, 2330–2339 (2010).20056185
608. Suschak JJ A CCHFV DNA vaccine protects against heterologous challenge and establishes GP38 as immunorelevant in mice NPJ Vaccines 2021 6 31 10.1038/s41541-021-00293-9 33654101
Suschak, J. J. et al. A CCHFV DNA vaccine protects against heterologous challenge and establishes GP38 as immunorelevant in mice. NPJ Vaccines 6, 31 (2021).33654101
609. Hawman DW A DNA-based vaccine protects against Crimean-Congo haemorrhagic fever virus disease in a Cynomolgus macaque model Nat. Microbiol. 2021 6 187 195 10.1038/s41564-020-00815-6 33257849
Hawman, D. W. et al. A DNA-based vaccine protects against Crimean-Congo haemorrhagic fever virus disease in a Cynomolgus macaque model. Nat. Microbiol. 6, 187–195 (2021).33257849
610. Tipih T Heise M Burt FJ Immunogenicity of a DNA-Based Sindbis Replicon Expressing Crimean-Congo Hemorrhagic Fever Virus Nucleoprotein Vaccines 2021 9 1491 10.3390/vaccines9121491 34960237
Tipih, T., Heise, M. & Burt, F. J. Immunogenicity of a DNA-Based Sindbis Replicon Expressing Crimean-Congo Hemorrhagic Fever Virus Nucleoprotein. Vaccines 9, 1491 (2021).34960237
611. Holman DH A complex adenovirus-vectored vaccine against Rift Valley fever virus protects mice against lethal infection in the presence of preexisting vector immunity Clin. Vaccin. Immunol. 2009 16 1624 1632 10.1128/CVI.00182-09
Holman, D. H. et al. A complex adenovirus-vectored vaccine against Rift Valley fever virus protects mice against lethal infection in the presence of preexisting vector immunity. Clin. Vaccin. Immunol. 16, 1624–1632 (2009).
612. Spik K Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus Vaccine 2006 24 4657 4666 10.1016/j.vaccine.2005.08.034 16174542
Spik, K. et al. Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus. Vaccine 24, 4657–4666 (2006).16174542
613. Dowall SD A Crimean-Congo hemorrhagic fever (CCHF) viral vaccine expressing nucleoprotein is immunogenic but fails to confer protection against lethal disease Hum. Vaccin. Immunother. 2016 12 519 527 10.1080/21645515.2015.1078045 26309231
Dowall, S. D. et al. A Crimean-Congo hemorrhagic fever (CCHF) viral vaccine expressing nucleoprotein is immunogenic but fails to confer protection against lethal disease. Hum. Vaccin. Immunother. 12, 519–527 (2016).26309231
614. Leventhal SS Replicating RNA vaccination elicits an unexpected immune response that efficiently protects mice against lethal Crimean-Congo hemorrhagic fever virus challenge EBioMedicine 2022 82 104188 10.1016/j.ebiom.2022.104188 35907368
Leventhal, S. S. et al. Replicating RNA vaccination elicits an unexpected immune response that efficiently protects mice against lethal Crimean-Congo hemorrhagic fever virus challenge. EBioMedicine 82, 104188 (2022).35907368
615. Elaldi N Efficacy of oral ribavirin treatment in Crimean-Congo haemorrhagic fever: a quasi-experimental study from Turkey J. Infect. 2009 58 238 244 10.1016/j.jinf.2009.01.014 19246100
Elaldi, N. et al. Efficacy of oral ribavirin treatment in Crimean-Congo haemorrhagic fever: a quasi-experimental study from Turkey. J. Infect. 58, 238–244 (2009).19246100
616. Oestereich L Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever PLoS Neglected Tropical Dis. 2014 8 e2804 10.1371/journal.pntd.0002804
Oestereich, L. et al. Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever. PLoS Neglected Tropical Dis. 8, e2804 (2014).
617. Hawman DW Favipiravir (T-705) but not ribavirin is effective against two distinct strains of Crimean-Congo hemorrhagic fever virus in mice Antivir. Res. 2018 157 18 26 10.1016/j.antiviral.2018.06.013 29936152
Hawman, D. W. et al. Favipiravir (T-705) but not ribavirin is effective against two distinct strains of Crimean-Congo hemorrhagic fever virus in mice. Antivir. Res. 157, 18–26 (2018).29936152
618. Wang Q In vitro and in vivo efficacy of a novel nucleoside analog H44 against Crimean-Congo hemorrhagic fever virus Antivir. Res. 2022 199 105273 10.1016/j.antiviral.2022.105273 35257725
Wang, Q. et al. In vitro and in vivo efficacy of a novel nucleoside analog H44 against Crimean-Congo hemorrhagic fever virus. Antivir. Res. 199, 105273 (2022).35257725
619. Hawman DW Efficacy of favipiravir (T-705) against Crimean-Congo hemorrhagic fever virus infection in cynomolgus macaques Antivir. Res. 2020 181 104858 10.1016/j.antiviral.2020.104858 32645335
Hawman, D. W. et al. Efficacy of favipiravir (T-705) against Crimean-Congo hemorrhagic fever virus infection in cynomolgus macaques. Antivir. Res. 181, 104858 (2020).32645335
620. Welch SR Identification of 2’-deoxy-2’-fluorocytidine as a potent inhibitor of Crimean-Congo hemorrhagic fever virus replication using a recombinant fluorescent reporter virus Antivir. Res. 2017 147 91 99 10.1016/j.antiviral.2017.10.008 29024765
Welch, S. R. et al. Identification of 2’-deoxy-2’-fluorocytidine as a potent inhibitor of Crimean-Congo hemorrhagic fever virus replication using a recombinant fluorescent reporter virus. Antivir. Res. 147, 91–99 (2017).29024765
621. Suleiman MN Congo/Crimean haemorrhagic fever in Dubai. An outbreak at the Rashid Hospital Lancet 1980 2 939 941 10.1016/S0140-6736(80)92103-0 6107588
Suleiman, M. N. et al. Congo/Crimean haemorrhagic fever in Dubai. An outbreak at the Rashid Hospital. Lancet 2, 939–941 (1980).6107588
622. Vassilenko SM Specific intravenous immunoglobulin for Crimean-Congo haemorrhagic fever Lancet 1990 335 791 792 10.1016/0140-6736(90)90906-L 1969533
Vassilenko, S. M. et al. Specific intravenous immunoglobulin for Crimean-Congo haemorrhagic fever. Lancet 335, 791–792 (1990).1969533
623. Bertolotti-Ciarlet A Cellular localization and antigenic characterization of crimean-congo hemorrhagic fever virus glycoproteins J. Virol. 2005 79 6152 6161 10.1128/JVI.79.10.6152-6161.2005 15858000
Bertolotti-Ciarlet, A. et al. Cellular localization and antigenic characterization of crimean-congo hemorrhagic fever virus glycoproteins. J. Virol. 79, 6152–6161 (2005).15858000
624. Golden JW GP38-targeting monoclonal antibodies protect adult mice against lethal Crimean-Congo hemorrhagic fever virus infection Sci. Adv. 2019 5 eaaw9535 10.1126/sciadv.aaw9535 31309159
Golden, J. W. et al. GP38-targeting monoclonal antibodies protect adult mice against lethal Crimean-Congo hemorrhagic fever virus infection. Sci. Adv. 5, eaaw9535 (2019).31309159
625. Mishra AK Structure and Characterization of Crimean-Congo Hemorrhagic Fever Virus GP38 J. Virol. 2020 94 e02005 e02019 10.1128/JVI.02005-19 31996434
Mishra, A. K. et al. Structure and Characterization of Crimean-Congo Hemorrhagic Fever Virus GP38. J. Virol. 94, e02005–e02019 (2020).31996434
626. Fels JM Protective neutralizing antibodies from human survivors of Crimean-Congo hemorrhagic fever Cell 2021 184 3486 3501.e3421 10.1016/j.cell.2021.05.001 34077751
Fels, J. M. et al. Protective neutralizing antibodies from human survivors of Crimean-Congo hemorrhagic fever. Cell 184, 3486–3501.e3421 (2021).34077751
627. Mishra AK Structural basis of synergistic neutralization of Crimean-Congo hemorrhagic fever virus by human antibodies Science 2022 375 104 109 10.1126/science.abl6502 34793197
Mishra, A. K. et al. Structural basis of synergistic neutralization of Crimean-Congo hemorrhagic fever virus by human antibodies. Science 375, 104–109 (2022).34793197
628. Allen ER A Protective Monoclonal Antibody Targets a Site of Vulnerability on the Surface of Rift Valley Fever Virus Cell Rep. 2018 25 3750 3758.e3754 10.1016/j.celrep.2018.12.001 30590046
Allen, E. R. et al. A Protective Monoclonal Antibody Targets a Site of Vulnerability on the Surface of Rift Valley Fever Virus. Cell Rep. 25, 3750–3758.e3754 (2018).30590046
629. Hao M Characterization of Two Neutralizing Antibodies against Rift Valley Fever Virus Gn Protein Viruses 2020 12 259 10.3390/v12030259 32120864
Hao, M. et al. Characterization of Two Neutralizing Antibodies against Rift Valley Fever Virus Gn Protein. Viruses 12, 259 (2020).32120864
630. McMillen CM A highly potent human neutralizing antibody prevents vertical transmission of Rift Valley fever virus in a rat model Nat. Commun. 2023 14 4507 10.1038/s41467-023-40187-z 37495594
McMillen, C. M. et al. A highly potent human neutralizing antibody prevents vertical transmission of Rift Valley fever virus in a rat model. Nat. Commun. 14, 4507 (2023).37495594
631. Gutjahr B Two monoclonal antibodies against glycoprotein Gn protect mice from Rift Valley Fever challenge by cooperative effects PLoS Negl. Trop. Dis. 2020 14 e0008143 10.1371/journal.pntd.0008143 32160203
Gutjahr, B. et al. Two monoclonal antibodies against glycoprotein Gn protect mice from Rift Valley Fever challenge by cooperative effects. PLoS Negl. Trop. Dis. 14, e0008143 (2020).32160203
632. Chapman NS Multifunctional human monoclonal antibody combination mediates protection against Rift Valley fever virus at low doses Nat. Commun. 2023 14 5650 10.1038/s41467-023-41171-3 37704627
Chapman, N. S. et al. Multifunctional human monoclonal antibody combination mediates protection against Rift Valley fever virus at low doses. Nat. Commun. 14, 5650 (2023).37704627
633. Chapman NS Potent neutralization of Rift Valley fever virus by human monoclonal antibodies through fusion inhibition Proc. Natl Acad. Sci. USA 2021 118 e2025642118 10.1073/pnas.2025642118 33782133
Chapman, N. S. et al. Potent neutralization of Rift Valley fever virus by human monoclonal antibodies through fusion inhibition. Proc. Natl Acad. Sci. USA 118, e2025642118 (2021).33782133
634. Wang Q Neutralization mechanism of human monoclonal antibodies against Rift Valley fever virus Nat. Microbiol. 2019 4 1231 1241 10.1038/s41564-019-0411-z 30936489
Wang, Q. et al. Neutralization mechanism of human monoclonal antibodies against Rift Valley fever virus. Nat. Microbiol. 4, 1231–1241 (2019).30936489
635. Cartwright HN Barbeau DJ McElroy AK Isotype-Specific Fc Effector Functions Enhance Antibody-Mediated Rift Valley Fever Virus Protection In Vivo mSphere 2021 6 e0055621 10.1128/mSphere.00556-21 34494884
Cartwright, H. N., Barbeau, D. J. & McElroy, A. K. Isotype-Specific Fc Effector Functions Enhance Antibody-Mediated Rift Valley Fever Virus Protection In Vivo. mSphere 6, e0055621 (2021).34494884
636. Zhao Y Equine immunoglobulin F(ab’)(2) fragments protect mice from Rift Valley fever virus infection Int. Immunopharmacol. 2018 64 217 222 10.1016/j.intimp.2018.09.002 30199846
Zhao, Y. et al. Equine immunoglobulin F(ab’)(2) fragments protect mice from Rift Valley fever virus infection. Int. Immunopharmacol. 64, 217–222 (2018).30199846
637. Wichgers Schreur PJ Multimeric single-domain antibody complexes protect against bunyavirus infections eLife 2020 9 e52716 10.7554/eLife.52716 32314955
Wichgers Schreur, P. J. et al. Multimeric single-domain antibody complexes protect against bunyavirus infections. eLife 9, e52716 (2020).32314955
638. Eaton BT Broder CC Middleton D Wang LF Hendra and Nipah viruses: different and dangerous Nat. Rev. Microbiol. 2006 4 23 35 10.1038/nrmicro1323 16357858
Eaton, B. T., Broder, C. C., Middleton, D. & Wang, L. F. Hendra and Nipah viruses: different and dangerous. Nat. Rev. Microbiol. 4, 23–35 (2006).16357858
639. Ternhag A Penttinen P [Nipah virus–another product from the Asian “virus factory”] Lakartidningen 2005 102 1046 1047 15892474
Ternhag, A. & Penttinen, P. [Nipah virus–another product from the Asian “virus factory”]. Lakartidningen 102, 1046–1047 (2005).15892474
640. Ciancanelli MJ Basler CF Mutation of YMYL in the Nipah virus matrix protein abrogates budding and alters subcellular localization J. Virol. 2006 80 12070 12078 10.1128/JVI.01743-06 17005661
Ciancanelli, M. J. & Basler, C. F. Mutation of YMYL in the Nipah virus matrix protein abrogates budding and alters subcellular localization. J. Virol. 80, 12070–12078 (2006).17005661
641. Chua KB Nipah virus outbreak in Malaysia J. Clin. Virol. 2003 26 265 275 10.1016/S1386-6532(02)00268-8 12637075
Chua, K. B. Nipah virus outbreak in Malaysia. J. Clin. Virol. 26, 265–275 (2003).12637075
642. Chua KB Nipah virus: a recently emergent deadly paramyxovirus Science 2000 288 1432 1435 10.1126/science.288.5470.1432 10827955
Chua, K. B. et al. Nipah virus: a recently emergent deadly paramyxovirus. Science 288, 1432–1435 (2000).10827955
643. Gazal S Nipah and Hendra Viruses: Deadly Zoonotic Paramyxoviruses with the Potential to Cause the Next Pandemic Pathogens 2022 11 1419 10.3390/pathogens11121419 36558753
Gazal, S. et al. Nipah and Hendra Viruses: Deadly Zoonotic Paramyxoviruses with the Potential to Cause the Next Pandemic. Pathogens 11, 1419 (2022).36558753
644. Wong KT Nipah virus infection: pathology and pathogenesis of an emerging paramyxoviral zoonosis Am. J. Pathol. 2002 161 2153 2167 10.1016/S0002-9440(10)64493-8 12466131
Wong, K. T. et al. Nipah virus infection: pathology and pathogenesis of an emerging paramyxoviral zoonosis. Am. J. Pathol. 161, 2153–2167 (2002).12466131
645. Gurley ES Person-to-person transmission of Nipah virus in a Bangladeshi community Emerg. Infect. Dis. 2007 13 1031 1037 10.3201/eid1307.061128 18214175
Gurley, E. S. et al. Person-to-person transmission of Nipah virus in a Bangladeshi community. Emerg. Infect. Dis. 13, 1031–1037 (2007).18214175
646. Sun B Phylogeography, Transmission, and Viral Proteins of Nipah Virus Virol. Sin. 2018 33 385 393 10.1007/s12250-018-0050-1 30311101
Sun, B. et al. Phylogeography, Transmission, and Viral Proteins of Nipah Virus. Virol. Sin. 33, 385–393 (2018).30311101
647. Rockx B Clinical outcome of henipavirus infection in hamsters is determined by the route and dose of infection J. Virol. 2011 85 7658 7671 10.1128/JVI.00473-11 21593160
Rockx, B. et al. Clinical outcome of henipavirus infection in hamsters is determined by the route and dose of infection. J. Virol. 85, 7658–7671 (2011).21593160
648. Kaza B Aguilar HC Pathogenicity and virulence of henipaviruses Virulence 2023 14 2273684 10.1080/21505594.2023.2273684 37948320
Kaza, B. & Aguilar, H. C. Pathogenicity and virulence of henipaviruses. Virulence 14, 2273684 (2023).37948320
649. Singh RK Nipah virus: epidemiology, pathology, immunobiology and advances in diagnosis, vaccine designing and control strategies - a comprehensive review Vet. Q. 2019 39 26 55 10.1080/01652176.2019.1580827 31006350
Singh, R. K. et al. Nipah virus: epidemiology, pathology, immunobiology and advances in diagnosis, vaccine designing and control strategies - a comprehensive review. Vet. Q. 39, 26–55 (2019).31006350
650. Broder CC A treatment for and vaccine against the deadly Hendra and Nipah viruses Antivir. Res. 2013 100 8 13 10.1016/j.antiviral.2013.06.012 23838047
Broder, C. C. et al. A treatment for and vaccine against the deadly Hendra and Nipah viruses. Antivir. Res. 100, 8–13 (2013).23838047
651. Dhondt KP Type I interferon signaling protects mice from lethal henipavirus infection J. Infect. Dis. 2013 207 142 151 10.1093/infdis/jis653 23089589
Dhondt, K. P. et al. Type I interferon signaling protects mice from lethal henipavirus infection. J. Infect. Dis. 207, 142–151 (2013).23089589
652. Iampietro M Activation of cGAS/STING pathway upon paramyxovirus infection iScience 2021 24 102519 10.1016/j.isci.2021.102519 34142033
Iampietro, M. et al. Activation of cGAS/STING pathway upon paramyxovirus infection. iScience 24, 102519 (2021).34142033
653. Iampietro M Control of Nipah Virus Infection in Mice by the Host Adaptors Mitochondrial Antiviral Signaling Protein (MAVS) and Myeloid Differentiation Primary Response 88 (MyD88) J. Infect. Dis. 2020 221 S401 s406 10.1093/infdis/jiz602 31853535
Iampietro, M. et al. Control of Nipah Virus Infection in Mice by the Host Adaptors Mitochondrial Antiviral Signaling Protein (MAVS) and Myeloid Differentiation Primary Response 88 (MyD88). J. Infect. Dis. 221, S401–s406 (2020).31853535
654. Valbuena G A human lung xenograft mouse model of Nipah virus infection PLoS Pathog. 2014 10 e1004063 10.1371/journal.ppat.1004063 24699832
Valbuena, G. et al. A human lung xenograft mouse model of Nipah virus infection. PLoS Pathog. 10, e1004063 (2014).24699832
655. Walpita P A VLP-based vaccine provides complete protection against Nipah virus challenge following multiple-dose or single-dose vaccination schedules in a hamster model NPJ Vaccines 2017 2 21 10.1038/s41541-017-0023-7 29263876
Walpita, P. et al. A VLP-based vaccine provides complete protection against Nipah virus challenge following multiple-dose or single-dose vaccination schedules in a hamster model. NPJ Vaccines 2, 21 (2017).29263876
656. Welch SR Defective Interfering Viral Particle Treatment Reduces Clinical Signs and Protects Hamsters from Lethal Nipah Virus Disease mBio 2022 13 e0329421 10.1128/mbio.03294-21 35297677
Welch, S. R. et al. Defective Interfering Viral Particle Treatment Reduces Clinical Signs and Protects Hamsters from Lethal Nipah Virus Disease. mBio 13, e0329421 (2022).35297677
657. Wong KT A golden hamster model for human acute Nipah virus infection Am. J. Pathol. 2003 163 2127 2137 10.1016/S0002-9440(10)63569-9 14578210
Wong, K. T. et al. A golden hamster model for human acute Nipah virus infection. Am. J. Pathol. 163, 2127–2137 (2003).14578210
658. Welch SR In Situ Imaging of Fluorescent Nipah Virus Respiratory and Neurological Tissue Tropism in the Syrian Hamster Model J. Infect. Dis. 2020 221 S448 s453 10.1093/infdis/jiz393 31665342
Welch, S. R. et al. In Situ Imaging of Fluorescent Nipah Virus Respiratory and Neurological Tissue Tropism in the Syrian Hamster Model. J. Infect. Dis. 221, S448–s453 (2020).31665342
659. Williamson MM Torres-Velez FJ Henipavirus: a review of laboratory animal pathology Vet. Pathol. 2010 47 871 880 10.1177/0300985810378648 20682803
Williamson, M. M. & Torres-Velez, F. J. Henipavirus: a review of laboratory animal pathology. Vet. Pathol. 47, 871–880 (2010).20682803
660. Torres-Velez FJ Histopathologic and immunohistochemical characterization of Nipah virus infection in the guinea pig Vet. Pathol. 2008 45 576 585 10.1354/vp.45-4-576 18587107
Torres-Velez, F. J. et al. Histopathologic and immunohistochemical characterization of Nipah virus infection in the guinea pig. Vet. Pathol. 45, 576–585 (2008).18587107
661. Genzer SC Alterations in Blood Chemistry Levels Associated With Nipah Virus Disease in the Syrian Hamster Model J. Infect. Dis. 2020 221 S454 s459 10.1093/infdis/jiz552 31747016
Genzer, S. C. et al. Alterations in Blood Chemistry Levels Associated With Nipah Virus Disease in the Syrian Hamster Model. J. Infect. Dis. 221, S454–s459 (2020).31747016
662. Clayton BA The Nature of Exposure Drives Transmission of Nipah Viruses from Malaysia and Bangladesh in Ferrets PLoS Negl. Trop. Dis. 2016 10 e0004775 10.1371/journal.pntd.0004775 27341030
Clayton, B. A. et al. The Nature of Exposure Drives Transmission of Nipah Viruses from Malaysia and Bangladesh in Ferrets. PLoS Negl. Trop. Dis. 10, e0004775 (2016).27341030
663. Pickering BS Protection against henipaviruses in swine requires both, cell-mediated and humoral immune response Vaccine 2016 34 4777 4786 10.1016/j.vaccine.2016.08.028 27544586
Pickering, B. S. et al. Protection against henipaviruses in swine requires both, cell-mediated and humoral immune response. Vaccine 34, 4777–4786 (2016).27544586
664. Mills JN Nipah virus infection in dogs, Malaysia, 1999 Emerg. Infect. Dis. 2009 15 950 952 10.3201/eid1506.080453 19523300
Mills, J. N. et al. Nipah virus infection in dogs, Malaysia, 1999. Emerg. Infect. Dis. 15, 950–952 (2009).19523300
665. Middleton DJ Experimental Nipah virus infection in pigs and cats J. Comp. Pathol. 2002 126 124 136 10.1053/jcpa.2001.0532 11945001
Middleton, D. J. et al. Experimental Nipah virus infection in pigs and cats. J. Comp. Pathol. 126, 124–136 (2002).11945001
666. Mungall BA Vertical transmission and fetal replication of Nipah virus in an experimentally infected cat J. Infect. Dis. 2007 196 812 816 10.1086/520818 17703410
Mungall, B. A. et al. Vertical transmission and fetal replication of Nipah virus in an experimentally infected cat. J. Infect. Dis. 196, 812–816 (2007).17703410
667. Geisbert TW Development of an acute and highly pathogenic nonhuman primate model of Nipah virus infection PloS One 2010 5 e10690 10.1371/journal.pone.0010690 20502528
Geisbert, T. W. et al. Development of an acute and highly pathogenic nonhuman primate model of Nipah virus infection. PloS One 5, e10690 (2010).20502528
668. Geisbert JB An Intranasal Exposure Model of Lethal Nipah Virus Infection in African Green Monkeys J. Infect. Dis. 2020 221 S414 s418 10.1093/infdis/jiz391 31665362
Geisbert, J. B. et al. An Intranasal Exposure Model of Lethal Nipah Virus Infection in African Green Monkeys. J. Infect. Dis. 221, S414–s418 (2020).31665362
669. Prasad AN A Lethal Aerosol Exposure Model of Nipah Virus Strain Bangladesh in African Green Monkeys J. Infect. Dis. 2020 221 S431 s435 10.1093/infdis/jiz469 31665351
Prasad, A. N. et al. A Lethal Aerosol Exposure Model of Nipah Virus Strain Bangladesh in African Green Monkeys. J. Infect. Dis. 221, S431–s435 (2020).31665351
670. Geisbert TW Feldmann H Broder CC Animal challenge models of henipavirus infection and pathogenesis Curr. Top. Microbiol. Immunol. 2012 359 153 177 22476556
Geisbert, T. W., Feldmann, H. & Broder, C. C. Animal challenge models of henipavirus infection and pathogenesis. Curr. Top. Microbiol. Immunol. 359, 153–177 (2012).22476556
671. Mire CE Pathogenic Differences between Nipah Virus Bangladesh and Malaysia Strains in Primates: Implications for Antibody Therapy Sci. Rep. 2016 6 30916 10.1038/srep30916 27484128
Mire, C. E. et al. Pathogenic Differences between Nipah Virus Bangladesh and Malaysia Strains in Primates: Implications for Antibody Therapy. Sci. Rep. 6, 30916 (2016).27484128
672. Prasad AN Resistance of Cynomolgus Monkeys to Nipah and Hendra Virus Disease Is Associated With Cell-Mediated and Humoral Immunity J. Infect. Dis. 2020 221 S436 s447 10.1093/infdis/jiz613 32022850
Prasad, A. N. et al. Resistance of Cynomolgus Monkeys to Nipah and Hendra Virus Disease Is Associated With Cell-Mediated and Humoral Immunity. J. Infect. Dis. 221, S436–s447 (2020).32022850
673. Marianneau P Experimental infection of squirrel monkeys with nipah virus Emerg. Infect. Dis. 2010 16 507 510 10.3201/eid1603.091346 20202432
Marianneau, P. et al. Experimental infection of squirrel monkeys with nipah virus. Emerg. Infect. Dis. 16, 507–510 (2010).20202432
674. Mire CE Single injection recombinant vesicular stomatitis virus vaccines protect ferrets against lethal Nipah virus disease Virol. J. 2013 10 353 10.1186/1743-422X-10-353 24330654
Mire, C. E. et al. Single injection recombinant vesicular stomatitis virus vaccines protect ferrets against lethal Nipah virus disease. Virol. J. 10, 353 (2013).24330654
675. Watanabe S Construction of a recombinant vaccine expressing Nipah virus glycoprotein using the replicative and highly attenuated vaccinia virus strain LC16m8 PLoS Negl. Trop. Dis. 2023 17 e0011851 10.1371/journal.pntd.0011851 38100536
Watanabe, S. et al. Construction of a recombinant vaccine expressing Nipah virus glycoprotein using the replicative and highly attenuated vaccinia virus strain LC16m8. PLoS Negl. Trop. Dis. 17, e0011851 (2023).38100536
676. Walpita P Vaccine potential of Nipah virus-like particles PloS one 2011 6 e18437 10.1371/journal.pone.0018437 21494680
Walpita, P. et al. Vaccine potential of Nipah virus-like particles. PloS one 6, e18437 (2011).21494680
677. Pastor Y A vaccine targeting antigen-presenting cells through CD40 induces protective immunity against Nipah disease Cell Rep. Med. 2024 5 101467 10.1016/j.xcrm.2024.101467 38471503
Pastor, Y. et al. A vaccine targeting antigen-presenting cells through CD40 induces protective immunity against Nipah disease. Cell Rep. Med. 5, 101467 (2024).38471503
678. Porotto M Inhibition of Nipah virus infection in vivo: targeting an early stage of paramyxovirus fusion activation during viral entry PLoS Pathog. 2010 6 e1001168 10.1371/journal.ppat.1001168 21060819
Porotto, M. et al. Inhibition of Nipah virus infection in vivo: targeting an early stage of paramyxovirus fusion activation during viral entry. PLoS Pathog. 6, e1001168 (2010).21060819
679. Dawes BE Favipiravir (T-705) protects against Nipah virus infection in the hamster model Sci. Rep. 2018 8 7604 10.1038/s41598-018-25780-3 29765101
Dawes, B. E. et al. Favipiravir (T-705) protects against Nipah virus infection in the hamster model. Sci. Rep. 8, 7604 (2018).29765101
680. Rodrigue V Current progress towards prevention of Nipah and Hendra disease in humans: A scoping review of vaccine and monoclonal antibody candidates being evaluated in clinical trials Trop. Med. Int. Health 2024 29 354 364 10.1111/tmi.13979 38415314
Rodrigue, V. et al. Current progress towards prevention of Nipah and Hendra disease in humans: A scoping review of vaccine and monoclonal antibody candidates being evaluated in clinical trials. Trop. Med. Int. Health 29, 354–364 (2024).38415314
681. Bossart KN A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection PLoS Pathog. 2009 5 e1000642 10.1371/journal.ppat.1000642 19888339
Bossart, K. N. et al. A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection. PLoS Pathog. 5, e1000642 (2009).19888339
682. Geisbert TW Therapeutic treatment of Nipah virus infection in nonhuman primates with a neutralizing human monoclonal antibody Sci. Transl. Med. 2014 6 242ra282 10.1126/scitranslmed.3008929
Geisbert, T. W. et al. Therapeutic treatment of Nipah virus infection in nonhuman primates with a neutralizing human monoclonal antibody. Sci. Transl. Med. 6, 242ra282 (2014).
683. Playford EG Safety, tolerability, pharmacokinetics, and immunogenicity of a human monoclonal antibody targeting the G glycoprotein of henipaviruses in healthy adults: a first-in-human, randomised, controlled, phase 1 study Lancet Infect. Dis. 2020 20 445 454 10.1016/S1473-3099(19)30634-6 32027842
Playford, E. G. et al. Safety, tolerability, pharmacokinetics, and immunogenicity of a human monoclonal antibody targeting the G glycoprotein of henipaviruses in healthy adults: a first-in-human, randomised, controlled, phase 1 study. Lancet Infect. Dis. 20, 445–454 (2020).32027842
684. Chen L Potent human neutralizing antibodies against Nipah virus derived from two ancestral antibody heavy chains Nat. Commun. 2024 15 2987 10.1038/s41467-024-47213-8 38582870
Chen, L. et al. Potent human neutralizing antibodies against Nipah virus derived from two ancestral antibody heavy chains. Nat. Commun. 15, 2987 (2024).38582870
685. Mathieu C Horvat B Henipavirus pathogenesis and antiviral approaches Expert Rev. Anti Infect. Ther. 2015 13 343 354 10.1586/14787210.2015.1001838 25634624
Mathieu, C. & Horvat, B. Henipavirus pathogenesis and antiviral approaches. Expert Rev. Anti Infect. Ther. 13, 343–354 (2015).25634624
686. Sharma V Zika virus: an emerging challenge to public health worldwide Can. J. Microbiol. 2020 66 87 98 10.1139/cjm-2019-0331 31682478
Sharma, V. et al. Zika virus: an emerging challenge to public health worldwide. Can. J. Microbiol. 66, 87–98 (2020).31682478
687. Roby JA Setoh YX Hall RA Khromykh AA Post-translational regulation and modifications of flavivirus structural proteins J. Gen. Virol. 2015 96 1551 1569 10.1099/vir.0.000097 25711963
Roby, J. A., Setoh, Y. X., Hall, R. A. & Khromykh, A. A. Post-translational regulation and modifications of flavivirus structural proteins. J. Gen. Virol. 96, 1551–1569 (2015).25711963
688. Mukhopadhyay S Kuhn RJ Rossmann MG A structural perspective of the flavivirus life cycle Nat. Rev. Microbiol. 2005 3 13 22 10.1038/nrmicro1067 15608696
Mukhopadhyay, S., Kuhn, R. J. & Rossmann, M. G. A structural perspective of the flavivirus life cycle. Nat. Rev. Microbiol. 3, 13–22 (2005).15608696
689. Klema VJ Padmanabhan R Choi KH Flaviviral Replication Complex: Coordination between RNA Synthesis and 5’-RNA Capping Viruses 2015 7 4640 4656 10.3390/v7082837 26287232
Klema, V. J., Padmanabhan, R. & Choi, K. H. Flaviviral Replication Complex: Coordination between RNA Synthesis and 5’-RNA Capping. Viruses 7, 4640–4656 (2015).26287232
690. van den Elsen K Quek JP Luo D Molecular Insights into the Flavivirus Replication Complex Viruses 2021 13 956 10.3390/v13060956 34064113
van den Elsen, K., Quek, J. P. & Luo, D. Molecular Insights into the Flavivirus Replication Complex. Viruses 13, 956 (2021).34064113
691. Liang Q Zika Virus NS4A and NS4B Proteins Deregulate Akt-mTOR Signaling in Human Fetal Neural Stem Cells to Inhibit Neurogenesis and Induce Autophagy Cell Stem Cell 2016 19 663 671 10.1016/j.stem.2016.07.019 27524440
Liang, Q. et al. Zika Virus NS4A and NS4B Proteins Deregulate Akt-mTOR Signaling in Human Fetal Neural Stem Cells to Inhibit Neurogenesis and Induce Autophagy. Cell Stem Cell 19, 663–671 (2016).27524440
692. Franke TF PI3K/Akt: getting it right matters Oncogene 2008 27 6473 6488 10.1038/onc.2008.313 18955974
Franke, T. F. PI3K/Akt: getting it right matters. Oncogene 27, 6473–6488 (2008).18955974
693. Parisien J-P Lenoir JJ Alvarado G Horvath CM The Human STAT2 Coiled-Coil Domain Contains a Degron for Zika Virus Interferon Evasion J. Virol. 2022 96 e0130121 10.1128/JVI.01301-21 34643427
Parisien, J.-P., Lenoir, J. J., Alvarado, G. & Horvath, C. M. The Human STAT2 Coiled-Coil Domain Contains a Degron for Zika Virus Interferon Evasion. J. Virol. 96, e0130121 (2022).34643427
694. Xia H An evolutionary NS1 mutation enhances Zika virus evasion of host interferon induction Nat. Commun. 2018 9 414 10.1038/s41467-017-02816-2 29379028
Xia, H. et al. An evolutionary NS1 mutation enhances Zika virus evasion of host interferon induction. Nat. Commun. 9, 414 (2018).29379028
695. Wu Y Zika virus evades interferon-mediated antiviral response through the co-operation of multiple nonstructural proteins in vitro Cell Discov. 2017 3 17006 10.1038/celldisc.2017.6 28373913
Wu, Y. et al. Zika virus evades interferon-mediated antiviral response through the co-operation of multiple nonstructural proteins in vitro. Cell Discov. 3, 17006 (2017).28373913
696. Zeng Q Making sense of flavivirus non-strctural protein 1 in innate immune evasion and inducing tissue-specific damage Virus Res. 2023 336 199222 10.1016/j.virusres.2023.199222 37716670
Zeng, Q. et al. Making sense of flavivirus non-strctural protein 1 in innate immune evasion and inducing tissue-specific damage. Virus Res. 336, 199222 (2023).37716670
697. Perera DR Ranadeva ND Sirisena K Wijesinghe KJ Roles of NS1 Protein in Flavivirus Pathogenesis ACS Infect. Dis. 2024 10 20 56 10.1021/acsinfecdis.3c00566 38110348
Perera, D. R., Ranadeva, N. D., Sirisena, K. & Wijesinghe, K. J. Roles of NS1 Protein in Flavivirus Pathogenesis. ACS Infect. Dis. 10, 20–56 (2024).38110348
698. Wu L An evolutionarily conserved ubiquitin ligase drives infection and transmission of flaviviruses Proc. Natl Acad. Sci. USA 2024 121 e2317978121 10.1073/pnas.2317978121 38593069
Wu, L. et al. An evolutionarily conserved ubiquitin ligase drives infection and transmission of flaviviruses. Proc. Natl Acad. Sci. USA 121, e2317978121 (2024).38593069
699. Petersen LR Jamieson DJ Honein MA Zika Virus N. Engl. J. Med. 2016 375 294 295 27355409
Petersen, L. R., Jamieson, D. J. & Honein, M. A. Zika Virus. N. Engl. J. Med. 375, 294–295 (2016).27355409
700. Hills SL Fischer M Petersen LR Epidemiology of Zika Virus Infection J. Infect. Dis. 2017 216 S868 S874 10.1093/infdis/jix434 29267914
Hills, S. L., Fischer, M. & Petersen, L. R. Epidemiology of Zika Virus Infection. J. Infect. Dis. 216, S868–S874 (2017).29267914
701. Sekaran SD Host immune response against DENV and ZIKV infections Front Cell Infect. Microbiol 2022 12 975222 10.3389/fcimb.2022.975222 36159640
Sekaran, S. D. et al. Host immune response against DENV and ZIKV infections. Front Cell Infect. Microbiol 12, 975222 (2022).36159640
702. Besnard M Evidence of perinatal transmission of Zika virus, French Polynesia, December 2013 and February 2014 Eur. Surveill. 2014 19 20751 10.2807/1560-7917.ES2014.19.13.20751
Besnard, M. et al. Evidence of perinatal transmission of Zika virus, French Polynesia, December 2013 and February 2014. Eur. Surveill. 19, 20751 (2014).
703. Russell K Male-to-Female Sexual Transmission of Zika Virus-United States, January-April 2016 Clin. Infect. Dis. 2017 64 211 213 10.1093/cid/ciw692 27986688
Russell, K. et al. Male-to-Female Sexual Transmission of Zika Virus-United States, January-April 2016. Clin. Infect. Dis. 64, 211–213 (2017).27986688
704. Leyser M Nascimento OJM Congenital Zika Virus Infection: Beyond Neonatal Microcephaly JAMA Neurol. 2017 74 610 10.1001/jamaneurol.2017.0048 28319237
Leyser, M. & Nascimento, O. J. M. Congenital Zika Virus Infection: Beyond Neonatal Microcephaly. JAMA Neurol. 74, 610 (2017).28319237
705. Giraldo MI Gonzalez-Orozco M Rajsbaum R Pathogenesis of Zika Virus Infection Annu Rev. Pathol. 2023 18 181 203 10.1146/annurev-pathmechdis-031521-034739 36151059
Giraldo, M. I., Gonzalez-Orozco, M. & Rajsbaum, R. Pathogenesis of Zika Virus Infection. Annu Rev. Pathol. 18, 181–203 (2023).36151059
706. Lazear HM A Mouse Model of Zika Virus Pathogenesis Cell Host Microbe 2016 19 720 730 10.1016/j.chom.2016.03.010 27066744
Lazear, H. M. et al. A Mouse Model of Zika Virus Pathogenesis. Cell Host Microbe 19, 720–730 (2016).27066744
707. Rossi SL Characterization of a Novel Murine Model to Study Zika Virus Am. J. Trop. Med. Hyg. 2016 94 1362 1369 10.4269/ajtmh.16-0111 27022155
Rossi, S. L. et al. Characterization of a Novel Murine Model to Study Zika Virus. Am. J. Trop. Med. Hyg. 94, 1362–1369 (2016).27022155
708. Grant A Zika Virus Targets Human STAT2 to Inhibit Type I Interferon Signaling Cell Host Microbe 2016 19 882 890 10.1016/j.chom.2016.05.009 27212660
Grant, A. et al. Zika Virus Targets Human STAT2 to Inhibit Type I Interferon Signaling. Cell Host Microbe 19, 882–890 (2016).27212660
709. Kumar A Zika virus inhibits type-I interferon production and downstream signaling EMBO Rep. 2016 17 1766 1775 10.15252/embr.201642627 27797853
Kumar, A. et al. Zika virus inhibits type-I interferon production and downstream signaling. EMBO Rep. 17, 1766–1775 (2016).27797853
710. Fernandes NC Experimental Zika virus infection induces spinal cord injury and encephalitis in newborn Swiss mice Exp. Toxicol. Pathol. 2017 69 63 71 10.1016/j.etp.2016.11.004 27899230
Fernandes, N. C. et al. Experimental Zika virus infection induces spinal cord injury and encephalitis in newborn Swiss mice. Exp. Toxicol. Pathol. 69, 63–71 (2017).27899230
711. Manangeeswaran M Ireland DD Verthelyi D Zika (PRVABC59) Infection Is Associated with T cell Infiltration and Neurodegeneration in CNS of Immunocompetent Neonatal C57Bl/6 Mice PLoS Pathog. 2016 12 e1006004 10.1371/journal.ppat.1006004 27855206
Manangeeswaran, M., Ireland, D. D. & Verthelyi, D. Zika (PRVABC59) Infection Is Associated with T cell Infiltration and Neurodegeneration in CNS of Immunocompetent Neonatal C57Bl/6 Mice. PLoS Pathog. 12, e1006004 (2016).27855206
712. Li S Zika Virus Fatally Infects Wild Type Neonatal Mice and Replicates in Central Nervous System Viruses 2018 10 49 10.3390/v10010049 29361773
Li, S. et al. Zika Virus Fatally Infects Wild Type Neonatal Mice and Replicates in Central Nervous System. Viruses 10, 49 (2018).29361773
713. Dowall SD A Susceptible Mouse Model for Zika Virus Infection PLoS Negl. Trop. Dis. 2016 10 e0004658 10.1371/journal.pntd.0004658 27149521
Dowall, S. D. et al. A Susceptible Mouse Model for Zika Virus Infection. PLoS Negl. Trop. Dis. 10, e0004658 (2016).27149521
714. Li H Zika Virus Infects Neural Progenitors in the Adult Mouse Brain and Alters Proliferation Cell Stem Cell 2016 19 593 598 10.1016/j.stem.2016.08.005 27545505
Li, H. et al. Zika Virus Infects Neural Progenitors in the Adult Mouse Brain and Alters Proliferation. Cell Stem Cell 19, 593–598 (2016).27545505
715. Smith DR Neuropathogenesis of Zika Virus in a Highly Susceptible Immunocompetent Mouse Model after Antibody Blockade of Type I Interferon PLoS Negl. Trop. Dis. 2017 11 e0005296 10.1371/journal.pntd.0005296 28068342
Smith, D. R. et al. Neuropathogenesis of Zika Virus in a Highly Susceptible Immunocompetent Mouse Model after Antibody Blockade of Type I Interferon. PLoS Negl. Trop. Dis. 11, e0005296 (2017).28068342
716. Aliota MT Characterization of Lethal Zika Virus Infection in AG129 Mice PLoS Negl. Trop. Dis. 2016 10 e0004682 10.1371/journal.pntd.0004682 27093158
Aliota, M. T. et al. Characterization of Lethal Zika Virus Infection in AG129 Mice. PLoS Negl. Trop. Dis. 10, e0004682 (2016).27093158
717. Govero J Zika virus infection damages the testes in mice Nature 2016 540 438 442 10.1038/nature20556 27798603
Govero, J. et al. Zika virus infection damages the testes in mice. Nature 540, 438–442 (2016).27798603
718. Ma W Zika Virus Causes Testis Damage and Leads to Male Infertility in Mice Cell 2017 168 542 10.1016/j.cell.2017.01.009 28129543
Ma, W. et al. Zika Virus Causes Testis Damage and Leads to Male Infertility in Mice. Cell 168, 542 (2017).28129543
719. Chan JF Zika Virus Infection in Dexamethasone-immunosuppressed Mice Demonstrating Disseminated Infection with Multi-organ Involvement Including Orchitis Effectively Treated by Recombinant Type I Interferons EBioMedicine 2016 14 112 122 10.1016/j.ebiom.2016.11.017 27884655
Chan, J. F. et al. Zika Virus Infection in Dexamethasone-immunosuppressed Mice Demonstrating Disseminated Infection with Multi-organ Involvement Including Orchitis Effectively Treated by Recombinant Type I Interferons. EBioMedicine 14, 112–122 (2016).27884655
720. Schuler-Faccini L Possible Association Between Zika Virus Infection and Microcephaly - Brazil, 2015 MMWR Morb. Mortal. Wkly Rep. 2016 65 59 62 10.15585/mmwr.mm6503e2 26820244
Schuler-Faccini, L. et al. Possible Association Between Zika Virus Infection and Microcephaly - Brazil, 2015. MMWR Morb. Mortal. Wkly Rep. 65, 59–62 (2016).26820244
721. Duarte G Zika Virus Infection in Pregnant Women and Microcephaly Rev. Bras. Ginecol. Obstet. 2017 39 235 248 10.1055/s-0037-1603450 28575919
Duarte, G. et al. Zika Virus Infection in Pregnant Women and Microcephaly. Rev. Bras. Ginecol. Obstet. 39, 235–248 (2017).28575919
722. Miner JJ Zika Virus Infection during Pregnancy in Mice Causes Placental Damage and Fetal Demise Cell 2016 165 1081 1091 10.1016/j.cell.2016.05.008 27180225
Miner, J. J. et al. Zika Virus Infection during Pregnancy in Mice Causes Placental Damage and Fetal Demise. Cell 165, 1081–1091 (2016).27180225
723. Cugola FR The Brazilian Zika virus strain causes birth defects in experimental models Nature 2016 534 267 271 10.1038/nature18296 27279226
Cugola, F. R. et al. The Brazilian Zika virus strain causes birth defects in experimental models. Nature 534, 267–271 (2016).27279226
724. Siddharthan V Zika virus infection of adult and fetal STAT2 knock-out hamsters Virology 2017 507 89 95 10.1016/j.virol.2017.04.013 28431283
Siddharthan, V. et al. Zika virus infection of adult and fetal STAT2 knock-out hamsters. Virology 507, 89–95 (2017).28431283
725. Miller LJ Zika Virus Infection in Syrian Golden Hamsters and Strain 13 Guinea Pigs Am. J. Trop. Med Hyg. 2018 98 864 867 10.4269/ajtmh.17-0686 29405107
Miller, L. J. et al. Zika Virus Infection in Syrian Golden Hamsters and Strain 13 Guinea Pigs. Am. J. Trop. Med Hyg. 98, 864–867 (2018).29405107
726. Deng Y-Q Intranasal infection and contact transmission of Zika virus in guinea pigs Nat. Commun. 2017 8 1648 10.1038/s41467-017-01923-4 29162827
Deng, Y.-Q. et al. Intranasal infection and contact transmission of Zika virus in guinea pigs. Nat. Commun. 8, 1648 (2017).29162827
727. Bierle CJ Assessing Zika virus replication and the development of Zika-specific antibodies after a mid-gestation viral challenge in guinea pigs PLoS One 2017 12 e0187720 10.1371/journal.pone.0187720 29099873
Bierle, C. J. et al. Assessing Zika virus replication and the development of Zika-specific antibodies after a mid-gestation viral challenge in guinea pigs. PLoS One 12, e0187720 (2017).29099873
728. Kumar M A guinea pig model of Zika virus infection Virol. J. 2017 14 75 10.1186/s12985-017-0750-4 28399888
Kumar, M. et al. A guinea pig model of Zika virus infection. Virol. J. 14, 75 (2017).28399888
729. Qiu H-Y Aerosolized Zika virus infection in Guinea pigs Emerg. Microbes Infect. 2022 11 2350 2358 10.1080/22221751.2022.2122577 36069671
Qiu, H.-Y. et al. Aerosolized Zika virus infection in Guinea pigs. Emerg. Microbes Infect. 11, 2350–2358 (2022).36069671
730. Westrich JA Characterization of subclinical ZIKV infection in immune-competent guinea pigs and mice J. Gen. Virol. 2021 102 001641 10.1099/jgv.0.001641 34410903
Westrich, J. A. et al. Characterization of subclinical ZIKV infection in immune-competent guinea pigs and mice. J. Gen. Virol. 102, 001641 (2021).34410903
731. Hutchinson EB The effect of Zika virus infection in the ferret J. Comp. Neurol. 2019 527 1706 1719 10.1002/cne.24640 30680733
Hutchinson, E. B. et al. The effect of Zika virus infection in the ferret. J. Comp. Neurol. 527, 1706–1719 (2019).30680733
732. Dudley DM A rhesus macaque model of Asian-lineage Zika virus infection Nat. Commun. 2016 7 12204 10.1038/ncomms12204 27352279
Dudley, D. M. et al. A rhesus macaque model of Asian-lineage Zika virus infection. Nat. Commun. 7, 12204 (2016).27352279
733. Koenig MR Infection of the maternal-fetal interface and vertical transmission following low-dose inoculation of pregnant rhesus macaques (Macaca mulatta) with an African-lineage Zika virus PLoS One 2023 18 e0284964 10.1371/journal.pone.0284964 37141276
Koenig, M. R. et al. Infection of the maternal-fetal interface and vertical transmission following low-dose inoculation of pregnant rhesus macaques (Macaca mulatta) with an African-lineage Zika virus. PLoS One 18, e0284964 (2023).37141276
734. Aid M Zika Virus Persistence in the Central Nervous System and Lymph Nodes of Rhesus Monkeys Cell 2017 169 610 620.e14 10.1016/j.cell.2017.04.008 28457610
Aid, M. et al. Zika Virus Persistence in the Central Nervous System and Lymph Nodes of Rhesus Monkeys. Cell 169, 610–620.e14 (2017).28457610
735. Hirsch AJ Zika Virus infection of rhesus macaques leads to viral persistence in multiple tissues PLoS Pathog. 2017 13 e1006219 10.1371/journal.ppat.1006219 28278237
Hirsch, A. J. et al. Zika Virus infection of rhesus macaques leads to viral persistence in multiple tissues. PLoS Pathog. 13, e1006219 (2017).28278237
736. Osuna CE Zika viral dynamics and shedding in rhesus and cynomolgus macaques Nat. Med. 2016 22 1448 1455 10.1038/nm.4206 27694931
Osuna, C. E. et al. Zika viral dynamics and shedding in rhesus and cynomolgus macaques. Nat. Med. 22, 1448–1455 (2016).27694931
737. Li X-F Characterization of a 2016 Clinical Isolate of Zika Virus in Non-human Primates EBioMedicine 2016 12 170 177 10.1016/j.ebiom.2016.09.022 27693104
Li, X.-F. et al. Characterization of a 2016 Clinical Isolate of Zika Virus in Non-human Primates. EBioMedicine 12, 170–177 (2016).27693104
738. Woollard SM Preliminary Studies on Immune Response and Viral Pathogenesis of Zika Virus in Rhesus Macaques Pathogens 2018 7 70 10.3390/pathogens7030070 30127237
Woollard, S. M. et al. Preliminary Studies on Immune Response and Viral Pathogenesis of Zika Virus in Rhesus Macaques. Pathogens 7, 70 (2018).30127237
739. Rosinski JR Frequent first-trimester pregnancy loss in rhesus macaques infected with African-lineage Zika virus PLoS Pathog. 2023 19 e1011282 10.1371/journal.ppat.1011282 36976812
Rosinski, J. R. et al. Frequent first-trimester pregnancy loss in rhesus macaques infected with African-lineage Zika virus. PLoS Pathog. 19, e1011282 (2023).36976812
740. Raasch LE Fetal loss in pregnant rhesus macaques infected with high-dose African-lineage Zika virus PLoS Negl. Trop. Dis. 2022 16 e0010623 10.1371/journal.pntd.0010623 35926066
Raasch, L. E. et al. Fetal loss in pregnant rhesus macaques infected with high-dose African-lineage Zika virus. PLoS Negl. Trop. Dis. 16, e0010623 (2022).35926066
741. Block LN Embryotoxic impact of Zika virus in a rhesus macaque in vitro implantation model† Biol. Reprod. 2020 102 806 816 10.1093/biolre/ioz236 31901091
Block, L. N. et al. Embryotoxic impact of Zika virus in a rhesus macaque in vitro implantation model†. Biol. Reprod. 102, 806–816 (2020).31901091
742. Steinbach RJ A neonatal nonhuman primate model of gestational Zika virus infection with evidence of microencephaly, seizures and cardiomyopathy PLoS One 2020 15 e0227676 10.1371/journal.pone.0227676 31935257
Steinbach, R. J. et al. A neonatal nonhuman primate model of gestational Zika virus infection with evidence of microencephaly, seizures and cardiomyopathy. PLoS One 15, e0227676 (2020).31935257
743. Martinot AJ Fetal Neuropathology in Zika Virus-Infected Pregnant Female Rhesus Monkeys Cell 2018 173 1111 1122.e10 10.1016/j.cell.2018.03.019 29606355
Martinot, A. J. et al. Fetal Neuropathology in Zika Virus-Infected Pregnant Female Rhesus Monkeys. Cell 173, 1111–1122.e10 (2018).29606355
744. Beckman D Neuroanatomical abnormalities in a nonhuman primate model of congenital Zika virus infection Elife 2022 11 e64734 10.7554/eLife.64734 35261339
Beckman, D. et al. Neuroanatomical abnormalities in a nonhuman primate model of congenital Zika virus infection. Elife 11, e64734 (2022).35261339
745. Tarantal AF Fetal Rhesus Monkey First Trimester Zika Virus Infection Impacts Cortical Development in the Second and Third Trimesters Cereb. Cortex 2021 31 2309 2321 10.1093/cercor/bhaa336 33341889
Tarantal, A. F. et al. Fetal Rhesus Monkey First Trimester Zika Virus Infection Impacts Cortical Development in the Second and Third Trimesters. Cereb. Cortex 31, 2309–2321 (2021).33341889
746. Raper J Long-term alterations in brain and behavior after postnatal Zika virus infection in infant macaques Nat. Commun. 2020 11 2534 10.1038/s41467-020-16320-7 32439858
Raper, J. et al. Long-term alterations in brain and behavior after postnatal Zika virus infection in infant macaques. Nat. Commun. 11, 2534 (2020).32439858
747. Coffey LL Intraamniotic Zika virus inoculation of pregnant rhesus macaques produces fetal neurologic disease Nat. Commun. 2018 9 2414 10.1038/s41467-018-04777-6 29925843
Coffey, L. L. et al. Intraamniotic Zika virus inoculation of pregnant rhesus macaques produces fetal neurologic disease. Nat. Commun. 9, 2414 (2018).29925843
748. Mavigner M Postnatal Zika virus infection is associated with persistent abnormalities in brain structure, function, and behavior in infant macaques Sci. Transl. Med. 2018 10 eaao6975 10.1126/scitranslmed.aao6975 29618564
Mavigner, M. et al. Postnatal Zika virus infection is associated with persistent abnormalities in brain structure, function, and behavior in infant macaques. Sci. Transl. Med. 10, eaao6975 (2018).29618564
749. Yiu G Evolution of ocular defects in infant macaques following in utero Zika virus infection JCI Insight 2020 5 e143947 10.1172/jci.insight.143947 33180748
Yiu, G. et al. Evolution of ocular defects in infant macaques following in utero Zika virus infection. JCI Insight 5, e143947 (2020).33180748
750. Dudley DM Infection via mosquito bite alters Zika virus tissue tropism and replication kinetics in rhesus macaques Nat. Commun. 2017 8 2096 10.1038/s41467-017-02222-8 29235456
Dudley, D. M. et al. Infection via mosquito bite alters Zika virus tissue tropism and replication kinetics in rhesus macaques. Nat. Commun. 8, 2096 (2017).29235456
751. Marlin R Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates Nat. Commun. 2022 13 5108 10.1038/s41467-022-32565-w 36042198
Marlin, R. et al. Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates. Nat. Commun. 13, 5108 (2022).36042198
752. Lecouturier V An optimized purified inactivated Zika vaccine provides sustained immunogenicity and protection in cynomolgus macaques NPJ Vaccines 2020 5 19 10.1038/s41541-020-0167-8 32194996
Lecouturier, V. et al. An optimized purified inactivated Zika vaccine provides sustained immunogenicity and protection in cynomolgus macaques. NPJ Vaccines 5, 19 (2020).32194996
753. Breitbach ME Primary infection with dengue or Zika virus does not affect the severity of heterologous secondary infection in macaques PLoS Pathog. 2019 15 e1007766 10.1371/journal.ppat.1007766 31369649
Breitbach, M. E. et al. Primary infection with dengue or Zika virus does not affect the severity of heterologous secondary infection in macaques. PLoS Pathog. 15, e1007766 (2019).31369649
754. de Alwis R Systemic inflammation, innate immunity and pathogenesis after Zika virus infection in cynomolgus macaques are modulated by strain-specificity within the Asian lineage Emerg. Microbes Infect. 2021 10 1457 1470 10.1080/22221751.2021.1943536 34120576
de Alwis, R. et al. Systemic inflammation, innate immunity and pathogenesis after Zika virus infection in cynomolgus macaques are modulated by strain-specificity within the Asian lineage. Emerg. Microbes Infect. 10, 1457–1470 (2021).34120576
755. Azar SR ZIKV Demonstrates Minimal Pathologic Effects and Mosquito Infectivity in Viremic Cynomolgus Macaques Viruses 2018 10 661 10.3390/v10110661 30469417
Azar, S. R. et al. ZIKV Demonstrates Minimal Pathologic Effects and Mosquito Infectivity in Viremic Cynomolgus Macaques. Viruses 10, 661 (2018).30469417
756. Koide F Development of a Zika Virus Infection Model in Cynomolgus Macaques Front. Microbiol. 2016 7 2028 10.3389/fmicb.2016.02028 28066354
Koide, F. et al. Development of a Zika Virus Infection Model in Cynomolgus Macaques. Front. Microbiol. 7, 2028 (2016).28066354
757. Berry N Mucosal Responses to Zika Virus Infection in Cynomolgus Macaques Pathogens 2022 11 1033 10.3390/pathogens11091033 36145466
Berry, N. et al. Mucosal Responses to Zika Virus Infection in Cynomolgus Macaques. Pathogens 11, 1033 (2022).36145466
758. Haddow AD High Infection Rates for Adult Macaques after Intravaginal or Intrarectal Inoculation with Zika Virus Emerg. Infect. Dis. 2017 23 1274 1281 10.3201/eid2308.170036 28548637
Haddow, A. D. et al. High Infection Rates for Adult Macaques after Intravaginal or Intrarectal Inoculation with Zika Virus. Emerg. Infect. Dis. 23, 1274–1281 (2017).28548637
759. Shofa M Repeated Intravaginal Inoculation of Zika Virus Protects Cynomolgus Monkeys from Subcutaneous Superchallenge Int J. Mol. Sci. 2022 23 14002 10.3390/ijms232214002 36430481
Shofa, M. et al. Repeated Intravaginal Inoculation of Zika Virus Protects Cynomolgus Monkeys from Subcutaneous Superchallenge. Int J. Mol. Sci. 23, 14002 (2022).36430481
760. Haddow AD Modeling mosquito-borne and sexual transmission of Zika virus in an enzootic host, the African green monkey PLoS Negl. Trop. Dis. 2020 14 e0008107 10.1371/journal.pntd.0008107 32569276
Haddow, A. D. et al. Modeling mosquito-borne and sexual transmission of Zika virus in an enzootic host, the African green monkey. PLoS Negl. Trop. Dis. 14, e0008107 (2020).32569276
761. O’Connor MA Early cellular innate immune responses drive Zika viral persistence and tissue tropism in pigtail macaques Nat. Commun. 2018 9 3371 10.1038/s41467-018-05826-w 30135445
O’Connor, M. A. et al. Early cellular innate immune responses drive Zika viral persistence and tissue tropism in pigtail macaques. Nat. Commun. 9, 3371 (2018).30135445
762. Adams Waldorf KM Congenital Zika virus infection as a silent pathology with loss of neurogenic output in the fetal brain Nat. Med. 2018 24 368 374 10.1038/nm.4485 29400709
Adams Waldorf, K. M. et al. Congenital Zika virus infection as a silent pathology with loss of neurogenic output in the fetal brain. Nat. Med. 24, 368–374 (2018).29400709
763. Adams Waldorf KM Fetal brain lesions after subcutaneous inoculation of Zika virus in a pregnant nonhuman primate Nat. Med. 2016 22 1256 1259 10.1038/nm.4193 27618651
Adams Waldorf, K. M. et al. Fetal brain lesions after subcutaneous inoculation of Zika virus in a pregnant nonhuman primate. Nat. Med. 22, 1256–1259 (2016).27618651
764. Chiu CY Experimental Zika Virus Inoculation in a New World Monkey Model Reproduces Key Features of the Human Infection Sci. Rep. 2017 7 17126 10.1038/s41598-017-17067-w 29215081
Chiu, C. Y. et al. Experimental Zika Virus Inoculation in a New World Monkey Model Reproduces Key Features of the Human Infection. Sci. Rep. 7, 17126 (2017).29215081
765. Lum F-M Multimodal assessments of Zika virus immune pathophysiological responses in marmosets Sci. Rep. 2018 8 17125 10.1038/s41598-018-35481-6 30459473
Lum, F.-M. et al. Multimodal assessments of Zika virus immune pathophysiological responses in marmosets. Sci. Rep. 8, 17125 (2018).30459473
766. Berry N High susceptibility, viral dynamics and persistence of South American Zika virus in New World monkey species Sci. Rep. 2019 9 14495 10.1038/s41598-019-50918-2 31601848
Berry, N. et al. High susceptibility, viral dynamics and persistence of South American Zika virus in New World monkey species. Sci. Rep. 9, 14495 (2019).31601848
767. Seferovic M Experimental Zika Virus Infection in the Pregnant Common Marmoset Induces Spontaneous Fetal Loss and Neurodevelopmental Abnormalities Sci. Rep. 2018 8 6851 10.1038/s41598-018-25205-1 29717225
Seferovic, M. et al. Experimental Zika Virus Infection in the Pregnant Common Marmoset Induces Spontaneous Fetal Loss and Neurodevelopmental Abnormalities. Sci. Rep. 8, 6851 (2018).29717225
768. Robbiani DF Risk of Zika microcephaly correlates with features of maternal antibodies J. Exp. Med. 2019 216 2302 2315 10.1084/jem.20191061 31413072
Robbiani, D. F. et al. Risk of Zika microcephaly correlates with features of maternal antibodies. J. Exp. Med. 216, 2302–2315 (2019).31413072
769. Gurung, S. et al. Translational Model of Zika Virus Disease in Baboons. J Virol. 92, e00186-18 (2018).
770. Gurung S Zika virus infection at mid-gestation results in fetal cerebral cortical injury and fetal death in the olive baboon PLoS Pathog. 2019 15 e1007507 10.1371/journal.ppat.1007507 30657788
Gurung, S. et al. Zika virus infection at mid-gestation results in fetal cerebral cortical injury and fetal death in the olive baboon. PLoS Pathog. 15, e1007507 (2019).30657788
771. Gurung S Early and mid-gestation Zika virus (ZIKV) infection in the olive baboon (Papio anubis) leads to fetal CNS pathology by term gestation PLoS Pathog. 2022 18 e1010386 10.1371/journal.ppat.1010386 35969617
Gurung, S. et al. Early and mid-gestation Zika virus (ZIKV) infection in the olive baboon (Papio anubis) leads to fetal CNS pathology by term gestation. PLoS Pathog. 18, e1010386 (2022).35969617
772. Peregrine J Zika Virus Infection, Reproductive Organ Targeting, and Semen Transmission in the Male Olive Baboon J. Virol. 2019 94 e01434 19 10.1128/JVI.01434-19 31597777
Peregrine, J. et al. Zika Virus Infection, Reproductive Organ Targeting, and Semen Transmission in the Male Olive Baboon. J. Virol. 94, e01434–19 (2019).31597777
773. Modjarrad K Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials Lancet 2018 391 563 571 10.1016/S0140-6736(17)33106-9 29217375
Modjarrad, K. et al. Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials. Lancet 391, 563–571 (2018).29217375
774. Abbink P Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys Science 2016 353 1129 1132 10.1126/science.aah6157 27492477
Abbink, P. et al. Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science 353, 1129–1132 (2016).27492477
775. Muthumani K In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine NPJ Vaccines 2016 1 16021 10.1038/npjvaccines.2016.21 29263859
Muthumani, K. et al. In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine. NPJ Vaccines 1, 16021 (2016).29263859
776. Dowd KA Rapid development of a DNA vaccine for Zika virus Science 2016 354 237 240 10.1126/science.aai9137 27708058
Dowd, K. A. et al. Rapid development of a DNA vaccine for Zika virus. Science 354, 237–240 (2016).27708058
777. Gaudinski MR Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials Lancet 2018 391 552 562 10.1016/S0140-6736(17)33105-7 29217376
Gaudinski, M. R. et al. Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials. Lancet 391, 552–562 (2018).29217376
778. Deering RP Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines Expert Opin. Drug Deliv. 2014 11 885 899 10.1517/17425247.2014.901308 24665982
Deering, R. P. et al. Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines. Expert Opin. Drug Deliv. 11, 885–899 (2014).24665982
779. Pardi N Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination Nature 2017 543 248 251 10.1038/nature21428 28151488
Pardi, N. et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature 543, 248–251 (2017).28151488
780. Chahal JS An RNA nanoparticle vaccine against Zika virus elicits antibody and CD8+ T cell responses in a mouse model Sci. Rep. 2017 7 252 10.1038/s41598-017-00193-w 28325910
Chahal, J. S. et al. An RNA nanoparticle vaccine against Zika virus elicits antibody and CD8+ T cell responses in a mouse model. Sci. Rep. 7, 252 (2017).28325910
781. Abbink P Stephenson KE Barouch DH Zika virus vaccines Nat. Rev. Microbiol 2018 16 594 600 10.1038/s41579-018-0039-7 29921914
Abbink, P., Stephenson, K. E. & Barouch, D. H. Zika virus vaccines. Nat. Rev. Microbiol 16, 594–600 (2018).29921914
782. Combredet C A molecularly cloned Schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice J. Virol. 2003 77 11546 11554 10.1128/JVI.77.21.11546-11554.2003 14557640
Combredet, C. et al. A molecularly cloned Schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice. J. Virol. 77, 11546–11554 (2003).14557640
783. López-Camacho C Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors Nat. Commun. 2018 9 2441 10.1038/s41467-018-04859-5 29934593
López-Camacho, C. et al. Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors. Nat. Commun. 9, 2441 (2018).29934593
784. Sapparapu G Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice Nature 2016 540 443 447 10.1038/nature20564 27819683
Sapparapu, G. et al. Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice. Nature 540, 443–447 (2016).27819683
785. Stettler K Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection Science 2016 353 823 826 10.1126/science.aaf8505 27417494
Stettler, K. et al. Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. Science 353, 823–826 (2016).27417494
786. Barba-Spaeth G Structural basis of potent Zika-dengue virus antibody cross-neutralization Nature 2016 536 48 53 10.1038/nature18938 27338953
Barba-Spaeth, G. et al. Structural basis of potent Zika-dengue virus antibody cross-neutralization. Nature 536, 48–53 (2016).27338953
787. Zou J Shi PY Strategies for Zika drug discovery Curr. Opin. Virol. 2019 35 19 26 10.1016/j.coviro.2019.01.005 30852345
Zou, J. & Shi, P. Y. Strategies for Zika drug discovery. Curr. Opin. Virol. 35, 19–26 (2019).30852345
788. Bernatchez JA Drugs for the Treatment of Zika Virus Infection J. Med Chem. 2020 63 470 489 10.1021/acs.jmedchem.9b00775 31549836
Bernatchez, J. A. et al. Drugs for the Treatment of Zika Virus Infection. J. Med Chem. 63, 470–489 (2020).31549836
789. Julander JG Efficacy of the broad-spectrum antiviral compound BCX4430 against Zika virus in cell culture and in a mouse model Antivir. Res 2017 137 14 22 10.1016/j.antiviral.2016.11.003 27838352
Julander, J. G. et al. Efficacy of the broad-spectrum antiviral compound BCX4430 against Zika virus in cell culture and in a mouse model. Antivir. Res 137, 14–22 (2017).27838352
790. Cardoso-Moreira M Developmental Gene Expression Differences between Humans and Mammalian Models Cell Rep. 2020 33 108308 10.1016/j.celrep.2020.108308 33113372
Cardoso-Moreira, M. et al. Developmental Gene Expression Differences between Humans and Mammalian Models. Cell Rep. 33, 108308 (2020).33113372
791. Wang S Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases Signal Transduct. Target Ther. 2023 8 149 10.1038/s41392-023-01408-5 37029123
Wang, S. et al. Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases. Signal Transduct. Target Ther. 8, 149 (2023).37029123
792. Li H Enhanced protective immunity against SARS-CoV-2 elicited by a VSV vector expressing a chimeric spike protein Signal Transduct. Target Ther. 2021 6 389 10.1038/s41392-021-00797-9 34759261
Li, H. et al. Enhanced protective immunity against SARS-CoV-2 elicited by a VSV vector expressing a chimeric spike protein. Signal Transduct. Target Ther. 6, 389 (2021).34759261
793. Vanhoutte F Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1/2 randomised, double-blind, placebo-controlled, dose-ranging trial EBioMedicine 2022 75 103811 10.1016/j.ebiom.2021.103811 35042081
Vanhoutte, F. et al. Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1/2 randomised, double-blind, placebo-controlled, dose-ranging trial. EBioMedicine 75, 103811 (2022).35042081
794. Launay O Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study EBioMedicine 2022 75 103810 10.1016/j.ebiom.2021.103810 35045362
Launay, O. et al. Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study. EBioMedicine 75, 103810 (2022).35045362
795. Lloyd-Price J Abu-Ali G Huttenhower C The healthy human microbiome Genome Med. 2016 8 51 10.1186/s13073-016-0307-y 27122046
Lloyd-Price, J., Abu-Ali, G. & Huttenhower, C. The healthy human microbiome. Genome Med. 8, 51 (2016).27122046
796. Parkin J Cohen B An overview of the immune system Lancet 2001 357 1777 1789 10.1016/S0140-6736(00)04904-7 11403834
Parkin, J. & Cohen, B. An overview of the immune system. Lancet 357, 1777–1789 (2001).11403834
797. Liu G Clinical Evaluation of Ebola Virus Disease Therapeutics Trends Mol. Med. 2017 23 820 830 10.1016/j.molmed.2017.07.002 28822631
Liu, G. et al. Clinical Evaluation of Ebola Virus Disease Therapeutics. Trends Mol. Med. 23, 820–830 (2017).28822631
798. Gilbert PB A Covid-19 Milestone Attained - A Correlate of Protection for Vaccines N. Engl. J. Med. 2022 387 2203 2206 10.1056/NEJMp2211314 36507702
Gilbert, P. B. et al. A Covid-19 Milestone Attained - A Correlate of Protection for Vaccines. N. Engl. J. Med. 387, 2203–2206 (2022).36507702
799. Bray M A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever J. Infect. Dis. 1998 178 651 661 10.1086/515386 9728532
Bray, M. et al. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J. Infect. Dis. 178, 651–661 (1998).9728532
800. Arnason G The Emergence and Development of Animal Research Ethics: A Review with a Focus on Nonhuman Primates Sci. Eng. Ethics 2020 26 2277 2293 10.1007/s11948-020-00219-z 32350758
Arnason, G. The Emergence and Development of Animal Research Ethics: A Review with a Focus on Nonhuman Primates. Sci. Eng. Ethics 26, 2277–2293 (2020).32350758
801. Carabelli AM SARS-CoV-2 variant biology: immune escape, transmission and fitness Nat. Rev. Microbiol. 2023 21 162 177 36653446
Carabelli, A. M. et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat. Rev. Microbiol. 21, 162–177 (2023).36653446
802. Deng, W. et al. Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques. Science, 369, 818–823 (2020).
803. FDA. Animal Rule Summary, <https://www.fda.gov/emergency-preparedness-and-response/mcm-regulatory-science/animal-rule-summary> (2017).
804. McMahan K Correlates of protection against SARS-CoV-2 in rhesus macaques Nature 2021 590 630 634 10.1038/s41586-020-03041-6 33276369
McMahan, K. et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature 590, 630–634 (2021).33276369
805. Chandrashekar A SARS-CoV-2 infection protects against rechallenge in rhesus macaques Science 2020 369 812 817 10.1126/science.abc4776 32434946
Chandrashekar, A. et al. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science 369, 812–817 (2020).32434946
806. McKay PF Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice Nat. Commun. 2020 11 3523 10.1038/s41467-020-17409-9 32647131
McKay, P. F. et al. Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice. Nat. Commun. 11, 3523 (2020).32647131
807. Earle KA Evidence for antibody as a protective correlate for COVID-19 vaccines Vaccine 2021 39 4423 4428 10.1016/j.vaccine.2021.05.063 34210573
Earle, K. A. et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine 39, 4423–4428 (2021).34210573
808. Fong Y Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial Nat. Microbiol. 2022 7 1996 2010 10.1038/s41564-022-01262-1 36357712
Fong, Y. et al. Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial. Nat. Microbiol. 7, 1996–2010 (2022).36357712
809. Weiskopf D Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome Sci. Immunol. 2020 5 eabd2071 10.1126/sciimmunol.abd2071 32591408
Weiskopf, D. et al. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome. Sci. Immunol. 5, eabd2071 (2020).32591408
810. Bradfute SB Bavari S Correlates of immunity to filovirus infection Viruses 2011 3 982 1000 10.3390/v3070982 21994766
Bradfute, S. B. & Bavari, S. Correlates of immunity to filovirus infection. Viruses 3, 982–1000 (2011).21994766
811. Baize S Inflammatory responses in Ebola virus-infected patients Clin. Exp. Immunol. 2002 128 163 168 10.1046/j.1365-2249.2002.01800.x 11982604
Baize, S. et al. Inflammatory responses in Ebola virus-infected patients. Clin. Exp. Immunol. 128, 163–168 (2002).11982604
812. Jonkmans N D’Acremont V Flahault A Scoping future outbreaks: a scoping review on the outbreak prediction of the WHO Blueprint list of priority diseases BMJ Glob. Health 2021 6 e006623 10.1136/bmjgh-2021-006623 34531189
Jonkmans, N., D’Acremont, V. & Flahault, A. Scoping future outbreaks: a scoping review on the outbreak prediction of the WHO Blueprint list of priority diseases. BMJ Glob. Health 6, e006623 (2021).34531189
813. Rathinam C Efficient differentiation and function of human macrophages in humanized CSF-1 mice Blood 2011 118 3119 3128 10.1182/blood-2010-12-326926 21791433
Rathinam, C. et al. Efficient differentiation and function of human macrophages in humanized CSF-1 mice. Blood 118, 3119–3128 (2011).21791433
814. Willinger T Human IL-3/GM-CSF knock-in mice support human alveolar macrophage development and human immune responses in the lung Proc. Natl Acad. Sci. USA 2011 108 2390 2395 10.1073/pnas.1019682108 21262803
Willinger, T. et al. Human IL-3/GM-CSF knock-in mice support human alveolar macrophage development and human immune responses in the lung. Proc. Natl Acad. Sci. USA 108, 2390–2395 (2011).21262803
815. Strowig T Transgenic expression of human signal regulatory protein alpha in Rag2−/−gamma(c)−/− mice improves engraftment of human hematopoietic cells in humanized mice Proc. Natl Acad. Sci. USA 2011 108 13218 13223 10.1073/pnas.1109769108 21788509
Strowig, T. et al. Transgenic expression of human signal regulatory protein alpha in Rag2−/−gamma(c)−/− mice improves engraftment of human hematopoietic cells in humanized mice. Proc. Natl Acad. Sci. USA 108, 13218–13223 (2011).21788509
816. Rongvaux A Human thrombopoietin knockin mice efficiently support human hematopoiesis in vivo Proc. Natl Acad. Sci. USA 2011 108 2378 2383 10.1073/pnas.1019524108 21262827
Rongvaux, A. et al. Human thrombopoietin knockin mice efficiently support human hematopoiesis in vivo. Proc. Natl Acad. Sci. USA 108, 2378–2383 (2011).21262827
817. Rongvaux A Development and function of human innate immune cells in a humanized mouse model Nat. Biotechnol. 2014 32 364 372 10.1038/nbt.2858 24633240
Rongvaux, A. et al. Development and function of human innate immune cells in a humanized mouse model. Nat. Biotechnol. 32, 364–372 (2014).24633240
818. Yu H A novel humanized mouse model with significant improvement of class-switched, antigen-specific antibody production Blood 2017 129 959 969 10.1182/blood-2016-04-709584 28077418
Yu, H. et al. A novel humanized mouse model with significant improvement of class-switched, antigen-specific antibody production. Blood 129, 959–969 (2017).28077418
819. Das R Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice Nat. Med. 2016 22 1351 1357 10.1038/nm.4202 27723723
Das, R. et al. Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice. Nat. Med. 22, 1351–1357 (2016).27723723
820. Sippel TR Human hematopoietic stem cell maintenance and myeloid cell development in next-generation humanized mouse models Blood Adv. 2019 3 268 274 10.1182/bloodadvances.2018023887 30696625
Sippel, T. R. et al. Human hematopoietic stem cell maintenance and myeloid cell development in next-generation humanized mouse models. Blood Adv. 3, 268–274 (2019).30696625
821. Wahl A Precision mouse models with expanded tropism for human pathogens Nat. Biotechnol. 2019 37 1163 1173 10.1038/s41587-019-0225-9 31451733
Wahl, A. et al. Precision mouse models with expanded tropism for human pathogens. Nat. Biotechnol. 37, 1163–1173 (2019).31451733
822. Kim HW Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine Am. J. Epidemiol. 1969 89 422 434 10.1093/oxfordjournals.aje.a120955 4305198
Kim, H. W. et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89, 422–434 (1969).4305198
823. Roy SK Bhattacharjee S Dengue virus: epidemiology, biology, and disease aetiology Can. J. Microbiol. 2021 67 687 702 10.1139/cjm-2020-0572 34171205
Roy, S. K. & Bhattacharjee, S. Dengue virus: epidemiology, biology, and disease aetiology. Can. J. Microbiol. 67, 687–702 (2021).34171205
824. Wan Y Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry J. Virol. 2020 94 e02015 e02019 10.1128/JVI.02015-19 31826992
Wan, Y. et al. Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry. J. Virol. 94, e02015–e02019 (2020).31826992
825. Takada A Feldmann H Ksiazek TG Kawaoka Y Antibody-dependent enhancement of Ebola virus infection J. Virol. 2003 77 7539 7544 10.1128/JVI.77.13.7539-7544.2003 12805454
Takada, A., Feldmann, H., Ksiazek, T. G. & Kawaoka, Y. Antibody-dependent enhancement of Ebola virus infection. J. Virol. 77, 7539–7544 (2003).12805454
826. Nakayama E Antibody-dependent enhancement of Marburg virus infection J. Infect. Dis. 2011 204 S978 S985 10.1093/infdis/jir334 21987779
Nakayama, E. et al. Antibody-dependent enhancement of Marburg virus infection. J. Infect. Dis. 204, S978–S985 (2011).21987779
827. Kuzmina NA Antibody-Dependent Enhancement of Ebola Virus Infection by Human Antibodies Isolated from Survivors Cell Rep. 2018 24 1802 1815.e1805 10.1016/j.celrep.2018.07.035 30110637
Kuzmina, N. A. et al. Antibody-Dependent Enhancement of Ebola Virus Infection by Human Antibodies Isolated from Survivors. Cell Rep. 24, 1802–1815.e1805 (2018).30110637
828. Jahrling PB Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates J. Infect. Dis. 2007 196 S400 S403 10.1086/520587 17940976
Jahrling, P. B. et al. Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates. J. Infect. Dis. 196, S400–S403 (2007).17940976
829. Oswald WB Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys PLoS Pathog. 2007 3 e9 10.1371/journal.ppat.0030009 17238286
Oswald, W. B. et al. Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog. 3, e9 (2007).17238286
830. Dye JM Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease Proc. Natl Acad. Sci. USA 2012 109 5034 5039 10.1073/pnas.1200409109 22411795
Dye, J. M. et al. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc. Natl Acad. Sci. USA 109, 5034–5039 (2012).22411795
831. Qiu X Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies Sci. Transl. Med. 2012 4 138ra181 10.1126/scitranslmed.3003876
Qiu, X. et al. Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci. Transl. Med. 4, 138ra181 (2012).
832. Wang S Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys Nat. Commun. 2020 11 5752 10.1038/s41467-020-19568-1 33188207
Wang, S. et al. Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys. Nat. Commun. 11, 5752 (2020).33188207
833. Zhou Y Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD Cell Rep. 2021 34 108699 10.1016/j.celrep.2021.108699 33485405
Zhou, Y. et al. Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD. Cell Rep. 34, 108699 (2021).33485405
834. Liu Y An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies Cell 2021 184 3452 3466.e3418 10.1016/j.cell.2021.05.032 34139176
Liu, Y. et al. An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies. Cell 184, 3452–3466.e3418 (2021).34139176
835. Li, D. et al. The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates. bioRxiv, https://www.biorxiv.org/content/10.1101/2020.12.31.424729v2 (2021).
836. Bolles M A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge J. Virol. 2011 85 12201 12215 10.1128/JVI.06048-11 21937658
Bolles, M. et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J. Virol. 85, 12201–12215 (2011).21937658
837. Tseng CT Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus PLoS One 2012 7 e35421 10.1371/journal.pone.0035421 22536382
Tseng, C. T. et al. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS One 7, e35421 (2012).22536382
838. Munoz FM Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data Vaccine 2021 39 3053 3066 10.1016/j.vaccine.2021.01.055 33637387
Munoz, F. M. et al. Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine 39, 3053–3066 (2021).33637387
839. Bewley KR Immunological and pathological outcomes of SARS-CoV-2 challenge following formalin-inactivated vaccine in ferrets and rhesus macaques Sci. Adv. 2021 7 eabg7996 10.1126/sciadv.abg7996 34516768
Bewley, K. R. et al. Immunological and pathological outcomes of SARS-CoV-2 challenge following formalin-inactivated vaccine in ferrets and rhesus macaques. Sci. Adv. 7, eabg7996 (2021).34516768
840. Hoffmann D CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2 Nat. Commun. 2021 12 4048 10.1038/s41467-021-24339-7 34193869
Hoffmann, D. et al. CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2. Nat. Commun. 12, 4048 (2021).34193869
841. Messaoudi I Amarasinghe GK Basler CF Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus Nat. Rev. Microbiol. 2015 13 663 676, 10.1038/nrmicro3524 26439085
Messaoudi, I., Amarasinghe, G. K. & Basler, C. F. Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus. Nat. Rev. Microbiol. 13, 663–676, (2015).26439085
842. Steiner S SARS-CoV-2 biology and host interactions Nat. Rev. Microbiol. 2024 22 206 225 10.1038/s41579-023-01003-z 38225365
Steiner, S. et al. SARS-CoV-2 biology and host interactions. Nat. Rev. Microbiol. 22, 206–225 (2024).38225365
843. Zhou B SARS-CoV-2 spike D614G change enhances replication and transmission Nature 2021 592 122 127 10.1038/s41586-021-03361-1 33636719
Zhou, B. et al. SARS-CoV-2 spike D614G change enhances replication and transmission. Nature 592, 122–127 (2021).33636719
844. Cool K Infection and transmission of ancestral SARS-CoV-2 and its alpha variant in pregnant white-tailed deer Emerg. Microbes Infect. 2022 11 95 112 10.1080/22221751.2021.2012528 34842046
Cool, K. et al. Infection and transmission of ancestral SARS-CoV-2 and its alpha variant in pregnant white-tailed deer. Emerg. Microbes Infect. 11, 95–112 (2022).34842046
845. Rathnasinghe, R. et al. The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human sera. medRxiv, https://www.medrxiv.org/content/10.1101/2021.01.19.21249592v1 (2021).
846. Wang R Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species Immunity 2021 54 1611 1621.e1615 10.1016/j.immuni.2021.06.003 34166623
Wang, R. et al. Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species. Immunity 54, 1611–1621.e1615 (2021).34166623
847. Abdelnabi R Comparing infectivity and virulence of emerging SARS-CoV-2 variants in Syrian hamsters EBioMedicine 2021 68 103403 10.1016/j.ebiom.2021.103403 34049240
Abdelnabi, R. et al. Comparing infectivity and virulence of emerging SARS-CoV-2 variants in Syrian hamsters. EBioMedicine 68, 103403 (2021).34049240
848. Thorne, L. G. et al. Evolution of enhanced innate immune evasion by the SARS-CoV-2 B.1.1.7 UK variant. bioRxiv, https://www.biorxiv.org/content/10.1101/2021.06.06.446826v1 (2021).
849. Kumar A Emerging SARS-CoV-2 variants can potentially break set epidemiological barriers in COVID-19 J. Med. Virol. 2022 94 1300 1314 10.1002/jmv.27467 34811761
Kumar, A. et al. Emerging SARS-CoV-2 variants can potentially break set epidemiological barriers in COVID-19. J. Med. Virol. 94, 1300–1314 (2022).34811761
850. Yinda CK Prior aerosol infection with lineage A SARS-CoV-2 variant protects hamsters from disease, but not reinfection with B.1.351 SARS-CoV-2 variant Emerg. Microbes Infect. 2021 10 1284 1292 10.1080/22221751.2021.1943539 34120579
Yinda, C. K. et al. Prior aerosol infection with lineage A SARS-CoV-2 variant protects hamsters from disease, but not reinfection with B.1.351 SARS-CoV-2 variant. Emerg. Microbes Infect. 10, 1284–1292 (2021).34120579
851. Mohandas S SARS-CoV-2 Delta Variant Pathogenesis and Host Response in Syrian Hamsters Viruses 2021 13 1773 10.3390/v13091773 34578354
Mohandas, S. et al. SARS-CoV-2 Delta Variant Pathogenesis and Host Response in Syrian Hamsters. Viruses 13, 1773 (2021).34578354
852. Brustolin M Protection against reinfection with D614- or G614-SARS-CoV-2 isolates in golden Syrian hamster Emerg. Microbes Infect. 2021 10 797 809 10.1080/22221751.2021.1913974 33825619
Brustolin, M. et al. Protection against reinfection with D614- or G614-SARS-CoV-2 isolates in golden Syrian hamster. Emerg. Microbes Infect. 10, 797–809 (2021).33825619
853. Gaudreault NN SARS-CoV-2 infection, disease and transmission in domestic cats Emerg. Microbes Infect. 2020 9 2322 2332 10.1080/22221751.2020.1833687 33028154
Gaudreault, N. N. et al. SARS-CoV-2 infection, disease and transmission in domestic cats. Emerg. Microbes Infect. 9, 2322–2332 (2020).33028154
854. Marsh GA ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets NPJ Vaccines 2021 6 67 10.1038/s41541-021-00315-6 33972565
Marsh, G. A. et al. ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets. NPJ Vaccines 6, 67 (2021).33972565
855. van Doremalen N Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models Sci. Transl. Med. 2021 13 eabh0755 10.1126/scitranslmed.abh0755 34315826
van Doremalen, N. et al. Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models. Sci. Transl. Med. 13, eabh0755 (2021).34315826
856. de Melo GD COVID-19-related anosmia is associated with viral persistence and inflammation in human olfactory epithelium and brain infection in hamsters Sci. Transl. Med. 2021 13 eabf8396 10.1126/scitranslmed.abf8396 33941622
de Melo, G. D. et al. COVID-19-related anosmia is associated with viral persistence and inflammation in human olfactory epithelium and brain infection in hamsters. Sci. Transl. Med. 13, eabf8396 (2021).33941622
857. Allnoch L Vascular Inflammation Is Associated with Loss of Aquaporin 1 Expression on Endothelial Cells and Increased Fluid Leakage in SARS-CoV-2 Infected Golden Syrian Hamsters Viruses 2021 13 639 10.3390/v13040639 33918079
Allnoch, L. et al. Vascular Inflammation Is Associated with Loss of Aquaporin 1 Expression on Endothelial Cells and Increased Fluid Leakage in SARS-CoV-2 Infected Golden Syrian Hamsters. Viruses 13, 639 (2021).33918079
858. Becker K Vasculitis and Neutrophil Extracellular Traps in Lungs of Golden Syrian Hamsters With SARS-CoV-2 Front. Immunol. 2021 12 640842 10.3389/fimmu.2021.640842 33912167
Becker, K. et al. Vasculitis and Neutrophil Extracellular Traps in Lungs of Golden Syrian Hamsters With SARS-CoV-2. Front. Immunol. 12, 640842 (2021).33912167
859. Yuan L Gender associates with both susceptibility to infection and pathogenesis of SARS-CoV-2 in Syrian hamster Signal Transduct. Target Ther. 2021 6 136 10.1038/s41392-021-00552-0 33790236
Yuan, L. et al. Gender associates with both susceptibility to infection and pathogenesis of SARS-CoV-2 in Syrian hamster. Signal Transduct. Target Ther. 6, 136 (2021).33790236
860. Takahashi T Sex differences in immune responses that underlie COVID-19 disease outcomes Nature 2020 588 315 320 10.1038/s41586-020-2700-3 32846427
Takahashi, T. et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature 588, 315–320 (2020).32846427
861. Rydyznski Moderbacher C Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity Cell 2020 183 996 1012.e1019 10.1016/j.cell.2020.09.038 33010815
Rydyznski Moderbacher, C. et al. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. Cell 183, 996–1012.e1019 (2020).33010815
862. Frieman MB SARS-CoV pathogenesis is regulated by a STAT1 dependent but a type I, II and III interferon receptor independent mechanism PLoS Pathog. 2010 6 e1000849 10.1371/journal.ppat.1000849 20386712
Frieman, M. B. et al. SARS-CoV pathogenesis is regulated by a STAT1 dependent but a type I, II and III interferon receptor independent mechanism. PLoS Pathog. 6, e1000849 (2010).20386712
863. Vijay R Critical role of phospholipase A2 group IID in age-related susceptibility to severe acute respiratory syndrome-CoV infection J. Exp. Med. 2015 212 1851 1868 10.1084/jem.20150632 26392224
Vijay, R. et al. Critical role of phospholipase A2 group IID in age-related susceptibility to severe acute respiratory syndrome-CoV infection. J. Exp. Med. 212, 1851–1868 (2015).26392224
864. Bajaj V Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections? Front. Physiol. 2020 11 571416 10.3389/fphys.2020.571416 33510644
Bajaj, V. et al. Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections? Front. Physiol. 11, 571416 (2020).33510644
865. Speranza E Age-related differences in immune dynamics during SARS-CoV-2 infection in rhesus macaques Life Sci. Alliance 2022 5 e202101314 10.26508/lsa.202101314 35039442
Speranza, E. et al. Age-related differences in immune dynamics during SARS-CoV-2 infection in rhesus macaques. Life Sci. Alliance 5, e202101314 (2022).35039442
866. Ma Y SARS-CoV-2 infection aggravates chronic comorbidities of cardiovascular diseases and diabetes in mice Anim. Model Exp. Med 2021 4 2 15 10.1002/ame2.12155
Ma, Y. et al. SARS-CoV-2 infection aggravates chronic comorbidities of cardiovascular diseases and diabetes in mice. Anim. Model Exp. Med 4, 2–15 (2021).
867. Blutt SE Estes MK Organoid Models for Infectious Disease Annu. Rev. Med. 2022 73 167 182 10.1146/annurev-med-042320-023055 34644153
Blutt, S. E. & Estes, M. K. Organoid Models for Infectious Disease. Annu. Rev. Med. 73, 167–182 (2022).34644153
868. Han Y Identification of SARS-CoV-2 inhibitors using lung and colonic organoids Nature 2021 589 270 275 10.1038/s41586-020-2901-9 33116299
Han, Y. et al. Identification of SARS-CoV-2 inhibitors using lung and colonic organoids. Nature 589, 270–275 (2021).33116299
869. Matsuyama S Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells Proc. Natl Acad. Sci. USA 2020 117 7001 7003 10.1073/pnas.2002589117 32165541
Matsuyama, S. et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc. Natl Acad. Sci. USA 117, 7001–7003 (2020).32165541
870. McCracken KW Howell JC Wells JM Spence JR Generating human intestinal tissue from pluripotent stem cells in vitro Nat. Protoc. 2011 6 1920 1928, 10.1038/nprot.2011.410 22082986
McCracken, K. W., Howell, J. C., Wells, J. M. & Spence, J. R. Generating human intestinal tissue from pluripotent stem cells in vitro. Nat. Protoc. 6, 1920–1928, (2011).22082986
871. Garcez PP Zika virus impairs growth in human neurospheres and brain organoids Science 2016 352 816 818 10.1126/science.aaf6116 27064148
Garcez, P. P. et al. Zika virus impairs growth in human neurospheres and brain organoids. Science 352, 816–818 (2016).27064148
872. Qian X Brain-Region-Specific Organoids Using Mini-bioreactors for Modeling ZIKV Exposure Cell 2016 165 1238 1254 10.1016/j.cell.2016.04.032 27118425
Qian, X. et al. Brain-Region-Specific Organoids Using Mini-bioreactors for Modeling ZIKV Exposure. Cell 165, 1238–1254 (2016).27118425
873. Watanabe M Self-Organized Cerebral Organoids with Human-Specific Features Predict Effective Drugs to Combat Zika Virus Infection Cell Rep. 2017 21 517 532 10.1016/j.celrep.2017.09.047 29020636
Watanabe, M. et al. Self-Organized Cerebral Organoids with Human-Specific Features Predict Effective Drugs to Combat Zika Virus Infection. Cell Rep. 21, 517–532 (2017).29020636
874. Song E Neuroinvasion of SARS-CoV-2 in human and mouse brain J. Exp. Med. 2021 218 e20202135 10.1084/jem.20202135 33433624
Song, E. et al. Neuroinvasion of SARS-CoV-2 in human and mouse brain. J. Exp. Med. 218, e20202135 (2021).33433624
875. Clevers H Modeling Development and Disease with Organoids Cell 2016 165 1586 1597 10.1016/j.cell.2016.05.082 27315476
Clevers, H. Modeling Development and Disease with Organoids. Cell 165, 1586–1597 (2016).27315476
876. Wong F de la Fuente-Nunez C Collins JJ Leveraging artificial intelligence in the fight against infectious diseases Science 2023 381 164 170 10.1126/science.adh1114 37440620
Wong, F., de la Fuente-Nunez, C. & Collins, J. J. Leveraging artificial intelligence in the fight against infectious diseases. Science 381, 164–170 (2023).37440620
877. Huang R Biological activity-based modeling identifies antiviral leads against SARS-CoV-2 Nat. Biotechnol. 2021 39 747 753 10.1038/s41587-021-00839-1 33623157
Huang, R. et al. Biological activity-based modeling identifies antiviral leads against SARS-CoV-2. Nat. Biotechnol. 39, 747–753 (2021).33623157
878. Chen H Systematic evaluation of machine learning methods for identifying human-pathogen protein-protein interactions Brief. Bioinform 2021 22 bbaa068 10.1093/bib/bbaa068 32459334
Chen, H. et al. Systematic evaluation of machine learning methods for identifying human-pathogen protein-protein interactions. Brief. Bioinform 22, bbaa068 (2021).32459334
879. Hie B Zhong ED Berger B Bryson B Learning the language of viral evolution and escape Science 2021 371 284 288 10.1126/science.abd7331 33446556
Hie, B., Zhong, E. D., Berger, B. & Bryson, B. Learning the language of viral evolution and escape. Science 371, 284–288 (2021).33446556
880. Bojar D Powers RK Camacho DM Collins JJ Deep-Learning Resources for Studying Glycan-Mediated Host-Microbe Interactions Cell Host Microbe 2021 29 132 144.e133 10.1016/j.chom.2020.10.004 33120114
Bojar, D., Powers, R. K., Camacho, D. M. & Collins, J. J. Deep-Learning Resources for Studying Glycan-Mediated Host-Microbe Interactions. Cell Host Microbe 29, 132–144.e133 (2021).33120114
881. Fisch D Defining host-pathogen interactions employing an artificial intelligence workflow Elife 2019 8 e40560 10.7554/eLife.40560 30744806
Fisch, D. et al. Defining host-pathogen interactions employing an artificial intelligence workflow. Elife 8, e40560 (2019).30744806
882. Lv H Application of artificial intelligence and machine learning for COVID-19 drug discovery and vaccine design Brief. Bioinform. 2021 22 bbab320 10.1093/bib/bbab320 34410360
Lv, H. et al. Application of artificial intelligence and machine learning for COVID-19 drug discovery and vaccine design. Brief. Bioinform. 22, bbab320 (2021).34410360
883. Cardillo AG Towards in silico Process Modeling for Vaccines Trends Biotechnol. 2021 39 1120 1130 10.1016/j.tibtech.2021.02.004 33707043
Cardillo, A. G. et al. Towards in silico Process Modeling for Vaccines. Trends Biotechnol. 39, 1120–1130 (2021).33707043
884. Mullowney MW Artificial intelligence for natural product drug discovery Nat. Rev. Drug Discov. 2023 22 895 916 10.1038/s41573-023-00774-7 37697042
Mullowney, M. W. et al. Artificial intelligence for natural product drug discovery. Nat. Rev. Drug Discov. 22, 895–916 (2023).37697042
885. Schadt EE Friend SH Shaywitz DA A network view of disease and compound screening Nat. Rev. Drug Discov. 2009 8 286 295 10.1038/nrd2826 19337271
Schadt, E. E., Friend, S. H. & Shaywitz, D. A. A network view of disease and compound screening. Nat. Rev. Drug Discov. 8, 286–295 (2009).19337271
886. Vatansever S Artificial intelligence and machine learning-aided drug discovery in central nervous system diseases: State-of-the-arts and future directions Med. Res. Rev. 2021 41 1427 1473 10.1002/med.21764 33295676
Vatansever, S. et al. Artificial intelligence and machine learning-aided drug discovery in central nervous system diseases: State-of-the-arts and future directions. Med. Res. Rev. 41, 1427–1473 (2021).33295676
887. Cumming JG Chemical predictive modelling to improve compound quality Nat. Rev. Drug Discov. 2013 12 948 962 10.1038/nrd4128 24287782
Cumming, J. G. et al. Chemical predictive modelling to improve compound quality. Nat. Rev. Drug Discov. 12, 948–962 (2013).24287782
888. Gleeson MP Hersey A Montanari D Overington J Probing the links between in vitro potency, ADMET and physicochemical parameters Nat. Rev. Drug Discov. 2011 10 197 208 10.1038/nrd3367 21358739
Gleeson, M. P., Hersey, A., Montanari, D. & Overington, J. Probing the links between in vitro potency, ADMET and physicochemical parameters. Nat. Rev. Drug Discov. 10, 197–208 (2011).21358739
889. Singhal D Curatolo W Drug polymorphism and dosage form design: a practical perspective Adv. Drug Deliv. Rev. 2004 56 335 347, 10.1016/j.addr.2003.10.008 14962585
Singhal, D. & Curatolo, W. Drug polymorphism and dosage form design: a practical perspective. Adv. Drug Deliv. Rev. 56, 335–347, (2004).14962585
890. Sánchez-Valle J Valencia A Molecular bases of comorbidities: present and future perspectives Trends Genet 2023 39 773 786 10.1016/j.tig.2023.06.003 37482451
Sánchez-Valle, J. & Valencia, A. Molecular bases of comorbidities: present and future perspectives. Trends Genet 39, 773–786 (2023).37482451
891. Perico L Immunity, endothelial injury and complement-induced coagulopathy in COVID-19 Nat. Rev. Nephrol. 2021 17 46 64 10.1038/s41581-020-00357-4 33077917
Perico, L. et al. Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. Nat. Rev. Nephrol. 17, 46–64 (2021).33077917
892. Bowen ET Ebola haemorrhagic fever: experimental infection of monkeys Trans. R. Soc. Trop. Med. Hyg. 1978 72 188 191 10.1016/0035-9203(78)90058-5 418537
Bowen, E. T. et al. Ebola haemorrhagic fever: experimental infection of monkeys. Trans. R. Soc. Trop. Med. Hyg. 72, 188–191 (1978).418537
893. Sword J Computed Tomography Imaging for Monitoring of Marburg Virus Disease: a Nonhuman Primate Proof-Of-Concept Study Microbiol. Spectr. 2023 11 e0349422 10.1128/spectrum.03494-22 37036346
Sword, J. et al. Computed Tomography Imaging for Monitoring of Marburg Virus Disease: a Nonhuman Primate Proof-Of-Concept Study. Microbiol. Spectr. 11, e0349422 (2023).37036346
894. Cross RW Combination therapy protects macaques against advanced Marburg virus disease Nat. Commun. 2021 12 1891 10.1038/s41467-021-22132-0 33767178
Cross, R. W. et al. Combination therapy protects macaques against advanced Marburg virus disease. Nat. Commun. 12, 1891 (2021).33767178
895. Carbonnelle C Natural History of to Support Medical Countermeasure Development Vaccines 2022 10 963 10.3390/vaccines10060963 35746571
Carbonnelle, C. et al. Natural History of to Support Medical Countermeasure Development. Vaccines 10, 963 (2022).35746571
896. Warren TK Delayed Time-to-Treatment of an Antisense Morpholino Oligomer Is Effective against Lethal Marburg Virus Infection in Cynomolgus Macaques PLoS Negl. Trop. Dis. 2016 10 e0004456 10.1371/journal.pntd.0004456 26901785
Warren, T. K. et al. Delayed Time-to-Treatment of an Antisense Morpholino Oligomer Is Effective against Lethal Marburg Virus Infection in Cynomolgus Macaques. PLoS Negl. Trop. Dis. 10, e0004456 (2016).26901785
897. Jiang Y MERS-CoV infection causes brain damage in human DPP4-transgenic mice through complement-mediated inflammation J. Gen. Virol. 2021 102 001667 10.1099/jgv.0.001667 34704923
Jiang, Y. et al. MERS-CoV infection causes brain damage in human DPP4-transgenic mice through complement-mediated inflammation. J. Gen. Virol. 102, 001667 (2021).34704923
898. Bryche B Massive transient damage of the olfactory epithelium associated with infection of sustentacular cells by SARS-CoV-2 in golden Syrian hamsters Brain Behav. Immun. 2020 89 579 586 10.1016/j.bbi.2020.06.032 32629042
Bryche, B. et al. Massive transient damage of the olfactory epithelium associated with infection of sustentacular cells by SARS-CoV-2 in golden Syrian hamsters. Brain Behav. Immun. 89, 579–586 (2020).32629042
899. Zhang AJ Severe Acute Respiratory Syndrome Coronavirus 2 Infects and Damages the Mature and Immature Olfactory Sensory Neurons of Hamsters Clin. Infect. Dis. 2021 73 e503 e512 10.1093/cid/ciaa995 32667973
Zhang, A. J. et al. Severe Acute Respiratory Syndrome Coronavirus 2 Infects and Damages the Mature and Immature Olfactory Sensory Neurons of Hamsters. Clin. Infect. Dis. 73, e503–e512 (2021).32667973
900. Zhao Y Ferrets: A powerful model of SARS-CoV-2 Zool. Res. 2023 44 323 330 10.24272/j.issn.2095-8137.2022.351 36799224
Zhao, Y. et al. Ferrets: A powerful model of SARS-CoV-2. Zool. Res. 44, 323–330 (2023).36799224
901. Zhu Y Lymphocyte cell population as a potential hematological index for early diagnosis of COVID-19 Cell Mol. Biol. 2020 66 202 206 10.14715/cmb/2020.66.7.31 33287943
Zhu, Y. et al. Lymphocyte cell population as a potential hematological index for early diagnosis of COVID-19. Cell Mol. Biol. 66, 202–206 (2020).33287943
902. Ware LB Matthay MA The acute respiratory distress syndrome N. Engl. J. Med. 2000 342 1334 1349, 10.1056/NEJM200005043421806 10793167
Ware, L. B. & Matthay, M. A. The acute respiratory distress syndrome. N. Engl. J. Med. 342, 1334–1349, (2000).10793167
903. Sinovac. Sinovac Receives Conditional Marketing Authorization in China for its COVID-19 Vaccine (Sinovac, 2021).
904. Castelli JM Effectiveness of mRNA-1273, BNT162b2, and BBIBP-CorV vaccines against infection and mortality in children in Argentina, during predominance of delta and omicron covid-19 variants: test negative, case-control study BMJ 2022 379 e073070 10.1136/bmj-2022-073070 36450402
Castelli, J. M. et al. Effectiveness of mRNA-1273, BNT162b2, and BBIBP-CorV vaccines against infection and mortality in children in Argentina, during predominance of delta and omicron covid-19 variants: test negative, case-control study. BMJ 379, e073070 (2022).36450402
905. Xia S Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials JAMA 2020 324 951 960 10.1001/jama.2020.15543 32789505
Xia, S. et al. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. JAMA 324, 951–960 (2020).32789505
906. Baden LR Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine N. Engl. J. Med. 2021 384 403 416 10.1056/NEJMoa2035389 33378609
Baden, L. R. et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 384, 403–416 (2021).33378609
907. Tai W A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2 Cell Res. 2020 30 932 935 10.1038/s41422-020-0387-5 32759966
Tai, W. et al. A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2. Cell Res. 30, 932–935 (2020).32759966
908. Keech C Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine N. Engl. J. Med. 2020 383 2320 2332 10.1056/NEJMoa2026920 32877576
Keech, C. et al. Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N. Engl. J. Med. 383, 2320–2332 (2020).32877576
909. Stuart ASV Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial Lancet 2022 399 36 49 10.1016/S0140-6736(21)02718-5 34883053
Stuart, A. S. V. et al. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. Lancet 399, 36–49 (2022).34883053
910. Lundgren JD A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19 N. Engl. J. Med. 2021 384 905 914 10.1056/NEJMoa2033130 33356051
Lundgren, J. D. et al. A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19. N. Engl. J. Med. 384, 905–914 (2021).33356051
911. Tignor GH Hanham CA Ribavirin efficacy in an in vivo model of Crimean-Congo hemorrhagic fever virus (CCHF) infection Antivir. Res. 1993 22 309 325 10.1016/0166-3542(93)90040-P 8279818
Tignor, G. H. & Hanham, C. A. Ribavirin efficacy in an in vivo model of Crimean-Congo hemorrhagic fever virus (CCHF) infection. Antivir. Res. 22, 309–325 (1993).8279818
912. Zivcec M Lethal Crimean-Congo hemorrhagic fever virus infection in interferon α/β receptor knockout mice is associated with high viral loads, proinflammatory responses, and coagulopathy J. Infect. Dis. 2013 207 1909 1921 10.1093/infdis/jit061 23417661
Zivcec, M. et al. Lethal Crimean-Congo hemorrhagic fever virus infection in interferon α/β receptor knockout mice is associated with high viral loads, proinflammatory responses, and coagulopathy. J. Infect. Dis. 207, 1909–1921 (2013).23417661
913. Bente DA Pathogenesis and immune response of Crimean-Congo hemorrhagic fever virus in a STAT-1 knockout mouse model J. Virol. 2010 84 11089 11100 10.1128/JVI.01383-10 20739514
Bente, D. A. et al. Pathogenesis and immune response of Crimean-Congo hemorrhagic fever virus in a STAT-1 knockout mouse model. J. Virol. 84, 11089–11100 (2010).20739514
914. Aligholipour Farzani T Bovine Herpesvirus Type 4 (BoHV-4) Vector Delivering Nucleocapsid Protein of Crimean-Congo Hemorrhagic Fever Virus Induces Comparable Protective Immunity against Lethal Challenge in IFNα/β/γR−/− Mice Models Viruses 2019 11 237 10.3390/v11030237 30857305
Aligholipour Farzani, T. et al. Bovine Herpesvirus Type 4 (BoHV-4) Vector Delivering Nucleocapsid Protein of Crimean-Congo Hemorrhagic Fever Virus Induces Comparable Protective Immunity against Lethal Challenge in IFNα/β/γR−/− Mice Models. Viruses 11, 237 (2019).30857305
915. Ranadheera C Characterization of a novel STAT 2 knock-out hamster model of Crimean-Congo hemorrhagic fever virus pathogenesis Sci. Rep. 2020 10 12378 10.1038/s41598-020-69054-3 32704046
Ranadheera, C. et al. Characterization of a novel STAT 2 knock-out hamster model of Crimean-Congo hemorrhagic fever virus pathogenesis. Sci. Rep. 10, 12378 (2020).32704046
916. Haddock E A cynomolgus macaque model for Crimean-Congo haemorrhagic fever Nat. Microbiol. 2018 3 556 562 10.1038/s41564-018-0141-7 29632370
Haddock, E. et al. A cynomolgus macaque model for Crimean-Congo haemorrhagic fever. Nat. Microbiol. 3, 556–562 (2018).29632370
917. Schwarz MM Rift Valley Fever Virus Infects the Posterior Segment of the Eye and Induces Inflammation in a Rat Model of Ocular Disease J. Virol. 2022 96 e0111222 10.1128/jvi.01112-22 36194021
Schwarz, M. M. et al. Rift Valley Fever Virus Infects the Posterior Segment of the Eye and Induces Inflammation in a Rat Model of Ocular Disease. J. Virol. 96, e0111222 (2022).36194021
918. Anderson GW Jr. Slone TW Jr. Peters CJ Pathogenesis of Rift Valley fever virus (RVFV) in inbred rats Microb. Pathogenesis 1987 2 283 293 10.1016/0882-4010(87)90126-4
Anderson, G. W. Jr., Slone, T. W. Jr. & Peters, C. J. Pathogenesis of Rift Valley fever virus (RVFV) in inbred rats. Microb. Pathogenesis 2, 283–293 (1987).
919. Morrill JC Pathogenesis of Rift Valley fever in rhesus monkeys: role of interferon response Arch. Virol. 1990 110 195 212 10.1007/BF01311288 1690534
Morrill, J. C. et al. Pathogenesis of Rift Valley fever in rhesus monkeys: role of interferon response. Arch. Virol. 110, 195–212 (1990).1690534
920. Smith DR Development of a novel nonhuman primate model for Rift Valley fever J. Virol. 2012 86 2109 2120 10.1128/JVI.06190-11 22156530
Smith, D. R. et al. Development of a novel nonhuman primate model for Rift Valley fever. J. Virol. 86, 2109–2120 (2012).22156530
921. Yedloutschnig RJ Dardiri AH Mebus CA Walker JS Abortion in vaccinated sheep and cattle after challenge with Rift Valley fever virus Vet. Rec. 1981 109 383 384 10.1136/vr.109.17.383 7340068
Yedloutschnig, R. J., Dardiri, A. H., Mebus, C. A. & Walker, J. S. Abortion in vaccinated sheep and cattle after challenge with Rift Valley fever virus. Vet. Rec. 109, 383–384 (1981).7340068
922. Rippy MK Topper MJ Mebus CA Morrill JC Rift Valley fever virus-induced encephalomyelitis and hepatitis in calves Vet. Pathol. 1992 29 495 502 10.1177/030098589202900602 1448895
Rippy, M. K., Topper, M. J., Mebus, C. A. & Morrill, J. C. Rift Valley fever virus-induced encephalomyelitis and hepatitis in calves. Vet. Pathol. 29, 495–502 (1992).1448895
923. Morrill JC Rift Valley fever MP-12 vaccine elicits an early protective immune response in mice Vaccine 2022 40 7255 7261 10.1016/j.vaccine.2022.10.062 36333222
Morrill, J. C. et al. Rift Valley fever MP-12 vaccine elicits an early protective immune response in mice. Vaccine 40, 7255–7261 (2022).36333222
924. Anthony T Vaccination with Rift Valley fever virus live attenuated vaccine strain Smithburn caused meningoencephalitis in alpacas J. Vet. Diagn. Invest. 2021 33 777 781 10.1177/10406387211015294 34041966
Anthony, T. et al. Vaccination with Rift Valley fever virus live attenuated vaccine strain Smithburn caused meningoencephalitis in alpacas. J. Vet. Diagn. Invest. 33, 777–781 (2021).34041966
925. Makoschey B Rift Valley Fever Vaccine Virus Clone 13 Is Able to Cross the Ovine Placental Barrier Associated with Foetal Infections, Malformations, and Stillbirths PLoS Negl. Trop. Dis. 2016 10 e0004550 10.1371/journal.pntd.0004550 27031621
Makoschey, B. et al. Rift Valley Fever Vaccine Virus Clone 13 Is Able to Cross the Ovine Placental Barrier Associated with Foetal Infections, Malformations, and Stillbirths. PLoS Negl. Trop. Dis. 10, e0004550 (2016).27031621
926. Caplen H Peters CJ Bishop DH Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development J. Gen. Virol. 1985 66 2271 2277 10.1099/0022-1317-66-10-2271 4045430
Caplen, H., Peters, C. J. & Bishop, D. H. Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development. J. Gen. Virol. 66, 2271–2277 (1985).4045430
927. Wichgers Schreur PJ Oreshkova N Moormann RJ Kortekaas J Creation of Rift Valley fever viruses with four-segmented genomes reveals flexibility in bunyavirus genome packaging J. Virol. 2014 88 10883 10893 10.1128/JVI.00961-14 25008937
Wichgers Schreur, P. J., Oreshkova, N., Moormann, R. J. & Kortekaas, J. Creation of Rift Valley fever viruses with four-segmented genomes reveals flexibility in bunyavirus genome packaging. J. Virol. 88, 10883–10893 (2014).25008937
928. Stachowiak B Weingartl HM Nipah virus infects specific subsets of porcine peripheral blood mononuclear cells PloS One 2012 7 e30855 10.1371/journal.pone.0030855 22303463
Stachowiak, B. & Weingartl, H. M. Nipah virus infects specific subsets of porcine peripheral blood mononuclear cells. PloS One 7, e30855 (2012).22303463
929. Mungall BA Feline model of acute nipah virus infection and protection with a soluble glycoprotein-based subunit vaccine J. Virol. 2006 80 12293 12302 10.1128/JVI.01619-06 17005664
Mungall, B. A. et al. Feline model of acute nipah virus infection and protection with a soluble glycoprotein-based subunit vaccine. J. Virol. 80, 12293–12302 (2006).17005664
930. Bossart KN A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge Sci. Transl. Med. 2012 4 146ra107 10.1126/scitranslmed.3004241 22875827
Bossart, K. N. et al. A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge. Sci. Transl. Med. 4, 146ra107 (2012).22875827
931. Zeitlin L Therapeutic administration of a cross-reactive mAb targeting the fusion glycoprotein of Nipah virus protects nonhuman primates Sci. Transl. Med. 2024 16 eadl2055 10.1126/scitranslmed.adl2055 38569014
Zeitlin, L. et al. Therapeutic administration of a cross-reactive mAb targeting the fusion glycoprotein of Nipah virus protects nonhuman primates. Sci. Transl. Med. 16, eadl2055 (2024).38569014
932. Wu K-Y Vertical transmission of Zika virus targeting the radial glial cells affects cortex development of offspring mice Cell Res. 2016 26 645 654 10.1038/cr.2016.58 27174054
Wu, K.-Y. et al. Vertical transmission of Zika virus targeting the radial glial cells affects cortex development of offspring mice. Cell Res. 26, 645–654 (2016).27174054
933. Magnani DM Fetal demise and failed antibody therapy during Zika virus infection of pregnant macaques Nat. Commun. 2018 9 1624 10.1038/s41467-018-04056-4 29691387
Magnani, D. M. et al. Fetal demise and failed antibody therapy during Zika virus infection of pregnant macaques. Nat. Commun. 9, 1624 (2018).29691387
934. Hirsch AJ Zika virus infection in pregnant rhesus macaques causes placental dysfunction and immunopathology Nat. Commun. 2018 9 263 10.1038/s41467-017-02499-9 29343712
Hirsch, A. J. et al. Zika virus infection in pregnant rhesus macaques causes placental dysfunction and immunopathology. Nat. Commun. 9, 263 (2018).29343712
935. Holmes EC The origins of SARS-CoV-2: A critical review Cell 2021 184 4848 4856 10.1016/j.cell.2021.08.017 34480864
Holmes, E. C. et al. The origins of SARS-CoV-2: A critical review. Cell 184, 4848–4856 (2021).34480864
936. Sall AA Origin of 1997-98 Rift Valley fever outbreak in East Africa Lancet 1998 352 1596 1597 10.1016/S0140-6736(05)61043-4 9843109
Sall, A. A. et al. Origin of 1997-98 Rift Valley fever outbreak in East Africa. Lancet 352, 1596–1597 (1998).9843109
937. Monath TP Lassa fever: review of epidemiology and epizootiology Bull. World Health Organ. 1975 52 577 592, 782738
Monath, T. P. Lassa fever: review of epidemiology and epizootiology. Bull. World Health Organ. 52, 577–592, (1975).782738
938. Kindhauser MK Zika: the origin and spread of a mosquito-borne virus Bull. World Health Organ. 2016 94 675 686c 10.2471/BLT.16.171082 27708473
Kindhauser, M. K. et al. Zika: the origin and spread of a mosquito-borne virus. Bull. World Health Organ. 94, 675–686c (2016).27708473
939. Plowright RK Ecological dynamics of emerging bat virus spillover Proc. Biol. Sci. 2015 282 20142124 25392474
Plowright, R. K. et al. Ecological dynamics of emerging bat virus spillover. Proc. Biol. Sci. 282, 20142124 (2015).25392474
